# EDGAR Filing Document

**Accession Number:** 0001757143
**File Stem:** 0001185185-26-001477
**Filing Date:** 2026-4
**Character Count:** 947095
**Document Hash:** 94d4a6b4a2202a7a7a847871fc0ea077
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-26-001477.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001185185-26-001477

**CONFORMED SUBMISSION TYPE**: 20-F

**PUBLIC DOCUMENT COUNT**: 164

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aesthetic Medical International Holdings Group Ltd
- **CENTRAL INDEX KEY:** 0001757143
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 20-F
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39088
- **FILM NUMBER:** 26888767

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1122 NANSHAN AVENUE
- **STREET 2:** NANSHAN DISTRICT
- **CITY:** SHENZHEN
- **NON US STATE TERRITORY:** GUANGDONG PROVINCE
- **PROVINCE COUNTRY:** F4
- **ZIP:** 518000
- **BUSINESS PHONE:** 917 609-0333

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1122 NANSHAN AVENUE
- **STREET 2:** NANSHAN DISTRICT
- **CITY:** SHENZHEN
- **NON US STATE TERRITORY:** GUANGDONG PROVINCE
- **PROVINCE COUNTRY:** F4
- **ZIP:** 518000

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 20-F**

**(Mark One)**

**☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES ACT OF 1934**

**OR**

**☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the fiscal year ended December 31, 2025**

**OR**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR**

**☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of event requiring this shell company report: ______________________________

**For the transition period from___________________to___________________**

Commission file number: 001-39088

**Aesthetic Medical International Holdings Group Limited**

(Exact name of Registrant as specified in its charter)

**N/A**

(Translation of Registrant's name into English)

**Cayman Islands**

(Jurisdiction of incorporation)

**1122 Nanshan Boulevard**

**Nanshan District, Shenzhen**

**Guangdong Province, China 518052**

(Address of principal executive offices)

**Wu Guanhua, Chief Financial Officer**

**E-mail: toby@pengai.com.cn**

**1122 Nanshan Boulevard**

**Nanshan District, Shenzhen**

**Guangdong Province, China 518052**

**Telephone: +86 (755) 2665 0533**

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered, pursuant to Section 12(b) of the Act

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**Title of each class** | **Trading Symbol(s)** |
| **American depositary shares, each representing three ordinary shares Ordinary shares, par value US$0.001 per share\*** | **PAIYY** |

---

\* Not for trading, but only in connection with the listing of the American depositary shares on the OTC Market.

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report:

As of December 31, 2025, there were 147,326,504 ordinary shares issued and outstanding.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☐ Yes ☒ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

☐ Yes ☒ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The
 term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards
 Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

☐ Yes ☒ No

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐ International Financial Reporting Standards as issued Other ☐ <br> by the International Accounting Standards Board ☒

If "Other" has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. ☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

☐ Yes ☐ No

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [INTRODUCTION](#a_001) | [INTRODUCTION](#a_001) | ii |
| [FORWARD-LOOKING INFORMATION](#a_002) | [FORWARD-LOOKING INFORMATION](#a_002) | iii |
| PART I. |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 1. | [Identity of Directors, Senior Management and Advisers](#a_003) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 2. | [Offer Statistics and Expected Timetable](#a_004) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 3. | [Key Information](#a_005) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 4. | [Information on the Company](#a_006) | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 4.A. | [Unresolved Staff Comments](#a_007) | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 5. | [Operating and Financial Review and Prospects](#a_008) | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 6. | [Directors, Senior Management and Employees](#a_009) | 114 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 7. | [Major Shareholders and Related Party Transactions](#a_010) | 127 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 8. | [Financial Information](#a_011) | 130 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 9. | [The Offer and Listing](#a_012) | 131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 10. | [Additional Information](#a_013) | 131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 11. | [Quantitative and Qualitative Disclosures About Market Risk](#a_014) | 144 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 12. | [Description of Securities Other Than Equity Securities](#a_015) | 145 |
| PART II. |  | 147 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 13. | [Defaults, Dividend Arrearages and Delinquencies](#a_016) | 147 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 14. | [Material Modifications to the Rights of Security Holders and Use of Proceeds](#a_017) | 147 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 15. | [Controls and Procedures](#a_018) | 147 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.A. | [Audit Committee Financial Expert](#a_019) | 148 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.B. | [Code of Ethics](#a_020) | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.C. | [Principal Accountant Fees and Services](#a_021) | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.D. | [Exemptions from the Listing Standards for Audit Committees](#a_022) | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.E. | [Purchases of Equity Securities by the Issuer and Affiliated Purchasers](#a_023) | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.F. | [Change in Registrant's Certifying Accountant](#a_024) | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.G. | [Corporate Governance](#a_025) | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.H. | [Mine Safety Disclosure](#a_026) | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.I. | [Disclosure Regarding Foreign Jurisdictions That Prevent Inspections](#a_027) | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.J. | [Insider Trading Policies](#a_028) | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 16.K. | [Cybersecurity](#a_029) | 150 |
| PART III. |  | 152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 17. | [Financial Statements](#a_030) | 152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 18. | [Financial Statements](#a_031) | 152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 19. | [Exhibits](#a_032) | 152 |
| [SIGNATURES](#a_033) | [SIGNATURES](#a_033) | 158 |

---

i

[**Table of Contents**](#TableOfContents)

**INTRODUCTION**

Unless otherwise indicated or the context otherwise requires, references in this annual report to:

● "ADSs" refers to our American depositary shares, each of which represents three of our ordinary shares;

● "ADV" refers to Peak Asia Investment Holdings V Limited and/or its affiliates as the case may be;

● "AIH" refers to Aesthetic Medical International Holdings Group Limited, a Cayman Islands exempted company; and we" "us" "our company" "the Company" "the Group" and "our" are to Aesthetic Medical International Holdings Group Limited and its subsidiaries, and in the context of describing our consolidated financial information;

● "China" or the "PRC" refers to the People's Republic of China, including Hong Kong, Macau and Taiwan, unless when refer to specific laws and regulations adopted by Mainland China; and "Mainland China" are to the People's Republic of China excluding Hong Kong, Macau and Taiwan;

● "Contractual Arrangements" refers to a series of contractual arrangements entered into by us with Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd., the Relevant Subsidiaries, Ms. Ma Xiuhua and Ms. Ding Wenting from 2018 to 2025 with respect to the Target Equity Interests, as detailed in "Item 4. Information on the Company—4.A. History and Development of the Company—Contractual Arrangements with respect to Target Equity Interests";

● "Founder" or "Founders" refers to Dr. Zhou Pengwu or/and Ms. Ding Wenting or/and their affiliates as the case may be.

● "Hawyu" refers to Hawyu (HK) Limited and/or its affiliates as the case may be;

● "Jiechuang" refers to Hainan Oriental Jiechuang Investment Partnership (Limited Partnership) and/or its affiliates as the case may be;

● "Lafang" refers to Lafang China Co., Ltd. and/or its affiliates as the case may be;

● "MY Universe" refers to MY Universe (HK) Limited and/or its affiliates as the case may be;

● "Wanda" refers to Australia Wanda International Company Limited and/or its affiliates as the case may be;

● "Relevant Subsidiaries" refers to, collectively, Shenzhen Pengai Xiuqi Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Xiuqi (formerly known as Shanghai Pengai Jiahong) Aesthetic Medical Outpatient Department Co., Ltd., Yantai Pengai Cosmetic Surgery Hospital Co., Ltd., Beijing Aomei Yixin Investment Consultant Co., Ltd., and its branch, Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic (collectively "Relevant Subsidiaries"), which were held by Mr. Zhou Qiuming or Dr. Zhou Pengwu directly or indirectly, with ownership percentages of 27%, 26%, 3%, 15%, 12%, 24%, and 25% respectively, as of December 31, 2025.

● "RMB" and "renminbi" refers to the legal currency of Mainland China;

● "shares" or "ordinary shares" refers to our ordinary shares, par value US$0.001 per share;

● "Target Equity Interests" refers to these equity interests held by Mr. Zhou Qiuming or Dr. Zhou Pengwu in the Relevant Subsidiaries, which constitute all of Mr. Zhou Qiuming or Dr. Zhou Pengwu's shareholdings in the Relevant Subsidiaries as of December 31, 2025.

● "US$," "U.S. dollars," "$," and "dollars" refers to the legal currency of the United States; and

We present our financial results in RMB. We make no representation that any RMB or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may be, at any particular rate, or at all. The PRC government imposes control over its foreign currency reserves in part through direct regulation of the conversion of RMB into foreign exchange and through restrictions on foreign trade. This annual report contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise specified, all translations of renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.9931 to US$1.00, which was the exchange rate on December 31, 2025 as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System.

We completed an initial public offering of our ADSs at an initial offering price of US$12.00 per ADS on October 29, 2019. On January 19, 2023, we transferred the listing of our ADSs from the Nasdaq Global Market to the Nasdaq Capital Market. On May 21, 2024, our ADSs were quoted on the Pink Open Market initially under the symbol "PAIYY" since the Nasdaq suspended the trading of our ADSs. Subsequently, we applied to upgrade from the Pink Open Market to the OTCQX Best Market and received approval on July 10, 2024. The ADSs, each representing three of our ordinary shares, par value US$0.001 per share, are now traded on the OTCQX Best Market under the symbol "PAIYY".

ii

[**Table of Contents**](#TableOfContents)

**FORWARD-LOOKING INFORMATION**

This annual report contains forward-looking statements that reflect our current expectations and views of future events. All statements other than statements of current or historical facts are forward-looking statements. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigations Reform Act of 1995.

You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:

● our business prospects, trends and conditions in the industry and markets in which we operate;

● our goals, business strategies and plans to achieve these strategies;

● our expected growth in, and market size of, our services in the markets we operate;

● expected changes in our revenue, costs and expenditures;

● our ability to offer new services in the markets and the industry we operate;

● our ability to continue to develop new technologies and/or update our existing technologies;

● growth of and trends of competition in our industry;

● general economic, political and business conditions in the markets in which we operate;

● changes to the regulatory environment and general outlook in the industry and markets in which we operate;

● the performance of the global financial markets, including changes in our ability to access the capital markets and changes in the levels of interest rates;

● our liquidity and financial condition;

● our relationship with, and other conditions affecting, our customers;

● our expectation regarding the use of the remainder of proceeds from our financing;

● our dividend policy; and

● other factors beyond our control.

These factors should not be construed as exhaustive and should be read with the other cautionary statements in this annual report, including but not limited to those listed under "Item 3. Key Information—3.D. Risk Factors."

These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. We operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in this annual report. You should read thoroughly this annual report and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.

This annual report contains certain data and information that we obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. Our industry may not grow at the rate projected by market data, or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on our business and the market price of our ADSs. In addition, the rapidly evolving nature of our industry results in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of our market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. The forward- looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this annual report and the documents that we refer to in this annual report and have filed as exhibits to the registration statement, of which this annual report is a part, completely and with the understanding that our actual future results may be materially different from what we expect.

iii

[**Table of Contents**](#TableOfContents)

**PART I.**

**Item 1. Identity of Directors, Senior Management and Advisers**

Not applicable.

**Item 2. Offer Statistics and Expected Timetable**

Not applicable.

**Item 3. Key Information**

Our Holding Company Structure and Their Respective Individual Shareholders

AIH is not a Chinese operating company but a Cayman Islands holding company with operations conducted through our subsidiaries incorporated in mainland China, or the PRC subsidiaries and through contractual arrangements with the Relevant Subsidiaries and this structure involves unique risks to investors. Investors are purchasing securities of a Cayman Islands holding company rather than securities of our subsidiaries that have substantive business operations in China and the Cayman Island holding company controls our subsidiaries in China primarily by direct equity ownership of up to 71.0% of the share interests of the Relevant Subsidiaries.

Chinese law imposes various restrictions on the direct foreign investment in PRC companies, including a limitation of 70% or less of equity interests or the rights held by foreign entities in PRC medical institutions. Consequently, contractual arrangements are entered into to provide investors with more exposure to foreign investment in seven Relevant Subsidiaries. We own 65% or more direct equity interest in each of the Relevant Subsidiaries and as a result we are able to control and consolidate such subsidiaries as a result of our direct majority equity ownership, among other things, and do not depend on the contractual arrangements in relation to the minority equity interest to control and consolidate such subsidiaries. The Contractual Arrangements enable us to (i) exercise control over the Target Equity Interests in the Relevant Subsidiaries, (ii) receive economic benefits from the Target Equity Interests in the Relevant Subsidiaries, and (iii) have an exclusive option to purchase all or part of the Target Equity Interests in the Relevant Subsidiaries when and to the extent permitted by PRC laws. A summary of certain material terms of the Contractual Arrangements is as follows. For more details of these contractual arrangements, see "Item 4. Information on the Company—4.A. History and Development of the Company—Contractual Arrangements with respect to Target Equity Interests" in this annual report.

● Loan Agreement. Under the loan agreements among Mr. Zhou Qiuming, Dr. Zhou Pengwu and Shenzhen Pengai Investment, Shenzhen Pengai Investment agrees to extend a loan to Mr. Zhou Qiuming and Dr. Zhou Pengwu in an equivalent amount to the purchase price to be paid by Mr. Zhou Qiuming and Dr. Zhou Pengwu for acquiring the Target Equity Interests. Pursuant to each of these loan agreements, Mr. Zhou Qiuming and Dr. Zhou Pengwu shall repay the loan by transferring the current and future economic interest of the Target Equity Interests to Shenzhen Pengai Investment.

● Economic Interest Transfer Agreement. Under the economic interest transfer agreements among Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries, the economic interest in relation to the Target Equity Interests currently held and subsequently acquired by Mr. Zhou Qiuming or Dr. Zhou Pengwu shall be transferred to Shenzhen Pengai Investment. Upon the execution of each economic interest transfer agreement, the repayment obligation of Mr. Zhou Qiuming or Dr. Zhou Pengwu under each loan agreement is deemed fully discharged.

● Exclusive Option Agreement. Under the exclusive option agreement among Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries, Mr. Zhou Qiuming and Dr. Zhou Pengwu irrevocably granted Shenzhen Pengai Investment an exclusive right to purchase, or have its designated person(s) to purchase, at its discretion, all or part of his equity interest in the Relevant Subsidiary, and the purchase price shall be the lowest price permitted by applicable PRC law.

● Equity Interest Pledge Agreements. Under the equity interest pledge agreement among Mr. Zhou Qiuming, Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries, Mr. Zhou Qiuming and Dr. Zhou Pengwu pledged all of the Target Equity Interests in Relevant Subsidiaries and agreed to pledge all future equity interest in the Relevant Subsidiary acquired by him to Shenzhen Pengai Investment to guarantee the performance by Mr. Zhou Qiuming or Dr. Zhou Pengwu and the Relevant Subsidiary of their respective obligations under the applicable agreements under the Contractual Arrangements. If the Relevant Subsidiary or Mr. Zhou Qiuming or Dr. Zhou Pengwu breaches any obligations under these agreements, Shenzhen Pengai Investment, as pledgee, will be entitled to dispose of the pledged equity and have priority to be compensated by the proceeds from the disposal of the pledged equity.

[**Table of Contents**](#TableOfContents)

● Power of Attorney. Under the proxy agreement and power of attorney executed by Mr. Zhou Qiuming and Dr. Zhou Pengwu, they irrevocably authorized Shenzhen Pengai Investment or its designated person(s) to exercise all of their shareholders' voting and other rights associated with the Target Equity Interests in each of the Relevant Subsidiaries.

● Spousal consent letter. Pursuant to relevant spousal consent letters executed by the spouse of Mr. Zhou Qiuming and the spouse of Dr. Zhou Pengwu, they unconditionally and irrevocably agreed that the equity interest in each of the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming and Dr. Zhou Pengwu and registered or to be registered in his name will be disposed of pursuant to the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney. They not to assert any rights over the equity interest in the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming or Dr. Zhou Pengwu. In addition, in the event that they obtain any equity interest in each of the Relevant Subsidiaries for any reason, they agreed to be bound by the Contractual Arrangements.

Nevertheless, the contractual arrangements related to Target Equity Interest, involves unique risks to investors in the ADSs and ordinary shares of our Company. The Contractual Arrangements may not be as effective as direct ownership in providing us with control over the Relevant Subsidiaries and we may incur substantial costs to enforce the terms of the Contractual Arrangements. If the Relevant Subsidiaries, Mr. Zhou Qiuming or Dr. Zhou Pengwu fail to perform their respective obligations under the Contractual Arrangements, we could be limited in our ability to enforce the Contractual Arrangements that effectively assigned us the voting rights in the Relevant Subsidiaries, since such contractual arrangements have not been tested in the courts of mainland China. Furthermore, if we are unable to maintain such effective assignment under the Contractual Arrangements, we may not be able to continue to consolidate the financial results of the Relevant Subsidiaries in our financial statements. In addition, there are also substantial uncertainties regarding the interpretation and application of current and future laws, regulations and rules of mainland China regarding the status of the rights of our Cayman Islands holding company with respect to the Contractual Arrangements with the Relevant Subsidiaries, Mr. Zhou Qiuming and Dr. Zhou Pengwu. It is uncertain whether any new laws or regulations of mainland China relating to such contractual arrangements will be adopted or if adopted, what they would provide. If we or any of the Relevant Subsidiaries is found to be in violation of any existing or future laws or regulations of mainland China, or fail to obtain or maintain any of the required permits or approvals, the PRC regulatory authorities would have broad discretion in accordance with the applicable laws and regulations to take action in dealing with such violations or failures. See "Item 3. Key Information—3.D. Risk Factors - Risks relating to our corporate structure – If the PRC government deems that the Contractual Arrangements do not comply with PRC laws and regulations, or if these laws and regulations or their interpretations change in the future, we could be subject to severe penalties or be forced to relinquish our interests received through the Contractual Arrangements" "Item 3. Key Information—3.D. Risk Factors - Risks relating to our corporate structure – The Contractual Arrangements may not be as effective in providing control as direct ownership and Relevant Subsidiaries or Mr. Zhou Qiuming or Dr. Zhou Pengwu may fail to perform their respective obligations under the Contractual Arrangements" "Item 3. Key Information—3.D. Risk Factors - Risks relating to our corporate structure – Mr. Zhou Qiuming or Dr. Zhou Pengwu may have potential conflicts of interest with us, which may materially and adversely affect our control over the Target Equity Interests." and " <u>Item 3. Key Information—3.D. Risk Factors - Risks relating to our corporate structure</u> – Any failure by our Relevant Subsidiaries and their other respective shareholders, including Mr. Zhou Qiuming or Dr. Zhou Pengwu, to perform their obligations under our contractual arrangements with them would have a material adverse effect on our business" in this annual report.

Our corporate structure is subject to risks associated with the Contractual Arrangements with the Relevant Subsidiaries. Our company and its investors may never have a direct ownership interest in the businesses that are conducted by the Relevant Subsidiaries. Uncertainties in the PRC legal system could limit our ability to enforce the Contractual Arrangements, and such contractual arrangements have not been tested in a court of law. If the PRC government finds that the agreements that establish the structure for operating our business in mainland China do not comply with the laws and regulations of mainland China, or if these regulations or the interpretation of existing regulations change or are interpreted differently in the future, we and the Relevant Subsidiaries could be subject to severe penalties or be forced to relinquish our interests in those operations. This would result in the Relevant Subsidiaries being deconsolidated, which would have a material effect on our operations and result in the value of our securities to significantly decline or become worthless. Our company, our PRC subsidiaries and the Relevant Subsidiaries, and investors of our company face uncertainty about potential future actions by the PRC government that could affect the enforceability of the Contractual Arrangements with the Relevant Subsidiaries and, consequently, significantly affect the financial performance of the Relevant Subsidiaries and our company as a whole. For a detailed description of the risks associated with our corporate structure, see "Item 3. Key Information – 3.D. Risk Factors – Risks Relating to Our Corporate Structure."

[**Table of Contents**](#TableOfContents)

As we are a holding company with substantive business operations in China, you should pay special attention to other disclosures included in this annual report and risk factors included herein. In particular, any failure of us to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to offer or continue to offer the ADSs, cause significant disruption to our business operations, and severely damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause the ADSs to significantly decline in value or become worthless. See "Item 3. Key Information – 3.D. Risk Factors – Uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with little advance notice, which could materially and adversely affect us." In addition, the PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy. Due to our business operations in Hong Kong, the regulatory actions related to data security or anti-monopoly concerns in Hong Kong may also impact our ability to conduct our business, accept foreign investments or list on a U.S. or foreign exchange. See "Item 3. Key Information – 3.D. Risk Factors – Risks relating to doing business in the PRC."

In this annual report, "AIH" refers to Aesthetic Medical International Holdings Group Limited, and "we" "us" "our company" "the Company" "the Group" and "our" refer to Aesthetic Medical International Holdings Group Limited and its subsidiaries, and in the context of describing our consolidated financial information.

The diagram below illustrates our corporate structure, including our principal subsidiaries and the Relevant Subsidiaries as of the date of this annual report:

![?????? AI ?????????????????????????????????](img_001.jpg)

Notes:

&nbsp;&nbsp;&nbsp;&nbsp;(1) As
of the date of this annual report, "Relevant Subsidiaries" are to, collectively, Shenzhen Pengai Xiuqi Aesthetic Medical
Hospital Co., Ltd., Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department
Co., Ltd., Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Xiuqi (formerly known as Shanghai Pengai
Jiahong) Aesthetic Medical Outpatient Department Co., Ltd., Yantai Pengai Cosmetic Surgery Hospital Co., Ltd., Beijing Aomei Yixin Investment
Consultant Co., Ltd., and its branch, Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic (collectively
"Relevant Subsidiaries"), which were held by Mr. Zhou Qiuming or Dr. Zhou Pengwu directly or indirectly, with ownership percentages
of 27%, 26%, 3%, 15%, 12%, 24%, and 25% respectively. We refer to these equity interests held by Mr. Zhou Qiuming or Dr. Zhou Pengwu
as the "Target Equity Interests," which constitute all of Mr. Zhou Qiuming or Dr. Zhou Pengwu's shareholdings in the
Relevant Subsidiaries.

[**Table of Contents**](#TableOfContents)

&nbsp;&nbsp;&nbsp;&nbsp;(2) As
of the date of this annual report, except for the Target Equity Interests representing all of Mr. Zhou Qiuming or Dr. Zhou Pengwu's
equity interests in the Relevant Subsidiaries which we consolidate through Contractual Arrangements as further described below, the remaining
equity interest in our PRC operating subsidiaries is held by Shenzhen Pengai Investment, unaffiliated third parties and certain of our
employees.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Other
major subsidiaries are those treatment center subsidiaries other than Relevant Subsidiaries under Shenzhen Pengai Hospital Investment
Management Co., Ltd. Shenzhen Pengcheng Hospital, Shenzhen Pengai Aesthetic Medical Hospital and Haikou Pengai Aesthetic Medical Hospital
Co., Ltd. were established before the effective date of the Foreign Investment Catalogue 2015 and thus, it is not subject to the 70%
foreign shareholding restrictions. For instance, Guangzhou Pengai Aesthetic Medical Hospital is controlled by Shenzhen Pengai Investment,
which holds its 70% equity interest, with the remaining 26% equity interest held by Dr. Zhou Pengwu. Unlike the typical variable interest
entity structure, this arrangement allows our Company to exert control over its subsidiaries through direct majority ownership rather
than purely relying on contractual arrangements. For details about other major subsidiaries as of the date of this annual report and
our beneficial interest in such subsidiaries, please see "Item 4. Information on the Company—Item 4.C. Organizational Structure."

**Cash and Asset Flows Through Our Organization**

AIH is a Cayman Islands holding company with no operations of its own. We conduct our operations in China primarily through our PRC subsidiaries and the Relevant Subsidiaries. As a result, our ability to pay dividends to the shareholders and to service any debt it may incur may depend upon dividends paid by our PRC subsidiaries. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict its ability to pay dividends to AIH. Under PRC laws and regulations, our PRC subsidiaries are subject to certain restrictions with respect to payment of dividends or other transfers of any of their net assets to us. Our PRC subsidiaries are permitted to pay dividends only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. PRC laws also require a foreign-invested enterprise to set aside at least 10% of its after-tax profits as the statutory common reserve fund until the cumulative amount of the statutory common reserve fund reaches 50% or more of such enterprises' registered capital, if any, to fund its statutory common reserves, which are not available for distribution as cash dividends. Remittance of dividends by a wholly foreign-owned enterprise out of mainland China is also subject to examination by the banks designated by the PRC State Administration of Foreign Exchange, or SAFE. These restrictions are benchmarked against the paid-up capital and the statutory reserve funds of our PRC subsidiaries. To the extent cash in our business is in China or in an entity in mainland China, the funds may not be available to fund operations or for other use outside of mainland China due to interventions in or the imposition of restrictions and limitations by the PRC government on our ability to transfer cash. As a result, our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business may be materially and adversely affected. For details, see "Item 3. Key Information - D. Risk Factors - Risk Factors - We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business."

[**Table of Contents**](#TableOfContents)

AIH, our Cayman Islands holding company, may transfer cash to its wholly owned subsidiaries by making capital contributions or providing intra-group loans, subject to certain restrictions under the applicable local laws, including the laws of mainland China. For the years ended December 31, 2022, 2023, 2024 and 2025, AIH made cash transfers of RMB95.7 million, RMB163.0 million, nil and nil, respectively, as capital contributions to our wholly owned PRC subsidiary, Peng Yi Da Business Consulting Co., Ltd. For the years ended December 31, 2022, 2023, 2024 and 2025, there were no cash or assets transfer made from our subsidiaries or the Relevant Subsidiaries to AIH. For the years ended December 31, 2022, 2023, 2024 and 2025, no assets other than above cash transactions were transferred between our Cayman Islands holding company and our subsidiaries, including the Relevant Subsidiaries; and no subsidiaries, including the Relevant Subsidiaries, paid dividends or made other distributions to the holding company.

The Company's management is directly supervising cash management. Our finance department is responsible for establishing the cash management policies and procedures among our subsidiaries and departments. Our finance department oversees the allocation of funds across all subsidiaries, including the Relevant Subsidiaries. Each transfer of cash between AIH, a subsidiary and a Relevant Subsidiary is subject to internal approval. Additionally, the approval of online banking transactions is centralized and managed at our headquarter in Shenzhen. The cash of the group is disbursed and applied to each operating entity based on the budget and operating conditions of such specific operating entity. Each cash requirement, after being raised by the relevant operating entity, is subject to two levels of review process by the finance department.

Under the laws of mainland China, AIH and our offshore subsidiaries may provide funding to our PRC subsidiaries only through capital contributions or loans, subject to satisfaction of applicable government registration and approval requirements, and our PRC subsidiaries are subject to certain restrictions with respect to paying dividends or transferring any of their net assets to AIH or our offshore subsidiaries. Although currently there are no equivalent or similar restrictions or limitations in Hong Kong on cash transfers in, or out of, Hong Kong or our Hong Kong subsidiaries, if certain restrictions or limitations in mainland China were to become applicable to cash transfers in and out of Hong Kong or our Hong Kong subsidiaries in the future, the funds in Hong Kong or our Hong Kong subsidiaries, likewise, may not be available to fund operations or for other use outside of Hong Kong. Therefore, to the extent cash in our business is in mainland China or Hong Kong or our mainland China subsidiaries or Hong Kong subsidiaries, the funds may not be available to fund operations or for other use outside of mainland China or Hong Kong due to interventions in or the imposition of restrictions and limitations by the PRC government on our ability to transfer cash.

As of the date of this annual report, no dividends or distributions were made to AIH by our subsidiaries or the Relevant Subsidiaries, and no dividends or distributions have been made to U.S. investors. We currently intend to retain all of our available funds and any future earnings to operate and expand our business and we do not expect to declare or pay any dividends on our ordinary shares or ADSs in the foreseeable future. See "Item 8. Financial Information—A. Consolidated Statements and Other Financial Information—Dividend Policy." Cash transfers from our Hong Kong subsidiaries to AIH or our offshore subsidiaries are subject to tax obligations imposed by Hong Kong laws to the extent applicable. For PRC and United States federal income tax considerations of an investment in our ADSs and/or ordinary shares, see "Item 10. Additional Information—E. Taxation."

**The Holding Foreign Companies Accountable Act**

Effective on December 12, 2023, we appointed Onestop Assurance PAC ("Onestop"), an independent registered public accounting firm, as our current auditor for the audit of our financial results of the three fiscal years ended December 31, 2025. On December 8, 2025, Onestop confirmed its continuation as our independent registered public accounting firm for the audit of our financial results for the financial year ending December 31, 2025. Onestop is headquartered in Singapore and is subject to laws in the United States pursuant to which the Public Company Accounting Oversight Board ("PCAOB") conducts regular inspections to assess their compliance with the applicable professional standards. The PCAOB has access to inspect and investigate registered firms in Singapore in accordance with a joint cooperative arrangement in place since 2008. However, if PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in mainland China, Hong Kong or any other jurisdictions and we use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the SEC, we would be identified as a "Commission-Identified Issuer" following the filing of the annual report on Form 20-F for the relevant fiscal year. There can be no assurance that we would not be identified as a Commission-Identified Issuer for any future fiscal year, and if we were so identified for two consecutive years, we would become subject to the prohibition on trading under the Holding Foreign Companies Accountable Act, or the HFCAA. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of our ADSs. The HFCAA, was enacted on December 18, 2020, as amended by the Consolidated Appropriations Act, 2023. The HFCAA states that if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three consecutive years beginning in 2021, the SEC will prohibit our shares or the ADSs from being traded on a national securities exchange or in the over-the-counter trading market in the United States. On December 16, 2021, PCAOB issued the HFCAA Determination Report, according to which our former auditor, Union Power HK CPA Limited, a registered public accounting firm headquartered in Hong Kong, a jurisdiction where the PCAOB determined that it had been unable to inspect or investigate completely registered public accounting firms headquartered there until December 2022. In May 2022, in connection with its implementation of the HFCAA, the SEC conclusively named our Company as a "Commission-Identified Issuer" following the filing of our annual report on Form 20-F for fiscal year 2021 with the SEC on May 16, 2022. On August 26, 2022, the PCAOB announced that it had signed a Statement of Protocol (the "SOP") with the China Securities Regulatory Commission and the Ministry of Finance of China. The SOP, together with two protocol agreements governing inspections and investigations, establishes a specific, accountable framework to make possible complete inspections and investigations by the PCAOB of audit firms based in mainland China and Hong Kong, as required under U.S. law. On December 15, 2022, the PCAOB announced that it was able to secure complete access to inspect and investigate PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong completely in 2022. The PCAOB Board vacated its previous 2021 determinations that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong. On December 29, 2022, the Consolidated Appropriations Act, 2023, was signed into law, which amended the HFCAA (i) to reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCAA from three years to two, and (ii) so that any foreign jurisdiction could be the reason why the PCAOB does not have complete access to inspect or investigate a company's auditors. As it was originally enacted, the HFCAA applied only if the PCAOB's inability to inspect or investigate because of a position taken by an authority in the foreign jurisdiction where the relevant public accounting firm is located. As a result of the Consolidated Appropriations Act, 2023, the HFCAA now also applies if the PCAOB's inability to inspect or investigate the relevant accounting firm is due to a position taken by an authority in any foreign jurisdiction. The denying jurisdiction does not need to be where the accounting firm is located. As such, whether the PCAOB will continue to conduct inspections and investigations completely to its satisfaction of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainty and depends on a number of factors out of our, and our auditor's, control, including positions taken by authorities of the PRC. The PCAOB is expected to continue to demand complete access to inspections and investigations against accounting firms headquartered in mainland China and Hong Kong in the future and states that it has already made plans to resume regular inspections in early 2023 and beyond. The PCAOB is required under the HFCAA to make its determination on an annual basis with regards to its ability to inspect and investigate completely accounting firms based in the mainland China and Hong Kong. The possibility of being a "Commission-Identified Issuer" and risk of delisting could continue to adversely affect the trading price of our securities. Should the PCAOB again encounter impediments to inspections and investigations in mainland China or Hong Kong as a result of positions taken by any authority in either jurisdiction, the PCAOB will make determinations under the HFCAA as and when appropriate. See "Risk Factors – Risks relating to doing business in the PRC – Our ADSs may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect auditors who are located in China. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections deprives our investors with the benefits of such inspections."

[**Table of Contents**](#TableOfContents)

The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our ordinary shares or the ADSs, or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless. For more information on various risks related to doing business in China, see "Item 3. Key Information—3.D. Risk Factors" section.

As of the date of this annual report, AIH, our Cayman Islands holding company and other subsidiaries of our Company have not received any inquiry, notice, warning or sanctions regarding the offering from the CSRC or any other PRC governmental authorities. However, since these statements and regulatory actions by the PRC government are newly published and detailed official guidance and related implementation rules have not been issued or taken effect, it is uncertain how soon the regulatory bodies in China will finalize implementation measures, and the impact the modified or new laws and regulations will have on the daily business operations of our PRC subsidiaries, our ability to accept foreign investments and list on an U.S. or other foreign exchange. For more information on various risks related to doing business in China, see the "Risk Factors" sections of this annual report.

**Permissions Required from the PRC Authorities for Our Operations**

We conduct our business primarily through our subsidiaries and consolidated affiliated entities in Mainland China. Our operations in China are governed by PRC laws and regulations. Recently, the PRC government has indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or involve foreign investment in China-based issuers, and initiated a series of regulatory actions and made a number of public statements, some of which are published with little advance notice, including stringent enforcement against illegal activities in the securities market, enhancing supervision over China-based companies listed overseas, adopting new measures to extend the scope of cybersecurity reviews, and expanding efforts in anti-monopoly enforcement. We may be subject to the approval, filing or other requirements of the China Securities Regulatory Commission, or the CSRC, or other PRC governmental authorities in connection with offshore offerings under current PRC laws, regulations and rules. However, we do not believe that approval of the cybersecurity review of the Cyberspace Administration of China, or the CAC is required under current PRC laws, regulations and rules at this stage, as we have not processed, and do not anticipate to process in the foreseeable future, personal information of more than one million users or persons and the data we handle in our business operations, either by its nature or in scale, does not normally trigger significant concerns over PRC national security. However, we cannot affirm that PRC regulators share the same interpretation. Because these statements and regulatory actions are new and subject to change, it is highly uncertain as to how quickly the legislative or administrative regulation making bodies in China will respond to companies, or what existing or new laws or regulations will be amended or promulgated, if any, or the potential impact such amended or new legislation will have on our daily business operations or our ability to accept foreign investments and list on a U.S. stock exchange. If we, our subsidiaries, or the Relevant Subsidiaries fail to obtain or maintain any requisite approvals with respect to our business operation or our future offerings of our equity securities to foreign investors, or if we inadvertently conclude that such approvals are not required, or if the applicable laws, regulations or interpretations thereof change and we become subject to the requirement of such additional permissions or approvals in the future, our ability to maintain our business operation or to offer or continue to offer securities to investors may be significantly limited or completely hindered. We cannot assure you that we will be able to obtain such permissions or approvals in a timely manner, or at all, and such approvals may be rescinded even if obtained. Any such circumstance could impede our efforts to improve our liquidity or maintain or expand our business operation, and may have a material adverse impact on our business, results of operations, financial condition and prospects, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the value of our securities to significantly decline or become worthless. For risks relating to approval of the CSRC, the oversight of the CAC, and other PRC government authorities, please refer to **"**Item 3. Key Information—D. Risk Factors — Risks relating to relating to doing business in the PRC.**"** As of the date of this annual report, in addition to regular business licenses, our PRC subsidiaries and consolidated affiliated entities that directly provide aesthetic medical services are required to obtain and maintain the relevant Medical Institution Practicing Licenses or, where applicable, clinic filing vouchers for their operations. Except for Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd., which had suspended operations as of the date of this annual report, our operating PRC treatment centers have obtained the relevant institution-level permits or filings required for their current operations. To our knowledge, no application for any such business license, permit or filing has been denied.

[**Table of Contents**](#TableOfContents)

**3. A. [Reserved]**

**3. B. Capitalization and Indebtedness**

Not applicable.

**3. C. Reasons for the Offer and Use of Proceeds**

Not applicable.

**3. D. Risk Factors**

**Summary Risk Factors**

Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows, and prospects. These risks are discussed more fully below and include, but are not limited to:

**Risks relating to our business and our industry**

● any future occurrence of force majeure events, natural disasters or outbreaks of contagious diseases in the PRC;

● our ability to obtain sufficient funding for our expansion plans;

● any decrease in supply or fluctuation in the cost of supplies;

● our ability to maintain proper inventory levels for our operations;

● the strength of our brand and reputation;

● increasing ongoing compliance costs in a heavily regulated industry;

● our compliance with PRC laws and regulations on medical advertisement;

● possible non-compliance incidents;

● customer complaints, claims and legal proceedings in the regular course of our operations from time to time;

● our ability to recruit and retain an adequate number of managers, doctors, nurses, image consultants and other support staff in our treatment centers;

● our ability to maintain the quality of the pharmaceuticals, medical equipment, medical supplies, injection materials, skincare products, implants and consumables we use; and

● unfavorable market perception of the overall aesthetic medical industry.

**Risks relating to our corporate structure**

● the Contractual Arrangements being compliant with PRC laws and regulations;

● the Contractual Arrangements being ineffective in providing control;

● potential conflicts of interest with Mr. Zhou Qiuming or Dr. Zhou Pengwu;

● the Contractual Arrangements being subject to scrutiny by the PRC tax authorities; and

● our PRC medical centers being deemed as "Sino-Foreign Equity Medical Institutions."

[**Table of Contents**](#TableOfContents)

**Risks relating to doing business in the PRC**

● increased labor costs and potential non-compliance caused by the enforcement of the PRC Labor Contract Law;

● changes in the PRC's economic, political and social conditions, as well as governmental policies, that may affect our business and operations as a result of our corporate structure with substantial operations in China. For details, see "Item 3. Key Information - D. Risk Factors - Risk Factors - The PRC's economic, political and social conditions, as well as governmental policies, could affect the business environment and financial markets in China, our ability to operate our business, our liquidity and our access to capital.";

● changes in laws, regulations and policies in mainland China and uncertainties with respect to the interpretation and enforcement of the laws, regulations and policies in mainland China and the fact that rules and regulations in mainland China may evolve quickly with any public consultation and advanced notice period being relatively short in terms of the time that we may need to fully adapt to such changes, all of which could adversely affect us. For details, see "Risk Factors - Uncertainties with respect to the interpretation and enforcement of PRC laws, rules and regulations could materially and adversely affect us.";

● The PRC government has significant authority in regulating our operations and may influence or intervene in our operations at any time. We operate through our subsidiaries in mainland China, Hong Kong, the British Virgin Islands and the United States. Actions by the PRC government to exert more control over offerings conducted overseas by, and foreign investment in, China-based issuers could result in a material change in our operations, and significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. For details, see "Risk Factors - The PRC government may intervene or exert influence on our operations at any time, which could result in a material adverse change in our operations and the value of our ADSs and ordinary shares."

● changes in international trade policies and barriers to trade or the emergence of a trade war;

● potential liabilities under the FCPA, Chinese anti-unfair competition laws and relevant tax laws;

● restrictions on currency exchange;

● potential liability or penalties and limitation on our ability to inject capital into these subsidiaries due to PRC regulations relating to investments in offshore companies by PRC residents; and

● the risks related to the enactment of the Holding Foreign Companies Accountable Act.

**Risks relating to the ADSs**

● our broad discretion to determine how to use the remaining net proceeds from our financing;

● the ability by our executive co-chairman and directors to control and exert significance influence over our company;

● provisions in our fourth amended and restated articles of association (as revised) limiting your ability to influence corporate matters;

● our reliance on exemptions from certain corporate governance requirements due to our "controlled company" status; and

● an increased risk of securities class action litigation.

In addition, our corporate structure and being based in and having the majority of our operations in China pose following significant regulatory, liquidity and enforcement risks to investors, which are described in further details in the "Risk Factors" section of this annual report, including risks that any actions by the Chinese government to exert more oversight and control over securities that are listed overseas or foreign investment in China-based issuers could significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of our securities to significantly decline or be worthless. See "Risk Factors".

[**Table of Contents**](#TableOfContents)

**Risks relating to our business and our industry**

**Any future occurrence of force majeure events, natural disasters or outbreaks of contagious diseases in the PRC could prevent us from effectively serving our customers and thus adversely affect our results of operations.**

Any occurrence of force majeure events, natural disasters or outbreaks of epidemics, including those caused by avian influenza or swine influenza, may restrict business activities in the areas affected and materially and adversely affect our business and results of operations. Since early 2013, there have been outbreaks of highly pathogenic avian flu, caused by the H7N9 virus, in certain parts of China; and in early 2009, there were reports of outbreaks of a highly pathogenic swine flu, caused by the H1N1 virus, in certain regions of Asia and Europe; in 2020, there was an outbreak of COVID-19 spreading in the PRC and globally.

Moreover, the PRC has experienced natural disasters like earthquakes, floods and droughts in the past few years. Any future occurrence of several natural disasters in the PRC may materially and adversely affect its economy and therefore our business. An outbreak of contagious diseases, and other adverse public health developments in China, would have a material adverse effect on our business operations. These could include restrictions on our ability to provide services to our customers, as well as cause temporary closure of our treatment centers. Such closures or service restrictions would severely disrupt our operations and adversely affect our financial condition and results of operations. We have not adopted any written preventive measures or contingency plans to combat any future occurrence of force majeure events, natural disasters or outbreaks of contagious diseases.

**If we fail to obtain sufficient funding for our expansion plans, our business and growth prospects may be adversely affected.**

Our operations consumes substantial amounts of cash. For discussion of liquidity and capital resources, see "Item 5. Operating and Financial Review and Prospects—5.B. Liquidity and Capital Resources." However, we have considered our cash flow from future operations and available borrowing facilities to conclude that we have sufficient financial resources to meet its financial obligations as and when they fall due in the coming 12 months. Given our current credit status and the current availability of capital, we believe that we will not encounter any major difficulties in obtaining additional borrowings. We may, however, require additional cash resources to finance our continued growth or other future developments, including any marketing initiatives or investments we may decide to pursue. The amount and timing of such additional financing needs will vary depending on the timing of our new treatment centers openings, investments in established and acquired treatment centers and the amount of cash flow from our operations. If our resources are insufficient to satisfy our cash requirements, we may seek additional financing. To the extent that we raise additional financing by selling additional equity, our shareholders may experience dilution. To the extent we engage in debt financing, the incurrence of indebtedness would result in increased debt service obligations and could result in operating and financing covenants that may, among other things, restrict our operations or our ability to pay dividends. Servicing such debt obligations could also be burdensome to our operations. If we fail to service the debt obligations or are unable to comply with such debt covenants, we could be in default under the relevant debt obligations and our liquidity and financial conditions may be materially and adversely affected.

Our ability to obtain additional capital on acceptable terms is subject to a variety of uncertainties, some of which are beyond our control, including general economic and capital market conditions, credit availability from banks or other lenders, the consents of our prior creditors, receipt of necessary PRC government approvals, investors' confidence in us, the performance of the aesthetic medical treatment industry in general, and our operating and financial performance in particular. We cannot assure you that future financing will be available in amounts or on terms acceptable to us, if at all. In the event that financing is not available or is not available on terms acceptable to us, our business, results of operations and growth prospects may be adversely affected.

[**Table of Contents**](#TableOfContents)

**We have not entered into any long-term supply agreements with our suppliers. A decrease in supply, or an increase in the cost, or quality supplies may adversely affect our business, financial condition and results of operations.**

For the years ended December 31, 2023, 2024 and 2025, our cost of inventories and consumables amounted to RMB204.9 million, RMB234.5 million, and RMB215.7 million (US$30.8 million), respectively, representing 56.8%, 56.1% and 55.5% of our total cost of sales and services rendered for the same periods, respectively. Consistent with industry practice, we have not entered into any long-term supply agreements with our suppliers and we cannot assure you that our suppliers will continue to supply to us on commercially reasonable terms, or at all. If any of our suppliers fail to supply sufficient quantities or experience fluctuations in market prices of the same, we may have to obtain replacements for such supplies from alternate suppliers. We cannot assure you that we will be able to do so in a timely manner at commercially reasonable terms. Any such disruption in supply may adversely affect the operations of our treatment centers, which may in turn adversely affect our business, results of operations, financial condition and prospects. In addition, should the prices of supplies increase significantly, we cannot assure you that we would be able to pass on any increase in purchase costs to our customers. Any substantial fluctuation in market prices of the supplies required in our operations may significantly increase our costs, resulting in us reducing, suspending or ceasing provision of certain types of services, thereby reducing our sales and profit.

Although the price of most consumables historically remained flat, we cannot guarantee that a shortage of supply will not arise in the future, or that our suppliers will not increase their prices. In the event that we are not able to source from any supplier on commercially reasonable terms, or at all, our business, financial condition and results of operation will be adversely affected.

In addition, while we strive to maintain stable supply chains, it**'**s important to note that any failure to meet procurement quantities as per potential procurement contracts with our suppliers may result in legal actions and compensation claims.

The U.S. - China trade friction has intensified restrictions on the export of advanced medical technologies and raw materials, some of which are critical to China**'**s med - aesthetic sector; for instance, high - end devices such as laser systems, radiofrequency machines, and ultrasonic tools - widely used in non - surgical procedures like skin resurfacing and anti - aging treatments - rely on U.S. - developed core components, and export controls or tariffs could delay equipment procurement, increase costs, or force substitutions with inferior alternatives, thus compromising service quality and safety, and key ingredients like hyaluronic acid (HA) fillers and botulinum toxin (BTX), though increasingly localized, still depend on U.S. - patented production processes, so trade barriers may disrupt supply chains, leading to inventory shortages and margin erosion.

**We may not be able to maintain proper inventory levels for our operations.**

To ensure adequate inventory supply, we must forecast inventory needs and place orders with our suppliers based on our estimates of future demand for particular products. We may not be able to accurately forecast demand for supplies because of the difficulties of estimating the demand for our services. In 2023, 2024 and 2025, our average inventory turnover days were 38.7 days, 23.7 days and 28.1 days, respectively. The volatile economic environment and fast-evolving demands and preferences of our customers have made accurate projection of inventory levels increasingly challenging.

Inventory levels in excess of customer demand may result in inventory obsolescence, a decline in inventory values, inventory write-downs or write-offs, or expiration of products, which would cause our gross margin to suffer and could impair the strength of our brand. High inventory levels may also require us to commit substantial capital resources, preventing us from using them for other important business purposes. Conversely, if we underestimate customer demand or if our suppliers fail to provide supplies to us in a timely manner, we may experience inventory shortages. Such inventory shortages might result in unfilled customer needs, damage to our reputation, and have a negative impact on customer relationships and reduce our sales. We cannot assure you that we will be able to maintain proper inventory levels for our operations and such failure may have an adverse effect on our business, financial condition, results of operations and prospects.

[**Table of Contents**](#TableOfContents)

**We depend significantly on the strength of our brand and reputation, and any damage to our brand or reputation could materially and adversely impact our business and results of operations.**

Our brand and reputation are critical to our success in China's rapidly growing aesthetic medical industry. We believe that our success and continued growth depends on the public perception of our brand name and our ability to protect and promote our brand name. Many factors which are important to help maintain and enhance our brand, are beyond our control and may negatively impact our brand and reputation. Such factors include:

● our ability to effectively control the quality of the services performed by our doctors and other medical staff, and to monitor the performance of such personnel as we continue to expand;

● our ability to maintain a convenient, standardized and reliable customer experience as customer preferences evolve and as we expand our service offerings; and

● our ability to increase brand awareness among existing and potential customers through various means of marketing and promotional activities.

Our failure to develop, maintain and enhance our brand and reputation may materially and adversely affect the level of market recognition of, and trust in, our services, which could result in decreased sales and loss of customers leading to a material adverse effect on our results of operations and cash flows.

In addition, allegations against us have appeared in online forums and news articles. These allegations have included claims of medical malpractice, dissatisfaction with treatment results, inappropriate sales tactics, arbitrary treatment service prices and the use of illegal pharmaceuticals. Any negative review, comment or allegation regarding our company, treatment centers or services by the media, our customers, our former employees or the public in the media or on online social networks may harm our brand, public image and reputation, which in turn may result in a loss of customers and business partners and have a material adverse effect on our business, financial condition, results of operations and prospects.

Furthermore, our customers may have expectations regarding the degree of improvement of their physical appearance resulting from our services. However, we cannot guarantee the results of our services since results vary depending on factors such as the medical history of our customers, their adherence to our pre-procedure and post-procedure instructions, their respective responses to procedures, unknown allergies and other factors beyond our control. It is also an inherent risk that the results of our services may lead to undesirable or unexpected outcomes, such as complications and injuries, or otherwise fail to meet our customers' expectations. Such undesirable or unexpected outcomes may result in customer dissatisfaction, requests for refunds, or complaints, claims or legal actions against us, which may lead to negative publicity. Any negative publicity may adversely harm our brand image and reputation and cause a deterioration in the level of market recognition of and trust in our services, thereby resulting in decreased sales and potential loss of customers and business partners as well as physicians and staff, and therefore have a material adverse effect on our business, results of operations, financial condition and prospects.

[**Table of Contents**](#TableOfContents)

**We conduct our business in a heavily regulated industry and incur ongoing compliance costs as well as face penalties for non-compliance.**

We conduct our business in a heavily regulated industry. The rules and regulations applicable to our business relate mainly to the licensing and supervision of treatment centers, the quality and licensing of medical facilities, equipment and services, the pricing, procurement and usage of pharmaceuticals and medical devices, the qualifications and practice of medical professionals, the protection of patient privacy and medical records, and the advertising, publicity and marketing of medical services. Our treatment centers are subject to periodic inspections, examinations, renewals, record-filing and other supervision by various government agencies and departments at the national, provincial and municipal levels. Any changes in laws, regulations, regulatory guidance, enforcement priorities or local implementation standards could require us to obtain additional licenses, permits, approvals, filings or certificates, impose additional conditions or requirements for the renewal or maintenance of existing licenses, or result in restrictions on, or invalidation of, licenses or permits that we currently hold.

In recent years, and further in 2025 and 2026, PRC regulators have continued to strengthen supervision over the aesthetic medical industry. Such developments include, among other things, clarification that so-called "light medical aesthetics" constitute medical activities and must be carried out in qualified medical institutions by qualified medical personnel, continued nationwide rectification and enforcement focused on medical quality and safety, stricter requirements concerning the use and protection of electronic medical record information and patient privacy, and heightened scrutiny over online publicity, livestreaming, "self-media" activities and other internet-based dissemination of medical-related content. In addition, effective January 1, 2026, for-profit aesthetic medical institutions are no longer included within the scope of "medical institutions" eligible for the VAT exemption applicable to medical services under PRC VAT rules, which may cause some or all of our aesthetic medical service revenue to become subject to VAT and increase our tax burden, pricing pressure and compliance costs. Regulatory focus has also continued to extend to the procurement and use of pharmaceuticals, medical devices and consumables, the scope of practice of medical personnel, the management of treatment items, the use of patient images and case materials, and the transparency of prices, fees, complaint channels and prior notice to patients.

In response to evolving regulatory requirements, we have taken measures to enhance our internal control and risk management systems. However, as a result of the growth in our operations, the number of treatment centers we manage, the complexity of the regulatory framework applicable to aesthetic medical services, and differences in local enforcement standards and interpretations, we have experienced, and may continue to experience, non-compliance incidents from time to time. The aesthetic medical services industry in China is subject to extensive and sometimes ambiguous regulations. As a result, industry participants, including us, face the risk of being found non-compliant with various legal and regulatory requirements. Such non-compliance could subject a service provider to administrative warnings and penalties, and in some cases temporary suspension. Examples of potential compliance risks in the industry include, but are not limited to, violations relating to: medical advertisements, malpractice, operation beyond the permitted scope of licenses or without required licenses, use of unqualified medical facilities, devices, pharmaceuticals or consumables, use of expired disinfectant, non-compliance with disposal requirements for medical waste, failure to evaluate occupational hazards, non-compliance with statistics regulations, non-compliance with fire protection regulations, failure to timely file required annual reports, failure to meet hygiene standards, failure to satisfy inspection requirements applicable to licensing or medical facilities, non-compliance with tax regulations, failure to meet standards relating to drafting and preservation of medical case records, non-compliance with regulations on prevention and handling of medical disputes, and non-compliance with requirements on public disclosure of service items, prices, fees or complaint channels. In addition, if we or our personnel are found to have blurred the boundary between medical aesthetics and life beauty services, used non-qualified personnel in regulated treatment activities, failed to satisfy requirements applicable to patient privacy, medical records, pricing transparency, treatment disclosure, medical quality and safety, or failed to comply with new or evolving local requirements regarding medical services, our treatment centers may be subject to inspections, rectification orders, warnings, fines, confiscation of illegal income, point deductions, suspension of operations, revocation or non-renewal of licenses or permits, civil claims, reputational harm, or, in serious cases, criminal liability.

We cannot assure you that our internal controls, compliance systems and remedial measures will be sufficient to prevent all future non-compliance incidents or to avoid all regulatory actions. Any material non-compliance, or any increase in the frequency or intensity of inspections and enforcement actions, could materially and adversely affect our business, financial condition, results of operations and prospects.

[**Table of Contents**](#TableOfContents)

**If we fail to comply with requirements relating to pricing transparency, prior notice to patients, disclosure of fees and complaint channels, we may face administrative penalties, consumer disputes and reputational harm.**

PRC laws, regulations and local implementation rules increasingly require medical institutions, including aesthetic medical institutions, to publicly disclose service items, prices, fees, charging standards and complaint channels, and to provide patients with clear prior notice of treatment items, pricing and other relevant information. These requirements may vary by locality and may continue to evolve. In particular, local rules and pricing notices applicable to aesthetic medical services may impose more specific requirements on the way treatment items, price components, fee descriptions and complaint channels are displayed or communicated to patients.

**If we fail to maintain adequate compliance with such requirements in any locality where we operate, or if our treatment centers are found to have inadequate disclosure, insufficient prior notice, misleading fee descriptions, or deficiencies in complaint-handling arrangements, we may be subject to warnings, rectification orders, fines, increased customer complaints, refund claims, consumer disputes and reputational harm. Any such events could materially and adversely affect our business, financial condition, results of operations and prospects. If we are unable to fully comply with PRC laws and regulations on medical advertisement, our brand image, results of operations and financial conditions could suffer significantly.**

As a medical aesthetic service provider, we must comply with the PRC Advertisement Law, the Administrative Measures on Medical Advertisement, the Administrative Measures for Internet Advertisement and other laws, regulations, regulatory guidance and enforcement requirements relating to medical advertisements, internet advertisements, online publicity and health science popularization. Medical advertisements generally may only be published by lawfully established medical institutions after obtaining the required medical advertisement review or approval documentation, and the content actually published must be consistent with the approved content. Medical advertisements and related publicity materials are subject to restrictions on treatment guarantees, efficacy or safety guarantees, absolute terms, false or misleading statements, improper comparisons, endorsements, use of patient names or images, and other prohibited content. In addition, PRC regulators have, in 2025, further clarified the distinction between lawful medical information disclosure or health science popularization and medical advertising or disguised medical advertising, and further strengthened supervision over short videos, livestreaming, "self-media" accounts, case-based promotion, traffic diversion and other online channels through which medical-related content is disseminated.

The regulatory framework applicable to medical beauty advertising and related publicity has become increasingly detailed and enforcement-focused. PRC regulators have in 2025 further clarified the enforcement principles applicable to medical advertising cases, including circumstances that may warrant no penalty, lighter or mitigated penalties, or heavier penalties, and have expressly addressed medical beauty advertisements that create appearance anxiety, target minors, contain absolute terms or otherwise violate advertising rules. PRC regulators have also clarified that certain factual disclosures by lawfully established medical institutions may, depending on the circumstances, fall outside the scope of medical advertising, while subjective promotion of medical institutions, treatment effects, equipment, treatment procedures, case-based promotion, and the addition of links or traffic-diversion entrances relating to specific medical services, drugs or medical devices may constitute medical advertising or disguised medical advertising. Internet platform operators may also bear increasing compliance responsibilities in relation to unlawful medical advertising.

In addition, on August 1, 2025, PRC regulators further strengthened the regulation of medical-related "self-media" content by requiring stricter credential verification, clearer display of credential information and stronger regulation of short-video, livestream and similar online channels, and by prohibiting uncertified accounts from producing professional medical science popularization content and prohibiting the use of health science popularization as disguised advertising or for improper traffic diversion. As a result, our own marketing activities, as well as activities conducted by our employees, medical personnel, KOLs, influencers, agents, marketing service providers or other third parties on our behalf, may be subject to heightened scrutiny.

In the past, some of our treatment centers have received administrative penalties for non-compliance with medical advertisement laws and regulations, including for publishing medical advertisements without having obtained relevant approval certificates, failing to strictly follow the approved scope and manner of publication, failing to display the relevant approval number, and publishing medical advertisements containing untrue, misleading or otherwise prohibited expressions. In recent years, and especially in 2025, the scope of potential non-compliance has expanded beyond traditional offline or static advertisements to include internet-based publicity, short videos, livestreams, "self-media" content, health science popularization used as disguised advertising, traffic diversion to specific medical services, improper use of patient-related materials, and other online promotional conduct.

If we, our employees, our medical personnel, or third parties acting for or on behalf of us are found to have violated applicable laws, regulations or regulatory guidance relating to medical advertisements or disguised medical advertising, we may be subject to warnings, rectification orders, fines, suspension of publication, takedown orders, withdrawal of advertisements, point deductions, suspension of business, revocation of the license for operating a particular medical department, revocation or non-renewal of the Medical Institution Practicing License, platform sanctions, account restrictions, traffic restrictions, customer claims, reputational harm and other adverse consequences. Any such violations, particularly if material, repeated or not timely rectified, could materially and adversely affect our business, financial condition, results of operations and prospects.

[**Table of Contents**](#TableOfContents)

**Our internal control system and compliance team may not be able to prevent all possible non-compliance incidents.**

We are subject to a number of regulations pertaining to the licensing of our treatment centers, the quality and the licensing of medical facilities, equipment and services, the pricing and procurement and usage of pharmaceuticals, and the licensing, conduct and number of medical professionals. We have established internal control process intended to ensure all of our employees and contractors comply with the relevant laws and regulations applicable to us. However, we cannot assure you that such controls will be effective to prevent all instances of non-compliance. Any failure of our internal controls could have a material adverse effect on our business, financial condition and results of operations.

**We are subject to customer complaints, claims and legal proceedings in the regular course of our operations from time to time, which could result in significant costs and materially and adversely affect our brand image, reputation and results of operations.**

We rely on our doctors and other medical staff in our treatment centers to make appropriate decisions regarding the treatment of our customers. However, we cannot assure you that every employee at our treatment centers will always act in accordance with the appropriate professional standard of care. Any deviation from the appropriate standard of care by our doctors and other medical staff, or any failure to properly manage our treatment centers' activities, may result in unsatisfactory treatment outcomes, patient injuries or, in extreme cases, deaths. Given the nature of the aesthetic medical industry and subjectiveness of the level of satisfaction with services provided, we are also susceptible to other types of complaints associated with our services from time to time. These include claims relating to (i) dissatisfaction with our customer service, (ii) disputes over charges, (iii) over-promising of treatment outcome, (iv) dissatisfaction with post-treatment recovery periods, and (v) general dissatisfaction with treatment results. In addition, due to the fact that the number of procedures we performed has increased over the years as part of our growth, the absolute number of such complaints, allegations and other claims, regardless of merits, has increased and may continue to increase. Such complains, allegations and claims, if not managed properly, could have a material adverse effect on our reputation, business, results of operations, financial condition and prospects.

With respect to settlement of client complaints, customers generally accept complimentary gifts, refunds, services or supplemental operations at no additional cost to settle their complaints. However, we have been and will still may be, required to pay monetary compensation to settle customer complaints and medical disputes. In addition, we may be subject to third-party liability claims and may be required to pay compensation to patients who suffer from unexpected adverse reactions to treatment received in our treatment centers, even if we were not at fault. As of the date of this annual report, we were named as the defendant in 21 ongoing litigations for our consolidated businesses in the PRC. While we believe many of the claims against us do not have merits, and plan to firmly defend our rights, we cannot assure that we will be able to achieve satisfactory outcome in those proceedings. The maximum amount of the damages claimed by the plaintiffs in those 21 proceedings in aggregate amounted to RMB45.0 million, not including their reasonable interest expenses. Furthermore, some dissatisfied customers may even resort to extreme actions.

We may be subject to similar customer complaints, serious incidents or lawsuits in the future and may not successfully prevent or address all customer complaints in the future. Any complaint, claim or legal proceeding, regardless of merit, if widely disseminated, could affect our corporate image and reputation in the industry, divert management resources and cause us to incur extra costs to handle these complaints and litigation matters. A settlement or successful claim against us can also result in significant costs, damages, compensation and reputational damage and adversely affect our business, results of operations and financial condition.

**If we are unable to recruit and retain an adequate number of managers, doctors, nurses, image consultants and other support staff in our treatment centers, our service quality and business strategy may suffer**

Our performance is largely dependent on the talent and efforts of highly skilled medical professionals. Our future success will in part depend on our ability to identify, hire and retain highly qualified medical professionals of all areas of our treatment centers. The recruitment of qualified physicians is competitive in the PRC due to their shortage. The near-term supply of specialist physicians is limited due to the length of training required, including academic study and clinical training, which can take more than eight years for certain medical specialties, as well as additional certification and licensing requirements for certain specialties. Competition for such qualified professionals is intense. We believe that physicians generally consider the following key factors when selecting medical institutions to join: reputation and culture, the efficiency of hospital management, the quality of facilities and support staff, the number of patient visits, compensation, training programs and location. Our treatment centers may not effectively compete with other aesthetic medical treatment centers or clinics in hiring qualified professionals. For our principal treatment centers, as of December 31, 2025, certain of our physicians were engaged in multi-site practice arrangements, and management confirmed that there were no material abnormalities relating to physician registration, multi-site practice registration or filing, pending registration changes, or other similar matters at such treatment centers. However, if PRC regulatory requirements relating to physician registration, multi-site practice or staffing become more stringent, or if we are unable to maintain stable and compliant physician resources across our treatment centers, we may not be able to recruit or retain sufficient seasoned and qualified physicians, and our business, financial condition and results of operations may be adversely affected.

Our success is also dependent on our ability to recruit and retain qualified medical institution administrators and medical professionals. It has become increasingly costly to recruit and retain medical professionals in recent years and there is no guarantee that we will be able to recruit and retain sufficient medical professionals in the future. If we do not succeed in attracting an appropriate number of qualified treatment center managers, nurses, image consultants or other support staff, our service quality and our ability to execute our business strategy may suffer. A shortage of skilled professionals could also require us to pay higher wages, which would reduce our profits and have a material and adverse effect on our operating results and financial performance.

[**Table of Contents**](#TableOfContents)

**If our physicians and other medical professionals do not obtain and maintain appropriate licenses, we may be subject to penalties against our treatment center, which could adversely affect our business.**

Medical practice in China is strictly regulated. Physicians, nurses and medical technicians who practice at medical institutions must hold practicing licenses and may only practice within the scope of their licenses and at the specific medical institutions at which their licenses are registered. Please see "Item 4. Information on the Company—4.B. Business Overview—Regulation" for more details. In addition, where physicians engage in multi-site practice or where registrations, filings or changes to practice locations or scopes are required, such arrangements remain subject to applicable PRC laws, regulations and administrative procedures. In practice, it takes some time for physicians, nurses and medical technicians to transfer their licenses from one medical institution to another or add any further service scope or another medical institution to their permitted practicing institutions. From time to time, some of our physicians, nurses and other medical professionals could be required to make such amendments to their licenses due to changes to the location or nature of their work. As of December 31, 2025, there were no material abnormalities relating to physician or other medical professional registration, multi-site practice registration or filing, pending registration changes, or other similar matters. However, we cannot assure you that such registrations, filings or amendments will always be completed in a timely manner in the future, or that our physicians, nurses and other medical professionals will at all times strictly comply with all applicable requirements or refrain from practicing outside the permitted scope of their respective licenses or registrations. Our failure to properly manage the employment, registration, filing and practice arrangements of our physicians, nurses and other medical professionals may subject us to administrative penalties against our treatment centers, which could adversely affect our business.

**We may fail to maintain the quality of the pharmaceuticals, medical equipment, medical supplies, injection materials, skincare products, implants and consumables we use. If these products do not meet the required standards, we could be exposed to liabilities and our business operations and reputation could suffer.**

Although we have adopted a series of measures for selecting suppliers, such as maintaining and updating a list of qualified suppliers, we cannot guarantee that all of the pharmaceuticals, medical equipment, medical supplies, injection materials, skincare products, implants and consumables we use are free of defects or substantially meet the relevant quality standards. We were involved in a lawsuit related to one of our patients who suffered severe complications after receiving a Botox injection at one of our treatment centers. Although the court found that all liability rested with the manufacturer, we cannot assure you that similar incidents will not occur in the future, or that such incidents will not materially and adversely affect us. Moreover, we launched new skincare products called The Four Beauty in January 2020, which are manufactured by a third party and sold in our treatment centers. We also launched 6 new non-surgical aesthetic medical treatment solutions with the support of new products and equipments in 2022. We introduced well-known equipment such as the Peninsula Golden MicroUltra, Peninsula Gold Microneedle V and purchased more advanced imported equipments including Thermage FLX and Lumenis M22 in 2023. In 2024, we bought more units of the equipment introduced in 2023 and added Jinbo's WYE-MOR Zhizhen Collagen Needle to enrich our premium product lineup. If the products provided by our suppliers are defective, of poor quality, or cause any adverse drug reaction, we could be subject to liability claims, complaints or related adverse publicity that could result in the imposition of penalties or even suspension of licenses by relevant authorities or compensation awarded by courts against us. We may also need to find suitable replacement products, which may lower our profit margins and result in delays in services to our customers.

[**Table of Contents**](#TableOfContents)

Our suppliers are also subject to extensive laws and regulations. If our suppliers violate applicable laws and regulations, our reputation or procurement may be materially and adversely affected. PRC laws and regulations require us to procure materials from qualified suppliers, with requisite licenses, permits or filings to operate their business. We cannot ensure that all of our suppliers maintain all the licenses required or the validity of their licenses at all times. We have been fined with insignificant amounts by regulators in the past for failure to maintain proper records of our suppliers' qualification expiration dates. It is possible we may in the future fail to comply with this requirement if, for example, our suppliers lose appropriate qualifications without our knowledge, which could result in penalties and fines. See "Item 4. Information on the Company—4.B. Business Overview—Regulation." In addition, we may be exposed to reputational damage or even liabilities for defective goods provided by our suppliers or negative publicity associated with our suppliers, and our results of operations could suffer as a result. To the best of our knowledge, as of December 31, 2025, no major supplier had been subject to any material penalty, and we had not encountered any material litigation or other material non-compliance issue relating to our suppliers or manufacturers that had materially affected our procurement or business operations.

**Our business, financial condition, results of operations and prospects may be adversely affected by an unfavorable market perception of the overall aesthetic medical industry.**

Aesthetic medical services have been gaining popularity in recent years. However, many consumers remain cautious about the risks inherent in aesthetic medical procedures. Media influences, peer perceptions, research indicating adverse health effects of aesthetic medical procedures or otherwise could lead to deterioration in the market perception of aesthetic medical treatments and to less demand for aesthetic medical services. In addition, if any allegation surfaces in the media or in social media forums of any accident, ineffectiveness of treatment, poor service standards or mishandling of sensitive personal information by any operator of aesthetic medical services, regardless of merit, the entire aesthetic medical industry and any industry participant including us could experience reputational harm. Our business, financial condition, results of operations and prospects may be materially and adversely affected as a result.

**We face intense competition, and if we do not compete successfully against new or existing competitors, we may lose our market share and our profitability may be adversely affected.**

We compete with private aesthetic hospitals and clinics and aesthetic medical departments in public general hospitals located in the same geographic areas as our treatment centers. We will also compete with future market entrants as the rapid growth of the aesthetic medical industry in the PRC may attract more domestic or international players to enter. Some of our existing and potential competitors may have competitive advantages, such as significantly greater financial, marketing or other resources and may be able to mimic and adopt our business model. We compete for customers primarily on the basis of location, price, the range and the quality of services that we offer and our brand name. We cannot assure you that we will be able to successfully compete against new or existing competitors. Any inability to successfully compete with new or existing competitors may prevent us from increasing or sustaining our revenue and profitability level and result in a loss of market share.

**If we are unable to adapt to changing aesthetic medical trends and our customers' changing needs, we will not be able to compete effectively, which may materially and adversely affect our business, financial condition and results of operations.**

The aesthetic medical market requires us to closely monitor the trends in the market and the needs of our customers, which may require us to introduce new products, technologies, devices, solutions, service categories and treatment procedures and enhance our existing services and procedures. We must maintain strong relationships with leading aesthetic medical institutions or consulting companies to ensure that we are accessing the latest technology and quickly and cost-effectively responding to our customers' changing needs. We may be required to incur development and acquisition costs to keep pace with new technologies, implement technological innovations or to replace obsolete technologies. If we fail to identify, develop and introduce new products, solutions, service categories, features, enhancements and technologies on a timely and cost-effective basis, demand for our services may decrease and we may not be able to compete effectively or attract customers, which may materially and adversely affect our business and results of operations.

**Our revenue is particularly sensitive to changes in economic conditions.**

Demand for our aesthetic medical services and the resulting spending by our customers are particularly sensitive to changes in general economic conditions and our customers' disposable incomes. We cannot assure you that the local economy in the places where we operate can sustain stable growth in consumer spending. In response to an actual or perceived economic downturn, people may reduce their spending on aesthetic medical services, which may materially and adversely affect our ability to generate revenue from these services, and our financial condition and results of operations.

**If we are unable to manage our growth effectively, we may not be able to capitalize on new business opportunities and our business and financial results may be materially and adversely affected.**

We have significantly expanded our business before 2021, but in 2021 the Company decided to strategically shift its development strategy from rapid national expansion to a more focused, stable and sustainable growth. In 2023, we entered into several equity transfer agreements with independent third parties regarding the sale of certain subsidiaries and entities. The subsidiaries include Shenzhen Miaoyan Medical Technology Investment Co., Ltd., Ningbo Beilun Pengai Aesthetic Medical Clinic Co., Ltd., and Stargaze Wealth Limited. The entities in which we held less than a 50% stake include Shenzhen Pengai Jiayan Aesthetic Medical Clinic, Shenzhen Huayan Yuese Health Management Consulting Co., Ltd., and Shenzhen Xuri Jiayan Aesthetic Technology Co., Ltd. In 2024, we deregistered several subsidiaries that were not in operations, including Hangzhou Pengai E-commerce Co., Ltd. in March 2024, Shengli Aesthetic Technology Investment (Hong Kong) Company Limited in April 2024, Yantai Guangcheng Health Technology Co., Ltd. in June 2024 and Shanghai Pengai Medical Technology Co., Ltd. in June 2024. Additionally, Newa Medical Aesthetic Limited was deregistered in February 2025. As of December 31, 2025, out of our existing network of nine treatment centers, we have established six treatment centers and acquired three treatment centers. Our organization may become larger and more complex with the addition of treatment centers in the future. Our expansion may require a significant amount of time from our management and substantial operational, financial and other resources.

[**Table of Contents**](#TableOfContents)

To manage our growth and expansion, and to attain and maintain profitability, we will continue to place significant demands on our management and on our administrative, operational and financial personnel and infrastructure. Our success also depends on our ability to recruit, train and retain additional qualified management personnel and professionals as well as other administrative, sales and marketing personnel. To accommodate our growth, we need to continue managing our relationships with our suppliers and customers. All of these endeavors will require substantial management attention and effort and significant additional expenditure. We cannot assure you that we will be able to manage any future growth effectively and efficiently, and any failure to do so may materially and adversely affect our ability to capitalize on new business opportunities, which in turn may have a material adverse effect on our business and financial results.

**We may have operations outside of China and may intend to expand our international operations, which exposes us to significant risks.**

We currently have operations throughout mainland China. Our business strategy may include further expanding our operations into new markets outside of mainland China. Our company may become larger and more complex with our intended plans to expand into new geographic areas, through a combination of acquisitions and organic growth. The success of our business therefore may depend, in large part, on our ability to operate successfully from geographically disparate locations and to further expand our international operations and sales. Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic and political risks that are different from those that we face in China. We cannot assure you that further international expansion will be successful.

Among the risks we believe are most likely to affect us include:

● lack of control, difficulties, inefficiencies and costs associated with staffing and managing foreign operations;

● potential distraction of management from our China operations;

● greater difficulty collecting accounts receivable and longer payment cycles;

● compliance with local laws and regulations and unexpected changes in regulatory requirements;

● reduced protection for intellectual property rights in some countries;

● the effectiveness of our policies and procedures designed to ensure compliance with similar anti-corruption, anti-money laundering, and sanction laws;

● possible tariffs and trade restrictions;

● foreign taxes;

● fluctuations in currency exchange rates;

● natural disasters, contagious disease outbreaks, travel restrictions, and war or terrorist activities; and

● political and economic instability.

Our failure to manage any of these risks successfully could harm our operations, reduce our revenue, and have other adverse effects on our operating results.

[**Table of Contents**](#TableOfContents)

**Execution of our strategies to grow our business depends on our ability to successfully expand into new geographic areas in a timely, cost-effective and non-disruptive manner.**

Execution of our strategies to grow our business depends partly on our ability to expand into new geographic areas in a timely, cost-effective and non-disruptive manner, through a combination of acquisitions and organic growth. Our ability to successfully expand into new markets depends on many factors including, among others, our ability to:

● identify suitable geographic markets for the type of services we offer;

● identify local consumer preferences;

● address local market competition;

● negotiate acceptable lease terms, including desirable tenant allowances;

● hire, train and retain a growing workforce of doctors and other personnel;

● successfully integrate new treatment centers into our existing control structure and operations, including our information technology systems; and

● secure financing or maintain sufficient capital to invest in new treatment centers or making acquisitions.

If we fail to expand into new markets in a timely and cost-effective manner, whether through organic growth or through acquisitions, our overall business growth strategy and prospects could be materially and adversely affected.

**We may be unable to identify or execute acquisition opportunities, businesses we acquire may have unknown or contingent liabilities, and we may not realize the benefits we anticipate from such acquisitions, which may materially and adversely affect our business, financial condition, results of operations and prospects.**

Our success depends on our ability to continually enhance and broaden our service offerings in response to changing customer demands, competitive pressures and innovation. We may consider opportunities to partner with or acquire other businesses, products or technologies that may enhance our services platform or technology, expand the breadth of our operations or customer base or advance our business strategies. We may not be able to identify suitable targets for acquisition, or negotiate commercially acceptable terms for acquisitions. Even if we are able to identify suitable targets, such acquisitions can be difficult, time consuming and costly and we may not be able to secure necessary financing for the acquisitions. Businesses that we acquire may have unknown or contingent liabilities, including liabilities for failure to comply with relevant laws, rules and regulations. In acquiring the treatment centers, we typically require sellers to indemnify us for any claims and liabilities that are in connection with or arise from a time prior to our acquisitions.

However, we could suffer reputational harm for actual or alleged inferior service or harm that occurred at treatment centers prior to our acquisition and need to respond to claims initially as unsatisfied customers will likely pursue their claims against the treatment centers and us. Depending on the circumstances of the sellers, the indemnities we receive from them may not be sufficient or forthcoming, due to bankruptcy or disappearance of sellers or otherwise. Historically, certain entities we acquired failed to comply with certain regulations and the sellers did not provide sufficient indemnities. As a result, we may be liable for historical defects. Even if we have received indemnities, our reputation may be harmed because of the sellers' historical defects. We maintain contact with the sellers of the treatment centers we acquired post acquisitions. The seller of our acquired treatment center, Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic, remains as minority shareholders of these subsidiaries. Moreover, any financial mitigation we receive from sellers of these treatment centers may not mitigate against any reputational harm we may suffer as a result of these claims. In addition, future acquisitions and subsequent integration of newly acquired assets and businesses into our own could be expensive and time-consuming, require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our business operations. Acquired assets or businesses may not generate the financial results we expect. If we are not able to identify, capture or execute opportunities to expand our operations successfully through acquisitions, or suffer reputational or financial harm caused by unknown or contingent liabilities of the treatment centers we acquire, our business, financial condition, results of operations and prospects could be materially and adversely affected.

[**Table of Contents**](#TableOfContents)

**Newly opened and acquired treatment centers may not achieve operating results as anticipated, which could materially and adversely affect our results of operations.**

**We are dependent on certain key members of our senior management and other key employees, and our business, financial condition, results of operations and prospects will suffer greatly if we lose their services.**

We are dependent on certain key members of our senior management team, some of whom have been with us since our inception, to manage our current operations and meet future business challenges. In particular, we rely on the expertise, experience and leadership of Mr. Zhang Chen, our executive co-chairman.

We do not maintain key personnel insurance. Competition for competent candidates in the industry is intense and the pool of competent candidates is limited. The loss of any key members of our senior management team could materially disrupt our operations and delay the implementation of our business strategies. In addition, we may not be able to locate suitable or qualified replacements, and may incur additional expenses to recruit and train new personnel, which could severely limit our business and growth. In addition, if any member of our senior management team or key employees joins a competitor or forms a competing business, we may lose know-how, trade secrets, customers and key professionals and staff. We have entered into employment agreements, confidentiality and non-compete agreements with all of the key members of our management team. We cannot assure you, however, the extent to which any of these agreements will be enforceable under the applicable laws. For more details, see "—Risks relating to doing business in the PRC—Uncertainties with respect to interpretation and enforcement of PRC laws, rules and regulations could materially and adversely affect us." If, as a result of similar incidents, or events, we may lose the services of key members of our senior management, which could have a material adverse effect on our business, financial condition and results of operations.

[**Table of Contents**](#TableOfContents)

**We may not be able to adequately protect our intellectual property rights, which could harm our brand and our business.**

We believe our trademarks and other intellectual property rights are crucial to our success. Our principal intellectual property rights include our trademarks for the "Pengai" brand. Although we rely on the registration of trademarks and applicable laws to protect our intellectual property rights, these measures may not be sufficient to prevent misappropriation of our intellectual property rights. There is no assurance that third parties will not infringe on our intellectual property rights. Our efforts to enforce or defend our intellectual property rights may not be adequate, may require significant attention from our management and may be costly. We may have to initiate legal proceedings to defend the ownership of our trademarks or brand against any infringement by third parties, which may be costly and time-consuming, and we might be required to devote substantial management time and resources in an attempt to achieve a favorable outcome. Furthermore, the outcome of any legal actions to protect our intellectual property rights may be uncertain. If we are unable to adequately protect or safeguard our intellectual property rights, our business, financial condition, results of operations and prospects may be adversely affected.

In addition, as permitted by the PRC laws, other parties may register trademarks which may look similar to our registered trademarks under certain circumstances, which may cause confusion among consumers. We may not be able to prevent other parties from using trademarks that are similar to ours and our consumers may confuse our treatment centers with others using similar trademarks. In such case, the goodwill and value of our trademarks and the public perception of our brand and our image may be adversely affected. A negative perception of our brand and image could have a material and adverse effect on our sales, and therefore on our business, financial condition, results of operations and prospects.

**Our business is subject to seasonality.**

Our operating results are exposed to seasonal fluctuations in demand for our services. We usually experience relatively higher customer visits in the second half of each financial year, which is mainly because we experience a higher number of customer visits for the period from October to December, primarily due to the Chinese National Day holiday, Christmas, and in anticipation of the subsequent New Year and Chinese New Year holidays. As such, our revenue is usually slightly higher in the second half of the year.

**Our historical financial and operating results may not be indicative of future performance, and we may not be able to achieve and sustain the historical level of revenue and profitability.**

Our historical results may not be indicative of future performance. Our financial and operating results may not meet the expectations of public market analysts or investors, which could cause the price of the ADSs to decline. Our revenue, cost, expenses and operating results may vary from period to period in response to a variety of factors beyond our control, including general economic conditions, new trends in the aesthetic medical market and our ability to control costs and operating expenses. Our operations largely depend on our ability to retain current customers and attract new ones, encourage more spending by our customers, continue adopting innovative technologies and introducing new services in response to customer demand, increase brand awareness through marketing and promotional activities and take advantage of any growth in the relevant markets. We cannot assure you that we will achieve any of them in the future. We believe that period-to-period comparisons of our operating results in the past may not be indicative of our future performance and you should not rely on them to predict the future performance of our operating results or ADSs.

[**Table of Contents**](#TableOfContents)

**Landlords' lack of required permits, failure to renew leases, failure to fulfill the procedure of leasing or substantial increases in rents may materially and adversely affect our business and financial performance.**

Most real estate for our treatment centers is leased. The availability of commercially attractive locations for our treatment centers is important to our business. Upon the expiry of each of the lease agreements, we have to negotiate terms of renewal with the relevant landlord. As there has been a general increase in rent for commercial properties in the PRC in recent years, and as a majority of our treatment centers are located on premises leased from independent third parties in central urban locations, there is no guarantee that we can renew the leases or negotiate new leases on similar or favorable terms (including, without limitation, on similar tenure and with similar rent) in the future, if at all, or that the leases will not be terminated early by the landlords. In the event that we are required to seek alternative locations for our treatment centers, there is no guarantee that we can secure comparable locations or negotiate leases on comparable terms. In addition, the use of certain of our leased buildings is inconsistent with the permitted use of such buildings or such land and some landlords or lessors did not obtain sufficient approvals, permits and registrations from the governmental authorities and the other third parties. If any challenge from any government authority or a third party arises, our lease agreement may be invalidated and we may also be required to relocate our operations. Furthermore, certain of our lease agreements have not been filed with the PRC authorities, which may subject us to fines if the relevant PRC authority requires us to rectify and we fail to do so within a specified period of time. In addition, certain of our leased properties are subject to mortgage. We may be forced to relocate in the event that the mortgagees are entitled to exercise their rights under the relevant mortgages. If we were forced to relocate, we might not be able to relocate to desirable locations in a timely and cost-effective manner. All these factors may have an adverse impact upon our business operation, financial position and our future potential growth.

**We are not in full compliance with social insurance, housing provident funds and income tax contributions.**

We are required to make social insurance, housing provident funds and income tax contributions for the benefit of employees of our PRC subsidiaries under PRC laws and regulations. Our PRC subsidiaries have not made social insurance, housing provident funds and income tax contributions in full for all of their employees. Companies operating in the PRC are also required to withhold individual income tax on employees' salaries based on the actual salary of each employee upon payment. Our PRC subsidiaries have not fully withheld the individual income tax in accordance with the relevant PRC laws and regulations.

Under the relevant PRC laws and regulations, the relevant PRC authorities may determine that we need to make supplemental social insurance and housing fund contributions and that we are subject to fines, supplementary payment and legal sanctions in relation to our failure to make social insurance and housing fund contributions in full for our employees, in which case our business, financial position or operation may be adversely affected. With respect to the underwithheld individual income tax, we may be required by relevant PRC authorities to make up sufficient withholding and pay late fees and fines. In addition, some of our PRC subsidiaries make social insurance for employees of other PRC subsidiaries, in which case we are subject to fines and adverse record on our credit files. If so, our business, financial position or operation may be adversely affected.

**Our business is subject to professional and other liabilities for which we may not be insured.**

We are exposed to potential liabilities that are inherent to the aesthetic medical and healthcare industries. Our treatment centers have been the subject of such claims in the past. To protect our business from the cost of any such claims, we may purchase product liability insurance that we believe to be appropriate for our operations. However, we may face liabilities that exceed our available insurance coverage or arise from claims outside the scope of our insurance coverage. Our insurance policies are subject to annual renewal, and we may not be able to obtain product liability insurance in the future on acceptable terms or at all. In addition, our insurance premiums could be subject to increases in the future, which may be material. If the coverage limits are inadequate to cover our liabilities or our insurance costs continue to increase as a result of liability claims or other litigation, then our business, financial condition and results of operations may be adversely affected.

**We could be exposed to risks related to our management of customers' medical data.**

Our treatment centers collect, generate, use, store and maintain customers' medical data, treatment records, consultation records, patient images and other information in the ordinary course of our business. A substantial portion of such information may constitute personal information, sensitive personal information, medical records or health-related information under applicable PRC laws and regulations. Medical institutions and their personnel are generally required to protect patient privacy and medical records and are prohibited from unauthorized, unlawful or otherwise non-compliant collection, access, use, transmission, disclosure or other misuse of patient information. We may also use certain customer-related information on an aggregated or de-identified basis for operational analysis, service improvement, customer management, publicity or marketing purposes.

[**Table of Contents**](#TableOfContents)

We are subject to a broad and evolving PRC legal and regulatory framework relating to cybersecurity, data security, personal information protection, electronic medical records, health and medical big data, cross-border data transfer, and confidentiality and archives management in connection with overseas securities offerings and listings. The interpretation and implementation of these laws and regulations continue to evolve and may impose additional compliance obligations, restrictions and costs on our business. In addition to the PRC Cybersecurity Law, the PRC Data Security Law and the PRC Personal Information Protection Law, PRC regulators have in recent years continued to strengthen regulation in this area. For example, on June 30, 2025, the National Health Commission issued the Notice on Further Strengthening the Management of the Use of Electronic Medical Record Information, which requires medical institutions to strengthen internal management over electronic medical record information, implement graded management and access controls, follow the minimum necessary/use principle, prohibit unauthorized or non-compliant collection, transmission or disclosure of patient information, ensure full-process traceability, and strengthen the management of personnel with temporary access and external service providers. In addition, on October 31, 2025, relevant PRC authorities issued the Negative List for Internet Health Science Popularization by Medical Personnel (Trial), which prohibits, among other things, the use of health science popularization to publish unlawful advertisements or conduct improper traffic diversion, livestream selling and other improper profit-making activities, unauthorized disclosure of patient personal information or identifiable patient images, and the dissemination of unverified, false or misleading content.

Because the aesthetic medical industry often relies on before-and-after images, consultation records, treatment records, customer profiling, digital marketing and online or "self-media" communications, we may face heightened regulatory, civil and reputational risks if patient-related materials are used, displayed or disseminated without proper authorization or in a manner deemed inconsistent with applicable law or regulatory guidance. We may also face increased scrutiny with respect to the handling of treatment records, electronic medical records, patient images, health science popularization content, physician-related online communications and other customer-facing or internet-based activities. Even if we do not intend to make customers' medical records publicly available, our practices with respect to data access, internal use, de-identification, publicity, marketing, personnel management and vendor management may nevertheless be challenged by regulators, customers or other third parties.

In addition, to the extent that we provide or make accessible any medical data, treatment records, patient images, personal information or related materials to offshore entities, service providers, professional advisers or regulators, or otherwise engage in activities that may constitute cross-border data transfer or implicate confidentiality and archives management requirements in connection with overseas securities offerings and listings, we may be subject to additional regulatory procedures, filings, assessments, restrictions or liabilities under PRC law. The applicable standards and thresholds in this area may continue to evolve, and we cannot assure you that PRC regulatory authorities would agree with our interpretation of the rules or with the compliance measures we have adopted.

Although we have adopted measures intended to protect customers' medical records and related information, including internal confidentiality rules, information access controls, and system protection measures, such measures may not always be effective. Our information technology systems could be breached through hacking, malware, ransomware, phishing, human error or other security incidents. Patient information, medical records, treatment data or images could also be leaked, improperly accessed, copied, transmitted, disclosed or misused as a result of employee misconduct or negligence, the conduct of medical personnel, contractors, temporary personnel, students, visiting personnel, external service providers, internet publicity activities, or deficiencies in internal controls or vendor management. We may also face heightened compliance burdens and regulatory risks if we are found to have failed to satisfy evolving requirements regarding electronic medical record management, de-identification standards, patient consent, personnel access control, vendor management, data retention, data traceability or cross-border data transfer.

If we fail to protect customers' medical records or other sensitive personal information, or if our collection, storage, access, processing, transmission, use or disclosure of medical data is found to violate applicable laws, regulations or regulatory requirements, we may incur additional compliance costs and liabilities, be subject to government investigations, inspections, rectification orders, warnings, fines, civil claims, litigation, adverse publicity, customer complaints, loss of trust, business disruption and reputational harm. In serious circumstances, we may also be required to suspend or modify certain business practices, marketing activities, data processing activities or information system arrangements. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects.

[**Table of Contents**](#TableOfContents)

**A technological failure, security breach or other disruptions of our computer network infrastructure and centralized information technology systems may interrupt our business.**

Our computer network infrastructure and information technology systems are critical for our operation, such as billing, financial and budgeting data, customer records and inventory. We regularly maintain, upgrade and enhance the capabilities of our information technology systems to meet operational needs. Any failure associated with our information technology systems, including those caused by power disruption or loss, natural disasters, computer viruses or hackers, network failures or other unauthorized tampering, may cause interruptions in our ability to provide services to our clients, keep accurate records, and maintain proper business operations, which may adversely affect our business, financial condition and results of operations.

In addition, a variety of our software systems are hosted by third-party service providers whose security and information technology systems are subject to similar risks. The failure of our or our service providers' information technology could disrupt our entire operation or result in decreased sales, increased overhead costs and product shortages, all of which could have a material adverse effect on our reputation, business, financial condition, results of operations and prospects.

**The significant amount of advertising and marketing expenses spent on enhancing our brand awareness may not be effective and may adversely affect our results of operations.**

We plan to enhance our brand recognition among our existing and target customers along with our expansion into new geographic areas. Our sales and marketing strategies are key to enhancing our brand awareness. In connection with our strategic expansion into new markets, we normally increase advertising of our brand through various advertising media platforms, which requires significant expenses before these newly opened treatment centers reach expected profit levels, thereby affecting our overall profitability. In 2023, 2024 and 2025, our advertising and marketing expenses were RMB164.2 million, RMB162.3 million and RMB157.1 million (US$22.5 million), respectively. We expect the trend of increased advertising and marketing spending to continue as we spend on an increasingly diverse array of online and mobile search engines, marketing and social media platforms. If we do not adequately spend on such platforms, or effectively select or utilize the right platforms, we may not generate the desired result from our advertising spending. Moreover, it may take months or several years to implement our sales and marketing strategies and such time is hard to predict. As a result, we cannot guarantee that our marketing spending or the marketing strategies we have adopted or plan to adopt will have their anticipated effect or generate sustainable revenue and profit.

**If we fail to maintain and further develop our direct sales force and partner networks, our business could suffer. Additionally, our third-party partners may not effectively promote our services or may engage in activities that could harm our reputation and sales of our products and services.**

We rely on our direct sales force and partner networks to generate sales, including referral arrangements with businesses in the beauty industry such as hairdressers. However, if we fail to maintain or develop our sales force and partner networks, or if any of our partners are ineffective in promoting our services or engage in activities that harm our reputation, it could have a material adverse effect on our ability to generate sales, which could have a material adverse effect on our business, financial condition and results of operations.

[**Table of Contents**](#TableOfContents)

**We may grant employee share options and other share-based compensation awards in the future. Any additional grant of employee share options and other share-based compensation awards in the future may have a material adverse effect on our results of operations.**

We have adopted and may in the future adopt employee share option plans for the purpose of granting share-based compensation awards to our employees, officers, directors and other eligible persons to incentivize their performance and align their interests with ours. For more information on these share incentive plans, see "Item 6. Directors, Senior Management and Employees—6.B. Compensation—Share Incentive Plan" and "Item 6. Directors, Senior Management and Employees—6.B. Compensation— Performance Incentive Plan." As a result of these grants and potential future grants, we expect to continue to incur significant share-based compensation expenses in the future. We are required to account for share-based compensation in accordance with IFRS 2—Share-based Payment, which generally requires a company to recognize, as an expense, the fair value of share options and other equity incentives to employees based on the fair value of equity awards on the date of the grant, with the compensation expense recognized over the period in which the recipient is required to provide service in exchange for the equity award. If we grant options or other equity incentives in the future, we could incur significant compensation charges and our results of operations could be adversely affected. The expenses associated with share-based compensation will decrease our profitability, and the additional awards issued under share-based compensation plans will dilute the ownership interests of our shareholders, including holders of our ADSs. However, if we limit the scope of our share-based compensation plan, we may not be able to attract or retain key personnel who expect to be compensated by such share-based awards.

**A material weakness was identified in our internal control over financial reporting before. If we fail to develop and maintain an effective system of internal control over financial reporting, we may be unable to accurately report our financial results or prevent fraud and our ability to comply with applicable regulations could be impaired.**

Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, it used the criteria established within the Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013 framework). Based on this assessment, our management has concluded that, as of December 31, 2020, our internal control over financial reporting was not effective. We and our independent registered public accounting firm identified one material weakness in our internal control over financial reporting. The material weakness identified was related to a lack of an effective control procedure to evaluate accounting of complex non-routine transactions. In the fiscal year 2023, 2024 or 2025, we have not identified any material weakness in our internal control over financial reporting.

As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

[**Table of Contents**](#TableOfContents)

We are a public company in the United States and are subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act, or Section 404, requires that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 20-F beginning with our annual report for the fiscal year ended December 31, 2020. In addition, we cease to be an "emerging growth company" as of December 31, 2025 as such term is defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting, unless we are still be classified as a non-accelerated filer. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, a public company's reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation.

During the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section 404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements for prior periods.

In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Implementing any appropriate changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management's attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.

If we are unable to conclude that we have effective internal controls over financial reporting, investors may lose confidence in our operating results, the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, the ADSs may not be able to remain listed on the OTCQX Best Market.

[**Table of Contents**](#TableOfContents)

**Risks relating to our corporate structure**

**If the PRC government deems that the Contractual Arrangements do not comply with PRC laws and regulations, or if these laws and regulations or their interpretations change in the future, we could be subject to severe penalties or be forced to relinquish our interests received through the Contractual Arrangements.**

According to the Industry Catalog for Guiding Foreign Investment (Revision 2015), or the Foreign Investment Catalog 2015, which became effective in April 2015, and replaced by the Special Administrative Measures (Negative List) for Access of Foreign Investment (2024 version), or the Negative List, promulgated by the NDRC and the Ministry of Commerce of the PRC, or the MOFCOM jointly on September 6, 2024 and came into effect on November 1, 2024, PRC law only allows foreign investment in PRC medical institutions through joint venture entities, and the foreign shareholding in these entities is limited to 70.0%, which percentage was stipulated in the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions, or the JV Interim Measures. We historically held more than 70.0% in nine of our PRC subsidiaries after the effective date of the Foreign Investment Catalog 2015, namely Yantai Pengai Jiayan Cosmetic Surgery Hospital Co., Ltd., Hangzhou Pengai Aesthetic Medical Clinic Co., Ltd., Chongqing Pengai Aesthetic Medical Hospital Co., Ltd., Changsha Pengai Aesthetic Medical Hospital Co., Ltd., Shanghai Pengai Aesthetic Medical Clinic Co., Ltd, Jiangsu Liangyan Hospital Management Co., Ltd., and Beijing Aomei Yixin Investment Consultant Co., Ltd., Guangzhou Pengai Xiuqi Aesthetic Medical Clinic Co., Ltd., and Shanghai Jiahong Aesthetic Medical Clinic Co., Ltd. We decreased our shareholdings in these PRC subsidiaries to 70.0% by transferring excess equity interests to Dr. Zhou Pengwu and certain of our employees in 2018, 2019, 2020 and 2021, subject to the completion of registration of share transfer to Dr. Zhou and the equity pledge. Between 2018 and 2024, we entered into a series of Contractual Arrangements with Dr. Zhou Pengwu, Mr. Zhou Qiuming, Shenzhen Pengai Investment, the Relevant Subsidiaries, Ms. Ma Xiuhua, and Ms. Ding Wenting regarding the Target Equity Interests. Some of these Relevant Subsidiaries were deregistered or divested during this period. Reference is made to the 6-K report of the Company filed with the SEC on August 17, 2023. As of December 31, 2023, Dr. Zhou Pengwu had concluded the transfer of his shares in four of the relevant subsidiaries to Mr. Zhou Qiuming, with one subsidiary remaining unaffected, namely Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd. As of December 31, 2025, the shareholding percentages in the Relevant Subsidiaries and the Target Equity Interests remained unchanged. For details of the Contractual Arrangements, see "Item 4. Information on the Company—4.A. History and Development of the Company—Contractual Arrangements with respect to Target Equity Interests."

In the opinion of Dacheng Law Offices LLP (Wuhan), our PRC legal counsel, the execution, delivery and performance of each of the Contractual Arrangements by the parties thereto, and the consummation of the transactions contemplated thereunder do not and will not result in any violation of any explicit requirement under applicable PRC Laws currently in effect. However, we have been advised by our PRC legal counsel that there are substantial uncertainties regarding the interpretation and application of current and future PRC laws, regulations and rules, including those relating to foreign investment restrictions and the Foreign Investment Law (as defined below). There can be no assurance that the PRC regulatory authorities will take a view that is consistent with the opinion of our PRC legal counsel.

The Chinese regulatory authorities could disallow our structure, which could result in a material change in our operations and the value of our securities could decline or become worthless. See "Item 3. Key Information—D. Risk Factors—Risks relating to doing business in the PRC" for recent regulatory initiatives implemented by the relevant PRC government entities. In addition, any actions by the Chinese government to exert more oversight and control over securities that are listed overseas or foreign investment in China-based issuers could significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of our securities to significantly decline or be worthless. In addition, it is uncertain whether any new PRC laws or regulations relating to Contractual Arrangements will be adopted, or if adopted, what they would provide.

If our ownership structure, Contractual Arrangements or businesses of the Relevant Subsidiaries are found to be in violation of any existing or future PRC laws or regulations, or if the Relevant Subsidiaries fail to obtain or maintain any of the required permits or approvals, the relevant PRC regulatory authorities would have broad discretion to take action in dealing with such violations or failures, including:

● revoking the Contractual Arrangements;

● imposing fines, confiscating the income from the Relevant Subsidiaries, or imposing other requirements with which we may not be able to comply;

● discontinuing or restricting our operations in the PRC;

[**Table of Contents**](#TableOfContents)

● imposing conditions or requirements with which we may not be able to comply; or

● taking other regulatory or enforcement actions that could be harmful to our business.

Any of these actions could materially and adversely affect our business, financial condition and results of operations. If any of these occurrences results in our failure to receive the economic benefits of the Target Equity Interests, we may not be able to consolidate the above in our consolidated financial statements in accordance with IFRS as issued by IASB.

**The Contractual Arrangements may not be as effective in providing control as direct ownership and Relevant Subsidiaries or Mr. Zhou Qiuming or Dr. Zhou Pengwu may fail to perform their respective obligations under the Contractual Arrangements.**

We directly own and hold less than 71.0% of equity interests in the Relevant Subsidiaries and will rely on the Contractual Arrangements to control the Target Equity Interests in the Relevant Subsidiaries. The Contractual Arrangements may not be as effective as direct ownership in controlling over the Target Equity Interests. If the Relevant Subsidiaries and/or Mr. Zhou Qiuming and/ or Dr. Zhou Pengwu fail to perform their respective obligations under the Contractual Arrangements, we may have to incur substantial costs and expend additional resources to enforce such Contractual Arrangements, and rely on legal remedies under PRC laws, including contractual remedies, which may not be sufficient or effective. These legal remedies may not be as effective as direct ownership in controlling the Target Equity Interests. All the agreements under the Contractual Arrangements are governed by and interpreted in accordance with PRC laws, and disputes arising from these Contractual Arrangements will be resolved through arbitration in Mainland China. However, the legal framework and system in Mainland China are not as developed as in some other jurisdictions, such as the United States. As a result, uncertainties in the interpretation and enforcement of PRC laws, rules and regulations could limit our ability to enforce Contractual Arrangements. Meanwhile, there are very few precedents and little formal guidance as to how Contractual Arrangements should be interpreted or enforced under PRC law. Significant uncertainties remain regarding the ultimate outcome of such arbitration. In addition, under PRC law, rulings by arbitrators are final, parties cannot appeal the arbitration results in courts, and if the losing parties fail to carry out the arbitration awards within a prescribed time limit, the prevailing parties may only enforce the arbitration awards in the PRC courts through arbitration award recognition proceedings, which would require additional expenses and cause a delay. If we fail to enforce Contractual Arrangements, or if we suffer significant delay or face other obstacles in the process of enforcing Contractual Arrangements, our control over the Target Equity Interests may be negatively affected.

**Any failure by our Relevant Subsidiaries and their other respective shareholders, including Mr. Zhou Qiuming or Dr. Zhou Pengwu, to perform their obligations under our contractual arrangements with them would have a material adverse effect on our business.**

If our Relevant Subsidiaries and their other respective shareholders, including Mr. Zhou Qiuming or Dr. Zhou Pengwu, fail to perform their respective obligations under the Contractual Arrangements, we may have to incur substantial costs and expend additional resources to enforce such arrangements. We may also have to rely on legal remedies under PRC law, including seeking specific performance or injunctive relief, and claiming damages, which we cannot assure will be effective under PRC law. For example, if other shareholders of our Relevant Subsidiaries refuse to transfer their equity interest in our Relevant Subsidiaries to us or our designee if we exercise the purchase option pursuant to the contractual arrangements, or if they otherwise act in bad faith toward us, then we may have to take legal actions to compel them to perform their contractual obligations. In addition, if any third parties claim any interest in such shareholders' equity interests in our Relevant Subsidiaries, our ability to exercise shareholders' rights or foreclose the share pledge according to the Contractual Arrangements may be impaired.

[**Table of Contents**](#TableOfContents)

All of the Contractual Arrangements are governed by and interpreted in accordance with PRC law, and disputes arising from the contractual arrangements will be resolved through arbitration in Mainland China. As a result, the evolving PRC legal system could limit our ability to enforce these contractual arrangements. See **"**—Risks relating to doing business in the PRC— Uncertainties with respect to the interpretation and enforcement of PRC laws, rules and regulations could materially and adversely affect us.**"** Meanwhile, there are very few precedents and little formal guidance as to how contractual arrangements in the context of a variable interest entity should be interpreted or enforced under PRC law. There remain significant uncertainties regarding the ultimate outcome of such arbitration should legal action become necessary. In addition, under PRC law, rulings by arbitrators are final, parties cannot appeal the arbitration results in courts, and if the losing parties fail to carry out the arbitration awards within a prescribed time limit, the prevailing parties may only enforce the arbitration awards in PRC courts through arbitration award recognition proceedings, which would require additional expenses and delay. In the event we are unable to enforce the Contractual Arrangements, or if we suffer significant delays or other obstacles in the process of enforcing these Contractual Arrangements, we may not be able to exert effective or complete control over our Relevant Subsidiaries or enjoy the economic benefit from such Relevant Subsidiaries, and our ability to conduct our business may be negatively affected.

**If the custodians or authorized users of our controlling non-tangible assets, including chops and seals, fail to fulfill their responsibilities, or misappropriate or misuse these assets, our business and operations may be materially and adversely affected.**

Under PRC law, legal documents for corporate transactions, including agreements and contracts that our business relies on, are executed using the chop or seal of the signing entity or with the signature of a legal representative whose designation is registered and filed with the relevant local branch of the SAMR. We generally execute legal documents by affixing chops or seals, rather than having the designated legal representatives sign the documents.

We have three major types of chops, corporate chops, contract chops and finance chops. We use corporate chops generally for documents to be submitted to government agencies, such as applications for changing business scope, directors or company name, and for legal letters. We use contract chops for executing leases and commercial contracts. We use finance chops generally for making and collecting payments, including issuing invoices. Use of corporate chops and contract chops must be approved by our legal department and administrative department, and use of finance chops must be approved by our finance department. The chops of our subsidiary (including our Relevant Subsidiaries) are generally held by the relevant entities so that documents can be executed locally. Although we usually utilize chops to execute contracts, the registered legal representatives of our subsidiaries or affiliated entities and their subsidiaries have the apparent authority to enter into contracts on behalf of such entities without chops, unless such contracts set forth otherwise.

In order to maintain the physical security of our chops, we generally have them stored in secured locations accessible only to the designated key employees of our internal control, legal, administrative or finance departments. Our designated legal representatives generally do not have access to the chops. Although we have approval procedures in place and monitor our key employees, including the designated legal representatives of our subsidiaries and affiliated entities and their subsidiaries, the procedures may not be sufficient to prevent all instances of abuse or negligence. There is a risk that our key employees or designated legal representatives could abuse their authority, for example, by binding our subsidiaries and affiliated entities and their subsidiaries with contracts against our interests, as we would be obligated to honor these contracts if the other contracting party acts in good faith in reliance on the apparent authority of our chops or signatures of our legal representatives. If any designated legal representative obtains control of the chop in an effort to obtain control over the relevant entity, we would need to have a shareholder or board resolution to designate a new legal representative and to take legal action to seek the return of the chop, apply for a new chop with the relevant authorities, or otherwise seek legal remedies for the legal representative's misconduct. If any of the designated legal representatives obtains and misuses or misappropriates our chops and seals or other controlling intangible assets for whatever reason, we could experience disruption to our normal business operations. We may have to take corporate or legal action, which could involve significant time and resources to resolve while distracting management from our operations, and our business and operations may be materially and adversely affected.

[**Table of Contents**](#TableOfContents)

**Mr. Zhou Qiuming or Dr. Zhou Pengwu may have potential conflicts of interest with us, which may materially and adversely affect our control over the Target Equity Interests.**

We have control over the Relevant Subsidiaries by directly holding no more than 71.0% of equity interest in each of the Relevant Subsidiaries, and we control the Target Equity Interests directly held by Mr. Zhou Qiuming or Dr. Zhou Pengwu through the Contractual Arrangements. Mr. Zhou Qiuming's role as the representative appointed by our ultimate controller, Mr. Wu Guiqian, may potentially lead to conflicts of interest within our company. Dr. Zhou Pengwu may have potential conflicts of interest with us due to his role as director of our company and director of certain of the Relevant Subsidiaries, as what is in the best interests of the Relevant Subsidiaries may not be in the best interests of our company. Mr. Zhou Qiuming or Dr. Zhou Pengwu may breach or refuse to renew the existing Contractual Arrangements we have with him and the Relevant Subsidiaries, which would materially and adversely affect our control over the Target Equity Interests and our ability to receive economic benefits in connection with the Target Equity Interests. If Mr. Zhou Qiuming or Dr. Zhou Pengwu breaches Contractual Agreements or otherwise has disputes with us, we may have to initiate arbitration or other legal proceedings, which involve significant uncertainty. Such disputes and proceedings may significantly distract our management's attention, adversely affect our ability to control the Target Equity Interests and otherwise result in negative publicity and adversely affect the reputation of our treatment centers. There is no assurance that the outcome of any such dispute or proceeding will be in our favor.

**Our Contractual Arrangements with the Relevant Subsidiaries may be subject to scrutiny by the PRC tax authorities and they may determine that we owe additional taxes, which could negatively affect our financial condition and the value of your investment.**

Under applicable PRC laws and regulations, arrangements and transactions among related parties may be subject to audit or challenge by the PRC tax authorities, and additional taxes and interest may be imposed. The PRC enterprise income tax law requires every enterprise in Mainland China to submit its annual enterprise income tax return together with a report on transactions with its related parties to the relevant tax authorities. The tax authorities may impose reasonable adjustments on taxation if they have identified any related party transactions that are inconsistent with arm's length principles. We may be subject to material and adverse tax consequences if the PRC tax authorities determine that the Contractual Arrangements between Shenzhen Pengai Investment, Mr. Zhou Qiuming, Dr. Zhou Pengwu and the Relevant Subsidiaries were not entered into on an arm's length basis and make special tax adjustments to the tax positions of Shenzhen Pengai Investment, Mr. Zhou Qiuming and Dr. Zhou Pengwu.

In addition, if Shenzhen Pengai Investment exercises the option to purchase all or any part of the Target Equity Interests, the equity interest transfer price may be subject to review and tax adjustment by the relevant tax authority. Mr. Zhou Qiuming or Dr. Zhou Pengwu will be subject to personal income tax on the difference between the equity interest transfer price and the amount he has paid to obtain the Target Equity Interests. According to the exclusive option agreement under the Contractual Arrangements, Mr. Zhou Qiuming or Dr. Zhou Pengwu may pay the remaining amount to Shenzhen Pengai Investment, and the amount to be received by Shenzhen Pengai Investment may also be subject to enterprise income tax. Such tax amounts could be substantial, and our financial condition may be adversely affected as a result.

Furthermore, the PRC tax authorities may impose any late payment fees and other penalties on the Relevant Subsidiaries for the adjusted but unpaid taxes according to the applicable regulations. Our financial position could be materially and adversely affected if any of the Relevant Subsidiaries' tax liabilities increase or if late payment fees and other penalties are imposed.

**If the PRC government deems our PRC medical centers as "Sino-Foreign Equity Medical Institutions," we could be subject to certain liabilities for failing to comply with the JV Interim Measures.**

Since the Foreign Investment Catalog 2015 became effective in April 2015, PRC law only allows foreign investment in PRC medical institutions through joint venture entities, and the foreign shareholding in these entities is limited to 70.0%, the percentage stipulated in the JV Interim Measures. We own and hold our equity interests in the PRC treatment centers indirectly through Pengai Investment. Since the JV Interim Measures do not address the equity percentage of a medical institution held indirectly by a non-PRC entity through its subsidiary in the PRC, we do not believe that we, both prior to and after we decreased our indirect shareholding in the Relevant Subsidiaries to 70.0%, are in violation of any explicit provision of the JV Interim Measures. However, we cannot assure you that the PRC regulatory authorities will not take a different view in the future. In the case that the PRC government authorities deem our PRC medical centers as a Sino-Foreign Equity Medical Institution, we may face liabilities for not meeting the requirements or administrative procedures for Sino-Foreign Equity Medical Institutions historically.

[**Table of Contents**](#TableOfContents)

**Risks relating to doing business in the PRC**

 ****

**The PRC government may intervene or exert influence on our operations at any time, which could result in a material adverse change in our operations and the value of our ADSs and ordinary shares.**

The PRC government has significant authority to intervene or exert influence on our business operations in various aspects at any time, which could result in a material adverse change in our operations and the value of our ADSs and ordinary shares. We operate through our subsidiaries in mainland China, Hong Kong, the British Virgin Islands and the United States. In particular, the operational and legal risks associated with being based in and having operations in mainland China also apply to our operations in Hong Kong and any laws or regulations of mainland China could become applicable to our operations in Hong Kong in the future at any time and with no advance notice. As Hong Kong currently operates under a different set of laws from mainland China, the laws, regulations and the discretion of the governmental authorities in mainland China discussed in this annual report are expected to apply to our entities and businesses in mainland China, rather than entities or businesses in Hong Kong. However, there can be no assurance as to whether the government of Hong Kong will enact laws and regulations similar to mainland China, or whether any laws or regulations of mainland China will become applicable to our operations in Hong Kong in the future. Therefore, uncertainties in the laws and regulations of mainland China from time to time and the interpretation and enforcement of the laws and regulations of mainland China could limit the legal protection available to you and us, hinder our ability to offer or continue to offer the ADSs, result in a material adverse effect on our business operations, and affect our reputation, which might further cause the ADSs to significantly decline in value or become worthless. Changes in the economic, political or social conditions, or government policies of mainland China could also materially and adversely affect our business, financial condition, and results of operations.

We cannot predict whether the resulting changes will have any adverse effect on our current or future business, financial condition or results of operations. Despite these economic reforms and measures, the PRC government continues to play a significant role in regulating industrial development, allocation of natural and other resources, production, pricing and management of currency, and there can be no assurance that the PRC government will continue to pursue a policy of economic reform or that the direction of reform will continue to be market friendly. Our ability to maintain our business operations in China through our subsidiaries and the Relevant Subsidiaries depends on a number of factors, including macro-economic and other market conditions. Our business, financial condition and results of operations may be materially and adversely affected by the following factors that are affected by a number of variables which are beyond our control:

● changes in political or social conditions of mainland China;

● changes in laws, regulations, and administrative directives or the interpretation thereof;

● measures which may be introduced to control inflation or deflation; and

● changes in the rate or method of taxation.

In addition, the PRC government has recently indicated that it may exert more oversight and control over offerings that are conducted overseas by or foreign investment in China-based issuers which may significantly limit or completely hinder our ability to offer or continue to offer securities and cause the value of such securities to significantly decline or be worthless. For example, on July 6, 2021, the PRC government authorities published the Opinions on Strictly Cracking down on Securities-related Illegal Activities in Accordance with the Law. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies and proposed to take effective measures, such as promoting the establishment of regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. On December 28, 2021, the CAC promulgated the Cybersecurity Review Measures, which came into effect on February 15, 2022. According to the Cybersecurity Review Measures, (i) critical information infrastructure operators that purchase network products and services and internet platform operators that conduct data processing activities shall be subject to cybersecurity review in accordance with the Cybersecurity Review Measures if such activities affect or may affect national security; and (ii) internet platform operators holding personal information of more than one million users and seeking to have their securities listed on a stock exchange in a foreign country are required to file for cybersecurity review with the Cybersecurity Review Office. On February 17, 2023, the CSRC released the Trial Measures, which came into effect on March 31, 2023. Pursuant to the Trial Measures, domestic companies that seek to offer or list securities overseas, whether directly or indirectly, should fulfill the filing procedures and report relevant information to the CSRC within three working days after submitting listing applications and subsequent amendments.

[**Table of Contents**](#TableOfContents)

Since these regulations are relatively new and remain unclear on how they will be interpreted, amended and implemented by the PRC government authorities, it remains uncertain whether we can obtain the specific regulatory approvals from, or complete the required filings with the CSRC, CAC or any other PRC government authorities for our future securities offering or for foreign investment in China-based issuers in a timely basis or at all. If we are unable to obtain such approvals or complete such filings, or such approvals or filings are rescinded even if obtained, our ability to offer or continue to offer securities to investors will be significantly limited or completely hindered and the value of such securities may be significantly declined or become worthless. In addition, implementation of industry-wide regulations directly targeting our operations could result in adverse effect on the value of our securities. Therefore, investors of our Company and our business face potential uncertainty from actions taken by the PRC government affecting our business and operations.

**The enforcement of the PRC Labor Contract Law, and other labor-related regulations in the PRC may increase our labor costs and limit our flexibility to use labor. Our failure to comply with PRC labor-related laws may expose us to penalties.**

On June 29, 2007, the Standing Committee of the National People's Congress of China enacted the PRC Labor Contract Law, which became effective on January 1, 2008 and was amended on December 28, 2012. The PRC Labor Contract Law introduces specific provisions related to fixed-term employment contracts, part-time employment, probation, consultation with labor unions and employee assemblies, employment without a written contract, dismissal of employees, severance, and collective bargaining, which together represent enhanced enforcement of labor laws and regulations. According to the PRC Labor Contract Law, an employer is obliged to sign an unfixed-term labor contract with any employee who has worked for the employer for 10 consecutive years and will reach the statutory retirement age within ten years. Further, if an employee requests or agrees to renew a fixed-term labor contract that has already been entered into twice consecutively, the resulting contract must have an unfixed term, with certain exceptions. The employer must pay economic compensation to an employee where a labor contract is terminated or expires in accordance with the PRC Labor Contract Law, except for certain situations which are specifically regulated. As a result, our ability to terminate employees is significantly restricted. In addition, the government has issued various labor-related regulations to further protect the rights of employees. According to such laws and regulations, employees are entitled to annual leave ranging from 5 to 15 days and are able to be compensated for any untaken annual leave days in the amount of three times their daily salary, subject to certain exceptions. In the event that we decide to change our employment or labor practices, the PRC Labor Contract Law and its implementation rules may also limit our ability to effect those changes in a manner that we believe to be cost-effective. In addition, as the interpretation and implementation of these new regulations are still evolving, our employment practices may not be at all times deemed in compliance with the new regulations. If we are subject to severe penalties or incur significant liabilities in connection with labor disputes or investigations, our business and financial conditions may be adversely affected.

Companies operating in Mainland China are required to participate in various government sponsored employee benefit plans, including certain social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentages of salaries, including bonuses and allowances, of their employees up to a maximum amount specified by the local government from time to time. The requirement to maintain employee benefit plans has not been implemented consistently by local governments in Mainland China given the different levels of economic development in different locations. We did not pay, or were not able to pay, certain past social security and housing fund contributions in strict compliance with the relevant PRC regulations for and on behalf of our employees due to differences in local regulations and inconsistent implementation or interpretation by local authorities in the PRC and varying levels of acceptance of the housing fund system by our employees. We may be subject to fines and penalties for our failure to make payments in accordance with the applicable PRC laws and regulations. We may be required to make up the contributions for these plans as well as to pay late fees and fines. We have not made any accruals for the interest on underpayments and penalties that may be imposed by the relevant PRC government authorities in the financial statements. If we are subject to penalties, late fees or fines in relation to the underpaid employee benefits, our financial condition and results of operations may be adversely affected.

[**Table of Contents**](#TableOfContents)

**The PRC's economic, political and social conditions, as well as governmental policies, could affect the business environment and financial markets in China, our ability to operate our business, our liquidity and our access to capital.**

Most of our operations are conducted in China. Accordingly, our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in China. China's economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange allocation of resources, an evolving regulatory resources, and a lack of sufficient transparency in the regulatory process. While the PRC economy has experienced significant growth over the past 40 years, growth has been uneven across different regions and among various economic sectors of China. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are currently applicable to us. In addition, in the past the PRC government implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operation. More generally, if the business environment in China deteriorates from the perspective of domestic or international investment, our business in China may also be adversely affected.

**Uncertainties with respect to the interpretation and enforcement of PRC laws, rules and regulations could materially and adversely affect us.**

We conduct our business primarily through our subsidiaries in China. PRC laws and regulations govern our operations in China. Our subsidiaries are generally subject to laws and regulations applicable to foreign investments in China, which may not sufficiently cover all of the aspects of our economic activities in China. In addition, the implementation of laws and regulations may be in part based on government policies and internal rules that are subject to the interpretation and discretion of different government agencies (some of which are not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not always be aware of any potential violation of these policies and rules. Such unpredictability regarding our contractual, property and procedural rights could adversely affect our business and impede our ability to continue our operations. Furthermore, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. These uncertainties could materially and adversely affect our business and results of operations.

In January 2015, the MOFCOM, published a discussion draft of the proposed Foreign Investment Law, or the 2015 Draft Foreign Investment Law. The National People's Congress published another discussion draft of the Foreign Investment Law and its amendment, or the 2018 Draft Foreign Investment Law, on December 2018 and January 2019 respectively. On March 15, 2019, the National People's Congress approved the Foreign Investment Law, which has come into effect since January 1, 2020, or the 2019 Foreign Investment Law. Among other things, the 2015 Draft Foreign Investment Law expands the definition of foreign investment and introduces the principle of "actual control" in determining whether a company should be treated as a foreign invested enterprise, or FIE. Once an entity falls within the definition of FIE, it may be subject to foreign investment "restrictions" or "prohibitions" set forth in a "negative list" to be separately issued by the State Council. If an FIE proposes to conduct business in an industry subject to foreign investment "restrictions" in the "negative list," the FIE must go through a pre-approval process. The 2019 Foreign Investment Law have revised the definition of "foreign investment" and removed all references to the definitions of "actual control" or "variable interest entity structure" under the 2015 Draft Foreign Investment Law, and have further specified that all "foreign investments" shall be conducted pursuant to the negative list issued or approved to be issued by the State Council.

Notwithstanding the above, the 2019 Foreign Investment Law stipulates that foreign investment includes foreign investors investing in China through any other methods under laws, administrative regulations or provisions prescribed by the State Council. There are possibilities that the Contractual Arrangements adopted by us will be deemed as a form of foreign investment, at which time it will be uncertain whether our investment in treatment centers in China and the Contractual Arrangements will be deemed to be in violation of the foreign investment regulations and how they will be handled. Therefore, there is no guarantee that the Contractual Arrangements, our business and operation will not be materially and adversely affected in the future due to the changes in PRC laws and regulations. In addition, any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention.

[**Table of Contents**](#TableOfContents)

Due to our status as a Cayman Islands holding company, in compliance with PRC law, we own no more than 70% equity interest in our PRC operating subsidiaries and Contractual Arrangements are entered into in relation to the minority equity interest. We are able to control and consolidate our PRC operating subsidiaries as a result of our direct majority equity ownership, among other things, and do not depend on the contractual arrangements in relation to the minority equity interest to control and consolidate our PRC operating subsidiaries. However, in the event that the Chinese regulatory authorities disallowed the contractual arrangements, it may negatively impact our operations or the value of our securities, although the negative impact may not be material, given that the affected equity interest would be no more than 30% of the total equity interest.

PRC government has complex regulatory requirements on the conduct of our business and it has recently promulgated certain regulations and rules to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless.

The General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Severely Cracking Down on Illegal Securities Activities According to Law, or the Opinions, which was made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Effective measures, such as promoting the construction of relevant regulatory systems, will be taken to deal with the risks and incidents of China-concept overseas listed companies. As of the date of this annual report, we have not received any inquiry, notice, warning, or sanctions from PRC government authorities in connection with the Opinions.

As such, the Company's business segments may be subject to various government and regulatory interference in the provinces in which they operate. We could be subject to regulation by various political and regulatory entities, including various local and municipal agencies and government sub-divisions. We incur increased costs necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply. Additionally, the governmental and regulatory interference could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.

On December 24, 2021, the China Securities Regulatory Commission, or the CSRC, together with other relevant government authorities in Mainland China issued the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments) and the Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), both of which were open for public comments until January 23, 2022. On February 17, 2023, the CSRC issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises, or the Trial Measures, which took effect on March 31, 2023. On the same date, the CSRC circulated Supporting Guidance Rules No. 1 through No. 5, Notes on the Trial Measures, Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and relevant CSRC Answers to Reporter Questions, or collectively, the Guidance Rules and Notice, on CSRC's official website. The Trial Measures, together with the Guidance Rules and Notice, reiterate the basic principles of the Draft Administrative Provisions and Draft Filing Measures and impose substantially the same requirements for the overseas securities offering and listing by domestic enterprises. Under the Trial Measures and the Guidance Rules and Notice, domestic enterprises conducting overseas securities offering and listing, either directly or indirectly, shall complete filings with the CSRC pursuant to the Trial Measures' requirements within three working days following the submission of an application for initial public offering or listing. Starting from March 31, 2023, enterprises that have been listed overseas or satisfy all of the following conditions shall be deemed as "Grandfathered Issuers" and are not required to complete the overseas listing filing immediately, but shall complete filings as required if they conduct refinancing or are involved in other circumstances that require filing with the CSRC: (i) the application for indirect overseas offering or listing shall have been approved by the relevant overseas regulatory authority or stock exchange prior to March 31, 2023 (as the SEC does not approve or disapprove of an offering, this requirement is interpreted to be the SEC's declaration of the registration statement to be effective with respect to this offering), (ii) the enterprise is not required to reapply for the approval of the relevant overseas regulatory authority or stock exchange, and (iii) such overseas securities offering or listing shall be completed before September 30, 2023. Any future securities offerings and listings outside of mainland China by our company, including but not limited to follow-on offerings, refinancing, secondary listings, and going private transactions, will be subject to the filing requirements with the CSRC under the Trial Measures, and we cannot assure you that we will be able to comply with such filing requirements in a timely manner, or at all.

[**Table of Contents**](#TableOfContents)

If it is determined that any approval, filing or other administrative procedure from the CSRC or other PRC governmental authorities is required for any future offering or listing, we cannot assure that we can obtain the required approval or accomplish the required filings or other regulatory procedures in a timely manner, or at all. If we fail to obtain the relevant approval or complete the filings and other relevant regulatory procedures, we may face sanctions by the CSRC or other PRC regulatory agencies, which may include fines and penalties on our operations in China, limitations on our operating privileges in China, restrictions on or prohibition of the payments or remittance of dividends by our PRC subsidiaries in China, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. As of the date of this annual report, we have not received any inquiry or notice or any objection to this offering from the CSRC, the CAC or any other PRC governmental authorities that have jurisdiction over our operations. However, given the current regulatory environment in the PRC, there remains uncertainty regarding the interpretation and enforcement of PRC laws, which can change quickly with little advance notice subject to any future actions of the PRC authorities. If the CSRC or other regulatory authorities later promulgate new rules or explanations requiring that we obtain their approvals or accomplish the required filing or other regulatory procedures for this offering, we may be unable to obtain a waiver of such approval requirements, if and when procedures are established to obtain such a waiver. Any failure of us to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to offer or continue to offer the ADSs, cause significant disruption to our business operations, and severely damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause the ADSs to significantly decline in value or become worthless.

We have been closely monitoring the development in the regulatory landscape in Mainland China, particularly regarding the requirement of approvals, including on a retrospective basis, from the CSRC, the CAC or other PRC authorities, as well as regarding any annual data security review or other procedures that may be imposed on us. If any approval, review or other procedure is in fact required, we are not able to guarantee that we will obtain such approval or complete such review or other procedure timely or at all. For any approval that we may be able to obtain, it could nevertheless be revoked and the terms of its issuance may impose restrictions on our operations and offerings relating to our securities.

**It may be difficult for overseas regulators to conduct investigations or collect evidence within China.**

Shareholder claims or regulatory investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to providing information needed for regulatory investigations or litigation initiated outside China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which became effective in March 2020, no foreign securities regulator is allowed to directly conduct investigations or evidence collection activities within the PRC territory. The Trial Measures and the Provisions on Confidentiality and Archives Administration also repeat the above principle and rule. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability for a foreign securities regulator to directly conduct investigations or evidence collection activities within China may further increase the difficulties you face in protecting your interests.

**Changes in international trade policies and barriers to trade or the emergence of a trade war may dampen growth in China and other markets where we operate, and our business operations and results may be negatively impacted.**

International trade disputes could result in tariffs and other protectionist measures that could adversely affect our business. Tariffs could increase our operating costs as well as the cost of the goods and products which could affect our customer's discretionary spending level. In addition, any escalation in existing trade tensions or the advent of a trade war, or news and rumors of the escalation of a potential trade war, could affect consumer confidence and have a material adverse effect on our business, results of operations and, ultimately, the trading price of our ADSs.

[**Table of Contents**](#TableOfContents)

Political tensions between the United States and China have escalated due to, among other things, the COVID-19 outbreak, the PRC National People's Congress' passage of Hong Kong national security legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC, and the executive orders issued by U.S. President in August 2020 that prohibit certain transactions with ByteDance Ltd., Tencent Holdings Ltd. and the respective subsidiaries of such companies. In addition, on December 31, 2020, the New York Stock Exchange commenced proceedings to delist securities of three major telecommunications service providers in China in light of an executive order prohibiting any transaction in publicly traded securities of certain China-based companies by any U.S. person. There remains uncertainty as to whether the New York Stock Exchange or relevant regulatory authorities will finally determine the executive order or additional regulatory rules or orders to be applicable and proceed with the delisting proceedings against these companies or any other China-based issuers listed in the United States. Rising political tensions could reduce levels of trades, investments, technological exchanges and other economic activities between the two major economies, which would have a material adverse effect on global economic conditions and the stability of global financial markets. Any of these factors could have a material adverse effect on our business, prospects, financial condition and results of operations. Furthermore, there have been media reports on deliberations within the U.S. government regarding potentially limiting or restricting China-based companies from accessing U.S. capital markets. If any such deliberations were to materialize, the resulting legislation may have a material and adverse impact on the stock performance of China-based issuers listed in the United States. It is currently unclear whether the proposed or additional legislations would be enacted that would have the effect of potentially limiting or restricting China-based companies from accessing U.S. capital markets.

**We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or the FCPA, Chinese anti-unfair competition laws and relevant tax laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.**

We are subject to the FCPA. The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject to the anti-bribery laws of other jurisdictions, particularly China. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.

Some of our PRC subsidiaries may pay commissions to or reimburse the expenses and costs incurred by individuals or entities if they recommend customers Pursuant to the Anti-Unfair Competition Law of the PRC, amended and effective on April 23, 2019, commissions to suppliers are permitted if the parties properly reflect such commissions in their financial records. On December 25, 2024, SCNPC promulgated the Revision Draft of Anti-Unfair Competition Law for public comments. As of the date of this annual report, the Revision Draft of Anti-unfair Competition Law has not been officially promulgated or implemented. We are also required to withhold individual income tax in the case the referee is an individual. We have reflected such commissions on our financial records and withheld individual income tax based on our understanding. However, as we do not regard the reimbursement of expenses and costs as part of the commissions, reimbursement paid to the referee may not be reflected on our financial records or have individual income tax withheld. There is no assurance that the relevant PRC authorities will take a view consistent with our understanding. As of the date of this annual report, we have not received any penalty decisions from any relevant PRC authorities. However, we cannot assure you that we will not be subject to penalty due to allegations of violating relevant commercial bribery or anti-unfair competition laws or tax laws in the future by the local authorities in the regions where we have operations or that we will be able to defend ourselves against such allegations. If we become subject to penalties or fines for violating relevant commercial bribery or anti-unfair competition laws and/or tax laws, our business and reputation may be adversely affected.

**Restrictions on currency exchange may limit our ability to receive and use financing in foreign currencies effectively.**

Our PRC subsidiaries' ability to obtain foreign exchange is subject to significant foreign exchange controls and, in the case of transactions under the capital account, requires the approval of and/or registration with PRC government authorities, including the Chinese State Administration of Foreign Exchange, or SAFE. In particular, if we finance our PRC subsidiaries by means of foreign debt from us or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local counterpart of the SAFE. If we finance our PRC subsidiaries by means of additional capital contributions, the amount of these capital contributions must first be registered or filed by the relevant government authority.

In the light of the various requirements imposed by PRC regulations on loans to, and direct investment in, PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations, filings or obtain the necessary government approvals on timely basis, if at all, with respect to future loans or capital contributions by us to our PRC subsidiaries. If we fail to complete such registrations, filings, or obtain such approval, our ability to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.

[**Table of Contents**](#TableOfContents)

**PRC regulations relating to investments in offshore companies by PRC residents may subject our PRC resident beneficial owners or our wholly foreign-owned subsidiaries in China to liability or penalties, limit our ability to inject capital into these subsidiaries, limit these subsidiaries' ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us.**

In October 2005, SAFE promulgated the Circular of the State Administration of Foreign Exchange on Issues Concerning the Regulation of Foreign Exchange in Equity Finance and Return Investments by Domestic Residents through Offshore Special Purpose Vehicles, or SAFE Circular 75, that requires PRC citizens or residents to register with SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas equity financing involving a roundtrip investment whereby the offshore entity acquires or controls onshore assets or equity interests held by the PRC citizens or residents.

In July 2014, SAFE promulgated the Circular on Issues Concerning the Foreign Exchange Administration over the Overseas Investment and Financing and Round-trip Investment by Domestic Residents via Special Purpose Vehicles, or SAFE Circular 37 and overruled SAFE Circular 75 on the same date. SAFE Circular 37 requires PRC residents or entities to register with of the SAFE or its local branches in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such PRC residents' legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a "special purpose vehicle." The term "control" under SAFE Circular 37 is broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by the PRC residents in the offshore special purpose vehicles by such means as acquisition, trust, proxy, voting rights, repurchase, convertible bonds or other arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle. According to the Circular of Further Simplifying and Improving the Policies of Foreign Exchange Administration Applicable to Direct Investment released in February 2015 by SAFE, local banks will examine and handle foreign exchange registration for overseas direct investment, including the initial foreign exchange registration and amendment registration under SAFE Circular 37 from June 2015. If the shareholders of the offshore holding company who are PRC residents do not complete their registration with the local SAFE branches, our wholly foreign-owned subsidiaries may be prohibited from distributing their profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore company, and the offshore company may be restricted in its ability to contribute additional capital to our wholly foreign-owned subsidiaries. Moreover, failure to comply with SAFE registration and amendment requirements described above could result in liability under PRC law for evasion of applicable foreign exchange restrictions.

To our knowledge, besides Dr. Zhou, who have fulfilled the registration under SAFE Circular 75, and besides Shanghai Qiangshi Business Information Consultant Co., Ltd., who has fulfilled the procedure of overseas investment for the purpose of purchasing and holding our company's ordinary shares through Wise Sunny Limited, we are not aware of any PRC residents or entities who hold direct or indirect interests in our company and are subject to SAFE filing or registration requirements, and we will request PRC residents who we know hold direct or indirect interests in our company, if any, to make the necessary applications, filings and amendments as required under SAFE Circular 37 and other related rules. However, we may not be informed of the identities of all the PRC residents or entities holding direct or indirect interest in our company, and we cannot provide any assurance that these PRC residents or entities will comply with our request to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of our PRC resident or entities shareholders to comply with the registration procedures set forth in these regulations may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiaries in China to distribute dividends and the proceeds from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into our wholly foreign-owned subsidiaries. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits to you could be materially and adversely affected.

[**Table of Contents**](#TableOfContents)

**PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in Mainland China.**

PRC regulations and rules concerning mergers and acquisitions including the Rules on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the M&A Rules, and other recently adopted regulations and rules with respect to mergers and acquisitions established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time consuming and complex. For example, the M&A Rules require that the MOFCOM be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise, if (i) any important industry is concerned, (ii) such transaction involves factors that have or may have impact on the national economic security, or (iii) such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. Moreover, according to the Anti-Monopoly Law of PRC, which was last amended on June 24, 2022 and became effective on August 1, 2022, and the Provisions of the State Council on the Threshold of Filings for Undertaking Concentrations, which was first issued in August 2008 and last amended on January 22, 2024, and the Provisions on the Review of Concentrations of Undertakings, which was issued on March 10, 2023 and became effective on April 15, 2023, the concentration of business undertakings by way of mergers, acquisitions or contractual arrangements that allow one market player to take control of or to exert decisive impact on another market player must also be notified in advance to the MOFCOM when the threshold is crossed and such concentration shall not be implemented without the clearance of prior notification. In addition, the Circular of the General Office of the State Council on the Establishment of Security Review System for the Merger and Acquisition of Domestic Enterprises by Foreign Investors that became effective in March 2011, and the Rules on Implementation of Security Review System for the Merger and Acquisition of Domestic Enterprises by Foreign Investors, or the Security Review Rules issued by the MOFCOM that became effective in September 2011 specify that mergers and acquisitions by foreign investors that raise "national defense and security" concerns and mergers and acquisitions through which foreign investors may acquire the de facto control over domestic enterprises that raise "national security" concerns are subject to strict review by the MOFCOM, and the rules prohibit any activities attempting to bypass a security review by structuring the transaction through, among other things, trusts, entrustment or contractual control arrangements. In the future, we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-mentioned regulations and other relevant rules to complete such transactions could be time consuming, and any required approval processes, including obtaining approval from the MOFCOM or its local counterparts may delay or inhibit our ability to complete such transactions. We believe that our business is not in an industry that raises "national defense and security" or "national security" concerns. However, the MOFCOM or other government agencies may publish explanations in the future determining that our business is in an industry subject to the security review, in which case our future acquisitions in the PRC, including those by way of entering into contractual control arrangements with target entities, may be closely scrutinized or prohibited. Our ability to expand our business or maintain or expand our market share through future acquisitions would as such be materially and adversely affected.

**Our business benefits from certain financial incentives and discretionary policies granted by local governments. Expiration of, or changes to, these incentives or policies would have an adverse effect on our results of operations.**

In the past, local governments in Mainland China granted certain financial incentives from time to time to our PRC subsidiaries as part of their efforts to encourage the development of local businesses. The Circular on the Relevant Tax Policies in Respect of Medical and Hygiene Institutions issued by the State Administration of Taxation, or the SAT and Ministry of Finance that became effective in July 2000 and amended in 2009, specifies that to support the development of profitable medical institution, the following preferential policy shall be applied to the income derived by profitable medical institution as is directly used to improve the medical and hygiene service conditions within three years after the date of obtaining practice registration: (1) the self-produced preparation for its own use shall be exempted from any value-added tax; and (2) the property, land, vehicles and vessels for the profitable medical institution's own use shall be exempted from real estate tax, land-use tax of cities and towns and operation tax of vehicle and ship. Upon the expiration of the term of three years for exempting from tax, the tax collection shall be restored. The Circular on Comprehensively Promoting the Pilot Program of the Collection of Value-added Tax in Lieu of Business Tax issued by the State Administration of Taxation, or the SAT, and Ministry of Finance that became effective in May 2016, specifies that medical institutions which provide the medical services are exempted from value-added tax during the pilot scheme period for levying VAT in place of business tax. The timing, amount and criteria of government financial incentives are determined within the sole discretion of the local government authorities and cannot be predicted with certainty before we actually receive any financial incentive. We generally do not have the ability to influence local governments in making these decisions. Local governments may decide to reduce or eliminate incentives at any time. In addition, some of the government financial incentives are granted on a project basis and subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific project therein. We cannot guarantee that we will satisfy all relevant conditions, and if we do so we may be deprived of the relevant incentives. We cannot assure you of the continued availability of the government incentives currently enjoyed by us. Any reduction or elimination of incentives would have an adverse effect on our results of operations.

[**Table of Contents**](#TableOfContents)

**If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.**

The PRC Enterprise Income Tax Law, or the EIT Law effective as of January 1, 2008 and amended on December 2018 and the Regulation on the Implementation of the EIT Law, effective as of January 1, 2008 and amended on April 2019, define the term "de facto management bodies" as "bodies that substantially carry out comprehensive management and control on the business operation, employees, accounts and assets of enterprises." Under the EIT Law, an enterprise incorporated outside of PRC whose "de facto management bodies" are located in PRC is considered a "resident enterprise" and will be subject to a uniform 25% enterprise income tax (EIT) rate on its global income. On April 22, 2009, PRC's State Administration of Taxation, or the SAT, in the Notice Regarding the Determination of Chinese-Controlled Offshore-Incorporated Enterprises as PRC Tax Resident Enterprises on the Basis of De Facto Management Bodies, or SAT Circular 82, further specified certain criteria for the determination of what constitutes "de facto management bodies." If all of these criteria are met, the relevant foreign enterprise may be regarded to have its "de facto management bodies" located in China and therefore be considered a PRC resident enterprise. These criteria include: (i) the enterprise's day-to-day operational management is primarily exercised in Mainland China; (ii) decisions relating to the enterprise's financial and human resource matters are made or subject to approval by organizations or personnel in China; (iii) the enterprise's primary assets, accounting books and records, company seals, and board and shareholders' meeting minutes are located or maintained in China; and (iv) 50% or more of voting board members or senior executives of the enterprise habitually reside in Mainland China. Although SAT Circular 82 only applies to foreign enterprises that are majority-owned and controlled by PRC enterprises, not those owned and controlled by foreign enterprises or individuals, the determining criteria set forth in SAT Circular 82 may be adopted by the PRC tax authorities as the test for determining whether the enterprises are PRC tax residents, regardless of whether they are majority-owned and controlled by PRC enterprises.

We believe that neither our company nor any of our subsidiaries outside of Mainland China is a PRC resident enterprise for PRC tax purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities, and uncertainties remain with respect to the interpretation of the term "de facto management body." If the PRC tax authorities determine that our company or any of its subsidiaries outside of Mainland China is a PRC resident enterprise for enterprise income tax purposes, that entity would be subject to a 25% enterprise income tax on its global income. In addition, we will also be subject to PRC enterprise income tax reporting obligations. If such entity derives income other than dividends from its wholly-owned subsidiaries in Mainland China, a 25% EIT on its global income may increase our tax burden. Dividends paid to a PRC resident enterprise from its wholly-owned subsidiaries in Mainland China may be regarded as tax-exempt income if such dividends are deemed to be "dividends between qualified PRC resident enterprises" under the EIT Law and its implementation rules. However, we cannot assure you that such dividends will not be subject to PRC withholding tax, as the PRC tax authorities, which enforce the withholding tax, have not yet issued relevant guidance.

In addition, if we are classified as a PRC resident enterprise for PRC tax purposes, we may be required to withhold tax at a rate of 10% from dividends we pay to our shareholders, including the holders of the ADSs, that are non-resident enterprises. In addition, non-resident enterprise shareholders (including the ADS holders) may be subject to a 10% PRC withholding tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within Mainland China. Furthermore, gains derived by our non-PRC individual shareholders from the sale of our shares and ADSs may be subject to a 20% PRC withholding tax. Furthermore, if we are deemed a PRC resident enterprise, dividends paid to our non-PRC individual shareholders (including the ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the case of dividends, may be withheld at source by us), if such gains are deemed to be from PRC sources. These rates may be reduced by an applicable tax treaty, but it is unclear whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in the ADSs or ordinary shares.

[**Table of Contents**](#TableOfContents)

**We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.**

We are a holding company, and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or to service any debt we may incur. If any of our PRC subsidiaries incur debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, Peng Yi Da, a wholly foreign-owned enterprise, may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund.

Our PRC subsidiaries generate primarily all of their revenue in renminbi, which is not freely convertible into other currencies. As result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their renminbi revenues to pay dividends to us.

In response to the persistent capital outflow in Mainland China and renminbi's depreciation against U.S. dollar in the fourth quarter of 2016, China's People's Bank of China, or the PBOC, and the SAFE have promulgated a series of capital control measure over recent months, including stricter vetting procedures for China-based companies to remit foreign currency for overseas investments, dividends payments and shareholder loan repayments.

The PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.

**We and our shareholders face uncertainties in the PRC with respect to indirect transfers of equity interests in PRC resident enterprises.**

The indirect transfer of equity interest in PRC resident enterprises by a non-PRC resident enterprise, or Indirect Transfer, is potentially subject to income tax in Mainland China at a rate of 10% on the gain if such transfer is considered as not having a commercial purpose and is carried out for tax avoidance. The SAT has issued several rules and notices to tighten the scrutiny over acquisition transactions in recent years. SAT Circular 7 sets out the scope of Indirect Transfers, which includes any changes in the shareholder's ownership of a foreign enterprise holding PRC assets directly or indirectly in the course of a group's overseas restructuring, and the factors to consider in determining whether an Indirect Transfer has a commercial purpose. An Indirect Transfer satisfying all the following criteria will be deemed to lack a bona fide commercial purpose and be taxable under PRC laws: (i) 75% or more of the equity value of the intermediary enterprise being transferred is derived directly or indirectly from the PRC taxable assets; (ii) at any time during the one-year period before the indirect transfer, 90% or more of the asset value of the intermediary enterprise (excluding cash) is comprised directly or indirectly of investments in mainland China, or 90% or more of its income is derived directly or indirectly from China; (iii) the functions performed and risks assumed by the intermediary enterprise and any of its subsidiaries that directly or indirectly hold the PRC taxable assets are limited and are insufficient to prove their economic substance; and (iv) the non-PRC tax payable on the gain derived from the indirect transfer of the PRC taxable assets is lower than the potential PRC income tax on the direct transfer of such assets. Nevertheless, a non-resident enterprise's buying and selling shares or ADSs of the same listed foreign enterprise on the public market will fall under the safe harbor available under SAT Circular 7 and will not be subject to PRC tax pursuant to SAT Circular 7.

On October 17, 2017, the State Administration of Taxation issued the Circular on Issues of Tax Withholding regarding Non-PRC Resident Enterprise Income Tax at Source, or SAT Circular 37, which came into effect on December 1, 2017 and amended on June 15, 2018. SAT Circular 37 further clarifies the practice and procedure of the withholding of nonresident enterprise income tax.

[**Table of Contents**](#TableOfContents)

However, as these rules and notices are relatively new and there is a lack of clear statutory interpretation, we face uncertainties regarding the reporting required for and impact on future private equity financing transactions, share exchange or other transactions involving the transfer of shares in our company by investors that are non-PRC resident enterprises, or the sale or purchase of shares in other non-PRC resident companies or other taxable assets by us. For example, the PRC tax authorities may consider that our current offering involves an indirect change of shareholding in our PRC subsidiaries and therefore it may be regarded as an Indirect Transfer under SAT Circular 7 or SAT Circular 37. Although we believe no SAT Circular 7 or SAT Circular 37 reporting is required on the basis that the current offering has commercial purposes and is not conducted for tax avoidance, the PRC tax authorities may pursue us to report under SAT Circular 7 or SAT Circular 37 and request that we and our PRC subsidiaries assist in the filing. As a result, we and our subsidiaries may be required to expend significant resources to provide assistance and comply with SAT Circular 7 or SAT Circular 37, or establish that we or our non-resident enterprises should not be subject to tax under SAT Circular 7 or SAT Circular 37, for the current offering or other transactions, which may have an adverse effect on our and their financial condition and day-to-day operations.

**Any failure to comply with PRC regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations.**

We have adopted a share incentive plan and a performance incentive plan pursuant to which we may grant share options or other equity incentives to our directors, employees or consultants in the future. In February 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules. In accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or non-PRC citizens residing in China for a continuous period of not less than one year, who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas publicly listed company, and complete certain procedures. We and our employees who are PRC citizens or who reside in China for a continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. However, any failure to comply with the SAFE registration requirements may subject them to fines and legal sanctions and may limit the ability of our PRC subsidiaries to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors and employees under PRC law.

**Our ADSs may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect auditors who are located in China. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections deprives our investors with the benefits of such inspections.**

The Holding Foreign Companies Accountable Act, or the HFCAA, was enacted on December 18, 2020. The HFCAA states if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three consecutive years beginning in 2021, the SEC shall prohibit our shares or ADSs from being traded on a national securities exchange or in the over the counter trading market in the U.S.

On March 24, 2021, the SEC adopted interim final rules to implement the disclosure and submission requirements of the HFCAA. An identified issuer shall be required to comply with these rules if the SEC identifies it as having a "non-inspection" year under a process to be subsequently established by the SEC. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which was signed into law on December 29, 2022, amending the HFCAA and requiring the SEC to prohibit an issuer's securities from trading on any U.S. stock exchange if its auditor is not subject to PCAOB inspections for two consecutive years instead of three consecutive years. On September 22, 2021, the PCAOB adopted a final rule implementing the HFCAA, which provides a framework for the PCAOB to use when determining, as contemplated under the HFCAA, whether the PCAOB is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction. On December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the HFCAA. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued determinations that it is unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and in Hong Kong, because of positions taken by PRC authorities in those jurisdictions.

[**Table of Contents**](#TableOfContents)

On August 26, 2022, the PCAOB announced that it had signed a Statement of Protocol (the "SOP") with the China Securities Regulatory Commission and the Ministry of Finance of China. The SOP, together with two protocol agreements governing inspections and investigations (together, the "SOP Agreement"), establishes a specific, accountable framework to enable complete inspections and investigations by the PCAOB of audit firms based in mainland China and Hong Kong, as required under U.S. law. The SOP Agreement remains unpublished and is subject to further explanation and implementation. Pursuant to the fact sheet with respect to the SOP Agreement disclosed by the SEC, the PCAOB shall have sole discretion to make its selection of audit firms for inspection or investigation and the PCAOB inspectors and investigators shall have a right to see all audit documentation without redaction. Under the PCAOB's rules, a reassessment of a determination under the HFCAA may result in the PCAOB reaffirming, modifying or vacating the determination.

On December 15, 2022, the PCAOB announced that it had secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. The PCAOB Board vacated its December 2021 determinations that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong. The PCAOB will continue to demand to inspect and investigate completely in mainland China and Hong Kong in the future and is planning to resume regular inspections in early 2023 and beyond, as well as to continue pursuing ongoing investigations and initiate new investigations as needed. However, the PCAOB's ability to continue to satisfactorily inspect or investigate registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainties and depends on a number of factors beyond our and our auditor's control.

On December 12, 2023, we appointed Onestop Assurance PAC, a public accounting firm registered with PCAOB, as our independent registered public accounting firm for the audit of our financial results for the three fiscal years ended December 31, 2023. On December 8, 2025, Onestop Assurance PAC confirmed its continuation as our independent registered public accounting firm for the audit of our financial results for the financial year ending December 31, 2025. Onestop Assurance PAC, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards.

The SEC is assessing how to implement other requirements of the HFCAA, including the listing and trading prohibition requirements described above.

Such uncertainty in the implementation of HFCAA and the regular inspections and assessments carried out by PCAOB could cause the market price of our ADSs to be materially and adversely affected, and our securities could be delisted or prohibited from being traded "over-the-counter" earlier than would be required by the HFCAA. If our securities are unable to be listed on another securities exchange by then, such a delisting would substantially impair your ability to sell or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with a potential delisting would have a negative impact on the price of our ADSs. Trading in our securities may also be prohibited under the HFCAA if the PCAOB determines that it cannot inspect or investigate completely our auditor, and as a result an exchange may delist our securities, causing the value of our ADSs to decline significantly.

[**Table of Contents**](#TableOfContents)

**Risks relating to the ADSs**

**We have broad discretion to determine how to use the remaining net proceeds from our financing and may use them in ways that may not enhance our results of operations or the price of the ADSs.**

Although we currently intend to use the remaining net proceeds from our financing in the manner described in the section titled "Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds—14.E. Use of Proceeds" in this annual report, our management will have broad discretion over the use of net proceeds from our financing, and we could spend the net proceeds from our financing in ways the holders of the ADSs may not agree with, or that do not yield a favorable return. Because of the number and variability of factors that will determine our use of the net proceeds from our financing, our use of these proceeds may differ substantially from our current plans. The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition and results of operation. You will not have the opportunity, as part of your investment decision, to assess whether proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of our financing.

***The trading price of the ADSs has been, and may continue to be, volatile due to our delisting from Nasdaq and transition to the OTCQX Best Market, potentially resulting in substantial losses for investors.***

 ****

On September 6, 2023, we received a notification letter from the Nasdaq, notifying us that we are not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq. In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until March 4, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

On March 6, 2024, we received a staff determination letter from Nasdaq stating that, we have not regained compliance with the minimum bid price rule within the 180-calendar day grace period and is not eligible for a second 180-calendar day grace period. Accordingly, the staff had determined to delist our securities from Nasdaq unless the we requests a hearing no later than 4:00 p.m. Eastern Time on March 13, 2024. We have made a timely request for a hearing on March 12, 2024 and the hearing was held on April 11, 2024. As a result, we have been granted additional grace period for continued listing on the Nasdaq Capital Market until September 3, 2024, subject to the approval from the Board on a reverse stock split before May 15, 2024 and the demonstration of the Company's compliance with the minimum bid price rule and all applicable requirements for continued listing on the Nasdaq Capital Market on or before September 3, 2024.

On May 17, 2024, we received a determination letter of the Hearings Panel (the "Panel") of Nasdaq, notifying us that the Panel determined to delist the Company's securities from Nasdaq, due to the failure to satisfy the continued listing conditions as previously disclosed. On July 19, 2024, we were delisted from Nasdaq when the staff of the Nasdaq Stock Market LLC filed a Form 25 Notification of Delisting. Our ADSs have been quoted on the Pink Open Market initially under the symbol "PAIYY" since the Nasdaq suspended the trading of our ADSs on May 21, 2024. Subsequently, we applied to upgrade from the Pink Open Market to the OTCQX Best Market and received approval on July 10, 2024. Our ADSs are currently quoted on the OTCQX Best Market under the symbol "PAIYY". In order to maintain the listing of our ADSs on the OTCQX Best Market, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding a minimum ongoing bid price of $0.10 per ADS, a minimum ongoing market capitalization of $5 million, audited annual reports, quarterly reports, material news disclosure, director independence and independent committee requirements, and certain corporate governance requirements. There can be no assurances that we will be able to comply with such applicable listing standards.

 ****

The OTCQX Best Market is significantly more limited market than Nasdaq. The quotation of our ADSs on the OTCQX Best Market may result in a less liquid market available for existing and potential stockholders to trade our ADSs, could depress the trading price of our ADSs and could have a long - term adverse impact on our ability to raise capital in the future.

**We may not be able to maintain the minimum bid price for continued qualification for the OTCQX Best Market.**

On February 11, 2026, the Company received a notification letter from OTC Markets Group, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under the OTCQX Rules for International Companies section 2.1(A) for continued qualification for the OTCQX International tier.

Even if the receipt of the notification letter does not have an immediate effect on the trading of our ADSs, the subsequent delisting may result in a less liquid market for our ADSs and increased price volatility. These factors could depress the trading price of our ADSs and could have a long-term adverse impact on our ability to raise capital in the future.

**Our ultimate controller, Mr. Wu Guiqian along with his associated entities, are able to control and exert significance influence over our company, and their interest may be different from or conflict with that of the holders of our ADSs.**

Our ultimate controller, Mr. Wu Guiqian, along with his associated entities, jointly control more than 50% of the voting power of our company. In addition, our directors Mr. Zhang Chen, Ms. Wu Binhua, Ms. Laurena Wu, and Ms. Wu Binqi are all family members of Mr. Wu Guiqian. In addition to the elections of our directors, Mr. Wu Guiqian and his associated entities are and will continue to be able to exert a significant degree of influence or actual control over other management and affairs and control matters requiring an approval from a majority of shareholders, including the merger, consolidation or sale of all or substantially all of our assets, and any other significant transaction. Mr. Wu Guiqian and his associated entities' interest might not always be aligned with the interests of our other shareholders.

[**Table of Contents**](#TableOfContents)

**Certain provisions in our fourth amended and restated articles of association (as revised) may limit your ability to influence corporate matters and could discourage others from pursuing any change of control transactions.**

Our fourth amended and restated articles of association (as revised), currently in effect, provides, among other things, that certain actions including the voluntary delisting of the our securities, a Change of Control Event (as defined in our fourth amended and restated articles of association (as revised)) and certain transfers or other disposals of any assets, businesses or securities of us or any of our subsidiaries, can only be approved by shareholders**'** resolutions. For more details, please see **"**Item 6. Directors, Senior Management and Employees—6.C. Board Practices—Appointment of directors by our principal shareholders**"** and **"**Item 10. Additional Information—10.B. Memorandum and Articles of Association—Ordinary Shares—Reserved Matters.**"**

As a result of these provisions in our fourth amended and restated articles of association (as revised), although holders of our ordinary shares have the same voting rights, certain shareholders such as Mr. Wu Guiqian, Ms. Laurena Wu, ADV, Dr. Zhou Pengwu and Ms. Ding Wenting and certain other parties will have considerable influence over certain corporate governance matters such as decisions regarding mergers, consolidations and the sale of all or substantially all of our assets and appointment of chief officers. Such principal shareholders may take actions that are not in the best interest of us or our other shareholders.

These provisions may also discourage, delay or prevent a change in control of our company, which could have the effect of depriving our other shareholders of the opportunity to receive a premium for their shares as part of a sale of our company and may reduce the price of our ADSs. These provisions may limit your ability to influence corporate matters and could discourage others from pursuing any potential merger, takeover or other change of control transactions that holders of our ordinary shares and ADSs may view as beneficial.

**We may be at an increased risk of securities class action litigation.**

Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. If we were to be sued, it could result in substantial costs and a diversion of management's attention and resources, which could harm our business.

**If securities analysts do not publish favorable research about our business or if they publish negative evaluations of our business, the price of the ADSs could decline.**

The trading market for the ADSs will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

***We are a "non-accelerated filer" as defined in the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to us as a "non-accelerated filer" will make the ADSs less attractive to investors.***

 ****

We are no longer eligible to be treated as an **"**emerging growth company**"** starting from the fiscal year of 2024 as defined under the Securities Act, but we remain classified as a **"**non-accelerated filer**"** based on our current public float and revenue levels. As a non-accelerated filer, we are exempt from certain enhanced disclosure requirements applicable to larger reporting companies, including the obligation to provide auditor attestation on climate-related risks and strategic expenditures. While these exemptions reduce our compliance burden, they may result in less comprehensive disclosures compared to accelerated or large accelerated filers. Investors may perceive this reduced transparency as a potential risk, as they might have less access to critical information regarding our climate-related strategies, financial impacts, and governance oversight. If such perceptions materialize, it could lead to reduced market liquidity for our ADSs and increased stock price volatility.

**As a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available to our shareholders.**

As a foreign private issuer, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by the Cayman Islands requirements. In addition, our officers, directors and principal shareholders are exempt from the "short-swing" profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know on a timely basis when our officers, directors and principal shareholders purchase, or sell, our ordinary shares or ADSs. We are required to file an annual report on Form 20 - F within four months of the end of each fiscal year. We also furnish information on Form 6 - K, including press releases and other material disclosures, as required under SEC rules for foreign private issuers. However, the information we are required to file with or furnish to the SEC will be less extensive and less frequent than those of U.S. domestic issuers who are required to file quarterly reports on Form 10 - Q and current reports on Form 8 - K. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.

[**Table of Contents**](#TableOfContents)

**As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the OTC Market corporate governance standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards.**

As a foreign private issuer, we are permitted to take advantage of certain corporate governance requirements under the OTC Market listing standards that allow us to follow Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law had no corporate governance regime which prescribes specific corporate governance standards as of the date of this annual report. To the extent we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.

**Because we are incorporated under Cayman Islands law and conduct our operations primarily in emerging markets, you may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited.**

We are an exempted company incorporated under the laws of the Cayman Islands. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands, or the Companies Act, and the common law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States.

There is uncertainty as to whether the courts of the Cayman Islands would (1) recognize or enforce against us judgments of courts of the United States based on certain civil liability provisions of U.S. securities laws, or (2) entertain original actions brought in the Cayman Islands against us or our directors or officers that are predicated upon the federal securities laws of the United States or the securities laws of any state in the United States.

The uncertainty with regard to Cayman Islands law relates to whether a judgment obtained from the United States courts under the civil liability provisions of the securities laws will be determined by the courts of the Cayman Islands as penal or punitive in nature. If such a determination is made, the courts of the Cayman Islands will not recognize or enforce the judgment against a Cayman Islands company. Because the courts of the Cayman Islands have yet to rule on whether such judgments are penal or punitive in nature, it is uncertain whether they would be enforceable in the Cayman Islands.

There is no statutory recognition in the Cayman Islands of judgments obtained in the United States, although the Cayman Islands will generally recognize as a valid judgment, a final and conclusive judgment in personam obtained in the federal or state courts in the United States under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in personam judgment for non-monetary relief, and would give a judgment based thereon provided that (i) such courts had proper jurisdiction over the parties subject to such judgment; (ii) such courts did not contravene the rules of natural justice of the Cayman Islands; (iii) such judgment was not obtained by fraud; (iv) the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands; (v) no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and (vi) there is due compliance with the correct procedures under the laws of the Cayman Islands.

[**Table of Contents**](#TableOfContents)

In addition, we conduct substantially all of our business operations in emerging markets, including mainland China, and substantially all of our directors and senior management are based in mainland China. Among our directors and officers, except for Ms. Li Yanyun, who is based in Singapore, and Ms. Laurena Wu, who resides in Hong Kong, all of our other directors and officers, including Mr. Zhang Chen, Dr. Zhou Pengwu, Ms. Wu Binhua, Ms. Wu Binqi, Mr. Zhang Changsuo, Mr. Zhou Xichun, Mr. Liu Bo, Mr. Chen Feng (replaced Ms. Xu Tianqing on October 30, 2024), Mr. Lin Yingzhou, Ms. Hu Qing and Mr. Wu Guanhua, reside in mainland China, and all or a substantial portion of their assets are located outside of the United States. As a result, it may be difficult or impossible for you to effect service of process within the United States upon us or these persons, or to bring an original action against us or against these individuals in a Cayman Islands, Hong Kong or mainland China court in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands, the mainland China, Hong Kong and of the jurisdictions where we operate may render you unable to enforce a judgment against our assets or the assets of our directors and officers. The SEC, U.S. Department of Justice and other authorities often have substantial difficulties in bringing and enforcing actions against non-U.S. companies and non-U.S. persons, including company directors and officers, in certain emerging markets, including mainland China. Additionally, our public shareholders may have limited rights and few practical remedies in emerging markets where we operate, as shareholder claims that are common in the United States, including class action securities law and fraud claims, generally are difficult or impossible to pursue as a matter of law or practicality in many emerging markets, including mainland China. For example, in mainland China, there are significant legal and other obstacles for the SEC, the DOJ and other U.S. authorities to obtaining information needed for shareholder investigations or litigation. Although the competent authorities in mainland China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, the regulatory cooperation with the securities regulatory authorities in the United States has not been efficient in the absence of a mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, or Article 177, which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of mainland China the PRC. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within mainland China may further increase difficulties faced by you in protecting your interests.

You may also experience difficulties in enforcing judgments of the United States courts obtained against us or our directors or officers in mainland China or Hong Kong as the United States and mainland China or Hong Kong do not have a bilateral treaty or multilateral convention in force on reciprocal recognition and enforcement of judgments. As a result, any United States judgment may only be enforceable in mainland China or Hong Kong provided that the conditions set forth in the laws of these jurisdictions are determined by the courts of mainland China or Hong Kong, as applicable, to have been fulfilled. For details of the limitations relating to the enforceability of civil liabilities, see "Item 6. Directors, Senior Management and Employees - Enforceability of Civil Liabilities."

As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or large shareholders than they would as public shareholders of a company incorporated in the United States.

**We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.**

As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer's most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our ordinary shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the OTC Market continued eligibility criteria and ongoing disclosure obligations. If we lost our foreign private issuer status, we would incur significant additional legal, accounting and other expenses that we do not incur as a foreign private issuer, in order to maintain a listing on a U.S. securities exchange.

[**Table of Contents**](#TableOfContents)

**We do not currently intend to pay dividends on our securities, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs.**

We have never declared or paid any dividends on our ordinary shares. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs at least in the near term, and the success of an investment in ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, to realize any future gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which our investors purchased their ADSs.

**There is no public market for our ordinary shares, and you may not be able to resell the ADSs at or above the price you paid, or at all.**

Our ADSs are quoted on the OTC Best Market, while there is no public market for our ordinary shares. The initial public offering price for the ADSs were determined by negotiations between us and the underwriters and may bear no relationship to the market price for the ADSs after our initial public offering. We cannot assure you that an active trading market for the ADSs will develop or maintain, or that the market price of the ADSs will increase above the initial public offering price. If an active trading market for the ADSs does not develop or maintain, the market price and liquidity of the ADSs will be materially and adversely affected.

**The market price for the ADSs may be volatile which could result in substantial loss to you.**

The market price for the ADSs is likely to be highly volatile and subject to wide fluctuations in response to factors, including the following:

● announcements of competitive developments;

● regulatory developments affecting us, our customers or our competitors;

● reputation of players in our industry or companies headquartered in China;

● announcements regarding litigation or administrative proceedings involving us;

● actual or anticipated fluctuations in our period-to-period operating results;

● changes in financial estimates by securities research analysts;

● additions or departures of our executive officers;

● fluctuations of exchange rates between the RMB and the U.S. dollar;

● release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs; and

● sales or perceived sales of additional ordinary shares or ADSs.

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. For example, since August 2008, multiple exchanges in the United States and other countries and regions, including China, experienced sharp declines in response to the growing credit market crisis and the recession in the United States. As recently as August 2015, the exchanges in China experienced a sharp decline. Prolonged global capital markets volatility may affect overall investor sentiment towards the ADSs, which would also negatively affect the trading prices for the ADSs.

[**Table of Contents**](#TableOfContents)

**Fluctuations in currency exchange rates may have a material adverse effect on our results of operations and the value of your investment.**

The value of the renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the renminbi to the U.S. dollar, and the renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the renminbi and U.S. dollar remained within a narrow band. In June 2010, the PBOC, announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed the renminbi to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, more recently, on August 11, 12 and 13, 2015, the PBOC significantly devalued the renminbi by fixing its price against the U.S. dollar 1.9%, 1.6%, and 1.1% lower than the previous day's value, respectively. On October 1, 2016, the renminbi joined the International Monetary Fund's basket of currencies that make up the Special Drawing Right, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the renminbi depreciated significantly while the U.S. dollar surged and China experienced persistent capital outflows. With the development of the foreign exchange market and progress towards interest rate liberalization and renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system. There is no guarantee that the renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces, PRC and U.S. government's policies and regulations may impact the exchange rate between the renminbi and the U.S. dollar in the future.

Significant revaluation of the renminbi may have a material adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars into renminbi for our operations, appreciation of the renminbi against the U.S. dollar would have an adverse effect on the renminbi amount we would receive from the conversion. Conversely, if we decide to convert our renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the renminbi would have a negative effect on the U.S. dollar amount available to us. In addition, appreciation or depreciation in the value of the renminbi relative to U.S. dollars would affect our financial results reported in U.S. dollar terms regardless of any underlying change in our business or results of operations.

Very limited hedging options are available in Mainland China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert renminbi into foreign currency.

**Substantial future sales or perceived sales of the ADSs in the public market could cause the price of the ADSs to decline.**

Sales of the ADSs in the public market after our initial public offering, or the perception that these sales could occur, could cause the market price of the ADSs to decline. As of December 31, 2025, we had 146,062,754 ordinary shares outstanding, including 29,987,856 ordinary shares represented by ADSs. The 146,062,754 ordinary shares outstanding exclude the 135,000 ordinary shares repurchased by us in 2020 and the 1,128,750 ordinary shares from the options outstanding under the Share Incentive Plan. All ADSs sold in our initial public offering are freely transferable without restriction or additional registration under the Securities Act. The remaining ordinary shares outstanding after our initial public offering became available for sale, subject to restrictions as applicable under Rule 144 under the Securities Act, upon the expiration of the 180-day lock-up arrangements entered into among us, the underwriters and other relevant parties on April 30, 2020. Reference is made to the press release of the Company filed with the SEC on July 20, 2022. All capitalized terms in this paragraph not otherwise defined herein shall have the meanings ascribed to them in this press release. During a twelve-month period following the Closing Date of August 16, 2023, none of the Founders or their Affiliates shall directly or indirectly engage in any Founder Transfer Transaction involving the Company Restricted Securities, unless approved by the Board and satisfying the specified conditions. Additionally, after the Closing Date, restrictions are placed on the transfer or disposition of Company Restricted Securities to any Person engaged in cosmetic medicine services in Greater China and its controlling shareholders and actual controllers, subject to Board approval. Furthermore, ADV is restricted from transferring Company Restricted Securities exceeding ten percent of the outstanding shares of the Company to such entities without prior written consent from the other Parties. These restrictions aim to maintain stability in the market and protect the interests of the Company and its stakeholders. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder, or the availability of these securities for future sale, will have on the market price of the ADSs.

[**Table of Contents**](#TableOfContents)

**Holders of ADSs have fewer rights than shareholders and must act through the depositary to exercise their rights.**

Holders of ADSs do not have the same rights as our registered shareholders. As a holder of our ADSs, you will not have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As an ADS holder, you will only be able to exercise the voting rights carried by the underlying ordinary shares indirectly by giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary. Upon receipt of your voting instructions, the depositary will try, as far as is practicable, to vote the ordinary shares underlying your ADSs in accordance with your instructions. If we ask for your instructions, then upon receipt of your voting instructions, the depositary will try to vote the underlying ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for your instructions, the depositary may still vote in accordance with instructions you give, but it is not required to do so. You will not be able to directly exercise your right to vote with respect to the underlying ordinary shares unless you withdraw the shares, and become the registered holder of such shares prior to the record date for the general meeting. When a general meeting is convened, you may not receive sufficient advance notice of the meeting to withdraw the shares underlying your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our memorandum and articles of association currently in effect, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the ordinary shares underlying your ADSs and becoming the registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to vote directly. If we ask for your instructions, the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We have agreed to give the depositary notice of shareholder meetings sufficiently in advance of such meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the shares underlying your ADSs are voted and you may have no legal remedy if the shares underlying your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders' meeting.

**Except in limited circumstances, the depositary for our ADSs gives us a discretionary proxy to vote the ordinary shares underlying your ADSs if you do not vote at shareholders' meetings, which could adversely affect your interests.**

Under the deposit agreement for the ADSs, if you do not vote, the depositary gives us a discretionary proxy to vote the ordinary shares underlying your ADSs at shareholders' meetings unless:

● we have instructed the depositary that we do not wish a discretionary proxy to be given;

● we have informed the depositary that there is substantial opposition as to a matter to be voted on at the meeting;

● a matter to be voted on at the meeting would have a material adverse impact on shareholders; or

● the voting at the meeting is to be conducted via a show of hands unless voting by poll is required by the applicable listing rules or our articles of association.

The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, except under the circumstances described above. This may make it more difficult for shareholders to influence the management of our company. In contrast, holders of our ordinary shares will not be subject to this discretionary proxy.

[**Table of Contents**](#TableOfContents)

**You may not receive distributions on the ADSs or any value for them if such distribution is illegal or impractical or if any required government approval cannot be obtained in order to make such distribution available to you.**

Although we do not have any present plan to pay any dividends, the depositary of the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses and any applicable taxes and governmental charges. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities whose offering would require registration under the Securities Act but are not so properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not reasonably practicable to distribute certain property. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under the U.S. securities laws any offering of ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.

**Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings.**

We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless either both the rights and any related securities are registered under the Securities Act, or the distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible, or allow them to lapse. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings.

**We may be classified as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. holders of the ADSs or ordinary shares.**

Depending upon the value of the ADSs and ordinary shares and the nature and composition of our assets and income over time, we could be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Based on the value of our outstanding ADSs and ordinary shares and the composition of our assets and income, we do not believe we were a PFIC for the taxable year ending December 31, 2024. However, there can be no assurance that we will not be a PFIC for the current taxable year. In addition, there can be no assurance that we will not be a PFIC for any future taxable year. PFIC status is a factual determination that must be tested each taxable year and will depend on the composition of our assets and income in each such taxable year.

We will be classified as a PFIC for any taxable year if either (i) at least 75% of our gross income for the taxable year is passive income or (ii) at least 50% of the value of our assets (based on a quarterly value of the assets during the taxable year) is attributable to assets that produce or are held for the production of passive income. In determining the average percentage value of our gross assets, the aggregate value of our assets will generally be deemed to be equal to our market capitalization (determined by the sum of the aggregate values of our outstanding equity) plus our liabilities. Accordingly, we could become a PFIC if our market capitalization were to decrease significantly while we hold substantial cash, cash equivalents or other assets that produce or are held for the production of passive income. In addition, because there are uncertainties in the application of the relevant PFIC rules, it is possible that the Internal Revenue Service, or IRS, may challenge our classification of certain income and assets as non-passive or our valuation of our tangible and intangible assets, which could result in a determination that we were a PFIC for the current or subsequent taxable years.

If we were classified as a PFIC in any taxable year in which a U.S. Holder (as defined in "Item 10. Additional Information—10.E. Taxation—United States Federal Income Taxation") holds the ADSs or ordinary shares, the U.S. Holder would generally be subject to additional taxes and interest charges on certain "excess distributions" we make and on the gain, if any, recognized on the disposition or deemed disposition of such U.S. Holder's ADS or ordinary shares, even if we are no longer a PFIC in the year of distribution or disposition. Moreover, such U.S. Holder would also be subject to special U.S. tax reporting requirements. For more information on the U.S. tax consequences to U.S. Holders that would result from our classification as a PFIC, see "Item 10. Additional Information—10.E. Taxation—United States federal income taxation—Passive foreign investment company."

[**Table of Contents**](#TableOfContents)

**You may have difficulty enforcing judgments obtained against us.**

We are a company incorporated under the laws of the Cayman Islands, and substantially all of our assets are located outside the United States. Substantially all of our current operations are conducted in the PRC. In addition, all of our directors and officers are nationals and residents of countries other than the United States. Among our directors and officers, except for Ms. Li Yanyun, who is based in Singapore, and Ms. Laurena Wu, who resides in Hong Kong, all of our other directors and officers, including Mr. Zhang Chen, Dr. Zhou Pengwu, Ms. Wu Binhua, Ms. Wu Binqi, Mr. Zhang Changsuo, Mr. Zhou Xichun, Mr. Liu Bo, Mr. Chen Feng (replaced Ms. Xu Tianqing on October 30, 2024), Mr. Lin Yingzhou, Ms. Hu Qing and Mr. Wu Guanhua, reside in mainland China, and all or a substantial portion of their assets are located outside of the United States. As a result, all or a substantial portion of the assets of these persons are located outside the United States. As a result, it may be difficult for you to effect service of process within the United States upon these persons. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors. In addition, there is uncertainty as to whether the courts of the Cayman Islands, Hong Kong or mainland China would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state.

The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. Courts of mainland China may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between Mainland China and the country where the judgment is made or on principles of reciprocity between jurisdictions. Mainland China does not have any treaties or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the courts of mainland China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. See **"**Item 6. Directors, Senior Management and Employees—Enforceability of Civil Liabilities.**"** for more details.

**You may be subject to limitations on transfers of your ADSs.**

Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

**Your rights to pursue claims against the depositary as a holder of ADSs are limited by the terms of the deposit agreement.**

Under the deposit agreement, any action or proceeding against or involving the depositary, arising out of or based upon the deposit agreement or the transactions contemplated thereby or by virtue of owning the ADSs may only be instituted in a state or federal court in New York, New York, and you, as a holder of our ADSs, will have irrevocably waived any objection which you may have to the laying of venue of any such proceeding, and irrevocably submitted to the exclusive jurisdiction of such courts in any such action or proceeding.

**ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.**

The deposit agreement governing the ADSs representing our ordinary shares provides that the federal or state courts in the City of New York have exclusive jurisdiction to hear and determine claims arising under the deposit agreement and in that regard, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.

[**Table of Contents**](#TableOfContents)

If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, as of the date of this annual report, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws had not been finally adjudicated by the United States Supreme Court. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement. It is advisable that you consult legal counsel regarding the jury waiver provision before investing in the ADSs.

If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action.

Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.

**Techniques employed by short sellers may drive down the market price of the ADSs.**

Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is in the short seller's interest for the price of the security to decline, many short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects in order to create negative market momentum and generate profits for themselves after selling a security short. These short attacks have, in the past, led to selling of shares in the market.

Public companies that have substantially all of their operations in China have been the subject of short selling. Notably, short sellers issued negative research reports about certain public companies based in Mainland China in early 2020, which attracted much attention of global investors. Much of the scrutiny and negative publicity has centered on allegations of a lack of effective internal control over financial reporting resulting in financial and accounting irregularities and mistakes, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result, many of these companies are now conducting internal and external investigations into the allegations and, in the interim, are subject to shareholder lawsuits and/or SEC enforcement actions.

It is not clear what effect such negative publicity could have on us. The negative publicity against other public companies based in Mainland China could also harm investors' confidence in Chinese companies in general, and thus affect our reputation and the market price of our ADSs. If we were to become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we could have to expend a significant amount of resources to investigate such allegations and/or defend ourselves. While we would strongly defend against any such short seller attacks, we may be constrained in the manner in which we can proceed against the relevant short seller by principles of freedom of speech, applicable state law or issues of commercial confidentiality. Such a situation could be costly and time-consuming, and could distract our management from growing our business. Even if such allegations are ultimately proven to be groundless, allegations against us could severely impact our business operations, and any investment in the ADSs could be greatly reduced or even rendered worthless.

[**Table of Contents**](#TableOfContents)

**Item 4. Information on the Company**

**4. A. History and Development of the Company**

We commenced operations in 1997 through Shenzhen Pengcheng Clinic, which became Pengcheng Hospital in 2003. Since then, we have expanded our business operations through acquisitions and organic growth. In particular, we established our second flagship hospital, Shenzhen Pengai Hospital, in 2005.

In May 2011, our company was incorporated in the Cayman Islands under the name of Pengai Hospital Management Corporation as our offshore holding company. Following certain name changes, our company changed its name to Aesthetic Medical International Holdings Group Limited in July 2018.

Peng Oi Investment (Hong Kong) Holdings Limited (formerly known as Peng Cheng Investment (Hong Kong) Holdings Limited) was incorporated in Hong Kong in July 2004. In July 2011, we acquired the entire equity interest in Peng Oi Investment (Hong Kong) Holdings Limited from Dr. Zhou Pengwu and Ms. Ding Wenting.

Dragon Jade Holdings Limited was incorporated in the British Virgin Islands, or the BVI in January 2014. Later in 2014, we transferred to Dragon Jade Holdings Limited our entire equity interest in Peng Oi Investment (Hong Kong) Holdings Limited in exchange for Dragon Jade Holdings Limited to issue and allot one fully paid share of US$1.00 to our company. Upon completion of the share swap, Dragon Jade Holdings Limited became a direct wholly-owned subsidiary of our company.

Peng Yida Business Consulting (Shenzhen) Co., Ltd. Is a direct wholly-owned subsidiary of Peng Oi Investment (Hong Kong) Holdings Limited, which was established in the PRC in December 2010.

Shenzhen Pengai Hospital Investment Management Co., Ltd. (formerly known as Shenzhen Pengcheng Hospital Investment Co., Ltd.), or Shenzhen Pengai Investment, is a direct wholly-owned subsidiary of Peng Yida Business Consulting (Shenzhen) Co., Ltd., which was established in the PRC in December 2004. Shenzhen Pengai Investment is the holding company of our operating subsidiaries in the PRC.

We acquired the entire equity interest in Newa Medical Aesthetics Limited in October 2015 to further extend our footprint to Hong Kong, which was then closed due to the COVID-19 pandemic.

We incorporated Stargaze Wealth Limited in the BVI in April 2017 and Aesthetic Medical International Holdings (Singapore) Pte. Ltd., formerly known as China Aesthetic Healthcare Holding (Singapore) Pte. Ltd., in Singapore in May 2017 to invest in our Singapore medical center, which was then divested in December 2023.

We have continuously expanded our footprint by investment in new treatment centers or acquisition of existing ones. In 2019, we established five and acquired three new treatment centers (in two of which we held minority equity interest before 2019) in cooperation with business partners. In 2020, we established one and acquired four new treatment centers, excluding treatment centers from Hanfei. For example, in November 2019, Nanchang Pengai Xiuqi was established with a registered capital of RMB15.0 million, which will replace Nanchang Pengai Aesthetic Medical Clinic Co., Ltd., or Nanchang Pengai, as we aim to enhance our business footprint in Jiangxi Province. In 2021, to further leverage our extensive operational experiences and resources in the Hong Kong and Mainland China and the Yangtz River Delta area in Mainland China, our wholly-owned subsidiary Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. Entered into a definitive equity transfer agreement (the "Agreement") with a shareholder of Guangzhou Meixi Aesthetic Medical Clinic Company Limited ("Meixi") on October 17, 2021. Pursuant to the Agreement, we purchased 73% of equity interests in Meixi from its existing shareholder. Meixi's name was changed to Guangzhou Pengai Xiuqi Aesthetic Medical Clinic Co., Ltd. ("Guangzhou Xiuqi"), and its financial statement was consolidated by us in November 2021. Following 2019, all treatment centers acquired or established were closed or divested due to the impact of COVID-19, with the exception of those located in Shanghai, Beijing, and Guangzhou.

[**Table of Contents**](#TableOfContents)

As of the date of this annual report, we have a strategically established network, comprising 9 wholly- or majority-owned centers. Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. had suspended operations as of the date of this annual report. Our treatment centers spread across major cities in mainland China, with major focus in the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtz River Delta area in Mainland China. We have completed the transfer of our equity interest in each of Changsha Pengai, Nanchang Pengai to business partners and the shutdown of Shenzhen Miaoyan as part of our region development plan, which are not counted in the number of our treatment centers in 2022. In 2023, as part of our initiative to divest non-performing assets, we entered into several equity transfer agreements with independent third parties regarding the sale of certain subsidiaries and entities. The subsidiaries include Shenzhen Miaoyan Medical Technology Investment Co., Ltd., Ningbo Beilun Pengai Aesthetic Medical Clinic Co., Ltd., and Stargaze Wealth Limited. The entities in which we held less than a 50% stake include Shenzhen Pengai Jiayan Aesthetic Medical Clinic, Shenzhen Huayan Yuese Health Management Consulting Co., Ltd., and Shenzhen Xuri Jiayan Aesthetic Technology Co., Ltd. In 2024, we deregistered several subsidiaries that were not in operations, including Hangzhou Pengai E - commerce Co., Ltd. in March 2024, Shengli Aesthetic Technology Investment (Hong Kong) Company Limited in April 2024, Yantai Guangcheng Health Technology Co., Ltd. in June 2024 and Shanghai Pengai Medical Technology Co., Ltd. in June 2024. Additionally, Newa Medical Aesthetic Limited was deregistered in February 2025.

In May 2021, we entered into definite share subscription agreement for the issuance of 5,329,410 ordinary shares to Lafang China Co., Ltd. ("Lafang"), a daily consumer products producer in China, at a sale price of US$8.50 every three ordinary shares (equivalent to US$8.50 per American Depositary Share of the Company), which amounted to US$15.1 million in proceeds. In May 2022, we entered into an amendment to the above share subscription agreement with Lafang. Pursuant to this amendment, we issued 21,413,276 ordinary shares to Hawyu (HK) Limited, a wholly-owned subsidiary of Lafang, at a sale price of RMB4.67 per ordinary share (equivalent to approximately US$2.1 per American Depositary Share based on the exchange rate as of May 31, 2022), which amounted to RMB100 million (US$15 million) in proceeds. The private placement was closed in July 2022. We utilized the money from this private placement to fund our business development and working capital.

In July 2022, we entered into a Subscription Agreement for the issuance of 36,402,570 ordinary shares to Jiechuang or its designated affiliates at a sale price of RMB4.67 per ordinary share (equivalent to approximately US$2.1 per American Depositary Share based on the exchange rate as of July 20, 2022), which amounted to RMB170 million (US$25 million) in proceeds. The private placement was closed in February 2023 through the issuance and allotment of 36,402,570 ordinary shares to MY Universe (HK) Limited as designated by Jiechuang. We utilized the money from this private placement to fund our business development and working capital.

[**Table of Contents**](#TableOfContents)

Concurrently with the Subscription Agreement with Jiechuang, we entered into a Share Purchase Agreement with Dr. Zhou Pengwu and Ms. Ding Wenting (the "Founders"), certain of our existing shareholders controlled by the Founders, and Wanda. Pursuant to the Share Purchase Agreement, Seefar Global Holdings Limited, Jubilee Set Investments Limited, and Pengai Hospital Management Corporation (collectively referred as to the "Sellers") agreed to sell and Wanda as the buyer agreed to purchase, an aggregate of 21,321,962 of our ordinary shares (the "Sale Share") for the total consideration in USD that is equivalent of RMB100 million, representing a price of RMB4.67 per Sale Share. The Founders entered into the Share Purchase Agreement as parties to the Share Purchase Agreement and guarantors for the Sellers.

Concurrently with the Subscription Agreement with Jiechuang, we entered into a Shareholders' Agreement with the Founders, Seefar, Jubilee and certain other parties. The Shareholders' Agreement governs, among other things, the appointment of our board of directors (the "Directors") and senior management, the notice, quorum and Directors' voting arrangement of board meetings, certain lock-up commitments of the Founders and their affiliates and pre-emptive rights mechanisms for our ordinary shares. Pursuant to the Shareholders' Agreement, we shall deliver two separate warrants to purchase our ordinary shares to Seefar and Wanda, respectively, on the date of completion of closings of both the Share Transfer and subscription of ordinary shares by Jiechuang. Upon the exercise and fulfillment of the terms of the Seefar and Wanda Warrants, we shall issue and allot 4,655,386 ordinary shares to Seefar and 6,423,983 ordinary shares to Wanda.

Concurrently with the Subscription Agreement with Jiechuang, we entered into a Cooperation Agreement with Peak Asia Investment Holdings V Limited ("ADV") and its affiliate, the Founders, Wanda and Jiechuang. The Cooperation Agreement provides, among other things, that: (i) upon the Closing, ADV shall, subject to the requisite approvals being obtained and continuing in force, convert the outstanding Principal Amount (as defined in the Convertible Note issued to ADV on September 17, 2020 (the "Note")) and the Conversion Catch-up Amount (as defined in the Note), at a conversion price that is equal to the USD equivalent of RMB4.203 per ordinary share; and (ii) we shall execute and deliver to ADV the warrant for the purchase of our shares to ADV on the date of the Cooperation Agreement (such warrant, the "Warrant"). The Warrant shall be effective on and from the Closing and shall be exercisable into ordinary shares of the Company in accordance with the terms thereof. The warrant exercise price shall be equal to the USD equivalent of RMB4.67 per ordinary share and may be settled, subject to the terms and conditions of Warrant, by way of cashless settlement and/or set-off against the Exit Payment (as defined in the Exit Payments Agreement entered into by ADV, the Company, the Founders on September 15, 2020). The Warrant shall contain customary registration rights and the Warrant Shares shall be freely transferable on the exercise of the Warrant.

Reference is made to the press release of the Company filed with the Securities and Exchange Commission (the "SEC") on July 20, 2022 and form 6-K of the Company filed with the SEC on February 16, 2023 and August 17, 2023 (collectively, "Previous Disclosure") in relation to, among other, closed a share purchase agreement, a subscription agreement, a shareholders' agreement and a cooperation agreement. All capitalized terms in this paragraph not otherwise defined herein shall have the meanings ascribed to them in the Previous Disclosure. We have closed our previously announced (i) Share Transfer of an aggregate of 21,321,962 ordinary shares of the Company from Sellers to Wanda pursuant to a share purchase agreement between the Company, the Founders, certain existing shareholders of the Company controlled by the Founders and Wanda dated July 20, 2022; (ii) issue of a total number of 12,088,808 ordinary shares of the Company to ADV at a conversion price of US dollars equivalent of RMB4.203 per ordinary share on August 16, 2023 pursuant to the Note issued to ADV on September 17, 2020 and the cooperation agreement between ADV and its affiliate, the Company, the Founders, Wanda and Jiechuang dated July 20, 2022; and (iii) issue of warrants to Seefar Global Holdings Limited and Wanda pursuant to the shareholder's agreement dated July 20, 2022. On August 18, 2023, Seefar Global Holdings Limited exercised its warrants to convert 1,956,516 shares at a consideration of US$1,956.52. On December 13, 2024, Seefar Global Holdings Limited exercised another tranche of warrants, which became exercisable date starting from August 18, 2024, to convert 2,698,870 shares at a consideration of US$2,698.87. ADV did not exercise its warrants, which expired on December 15, 2024, to convert the US$2.7 million Exit Payment into our ordinary shares. The repayment of US$2.7 million from the Company to ADV is contingent upon further notice from ADV. As of the date of this annual report, the Company has outstanding warrants issued to Wanda, entitling Wanda to purchase 6,423,983 ordinary shares at the USD equivalent of RMB4.67 per share before August 16, 2025.

Our website addresses are website https://ir.aihgroup.net. The information contained in, or accessible from, our website or any other website does not constitute a part of this annual report. The SEC maintains a website at www.sec gov that contains reports proxy, and information statements, and other information regarding issuers that file electronically with the SEC using its EDGAR system.

**4. B. Business Overview**

**Mission**

Our mission is to bring beauty, health and confidence to everyone by delivering safe, high quality aesthetic medical services. We plan to achieve the mission by maintaining and strengthening our leading market position and brand in the aesthetic medical treatment market in China with major focus in the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtz River Delta area.

**Overview**

We are a leading provider of aesthetic medical services in China. Leveraging over 20 years of clinical experience, we provide one-stop aesthetic service offerings that include (1) surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation and liposuction, (2) non-surgical aesthetic treatments which comprise minimally invasive treatments and energy-based treatments such as laser, ultrasound and radiofrequency treatments, and (3) other aesthetic services such as cosmetic dentistry, as well as general medical services. As one of the market leaders in China, we believe we are well-positioned to benefit from the favorable tailwinds, including growing social acceptance of aesthetic medical services.

[**Table of Contents**](#TableOfContents)

We generate our revenue primarily from providing aesthetic treatments. We have grown our network significantly since our operation commenced in 1997. As of the date of this annual report, we have a strategically established network comprising 9 wholly- or majority-owned treatment centers. Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. had suspended operations as of the date of this annual report. Our treatment centers spread across major cities in China, with major focus in the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtz River Delta area in Mainland China. As we continue to expand our network, one of our core business strategies is to develop our "flagship" medical institutions, which are typically large-scale full-service treatment centers that contribute a significant proportion of our revenue and are staffed with our most experienced doctors. We believe that developing flagship medical institutions will not only improve our brand awareness in the surrounding area, but also enable us to provide high-end, specialized, and complex medical services to customers referred from smaller-scale treatment centers within our network. We currently have two flagship medical institutions, i.e., Pengcheng Hospital and Shenzhen Pengai. Our scalable business model is built on our highly standardized operating procedures across a centralized network, which we believe has allowed us to quickly and successfully expand. We intend to continue to expand our network into new cities throughout mainland China through organic growth as well as strategic acquisitions, and strategically restructure and focus more on our core markets in the form of Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze Delta Area, where we see larger growth potential.

Since our inception, we have been committed to delivering high quality services to our customers. Our doctors have rich experience in providing both surgical and non-surgical aesthetic medical services. We believe our team of highly qualified and experienced medical professionals, as well as our stringent safety controls, have underpinned our strong reputation as we continue to attract and retain customers and receive industry recognition for our high quality services. We have received a number of high-profile awards. In 2020, we co-published the 2020 White Paper for the Aesthetic Medical Service Industry in China, along with Forbes China, which was a recognition of our leading position in the industry. In 2021, we have received a number of high-profile awards, including "Agency of the Year Award for Outstanding Performance" by Aesthetic Medical Industry Notes, "Annual Quality, Safe and Secure Aesthetic Medical Agency in 2021" by Shenzhen Association of Plastics and Aesthetics, and "the Best New Digital Media Operation Innovation Award in 2021" by Allergan. In addition, in September 2021, we launched a preliminary plan for business strategies and restructing to optimize our business operations, aiming to achieve a more focused market delineation, steadier development and healthier portfolio. In 2022, the famous high-end hyaluronic acid supplier Allergan gave us the award of CoolSculpting Strategic Partner of the Year 2022 in recognition of our industry-leading role in high-quality compliance operations. In 2023, we were honored to receive the "2022 Annual Quality, Safe and Secure Aesthetic Medical Institution" award from the Shenzhen Association of Plastics and Aesthetics, as well as the "2023 Meituan Polaris Aesthetic Medical Institution" award from Meituan, one of China's largest platforms for online aesthetic medical customer acquisition, further solidifying our position as a benchmark in the aesthetic medical industry in Shenzhen. In 2024, we continued our excellence by winning the "2023 Annual Quality, Safe and Secure Aesthetic Medical Institution" award from the Shenzhen Association of Plastics and Aesthetics, and the "2024 Meituan Polaris Aesthetic Medical Institution" award from Meituan, reaffirming our leading role in the industry.

**Business model**

We generate revenue primarily from our core business providing surgical aesthetic treatment services and non-surgical aesthetic treatment services, comprising minimally invasive treatments and energy-based treatments (surgical and non-surgical treatments together contributed to 90.5%, 90.4% and 92.4% of our revenue in 2023, 2024 and 2025, respectively), as well as non-core business providing general healthcare and other aesthetic services (contributed to 9.4%,9.6% and 7.6% of our revenue in 2023, 2024 and 2025, respectively). We offer a wide range of surgical and non-surgical aesthetic treatments to cater to the various needs of our customers. The following table sets forth our revenue by service offering for the years indicated:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2023** | **2024** | **2024** | **2025** | **2025** | **2025** |
|  | **RMB** | | **RMB** | | **RMB** | **US$** | |
|  | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Non-surgical aesthetic medical services |  |  |  |  |  |  |  |
| Minimally invasive aesthetic treatments | 234811 | 34.4% | 235624 | 31.5% | 246172 | 35202 | 31.4% |
| Energy-based treatments | 240063 | 35.2% | 322212 | 42.6% | 294910 | 42172 | 40.8% |
| Sub-total | 474874 | 69.6% | 557836 | 74.1% | 541082 | 77374 | 74.9% |
| Surgical aesthetic medical services | 143057 | 21.0% | 125369 | 16.3% | 126790 | 18131 | 17.5% |
| General healthcare services and other aesthetic medical services | 64656 | 9.4% | 72466 | 9.6% | 54983 | 7862 | 7.6% |
| **Total** | 682587 | 100% | 755671 | 100% | 722855 | 103367 | 100% |

---

[**Table of Contents**](#TableOfContents)

In addition, the following table sets forth our other key operating metrics, such as the number of procedures performed and the average spending per aesthetic procedure, for the years indicated:

---

| | | | |
|:---|:---|:---|:---|
| | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
| <br>**Key operating metrics** | **2023** | **2024** | **2025** |
| Number of doctors (full-time and part-time) | 142 | 148 | 156 |
| Number of surgical treatments | 33865 | 31056 | 27227 |
| Average spending per surgical procedure (in RMB) | 4224 | 3963 | 4657 |
| Number of non-surgical treatments | 489723 | 642078 | 605769 |
| Average spending per non-surgical procedure (in RMB) | 970 | 898 | 893 |
| Total number of aesthetic treatments | 523588 | 655134 | 632996 |
| % surgical treatments | 6.5% | 4.7% | 4.3% |
| % non-surgical treatments | 93.5% | 95.3% | 95.7% |

---

 ****

**Overview of aesthetic services**

*Non-surgical aesthetic medical services*

Our non-surgical aesthetic medical services primarily comprise (1) energy-based treatments and (2) minimally invasive aesthetic treatments. Depending on the complexity, materials used and scope of the procedure, our treatments vary significantly in price. The following table provides a summary of the key services we provide and information in 2025.

---

| | | |
|:---|:---|:---|
| <br>**Level 1 classification** | <br>**Level 2 classification** | **Price range per**<br>**standard**<br>**procedure**<br>**(RMB)** |
| Energy-based treatment | Epidermal energy-based treatments | 200 - 100000 |
|  | Mesotherapy | 100 - 41000 |
| Minimally invasive treatment | Botox injection | 500 - 44000 |
|  | Hyaluronic acid injection | 500 - 218400 |
|  | Thread lift | 2000 - 60000 |

---

To ensure the consistency quality and safety in our procedures, we utilize a standardized process for the treatments. These aesthetic procedures are typically completed within one hour, with recovery time of up to one week, depending on the type of procedure and the customer's physical conditions.

In 2022, we launched 6 new non-surgical aesthetic medical treatment solutions with the support of new products and equipments, as to Multi-dimensional Pigmentation Clearing, Non-invasive Body Shaping, Collagen Ion Cannon, 6G laying Thin, Acne bacteria Balance, and White Moonlight. We introduced various well-known aesthetic medical products, such as Rejuran produced by Pharma Research Products Co., Ltd., CureWhite produced by IMEIK Technology Development Co., Ltd., Ellanse produced by Huadong Medicine Co., Ltd., Loviselle produced by Changchun SinoBiomaterials Co., Ltd., and purchased advanced energy-based treatment equipment to further expand our service offerings, including the Alma Opus Plasma, and Solta Medical Thermage FLX. In 2023, we introduced three major treatment solutions and one collagen product. The three major solutions include Multi-dimensional Pigmentation Clearing 3.0, Baby Face 3.0, and Skin Infusion Series. Additionally, we launched one collagen product named See Sense Collagen 3+17 Type. We are committed to continuously developing constructive treatment solutions for our customers in the future. In 2024, we launched three key treatments with strong market competitiveness and Pengai's unique elements: "Collagen Subscription", "Collagen Planting", and the "Needle & MicroUltra Combo". These treatments can enhance our brand awareness and boost customer satisfaction and loyalty.

[**Table of Contents**](#TableOfContents)

*Minimally invasive aesthetic treatments*

Minimally invasive aesthetic treatments are non-surgical procedures that can help individuals improve their appearance with minimal or no incisions. These treatments are typically performed in fifteen minutes to two hours with minimal pain and mild bruising or swelling, whilst achieving immediate effects. Recovery time varies depending upon the service type, but generally the healing period is between one to two weeks.

To ensure consistency of quality and safety, all our injection treatments follow a standardized procedure that involves the application of numbing cream, disinfection of the treatment area which has been identified and marked by our doctors and injection at the treatment area with a sterilized syringe. After the injection, the treated area is cleaned, shaped and iced.

*Energy-based treatments*

We offer a range of epidermal energy-based treatments using high-grade equipment from China, Germany, Israel and the United States. Our standardized procedures for energy-based treatments, which typically take less than one hour, involve the following steps: facial cleansing, application of numbing cream or anesthetic to the treatment area, disinfection, methodical application of the energy-based treatment, including testing on a small area before adjusting the level of energy-based intensity accordingly. To achieve and maintain optimal results, customers may choose to repeat the procedure, depending on the type of procedure and customer reaction to the treatment.

Mesotherapy is catagorized within energy-based treatment due to naming conventions. We offer a wide range of mesotherapy treatments using injection materials from low end to high end according to customer spending power and skin needs.

*Surgical aesthetic medical services*

We provide customary surgical aesthetic medical services, including double eye lid surgery, rhinoplasty, breast augmentation, liposuction and facelifts, among others. Surgical aesthetic treatments typically involve local or full anesthesia, and an extended recovery time. All of our surgical aesthetic treatments are performed in fully equipped operating rooms in our treatment centers. Depending on the complexity of the procedure and the physicians involved, our treatments vary significantly in price. The following table sets forth our main surgical aesthetic treatments and information in 2025.

---

| | | |
|:---|:---|:---|
| <br>**Treatment** | <br>**Description** | **Price range per**<br>**standard**<br>**procedure**<br>**(RMB)** |
| Eye surgery | Change the shape or appearance of the eyes, eyelids | 1500- 29800 |
| Nose surgery / rhinoplasty | Change the shape or appearance of the nose by adding fillers or cartilage | 2000- 50000 |
| Breast augmentation | Procedures designed to enlarge/reduce or change the shape of the breasts | 3980- 116350 |
| Liposuction | Procedure in which excess fatty tissue is removed from a specific part of the body through suction | 2000- 47900 |

---

Due to their complexity, we require all our surgical aesthetic treatments to be attended (or performed) by doctors with a high level of experience. To ensure the consistency of quality and safety in our procedures we utilize a standardized process for the treatment. These procedures are typically completed within one to three hours, with recovery time ranging from one to twelve months, depending on the type of procedure and the customer's physical conditions.

*General healthcare services and other aesthetic medical services*

We provide a range of medical services through our Pengcheng Hospital, primarily in internal medicine and traditional Chinese medicine. We also provide other aesthetic medical services, primarily in aesthetic dentistry, aesthetic traditional Chinese medicine and hair loss treatments. Our aesthetic traditional Chinese medical treatments, unlike western medical treatments, which are clinically proven, include herbal oral medications, dietary advice, herbal poultices and foot baths, ultraviolet negative ion beauty treatments, ultrasounds, iontophoresis (use of local electric current) and acupuncture, cupping, massage and skin scraping (known as "gua sha" in China). Historically we have provided additional general healthcare services, including otolaryngology, bromhidrosis treatment and abortion, which we have discontinued.

[**Table of Contents**](#TableOfContents)

**Aesthetic services process**

We have developed, improved and implemented highly standardized operational procedures across our treatment centers through years of industry experience and accumulated know-how. Our process focuses on providing customized services and high quality customer experiences. The following diagram illustrates a typical aesthetic service process, which involves image consultants, doctors, nurses and customer service personnel.

![fc_servicesprocess-bw.jpg](img_002.jpg)

[**Table of Contents**](#TableOfContents)

In 2022, we implemented new internal operational protocols by establishing new standard operating procedure (SOP) to ensure customers receive better and consistent services across all its treatment centers. Employees were also required to record all the medical treatments handled, with detailed operating procedures as well as the marketing strategies used for internal reference. Through case studies of these records, we were able to improve our service quality, and provide the most standardized and suitable solutions to customers. In addition, we have been working with an experienced consulting team on a training program for our front-line employees, including reception, customer services, operating managers, e-commerce staff and assistant medical practitioners. We believe that these measures would lay a solid foundation for our future business growth and expansion, in a way that the infrastructure would allow easy business replication. To better evaluate the service quality of all our centers, we engaged mystery shoppers, who discretely visit each treatment center with a budget of RMB1,000 and provide assessments on user experience for management's review.

In 2023, approximately 100 mystery shoppers visited each of our 10 treatment centers, providing valuable assessments and feedback. This policy has motivated the management teams at each center to prioritize service quality and attitudes, given that their bonuses are tied to the satisfaction of mystery shoppers. Over the course of two years of mystery shopper evaluations, significant improvements have been observed in both service quality and attitudes across all treatment centers. As a result, SOP has been established across all 10 centers, ensuring uniformity in procedures and enhancing overall efficiency.

In 2023, we also conducted numerous specialized training sessions, including those for doctors, physician assistants, nursing supervisors, expert service assistants, marketing planners, e-commerce operators, consultants, telephone network counselors, customer service managers, and customer service representatives. These trainings aimed to enhance the professional competence of our staff and ensure the effective implementation of our SOP. We believe these measures can improve treatment and service quality of all centers, which support business scalability and sustainable growth in the long run.

In 2024, over 100 mystery shoppers provided valuable feedback on the SOPs of our ten treatment centers, contributing to significant improvements in service delivery and making service sequences and connections clearer and more streamlined. By inviting mystery shoppers with varying levels of purchasing power, we enhanced customer segmentation services across our ten treatment centers. This approach allowed us to provide comprehensive VIP services to high - spending customers while delivering efficient and cost - effective services to mass - market customers.

In 2024, our training department introduced a new reserve head nurse training program, helping our ten treatment centers identify and select outstanding nurses. Additionally, the training department placed greater emphasis on hands - on practice and assessment, integrating training and practice by ensuring every training session is accompanied by an assessment, and key courses are emphasized through both training and evaluation. These two new initiatives have strengthened our talent development program and significantly improved the practical skills of frontline staff.

[**Table of Contents**](#TableOfContents)

**Our treatment centers**

As of the date of this annual report, we have an extensive presence in mainland China, with locations in 7 cities. All of our treatment centers are wholly- or majority-owned. The following map illustrates our network in mainland China.

![](img_003.jpg)

Our current network comprises 9 treatment centers across mainland China, including two flagship hospitals. Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. had suspended operations as of the date of this annual report. Based on relevant Chinese regulations, the treatment centers in our network can be classified as the following:

● Hospital, which meets the minimum standard for Grade I general hospital, including certain prescribed clinical and medical departments, and medical personnel requirements; or

● Outpatient department, which meets certain prescribed clinical department and medical personnel requirements and typically comprises aesthetic treatment consultation rooms, aesthetic surgery, aesthetic dermatology and dentistry, amongst other departments.

● Clinic, which meets certain prescribed clinical department and medical personnel requirements and typically comprises one or two of the departments of aesthetic surgery, aesthetic dermatology, aesthetic dentistry, aesthetic traditional Chinese medicine.

For more information on the definitions of each type of medical institution, please refer to "—Regulation—Regulations on the administration and classification of medical institutions."

[**Table of Contents**](#TableOfContents)

One of our core strategies is to develop our flagship hospitals, which are large-scale, full-service hospitals located at the epicenter of our regional network hubs and accompanied by our smaller-scale treatment centers in the surrounding vicinity. Our flagship hospitals contribute a meaningful proportion of our revenue and are staffed with our most experienced doctors.

The premises of the majority of our treatment centers are leased, while part of Huizhou Pengai and part of Pengcheng Hospital are our owned properties. The following table provides a summary of our treatment centers, including key operational data, as of December 31, 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| <br>**Treatment center(9)** |<br>**Acquired /**<br>**invested** | **Date of**<br>**establishment /**<br>**acquisition /**<br>**investment** | **Classification**<br>**in accordance**<br>**with Chinese**<br>**regulation** |<br>**GFA**<br>**(sq.m.)** |<br>**Beneficial**<br>**Interest** |
| Shenzhen Pengcheng <sup>(L)</sup> | Established | December 2003 | Hospital | 8249 | 100.0% |
| Shenzhen Pengai<sup>(L)</sup> | Established | November 2005 | Hospital | 6182 | 100.0% |
| Haikou Pengai<sup>(M)</sup> | Established | March 2011 | Hospital | 2169 | 87.0% |
| Huizhou Pengai<sup>(M)</sup> | Established | June 2011 | Hospital | 3283 | 67.5% |
| Shanghai Pengai<sup>(M)</sup> | Established | January 2014 | Outpatient Department | 953 | 80.0%<sup>(3)</sup> |
| Shenzhen Pengai Xiuqi<sup>(M)</sup> | Acquired | May 2017 | Hospital | 2052 | 94.0%<sup>(7)</sup> |
| Yantai Pengai<sup>(M)</sup> | Established | June 2018 | Hospital | 3062 | 95.0%<sup>(5)</sup> |
| Beijing Pengai<sup>(S)</sup> | Acquired | January 2021 | Clinic | 713 | 95.0%<sup>(6)(8)</sup> |
| Guangzhou Pengai Xiuqi<sup>(M)</sup> | Acquired | November 2021 | Outpatient Department | 900 | 73.0%<sup>(4)</sup> |

---

Notes:

\* To streamline the management of our network of treatment centers, we strategically categorize our treatment centers based on a number of factors, including, among other things, the cities they are located in and the size of the treatment centers. In the table above, large, medium and small treatment centers are denoted with (L), (M) and (S), respectively.

(1) Indicates
flagship hospitals.

(2) Includes
12.0% equity interest held by Dr. Zhou Pengwu, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(3) Includes
15.0% equity interest held by Dr. Zhou Pengwu, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(4) Includes
3% equity interest held by Mr. Zhou Qiuming, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(5) Includes
24% equity interest held by Mr. Zhou Qiuming, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(6) Includes
25% equity interest held by Mr. Zhou Qiuming, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(7) Includes
27% equity interest held by Mr. Zhou Qiuming, for which we are entitled to relevant economic benefits pursuant to the Contractual Arrangements.

(8) Includes
25% of its parent company's equity interest held by Mr. Zhou Qiuming, for which we are entitled to relevant economic benefits pursuant
to the Contractual Arrangements.

(9) Includes
15% of its parent company's equity interest held by Dr. Zhou Pengwu, for which we are entitled to relevant economic benefits pursuant
to the Contractual Arrangements.

(10) English
names of treatment centers for the indicative purpose only.

[**Table of Contents**](#TableOfContents)

In 2025, we generated 84.0% of our revenue from our top five treatment centers. The following table sets forth the revenue from these five treatment centers in 2023, 2024 and 2025.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2023** | **2024** | **2024** | **2025** | **2025** | **2025** |
|  | **RMB**<br>**(in thousands)** |<br>**%** | **RMB**<br>**(in thousands)** |<br>**%** | **RMB**<br>**(in thousands)** | **USD**<br>**(in thousands)** |<br>**%** |
| Shenzhen Pengai\* | 200237 | 29.3% | 207795 | 27.5% | 201628 | 28832 | 27.9% |
| Shenzhen Pengcheng\* | 248738 | 36.5% | 286898 | 38.0% | 263831 | 37727 | 36.5% |
| Shanghai Pengai | 44422 | 6.5% | 50287 | 6.7% | 52529 | 7512 | 7.3% |
| Shenzhen Pengai Xiuqi | 51431 | 7.5% | 62418 | 8.3% | 57187 | 8178 | 7.9% |
| Yantai Pengai |  |  |  |  | 31819 | 4550 | 4.4% |
| Huizhou Pengai | 36952 | 5.4% | 44802 | 5.9% |  |  |  |
| **Subtotal top five treatment centers** | **581780** | **85.2%** | **652200** | **86.3%** | **606994** | **86799** | **84.0%** |
| **Total** | **682587** | **100%** | **755671** | **100%** | **722855** | **103367** | **100%** |

---

\* Indicates flagship hospitals

**Summary information on our flagship hospitals**

*Shenzhen Pengai*

Founded in November 2005, Shenzhen Pengai Hospital was established as our second flagship hospital and was our second largest revenue contributor in 2024. Shenzhen Pengai Hospital has a gross floor area of approximately 6,182 sq.m. with 7 surgical rooms and 38 treatment rooms. As of December 31, 2025, Shenzhen Pengai Hospital had 7 major departments including plastic surgery, aesthetic dermatology, aesthetic traditional Chinese medicine, aesthetic dentistry, anesthesiology, medical laboratory, and medical imaging.

Shenzhen Pengai Hospital serves as the training base for the Dalian Medical University College of Aesthetic and Plastic Surgery. As of December 31, 2025, Shenzhen Pengai Hospital had 263 employees, including 36 doctors, 49 nurses, 8 other medical staff and 170 non-medical staff.

In February 2022, Shenzhen Pengai announced the successful completion of its recent renovation project, which has transformed its first floor into a state-of-the-art reception center to offer customers a comfortable and innovative environment for their aesthetics needs. On March 8, a Brand Upgrade & 2023 Aesthetic Medical Industry Standardization Initiative Ceremony was successfully held in Shenzhen Pengai. The senior officers of our group, leaders of the China Association of Plastic Surgery, national strategic partners, industry experts and media partners gathered in Shenzhen Pengai to witness the strategic upgrade of the Pengai Aesthetic medical brand and explore the new concept of healthy development of the industry.

---

| | |
|:---|:---|
| ![](img_004.jpg) | ![](img_005.jpg) |

---

[**Table of Contents**](#TableOfContents)

*Pengcheng Hospital*

Founded in 1997, Pengcheng Hospital became our first flagship hospital in 2003 to provide both aesthetic medical services and general healthcare and other aesthetic services. Pengcheng Hospital was also our largest revenue contributor in 2025. As of the date of this annual report, this treatment center has a gross floor area of approximately 8,250 sq.m. with 7 surgical rooms and 59 treatment rooms. It is equipped with advanced medical devices, such as Thermage radiofrequency systems, Body-Jet liposuction systems and Aesculap flexible neuroendoscopy systems. As of December 31, 2025, Pengcheng Hospital had 19 major clinical departments, including plastic surgery, aesthetic dermatology, aesthetic traditional Chinese medicine, aesthetic dentistry, surgical, gynecology, internal medicine, otorhinolaryngology, laboratory testing, radiology, anesthesiology etc. As of December 31, 2025, Pengcheng Hospital had 443 employees, including 29 doctors, 83 nurses, 25 other medical staff and 296 non-medical staff.

In December 2024, Shenzhen Pengcheng Hospital received an administrative penalty decision letter from the Health Commission of Shenzhen Municipality. The letter stated that due to over-treatment misconduct involving nine patients, the hospital was required to refund RMB25,448 in illegal earnings and pay a fine of RMB448,026. Additionally, the hospital faced a six-month restriction on conducting business in traditional Chinese medicine and surgery.

---

| | |
|:---|:---|
| ![](img_006.jpg) | ![](img_007.jpg) |

---

**Integration**

Efficient and effective integration of new treatment centers into our network is an important component of our business strategies and a driver of our success. Crucial to successful integration of acquired treatment centers is our post-acquisition integration plan, which involves a dedicated post-acquisition taskforce that conducts a detailed review of the acquired treatment center's equipment, systems and personnel. In particular, we focus on ensuring that the medical professionals at the acquired treatment centers comply with our country-wide protocols and meet our quality standards. In order to retain these personnel, we offer a compelling employment package that includes ongoing training and a performance-based compensation scheme that aligns their interest with those of the treatment centers.

Aside from service protocols and quality of staff, we also maintain standardized indoor decor to lend consistency to the look and feel of our treatment centers. We regularly review and adjust the mix and focus of clinical departments to leverage each treatment center's unique strengths to enhance its reputation and profile.

[**Table of Contents**](#TableOfContents)

**Our customers**

Our customers are primarily female individuals residing in China. The majority of our customers are aged between 18 and 30, and this age cohort represented 44% of our customer base in 2025, while customers in the 31 to 40 and above 40 age cohorts represented 36% and 19% of our customer base in 2025, respectively.

The following table provides a snapshot of our active customer base.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2023** | **2024** | **2024** | **2025** | **2025** |
|  | **Number of**<br>**customers** |<br>**%** | **Number of**<br>**customers** |<br>**%** | **Number of**<br>**customers** |<br>**%** |
| New customers | 83247 | 36.5% | 110825 | 41.6% | 98442 | 40.3% |
| Repeat customers | 144857 | 63.5% | 155320 | 58.4% | 145801 | 59.7% |
| **Total active customers** | **228104** | **100%** | **266145** | **100%** | **244243** | **100%** |

---

Our active customer base, defined as customers who have received at least one procedure in the relevant year, was 228,104, 266,145, and 244,243 respectively, in 2023, 2024 and 2025, representing a CAGR of 3.5%. Our treatments are transactional in nature and we have not entered into any long-term agreements with our customers.

**Customer service**

Our customer service team plays a critical role in the service process and is responsible for following up with our customers (including courtesy check-in calls), collecting customer feedback and handling general customer complaints.

A key component of the services we provide to our customers is the consultation with our image consultants, who provide personalized treatment plan to each customer prior to him/her undertaking the aesthetic treatment. Our image consultants provide advice on the type of treatment, how it should be executed and other factors relevant to achieving an optimal aesthetic outcome that addresses the customer's needs. These consultations help to enhance the aesthetic outcome of treatments and are highly valued by our customers.

**Customer feedback system**

In order to enhance customer loyalty and establish long-term customer relationships, we have implemented a customer feedback system which enables us to improve our treatments and services to meet customers' needs. We collect feedback through various channels, including our customer service hotline, the comment collection box at each treatment center and face-to-face communication with the staff at our treatment centers. Our staff is required to keep records of all feedback, whether through centralized handling of feedback made through our service hotline at our company headquarters in Shenzhen, daily inspection of the comment collection box at each treatment center or records prepared after customer interviews. These records are reviewed by the customer service managers at each treatment center before thorough analysis and appropriate follow-up actions are undertaken.

Due to the nature of our business and the subjective nature of the level of satisfaction with aesthetic medical services, we receive complaints from time to time. Customer complaints are usually in relation to staff attitude, dispute over pricing (competitor offering an equivalent service for less), over-promise, longer than expected recovery time or general dissatisfaction with treatment results, which includes potential side effects. The majority of customer complaints relate to general dissatisfaction with treatment results.

The overall number of complaints we typically receive is low—we received 234, 267 and 225 complaints for the years ended December 31, 2023, 2024 and 2025, respectively, based on the finalized **"**Settlement Agreements**"** signed by both parties. The total number of complaints received represented 0.05%, 0.04% and 0.03% of the total number of aesthetic treatments provided for the years ended December 31, 2023, 2024 and 2025, respectively. In particular, the percentage of the number of customer complaints attributable to general dissatisfaction with treatment results out of the total number of aesthetic treatment procedures we performed in 2023, 2024 and 2025, respectively, was level at approximately 0.05%, 0.04% and 0.03%.

[**Table of Contents**](#TableOfContents)

**Management of complaints**

Our customer service department is responsible for handling customer complaints. In order to ensure prompt and proper handling of customer complaints, we have implemented strict internal guidelines which are administered at the treatment center level. Where (i) a customer demands compensation for an amount of more than RMB10,000 or a refund for an amount of more than RMB50,000, (ii) a customer has raised the same issue more than three times, (iii) we may be exposed to reputational damage or operational disruption (in particular if media may become involved) or (iv) they relate to potential wrongdoing of a treatment center or its personnel which may constitute medical malpractice according to the Medical Malpractice Regulation, the complaint would be escalated to the designated customers' complaint settlement operations team under our medical safety control department for specific follow up.

We generally offer free treatments and/or partial or full refunds to settle complaints. Occasionally, we may provide additional compensation to settle customer complaints on a case-by-case basis.

In order to ensure the highest level of customer satisfaction and to maintain our strong brand name, we have taken a relatively generous approach in offering such refunds and compensation historically. In 2023, 2024 and 2025, the amount of refunds and compensation incurred was RMB2.4, RMB3.3 million and 2.9 million (US$0.4 million) , respectively, representing 0.4%, 0.04% and 0.4% of our total revenue for the corresponding period. The significant increase in refunds and compensation in 2024 is due to stricter standards implemented starting from 2024, which now include complimentary services or products provided to dissatisfied customers, valued at their original price (i.e., full price). We believe that the number of complaints we received and the amount of refunds and compensation incurred were insignificant, considering the size of our operation, the nature of our industry, and the relatively generous approach we took in offering such refunds and compensation. We seek to further enhance the quality of our service offerings and upkeep our rigorous medical standards, to continue to maintain the customer complaints we received at a low level.

**Our suppliers**

As of December 31, 2025, we had approximately 393 suppliers, providing us with a diverse selection of medical equipment, supplies and medical consumables. Our suppliers fall into five key categories: medical devices, energy-based equipment, implants, injection materials and other medical consumables. In general, we have worked with our major suppliers for more than ten years and believe we maintain strong relationships with them. In 2023, 2024 and 2025, our five largest suppliers in each respective year in aggregate accounted for 24.2%, 30.0% and 29.0%, respectively, of our total amount of purchases, and our single largest supplier accounted for 9.3%, 9.4% and 11.0% of our total amount of purchases, during the same periods, respectively.

We have a system for selecting reliable and quality suppliers, with a selection and review process based on qualification of the business and/or products, pricing, reputation, service quality, delivery schedule and product offering. We maintain multiple suppliers for key categories of purchases to ensure continuity and quality of supply. Payment terms with the majority of our suppliers are on open account. Certain suppliers grant us credit periods ranging from 10 to 60 days, although we generally pay on delivery.

During the three years ended December 31, 2025, we did not encounter any major problems in sourcing despite not having long-term contracts with our suppliers, nor did we encounter any business disruption due to supply shortages or delays. In any event, we believe any shortage or delay in the supply of implants, injection materials and medical consumables will not have any material impact on us as we are able to switch to other suppliers with comparable quality and prices.

To the knowledge of our directors, none of our directors or any shareholder who owns more than 5% of our issued share capital, nor any of their respective associates, has any ownership interest in any of our five largest suppliers.

[**Table of Contents**](#TableOfContents)

**Our equipment**

We are committed to utilizing high quality equipment for our services. We owned a wide variety of energy-based treatment and non-surgical aesthetic equipment. Our key equipment includes the *Lumenis M22, Alma Harmony XL pro, Candela Picoway, Fotona4D Pro, Peninsula MicroUltra, Peninsula Gold Microneedle, Alma Accent XL, Alma BeautiFill and Thermage FLX,* and play an important role in achieving high quality aesthetic outcomes for our customers. We source our energy-based equipment and related components from our suppliers in the United States, Europe, and China. In 2023, 2024 and 2025, we entered into sale-and-lease-back arrangements with a third party financial lease service provider for a term of two years with an aggregate principal amount of RMB47.5 million, RMB42.0 million and RMB49.5 million, respectively. The net book value of equipment under such arrangements accounts for approximately 16%, 18% and 17% of the total value of our equipment in 2023, 2024 and 2025, respectively. We believe finance lease is a common approach for financing activities.

**Sales and marketing**

As of December 31, 2025, we had an effective, disciplined sales and marketing team of 135 who, in addition to a base salary, generate commissions based on the number and types of procedures sold. We have strict policies governing our sales and marketing activities to ensure the consistency of our offering and our customers' experience. For example, we have standardized service catalogs, sales scripts and price lists throughout the network, with management and/or supervisor approval required for deviations such as discounts. In addition, prior to effecting each sale transaction, the treatments proposed by our sales staff are reviewed and approved by our doctors to ensure feasibility and compliance with internal policies. Customers then pay in full prior to receiving the treatments, using a range of payment methods.

We also have a dedicated marketing team responsible for analyzing market intelligence, organizing advertising activities, evaluating marketing campaigns and assisting in the preparation of promotional materials. Given the size of Chinese market, marketing efforts for each of our treatment centers are primarily initiated and implemented by the marketing personnel situated at each treatment center with the support of our headquarters. Each treatment center's marketing efforts are tailored to customers in the region where the treatment center is based. These marketing efforts are focused on (1) informing customers of the comprehensive aesthetic medical services that we offer; and (2) emphasizing the high level of customer satisfaction. For example, we hold themed marketing events when opening new treatment centers and introducing new treatments. In addition, we also host conferences and invite our potential clients and promote our services.

In the second quarter of 2022, we have developed new customer acquisition strategies through the establishment of online and offline collaboration with renowned enterprises to target potential customers with high level of consumption. These new B2B methods have complemented our existing B2C marketing initiatives and helped optimize our overall marketing efficiency.

In addition to the private domain channel introduced in the second quarter, we started collaboration with key opinions leaders (KOLs) and tapped into livestreaming e-commerce. The campaign was successful and effective in expanding target audience to younger generation who has strong demand in self-care and aesthetic related consumption.

Based on our extensive experience in China, we have obtained an in-depth understanding of the needs and preferences of our customers. Our extensive local knowledge allows us to carry out a wide range of creative marketing events and/or initiatives which cater to local preferences.

In 2023, we further enhanced our marketing strategies by integrating the Xiaohongshu (Little Red Book) platform, unifying the management of marketing activities across all medical institutions. This consolidation significantly improved operational efficiency and heightened the exposure of our brand. Additionally, we expanded our reach by launching livestreaming on Douyin (TikTok). Transitioning from individual live broadcasts by various medical institutions, we adopted a unified approach by collaborating with Douyin influencers. Customers could seamlessly order medical services during livestream sessions, with the added convenience of utilizing services across all company-affiliated medical facilities.

Since February 2024, the PRC government has implemented a series of policies prohibiting public domain livestreaming, which has had a certain impact on our livestreaming business. Nevertheless, based on the prevailing circumstances, most private domain livestreams can still operate normally. Therefore, we will adjust our marketing strategies accordingly in response to regulatory changes to ensure the continued acquisition of new customers.

[**Table of Contents**](#TableOfContents)

**Competition**

The aesthetic medical services market in China is highly competitive and fragmented with numerous market participants. Our competitors include major privately-owned multi-site operators in China such as Mylike, Yestar, brands under Lancy Co.,Ltd., Aist and Evercare. We believe the principal competitive factors in this market are price and quality of service, variety of services rendered, convenience and proximity of treatment center location to place of business or residence, brand recognition and reputation, targeted marketing and customized services.

We also face intense competition in our general healthcare service business. We compete primarily with other treatment centers in our areas of operation. Key competitive factors include healthcare service quality, reputation, convenience and price. We expect new competitors in the general healthcare service industry will continue to emerge given the state of China healthcare reform and the central and local governments' supportive policies towards public healthcare reform and private capital investment in the healthcare services industry. For a discussion of risks relating to competition, see "Item 3. Key Information—3.D. Risk Factors—Risk relating to our business and our industry—We face intense competition, and if we do not compete successfully against new or existing competitors, we may lose our market share and our profitability may be adversely affected."

**Intellectual property**

As of December 31, 2025, we had (i) 40 registered trademarks, 35 of which are in mainland China and 5 in Hong Kong, (ii) 34 registered domain names, of which all are registered in mainland China, and (iii) 5 registered patents, of which all are registered in mainland China. Our principal intellectual property rights are our registered trademarks such as "鹏爱" (Pengai), as well as our patented technologies, which include a device and method for measuring facial symmetry and a device and method for mandibular shaping.

We recognize the importance of protecting and enforcing our intellectual property rights. We have registered all the principal trademarks, patents and internet domain names in China that are necessary for us to carry out our business operations. We will take the necessary legal action to protect our intellectual property rights if we discover any infringement of those rights.

As of the date of this annual report, we were not aware of any material infringement of our intellectual property rights and we believe that we have taken reasonable measures to prevent infringement of our own intellectual property rights. As of the date of this annual report, we did not have any pending or, to our knowledge, threatened claims against us or any of our subsidiaries relating to the infringement of any intellectual property rights owned by third parties. For risks related to any failure to protect our intellectual property rights, see "Item 3. Key Information—3.D. Risk Factors—Risk relating to our business and our industry—We may not be able to adequately protect our intellectual property rights, which could harm our brand and our business."

In order to maintain our substantial market position in the aesthetic medical services market in China, we have active dialogue and exchange of information and experts with well-respected aesthetic medical institutions and consulting companies in mainland China to learn about and adopt new aesthetic medical treatments and advanced technologies. Any knowledge gleaned from these exchanges is shared with our medical staff via our training programs. We believe this allows us to strengthen our technological advantage in this market and anticipate and respond quickly to our customers' needs and improve the quality, safety and efficiency of our services.

We do not maintain product liability insurance for the medical devices and energy-based equipment. We do not maintain business interruption insurance or key employee insurance for our executive officers or professional malpractice liability insurance for key doctors and medical staff in most of our aesthetic medical treatment centers because the non-surgical aesthetic treatments, which contribute a major portion of our revenue, are less invasive, quicker to recover and therefore less risky.

**Regulation**

Substantially all of our operations are in PRC and our business is subject to supervision and regulation by the PRC government. Below sets forth a summary of the most significant laws, rules, regulations and policies related to the aesthetic medical industry and our business in the PRC.

[**Table of Contents**](#TableOfContents)

**Regulations on the institutional reforms of medical institutions**

**Promotion Law on Basic Medical and Healthcare**

The Promotion Law on Basic Medical and Healthcare, which were promulgated on December 28, 2019 by the Standing Committee of the National People's Congress and became effective on June 1, 2020, stipulates specific support for socially-run medical care institutions, granting socially-run medical care institutions similar rights enjoyed by public hospitals. Prior to the its promulgation, the State also supported the subdivision of disciplines among socially-run medical care institutions (including ophthalmology, orthopedics, stomatology, gynecology, pediatrics, oncology, psychiatry and medical cosmetology, etc.), gradually cancelled staffing among public hospitals, lessened entry barriers for socially-run medical care institutions and enhanced supervision, and introduced a series of policies and regulations encouraging social capital invested or funded elderly healthcare institutions or rehabilitation institutions, thereby demonstrating the support of the State for socially-run medical care institutions.

**Opinions on Further Promoting the Reform of Medicine and Health System**

The Opinions on Further Promoting the Reform of Medicine and Health System, or the Opinions, which were promulgated by the Central Committee of the Communist Party of the PRC and the State Council and became effective on March 17, 2009, advocate a range of measures to reform medical institutions in China and to establish a basic medicine and health system covering urban and rural residents. Measures aimed at reforming medical institutions include: (i) separating governmental agencies from public medical institutions; (ii) separating for-profit medical institutions from not-for-profit medical institutions; (iii) separating sponsorship from operations of public hospitals; and (iv) separating pharmaceutical dispensing from pharmaceutical prescription. The Opinions include proposals for the establishment and improvement of corporate governance systems of public medical institutions, and checks and balances in decision-making, execution and supervision processes between organizers and operators of public medical institutions. The Opinions also promote private capital investment in medical institutions (including investments by foreign investors), the development of private medical institutions and the reform of public medical institutions (including those established by state-owned enterprises) through private capital investment.

**Notice on Further Encouraging and Guiding Private Capital to Invest in Medical Institutions**

The Notice of the State Council on Forwarding the Opinions of the National Development and Reform Commission, or the NDRC, the Ministry of Health and the other three departments, on Further Encouraging and Guiding Private Capital to Invest in Medical Institutions, which was promulgated by the General Office of the State Council and became effective on November 26, 2010, states that the PRC government encourages and supports investments by private investors in medical institutions of various types. For example, private investors are permitted to apply for approval to establish for-profit or not-for-profit medical institutions. They are also encouraged to participate in the reform of existing public hospitals, including those established by state-owned enterprises, by converting them into private not-for-profit medical institutions in order to systematically reduce the proportion of public hospitals in the system, and to set up hospital management companies to provide specialized services.

In addition, private medical institutions with experience in the provision of healthcare services and a good reputation may be selected as participants in the restructuring of hospitals established by state- owned enterprises through pilot reform programs. They are also encouraged to modernize their hospital management, establish standardized corporate governance structures, improve their cost control and quality management systems, and employ professional managers to manage their hospital, such as by engaging or authorizing domestic or overseas medical institutions with professional experience to participate in the management of their hospitals to improve efficiencies, as well as improve their clinical research and build up their research and development teams. Medical institutions are also encouraged to develop into large, sophisticated, technology-intensive medical groups and adopt brand-focused development strategies to build good reputations.

**Several Opinions on Promoting the Development of Healthcare Service Industry**

Several Opinions on Promoting the Development of Healthcare Service Industry, or the 2013 Opinions, was promulgated by the State Council and became effective on September 28, 2013. The 2013 Opinions encourage the private sector to invest in the healthcare service industry by various means including new establishments and participation in restructuring, and also encourage private capital to invest in not-for-profit medical institutions for providing basic healthcare services. The 2013 Opinions also propose the idea of relieving the requirements for Sino-foreign equity/cooperative joint venture medical institutions and expanding the eligibility for wholly foreign-invested medical institutions in the pilot program.

[**Table of Contents**](#TableOfContents)

**Several Opinions on Accelerating the Development of Medical Institutions with Social Capital**

Several Opinions on Accelerating the Development of Medical Institutions with Social Capital, which was promulgated by the National Health and Family Planning Commission and the State Administration of Traditional Chinese Medicine and became effective on December 30, 2013, specifies the policies that support the development of privately-funded medical institutions, which include (i) gradual relief of foreign capital investment in medical institutions, (ii) reduction of the requirements in the service sector, allowing social capital investment in the areas which are not explicitly prohibited, (iii) reduction of the requirements for the deployment and use of large medical equipment in private hospitals, (iv) improvement of supporting policies for the development of private hospitals in areas such as medical insurance and price control, and (v) acceleration of the approval process regarding the establishment and operation of private hospitals.

**Several Policies and Measures Regarding Promoting Private Investment in Medical Institutions and Accelerating Development**

Several Policies and Measures Regarding Promoting Private Investment in Medical Institutions and Accelerating Development, which was promulgated by the General Office of the State Council and effective on June 11, 2015, provides for (i) elimination and cancellation of administrative authorities' unreasonable requirements for pre-examination and pre-approval regarding the establishment of medical institutions, and the reduction in the time required for making such examination and approval, (ii) reasonable control of the number and scale of public medical institutions and the exploration of the space for development of the medical institutions through private capital investments, (iii) support for the listing and financing of eligible and qualified for-profit medical institutions funded by private capital investments, and (iv) encouragement for private investors with managerial experience in medical institutions to participate in the management of public medical institutions in various forms such as through hospital management groups and subject to a clear distribution of power and responsibilities.

**Opinions on Encouraging Social Forces to Provide Multi-layered and Diverse Healthcare Services**

Opinions on Encouraging Social Forces to Provide Multi-layered and Diverse Healthcare Services, which were promulgated by the General Office of the State Council on May 16, 2017, stipulate the policies to actively support social forces to go deep into the niche service market, such as specialized medical services, expand the effective supply of services, and foster professionalized advantages. A number of competitive branded service agencies will be formed at a rapid pace for such specialties including but not limited to aesthetic medical services.

**Decisions of the Central Committee of the Communist Party of the PRC on Several Major Issues Concerning Comprehensively Deepening Reforms**

The Decisions of the Central Committee of the Communist Party of the PRC on Several Major Issues Concerning Comprehensively Deepening Reforms, which was promulgated by the Central Committee of the Communist Party of the PRC and became effective on November 12, 2013, promotes private sector investment in the healthcare service industry and in other services industries that are poorly funded or in need of diversification. It also permits doctors to have a multi-site practice and allows privately funded medical institutions to benefit from the medical insurance system.

[**Table of Contents**](#TableOfContents)

**Regulations on the administration and classification of medical institutions**

**Administrative Measures on Medical Institutions and its Implementing Measures**

The Administrative Measures on Medical Institutions, which was promulgated on February 26, 1994 by the State Council, came into effect on September 1, 1994 and was amended on February 6, 2016 and March 29, 2022, effective on May 1, 2022, and the Implementation Measures of the Administrative Measures on Medical Institutions, which was promulgated by the Ministry of Health on August 29, 1994, came into effect on September 1, 1994, and was amended in 2006, 2008, and 2017, require that the establishment of medical institutions to be reviewed and approved by healthcare administrative departments at or above the county level and an Approval Letter of Establishment of Medical Institution to be obtained from competent healthcare administrative departments. In addition, any entity or individual that intends to establish a medical institution must follow the application approval procedures and register with the relevant healthcare administrative authorities to obtain a Medical Institution Practicing License.

**Law on Maternal and Infant Healthcare and Its Implementation Measures**

The Law on Maternal and Infant Healthcare, which was promulgated by the Standing Committee of the National People's Congress on October 27, 1994, came into effect on June 1, 1995, and was amended on August 27, 2009 and November 4, 2017, and the Implementation Measures of the Law of the People's Republic of China on Maternal and Infant Healthcare, which was promulgated by the State Council and came into effect on June 20, 2001 and was last amended on July 20, 2023, require medical institutions engaged in (i) genetic disease diagnosis and prenatal diagnosis, (ii) pre-marital medical examinations, or (iii) midwifery services, ligature operations or operations for termination of gestation, to be licensed by the public health administrative authority of different levels as required to obtain the corresponding qualification certificates.

**Administrative Measures for the Examination of Medical Institutions (For Trial Implementation)**

The Administrative Measures for the Examination of Medical Institutions (For Trial Implementation), which was promulgated by the Ministry of Health and came into effect on June 15, 2009, stipulates that a medical institution's Medical Institution Practicing License is subject to periodic examinations and verifications by the registration authorities. Such examinations and verifications are based on records and points generated by point management system for malpractice of medical institutions, established by local health administrative departments. The verification period is three years for general hospitals, traditional Chinese medicine hospitals, western medicine and traditional Chinese medicine hospitals, ethnic minority medicine and specialized hospitals, as well as sanitariums, rehabilitation hospitals, maternity and children's healthcare centers, emergency centers, clinical laboratories and specialized disease prevention institutions equipped with more than 100 beds, and one year for other medical institutions. In the event that a medical institution fails to apply for verification as required and post re-verification procedures are unsuccessful, the registration authorities may cancel such medical institution's Medical Institution Practicing License.

**Administrative Measures for Aesthetic Medical Services**

The Administrative Measures for Aesthetic Medical Services, which was promulgated by the Ministry of Health on January 22, 2002, came into effect on May 1, 2002, and was amended in 2009 and 2016, requires applicants for establishing aesthetic medical institutions or aesthetic medical departments within medical institutions to meet certain requirements. Aesthetic medical institutions may not commence operation before obtaining a Medical Institution Practicing License. Service items provided by aesthetic medical institutions or aesthetic medical departments within medical institutions must be approved by designated specialized academic associations and filed with relevant authorities.

**Classification Catalog of Aesthetic Medical Items**

The Classification Catalog of Aesthetic Medical Items, which was promulgated by the Ministry of Health and came into effect on December 11, 2009, classifies aesthetic medical services into four categories: (i) aesthetic surgical items (further divided into four grades) (ii) aesthetic dentistry items (iii) aesthetic dermatological items, and (iv) aesthetic Chinese medicine items. Provincial-level counterparts of the Ministry of Health may adjust the catalog based on local circumstances. Every medical institution will be registered with one or more categories from the day of establishment and is only allowed to conduct medical activities specifically provided under such categories.

**Opinions on Implementing Classification Administration of Urban Medical Institutions**

The Opinions on Implementing Classification Administration of Urban Medical Institutions, which was promulgated jointly by the Ministry of Health, State Administration of Chinese Traditional Medicine, the Ministry of Finance and National Development and Reform Commission on July 18, 2000 and came into effect on September 1, 2000, states that whether a medical institution is classified as not-for-profit or for-profit will be based on such medical institution's business objectives, service purposes and implementation of various financial, taxation, pricing and accounting policies, provided that governments may not operate for-profit medical institutions. Medical institutions have to file written statements regarding their not-for-profit or for-profit status with relevant healthcare authorities when completing the application, registration and re-examination procedures in accordance with relevant laws, and the handling authority of health will, jointly with other relevant authorities, decide the not-for-profit/for-profit status for such medical institution based on the source of its investment and the nature of its business.

[**Table of Contents**](#TableOfContents)

***Categories of Medical Institutions in the PRC***

According to the Basic Standards for Medical Institutions (For Trial Implementation), which was promulgated on September 2, 1994 and partly abrogated on August 2, 2010, March 15, 2011, December 5, 2011 and December 20, 2022, and the Interim Measures for the Assessment of Medical Institutions promulgated by the Ministry of Health on September 21, 2011, medical institutions in the PRC are divided into three classes (Class I, II and III) with regard to their medical practice conditions, including but not limited to, the amount of registered beds, treatment departments, personnel, properties, equipment, completeness of their internal rules and regulations as well as payment of registered capital.

&nbsp;&nbsp;&nbsp;&nbsp;(i) Grade
I general hospitals must be at a minimum equipped with, among others, (a) 20 to 99 hospital beds, (b) clinical departments including
emergency rooms, internal medicine, surgery, obstetrics and gynecology, preventive healthcare section; (c) medical departments including
pharmacy, laboratory, x-ray room, and a disinfection supply room, and (d) 0.7 relevant health technicians per hospital bed, three doctors,
five nurses, health technicians of medicament, inspection and radiation and one doctor of chief level or above.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) Outpatient
departments must be at a minimum be equipped with, among others, (a) no less than five clinical departments including three clinical
departments that are either emergency rooms, internal medicine or surgery and two clinical departments that are either obstetrics and
gynecology, pediatrics, traditional Chinese medicine, ophthalmology, otolaryngology, stomatology and prevention and health; (b) medical
departments including pharmacy, laboratory, X-ray room, treatment room, disposal room and disinfection supply room at least and (c) no
less than five doctors including one doctor at the associate-chief level and above, one doctor for each clinical department, five nurses
including one nurse with nurse-in-charge title and above and one health technician with relevant specialty for each medical laboratory.

**Basic Standard for Aesthetic Medical Institution and Aesthetic Medical Department (For Trial Implementation)**

The Basic Standard for Aesthetic Medical Institution and Aesthetic Medical Department (For Trial Implementation), which was promulgated by the Ministry of Health and came into effect on April 16, 2002, specifies basic standards that aesthetic medical hospitals, aesthetic medical outpatient departments, aesthetic medical clinics and aesthetic medical specialty departments should meet, such as the required number of beds, clinical departments and medical personnel. Certain basic standards for each type of aesthetic medical institutions are set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;(i) Aesthetic
medical hospitals must be equipped with, among others, (a) more than 20 hospital beds, 12 aesthetic treatment beds and four dentistry
complex therapy chairs, (b) clinical departments including an aesthetic treatment consultation room, aesthetic surgery, aesthetic dentistry,
aesthetic dermatology, aesthetic traditional Chinese medicine, aesthetic treatment room and anesthesiology, and (c) at least 1.03 relevant
healthcare technicians per bed (chair), 0.4 nurse per bed (chair), six doctors at the associate-chief level and above with relevant specialties,
two nurses with nurse-in-charge title and above and one attending specialist doctor for each department.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) Aesthetic
medical outpatient departments must be at a minimum equipped with, among others, (a) four aesthetic treatment beds, two operation tables,
two dentistry complex therapy chairs and two observation beds, (b) clinical departments including an aesthetic treatment consultation
room, aesthetic surgery, aesthetic dentistry and aesthetic dermatology (may also have an aesthetic traditional Chinese medicine department
and aesthetic treatment rooms), and (c) at least 2.4 relevant healthcare technicians per operation table, 1.03 relevant healthcare technicians
and 0.4 nurse per observation bed and dentistry complex therapy chair, five registered doctors including at least one doctor at the associate-chief
level and above with relevant specialties and one registered nurse, and one attending specialist doctor for each department.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) Aesthetic
medical clinics must be at a minimum equipped with, among others, (a) two aesthetic treatment beds, or one operation table and one observation
bed or one dentistry complex therapy chair, (b) no more than two clinical departments that are aesthetic surgery, aesthetic dermatology,
aesthetic dentistry and aesthetic traditional Chinese medicine; (c) at least one attending specialist doctor and one nurse for each department.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) Aesthetic
medical specialty departments must be at a minimum equipped with, among others, (a) four aesthetic treatment beds, one operation table,
one dentistry complex therapy chair and one observation bed, (b) clinical departments including aesthetic treatment consultation room
and aesthetic treatment room, and at least two clinical departments that are either aesthetic surgery, aesthetic dermatology, aesthetic
dentistry and aesthetic traditional Chinese medicine, and (c) at least 2.4 relevant healthcare technicians per operation table, 1.03
relevant healthcare technicians and 0.4 nurse per observation bed and dentistry complex therapy chair, one attending specialist doctor
and one registered nurse for each department.

[**Table of Contents**](#TableOfContents)

***Circular on Further Strengthening Comprehensive Regulatory Enforcement in the Medical Beauty Industry***

 

On April 3, 2020, the State Administration for Market Regulation, National Health Commission of the PRC, National Medical Products Administration of the PRC, Office of the Central Cyberspace Affairs Commission, among others, jointly promulgated the Circular on Further Strengthening Comprehensive Regulatory Enforcement in the Medical Beauty Industry, which stipulate that medical beauty services shall be implemented by a surgeon or physician in charge or the practicing physician under the guidance of the surgeon or physician in charge in accordance with the registered medical beauty service items in the medical institutions that set up medical beauty related subjects. No organization or individual shall carry out medical beauty services without meeting the legal conditions. Medical beauty institutions shall purchase drugs and medical devices in enterprises with production and operation qualifications. Medical beauty advertisements belong to medical advertisements, and non-medical institutions shall not publish medical advertisements.

***Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services***

 ****

On May 28, 2021, the State Administration for Market Regulation, State Administration of Traditional Chinese Medicine, National Health Commission of the PRC, National Medical Products Administration of the PRC, Office of the Central Cyberspace Affairs Commission, among others, jointly promulgated the Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services, which stipulate that in order to further safeguard the legitimate rights and interests of consumers and protect people's health and life safety, the foresaid departments are scheduled to carry out special rectification work against illegal medical and beauty services nationwide from June to December 2021. The work tasks mainly include: (i) severely crack down on illegal activities related to medical beauty, (ii) strictly standardize the behavior of medical beauty service, (iii) severely crack down on the illegal manufacture, sale of drugs and medical devices, and (iv) seriously investigate and prosecute illegal advertising and internet information.

***Guiding Opinions on Further Strengthening the Supervision of the Medical Aesthetics Industry***

 ****

On May 4, 2023, the State Administration for Market Regulation, the Ministry of Commerce, State Administration of Traditional Chinese Medicine, National Health Commission of the PRC, National Medical Products Administration of the PRC, among others, jointly promulgated the Guiding Opinions on Further Strengthening the Supervision of the Medical Aesthetics Industry, which stipulates the guiding opinions on the following aspects: (i) strengthening the access management of the medical aesthetics industry; (ii) strengthening the comprehensive supervision during and after relevant events; (iii) strengthening the supervision of related fields and industries; (iv) strengthening the organization and leadership.

**Regulations on the supervision over pharmaceuticals and medical services in medical institutions**

**Pharmaceutical Administration Law of the People's Republic of China and Its Implementation Regulations**

The Pharmaceutical Administration Law of the People's Republic of China, which was promulgated by the Standing Committee of the National People's Congress on September 20, 1984, came into effect on July 1, 1985, and was amended in 2001, 2013, 2015 and 2019, and the Regulations for the Implementation of the Pharmaceutical Administration Law of the People's Republic of China, which was promulgated by the State Council on August 4, 2002, came into effect on September 15, 2002, and was amended on February 6, 2016, March 2, 2019 and January 20, 2025, provide that medical institutions may only purchase pharmaceuticals from licensed enterprises engaged in pharmaceutical manufacturing and distribution (except for the purchase of those Chinese herbal medicines that are not administrated by the approval number system). Also, medical institutions must establish an examination and inspection system to verify the qualification certificates and other specifications of the pharmaceuticals they purchase, and may not purchase or use pharmaceuticals that do not satisfy the relevant requirements. In addition, medical institutions must adopt and implement a pharmaceutical storage system and take necessary measures to ensure the quality of the pharmaceuticals such as providing refrigeration or be freeze-proof, damp-proof, pest-proof, and mouse-proof. Medical institutions are also required to retain certain qualified pharmaceutical technician personnel. Non-pharmaceutical technician personnel are prohibited from directly engaging in drug-related technical work. Obtaining an Import Permit Certificate or an Export Permit Certificate issued by the drug administration department of the State Council is also required for the import and export of narcotics and permitted psychotropic substances.

[**Table of Contents**](#TableOfContents)

 ****

**Measures for the Supervision and Administration of Drug Quality in Operation and Usage**

On September 14, 2023, the State Administration for Market Regulation promulgated the Measures for the Supervision and Administration of Drug Quality in Operation and Usage, or the Measures, which came into effective on January 1, 2024. The Measures provides that medical institutions shall establish a drug quality management system and be responsible for the quality management in the whole process of purchase, storage and use of drugs by them. Where any medical institution fails to set up a special quality management department or personnel, or fails to perform its obligations of inspection of incoming goods, storage and maintenance of drugs, suspension of use, reporting, etc. in accordance with the provisions under the Measures, the competent authority shall order it to make corrections within a time limit and notify the competent health authority of the matter, and such medical institution will be subject to fines if it fails to make corrections within the time limit, the violation is serious or there are serious consequences caused by such violation.

**Measures for the Supervision and Administration of Pharmaceuticals in Medical Institutions (for Trial Implementation)**

The Measures for the Supervision and Administration of Pharmaceuticals in Medical Institutions (for Trial Implementation), which was promulgated by the China Food and Drug Administration, or the CFDA, on October 11, 2011 and came into effect the same date, requires medical institutions to purchase pharmaceuticals from enterprises qualified for the production or distribution of pharmaceuticals and comply with certain standards regarding the storage, safekeeping, preparation and use of such pharmaceuticals. Any pharmaceutical prepared by a medical institution must be used by and for that same medical institution only. Medical institutions are prohibited from selling prescription pharmaceuticals directly to the public via mail, online or over the counter.

***Measures for the Classification and Administration of Prescription Pharmaceuticals and Non-prescription Pharmaceuticals (For Trial Implementation)***

The Measures for the Classification and Administration of Prescription Pharmaceuticals and Non-prescription Pharmaceuticals (For Trial Implementation), which was promulgated by State Drug Administration on June 18, 1999 and came into effect on January 1, 2000, sets forth the principals for the classification and administration of prescription pharmaceuticals and non-prescription pharmaceuticals based on their types, specifications, indications, dosage and supply channels. According to this measure, prescription pharmaceuticals may only be produced, purchased and used by licensed doctors' prescription and licensed associate doctors, while non-prescription pharmaceuticals may be produced, purchased and used by anyone at their discretion without licensed doctors or licensed associate doctors' prescription.

**Regulations on Centralized Pharmaceutical Procurement by Medical Institutions**

The Opinions on Further Regulating Centralized Pharmaceutical Procurement by Medical Institutions, which was jointly promulgated by the Ministry of Health and five other departments on January 17, 2009, and the Interpretations of Issues Related to the Opinions on Further Regulating Centralized Pharmaceutical Procurement by Medical Institutions, which was jointly promulgated by the Ministry of Health and five other departments on June 19, 2009, as well as the Administrative Measures for Supervision on Centralized Pharmaceutical Purchase and the Standards of Centralized Pharmaceutical Procurement Work for Medical Institutions jointly promulgated by the Ministry of Health and six other departments on June 2, 2010 and July 7, 2010, respectively, provide the general framework and detailed operational procedures regarding the centralized pharmaceutical procurement mechanism that requires non-profit medical institutions established by governments or state-owned enterprises to procure pharmaceuticals through the non-profit centralized pharmaceutical procurement platform organized by the competent governmental authorities. Medical institutions of other forms, are also encouraged to participate in the centralized pharmaceutical procurement system.

**Regulations on Prices of Pharmaceuticals and Medical Services**

The Notice on Issuing Opinions on Reforming the Price Formation Mechanism of Drugs and Medical Services, which was jointly promulgated by the NDRC, the Department of Health, and the Ministry of Human Resources and Social Security, came into effect on November 9, 2009. It provides that the price for basic healthcare services provided by non-profit medical institutions have to be set by government-directed pricing guidelines, while the price for healthcare services provided by for-profit medical institutions and certain special categories of healthcare services provided by non-profit medical institutions may be determined by the market.

According to the Notice of Issues Related to the Implementation of Market Price Adjustment by Non-public Medical Institutions, which was promulgated and implemented on March 25, 2014 by the National Development and Reform Commission, National Health and Family Planning Commission and the Ministry of Human Resources and Social Security, private for-profit medical institutions may set their own pricing for medical services, but such pricing must be determined according to principles of fairness, legitimacy and good faith and maintained at a relatively stable price level within a specific period. In addition, prices of medical services and pharmaceuticals must be displayed publicly to patients through various means, and medical institutions must take the initiative to receive social supervision.

[**Table of Contents**](#TableOfContents)

The Opinions on Promoting Pharmaceutical Pricing Reform, which was promulgated by the National Development and Reform Commission, National Health and Family Planning Commission, Ministry of Human Resources and Social Security and four other departments on May 4, 2015 and came into effect on the same date, sets forth that from June 1, 2015, except for narcotic drugs and Class I psychotropic drugs, the pricing of drugs formulated by the government will be abolished. The pricing of narcotic drugs and Class I psychotropic drugs is still temporarily regulated by the NDRC which sets the maximum ex-factory and maximum retail prices until new regulation on pricing is implemented. The pricing for other drugs may be determined by manufacturers and sellers on their own based on the cost of production and operation as well as market supply and demand.

According to the Pilot Scheme of Deepening the Reform of Medical Services Price, which was promulgated and implemented on August 25, 2021 by the National Health Commission of the PRC and seven other departments, private for-profit medical institutions may set their own pricing for medical services, but such pricing must be reasonable pricing and determined in accordance with principles of fairness, legitimacy and good faith, and consistency between quality and price, and those included in the medical insurance fund to be paid shall be managed in accordance with the medical insurance agreements.

On June 18, 2025, the National Healthcare Security Administration issued the Guidelines for Establishing Price Items for Cosmetic and Plastic Surgery Medical Services (Trial), which standardized 101 cosmetic and plastic surgery medical service price items. According to the relevant official policy interpretation, the Guidelines do not change the market-based pricing approach applicable to cosmetic and plastic surgery medical services, but are intended to unify price item nomenclature and regulate the pricing behavior of medical institutions. The official interpretation further notes that common aesthetic services, including filling injection and skin beauty treatment by light or laser, ultrasound and radiofrequency, shall be incorporated into standardized price item nomenclature. The National Healthcare Security Administration also indicated that qualified medical institutions should, with reference to such Guidelines, reasonably determine prices in accordance with the principles of fairness, good faith and consistency between quality and price, and timely disclose such prices to the public. Accordingly, if we fail to properly standardize the naming, pricing or public disclosure of our cosmetic and plastic surgery service items, we may be subject to regulatory scrutiny, rectification requirements or other adverse consequences.

**Administrative Measures for Pharmaceutical Importation**

The Administrative Measures for Pharmaceutical Importation, which was jointly promulgated by the Ministry of Health and the General Administration of Customs on August 18, 2003 and amended on August 24, 2012, provides that imported pharmaceuticals may be registered and cleared for customs only after obtaining an Imported Pharmaceutical Registration Certificate, a Pharmaceutical Product Registration Certificate or an Imported Pharmaceutical Permit, as applicable.

***Administrative Measures on Drug Recalls***

 ****

The Administrative Measures on Drug Recalls, which was promulgated by National Medical Products Administration on October 24, 2022 and came into effect on November 1, 2022, requires that drug manufacturers, drug distributors and drug users shall actively assist the drug marketing authorization holder, or the holder, in investigating and evaluating the drugs with possible quality problems or other potential safety hazards, take the initiative to cooperate with the holder in fulfilling the obligation of recalls, timely transmit and give feedback of the information on drug recalls according to the recall plan, control and recall the drugs with quality problems or other potential safety hazards. Where a drug manufacturer, drug distributor or drug user finds that the drugs manufactured, sold or used by it may have quality problems or other potential safety hazards, it shall notify the holder in a timely manner, suspend the production, release, sale and use of the drugs when necessary, and report to the drug regulatory department of the government of the province, autonomous region or centrally-administered municipality where it is located. The information in the notice and report shall be authentic. The holder, drug manufacturer, drug distributor and drug user shall establish and implement a drug traceability system as required, keep complete purchase and sale records, and ensure the traceability of the drugs on the market. Drug manufacturers, drug distributors and drug users shall cooperate with the holder in the investigation of the quality problems or other potential safety hazards of the drugs concerned, and provide relevant materials.

[**Table of Contents**](#TableOfContents)

**Administrative Measures for the Control of Radioactive Pharmaceuticals**

The Administrative Measures for the Control of Radioactive Pharmaceuticals, which was promulgated by the State Council, came into effect on January 13, 1989, and lastly amended on January 20, 2025, requires medical institutions to comply with relevant national regulations and rules concerning radioisotope health protection when using radioactive pharmaceuticals. Any medical institution wishing to use radioactive pharmaceuticals must obtain a License for the Use of Radioactive Pharmaceuticals of the corresponding grade from the supervision and administration department of pharmaceuticals at the provincial, regional or municipal levels, as applicable. The License for the Use of Radioactive Pharmaceuticals is valid for five years and is of varying grades based on the technical skill and professional level of the radiological personnel and the equipment conditions of such medical institution. In addition, the preparation or use of radioactive preparations must meet the relevant provisions of the Pharmaceutical Administration Law of the People**'**s Republic of China and the implementing rules thereof.

**Regulations on the Administration of Narcotic Pharmaceuticals and Psychotropic Substances**

The Regulations on the Administration of Narcotic Pharmaceuticals and Psychotropic Substances, which was promulgated by the State Council on August 3, 2005 and was amended on December 7, 2013 and February 6, 2016, provides that if a medical institution needs to use any narcotic pharmaceutical or Class I psychotropic substance, such medical institution must, upon approval by the competent public health department, obtain the Seal Card for the Purchase and Use of Narcotic Pharmaceuticals and Class I Psychotropic Substances, or the Seal Card. If a medical institution with a Pharmaceutical Preparation Certificate for Medical Institutions and a Seal Card needs to dispense for clinical use any narcotic pharmaceutical or psychotropic substance that is not available on the market, the preparation of such pharmaceutical or psychotropic substance will be subject to approval by the competent provincial, regional or municipal pharmaceutical regulatory department where the medical institution is located. Such prepared narcotic pharmaceutical or psychotropic substance may only be dispensed by the medical institution that prepared it and may only be used in the institution itself and may not be marketed.

**Measures for the Administration of Prescriptions**

The Measures for the Administration of Prescriptions, which was promulgated on February 14, 2007 and came into effect on May 1, 2007 by the Ministry of Health, provides the standards and format of prescriptions, the principles of prescription writing that doctors must abide by, and other regulations related to the provision and preparation of prescriptions. In accordance with the Measures for the Administration of Prescriptions, a registered doctor must acquire the prescription rights in the medical institution where he or she is registered. The prescription prescribed by the assistant doctor is then valid upon the signature or personal seal of the doctor in the same medical institution.

**Regulations on the supervision over medical equipment in medical institutions**

**Regulations on the Supervision and Administration of Medical Devices**

The Regulations on the Supervision and Administration of Medical Devices, or the Regulations on Medical Devices, which was promulgated by the State Council on January 4, 2000, amended on March 7, 2014, May 4, 2017, February 9, 2021, and December 6, 2024 and took effect on January 20, 2025, regulates the management of medical device manufacturing and the supervision, distribution and use of medical devices as well as relevant legal obligations. Pursuant to the Regulations on Medical Devices, medical device enterprises and medical institutions may only purchase medical devices from properly licensed enterprises. Medical institutions may not use unregistered, uncertified, expired, ineffective or outdated medical devices. Disposable medical devices may not be used repeatedly and medical institutions must destroy used disposable medical devices in accordance with relevant rules and keep records such disposal.

**Administrative Measures on Radiotherapy**

According to the Administrative Measures on the Radiotherapy, which was promulgated by the Ministry of Health on January 24, 2006, came into effect on March 1, 2006 and was amended on January 19, 2016, medical institutions engaged in radio diagnosis and radiotherapy must be equipped with the conditions required for conducting radio diagnosis and radiotherapy, and apply for a License for Radiotherapy issued by the competent public health administrative authorities. Medical institutions may not conduct radio diagnosis and radiotherapy if they fail to obtain the License for Radio-diagnosis and Radiotherapy or to register with radio diagnosis and radiotherapy on the Medical Institution Practicing License. During the course of radiotherapy, medical institutions must take protective measures in accordance with the relevant laws and regulations.

[**Table of Contents**](#TableOfContents)

**Regulations on the Safety and Protection of Radioisotopes and Radiation-emitting Devices and Measures for Administration of the Safety Licensing of Radioactive Isotopes and Radioactive Equipment**

The Regulations on the Safety and Protection of Radioisotopes and Radiation-emitting Devices, which was promulgated by the State Council on September 14, 2005, came into effect on December 1, 2005 and was revised on July 29, 2014 and March 2, 2019, and the Measures for Administration of the Safety Licensing of Radioactive Isotopes and Radioactive Equipment, which was promulgated by the Ministry of Environmental Protection (currently known as the Ministry of Ecology and Environment) on January 18, 2006 and amended on December 6, 2008, December 12, 2017, August 22, 2019 and January 4, 2021, respectively, require any entity engaging in the production, sale or use of radioisotopes or radiation-emitting devices of different categories to obtain a Safety License for Radiation. In addition, medical institutions using radioisotopes or radiation-emitting devices for diagnosis and treatment are required to obtain a permit for radiological diagnostic and therapeutic techniques and medical radiation.

**Announcement regarding the Adjustment of Certain Content in the Medical Devices Classification Catalog**

On March 28, 2022, the National Medical Products Administration promulgated the Announcement regarding the Adjustment of Certain Content in the Medical Devices Classification Catalog, which provides that, among others, since April 1, 2024, radiofrequency therapy devices and radiofrequency skin treatment devices that have not obtained registration certificates of medical devices in accordance with the law shall not be produced, imported or sold.

**Administrative Measures on the Deployment and Use of Large Medical Equipment (for Trial Implementation)**

The Administrative Measures on the Deployment and Use of Large Medical Equipment (for Trial Implementation), which was jointly promulgated by the National Health Commission and the State Drug Administration and became effective on May 22, 2018, provides that the State implements classified and categorized allocation plans and license management to large medical equipment according to the Catalog of Large Medical Equipment. Large medical equipment refers to medical equipment with complicated technology, large capital input, high operating cost, great impact on medical expenses and included in the catalog management. Medical institutions that intend to purchase large medical equipment must apply to the competent health administrative authorities and purchase the approved large medical equipment upon the receipt of a License for the Deployment of Large Medical Equipment.

**Administrative Measures for Medical Consumables for Medical Institutions (for Trial Implementation)**

Administrative Measures for Medical Consumables for Medical Institutions (for Trial Implementation) or the Measures for Medical Consumables for Medical Institutions was jointly promulgated by the National Health Commission and the National Administration of Traditional Chinese Medicine on June 6, 2019 and came into effect on September 1, 2019. Measures for Medical Consumables for Medical Institutions provide for the definition and classification of medical consumables, and state that whole-process administration will be imposed on work related to medical consumables, including selection, procurement, receiving inspections, storage, distribution, clinical use, monitoring, and evaluation. Measures for Medical Consumables for Medical Institutions state that medical consumables will be subject to unified procurement, adding that clinical use of medical consumables is administered at three different levels, and for this purpose, medical consumables are divided into three classes, i.e. Class I, Class II and Class III. Class I medical consumables are utilized by medical technicians, while Class II medical consumables are used by qualified medical technicians after they have received the necessary training, and Class III medical consumables, as stipulated by relevant administrative provisions on medical technologies, are used by those medical technicians who obtain the qualification to make relevant technical operations. Furthermore, Measures for Medical Consumables for Medical Institutions require that medical consumables usable by medical institutions shall fall in a limited range of varieties, to limited specifications and in a limited quantity, and the number of enterprises supplying the medical consumables with the same or similar functions should be controlled as well.

***Announcement of the National Medical Products Administration on Further Clarifying Requirements for Radiofrequency Therapy Devices***

 

The Announcement of the National Medical Products Administration on Further Clarifying Requirements for Radiofrequency Therapy Devices, which was promulgated by National Medical Products Administration on July 2, 2024 and effective on the same day, provides that, as of April 1, 2026, radiofrequency therapy devices and radiofrequency skin therapy devices listed in the annex of the Announcement on Adjusting Part of the Content of the Medical Device Classification Catalog, shall not be produced, imported, or sold without obtaining the medical device registration certificate. Registrants and manufacturers of radiofrequency therapy devices and radiofrequency skin therapy devices should effectively fulfill their responsibilities for product quality and safety, comprehensively strengthen quality management throughout the product lifecycle, and ensure that the marketed products are safe and effective.

[**Table of Contents**](#TableOfContents)

**Regulations on medical personnel of medical institutions**

**Physicians Law of the People's Republic of China**

The Physicians Law of the People's Republic of China, promulgated by the Standing Committee of the National People's Congress on August 20, 2021 and came in effect on March 1, 2022, which replaced the Law on Medical Practitioners of the People's Republic of China, promulgated by the Standing Committee of the National People's Congress on June 20, 1998. The Physicians Law of the People's Republic of China provides that physicians in the PRC must obtain qualification licenses for their medical profession. Qualified physicians and qualified assistant physicians must register with the relevant health administrative authorities at or above the county level. After registration, physicians may practice in their registered institution within the registered practicing categories and practicing scope.

***Administrative Measures for the Registration of Medical Practitioners***

Administrative Measures for the Registration of Medical Practitioners, which was promulgated by the National Health and Family Planning Commission on February 28, 2017 and came into effect on April 1, 2017, provides that the State has established an information system for medical practitioner administration to carry out e-registration and online administration. Upon gaining a qualification license to practice as a doctor, medical practitioners may conduct activities related to medical care, disease prevention or healthcare according to their registered area, category and scope of practice. Medical practitioners serving in several institutions within the same place of practice shall determine a specific institution as the main practicing institution, and apply for registration with the competent health and family planning administrative authority that approves the practice of the institution. For other institutions where the physician intends to practice, the physicians must apply with the administrative departments of health and family planning that approves the practice of such institutions, indicating the locations and names of such institutions.

**Trial Regulations on the Position of Health Technical Personnel**

**Regulations on Nurses**

The Regulations on Nurses, which was promulgated by the State Council on January 31, 2008, came into effect on May 12, 2008 and was amended on March 27, 2020, provides that a nurse shall apply to the competent health administrative department that approves the establishment of the medical institution in which he or she intends to practice or that processes the record-filing of the said medical institution and obtain a Nurse's Practicing Certificate. The practicing nurse registration is valid for five years. The number of nurses at a medical institution may not be less than the standard number set by the public health administrative authority of the State Council.

**Administrative Measures for Aesthetic Medical Services**

The Administrative Measures for Aesthetic Medical Services, which was promulgated by the Ministry of Health on January 22, 2002, came into effect on May 1, 2002, and was amended on February 13, 2009 and January 19, 2016, requires medical practitioners of aesthetic medical services to obtain the qualification license of aesthetic medical chief doctor or provide aesthetic medical clinical services under supervision of licensed chief doctors. An aesthetic medical chief doctor is required to have, among others, (a) a doctor's qualification and registration with relevant authority, (b) working experience with relevant clinical specialties, and (c) aesthetic medical training or an advanced education certificate or no less than one year of clinical working experience in the aesthetic medical services.

Personnel providing aesthetic medical nursing services must also meet relevant requirements including but not limited to (a) nurse qualifications and registrations with relevant authorities, (b) no less than two years of nursing working experience, and (c) aesthetic medical nursing training or advanced education certificates or not less than six months of clinical nursing working experience in the aesthetic medical services. The chief doctor responsible for aesthetic surgeries must also have at least six years of clinical working experience in the aesthetic surgery departments or plastic surgery departments. The chief doctor responsible for aesthetic dentistry treatment must also have at least five years of clinical working experience in aesthetic dentistry departments or stomatology departments. The chief doctor responsible for aesthetic traditional Chinese medicine treatment or aesthetic dermatological treatment must also have at least three years of clinical working experience in traditional Chinese medicine or dermatology.

[**Table of Contents**](#TableOfContents)

**Regulations on Physicians' Multi-sited Practice**

Several Opinions on Accelerating the Development of Medical Institutions with Social Capital, which was promulgated on December 30, 2013 by the National Health and Family Planning Commission and the State Administration of Traditional Chinese Medicine, specifically states that multi-sited practice of physicians is permitted. Medical personnel can orderly move among medical institutions owned by different entities.

The Notice on Issuing Opinions on Promoting and Regulating Physicians' Multi-sited Practice, which was jointly promulgated by the National Health and Family Planning Commission, National Development and Reform Commission, and the Ministry of Human Resources and Social Security on November 5, 2014 and came into effect on the same date, requires that physicians with multi-sited practice to meet the following criteria: (1) be qualified for intermediate or higher professional and technical positions, and have been engaged in the same profession for no less than five years, (2) be healthy and be competent for multi-sited practice, and (3) have no unqualified record in the periodic assessments of physicians in the last two consecutive cycles. It also states that registration management applies to multi-sited practices.

**Interim Administrative Measures for Temporary Medical Practicing in Mainland China by Foreign Doctors**

The Interim Administrative Measures for Temporary Medical Practicing in Mainland China by Foreign Doctors, which was promulgated by the Department of Health on October 7, 1992, came into effect on January 1, 1993, and was amended on November 28, 2003 and January 19, 2016, provides that temporary medical practice in China by foreign doctors refers to clinical diagnosis and treatment business activities that are carried out for a period of less than one year by foreign doctors licensed in other countries who are invited to come to or employed in Mainland China. Foreign doctors wishing to engage in temporary medical practice in Mainland China must be registered and issued a License of Short-term Medical Practicing by Foreign Doctors. The effective period for a short-term practicing foreign doctor permit in China does may exceed one year, but foreign doctors may re-apply for such registration upon the expiration of their previous registration.

**Notice on Issues Related to Strengthening the Management of Medical Aesthetic In-charge Physicians**

According to the Notice on Issues Related To Strengthening the Management of Medical Aesthetic In-charge Physicians, which were promulgated by the National Health and Family Planning Commission on March 17, 2017, medical institutions to carry out aesthetic medical service, should comply with the Administrative Measures for Aesthetic Medical Services, to check and ratify the specialty of the medical aesthetic in-charge physicians of the medical institution.

**Management Measures of Qualification and Practice of Aesthetic Medical Attending Doctors (for Trial Implementation)**

The Management Measures of Qualification and Practice of Aesthetic Medical Attending Doctors (for Trial Implementation), which was promulgated by the Health and Family Planning Commission of Guangdong Province on March 17, 2014 and became effective on May 1, 2014, provides that practicing doctors conducting aesthetic medical activities in Guangdong Province should obtain the Qualification Certificate of Aesthetic Medical Attending Physicians in Guangdong Province before conducting aesthetic medical diagnosis and treatment activities. After obtaining the Qualification Certificate of Aesthetic Medical Attending Physicians in Guangdong Province, they may only conduct aesthetic medical diagnosis and treatment activities in accordance with the approved category of aesthetic medical doctors, the registered practice place and the practice scope. Doctors without the Qualification Certificate of Aesthetic Medical Attending Physicians in Guangdong Province shall engage in aesthetic medical activities under the guidance of attending doctors holding such qualification certificate, and shall not independently conduct aesthetic medical activities. Attending doctors conducting aesthetic medical activities that are beyond the registered doctor's category or are out of the registered practice place will be prohibited from conducting aesthetic medical activities for 6 months and will be required to attend trainings on laws and regulations.

[**Table of Contents**](#TableOfContents)

**Regulations on anti-corruption and anti-commercial bribery**

The PRC governmental departments have formulated relevant laws and regulations for standardizing the anti-corruption and anti-commercial bribery in the medical treatment and healthcare industry.

**Code of Conduct for the Practitioners of Medical Institutions**

The Code of Conduct for the Practitioners of Medical Institutions, or the Code, was jointly promulgated by the Ministry of Health, the State Food and Drug Administration, the State Administration of Traditional Chinese Medicine and came into effect on June 26, 2012, providing the basic rules of conduct for practitioners at medical institutions, managerial persons, doctors, nurses, pharmaceutical technicians, medical technicians and other relevant persons. The Code applies to practitioners of all levels and classes at medical institutions. Pursuant to the Code, practitioners in medical institutions must perform their duties honestly, be self-disciplined, and abide by medical ethics. Accordingly, such practitioners may not ask for or illegally receive any property from patients, receive improper benefits by leveraging their positions, receive such rebates or commissions, in various form or titles, offered by personnel in creating or operating an enterprise related to medical equipment and machinery, pharmaceuticals, and chemical agents, participate in operational entertainment arranged, organized or paid by such personnel, gain access to or acquire the basic medical protection fund by cheating or facilitate such improper acquisition by others, violate the laws by participating in advertisement for medical treatments and marketing and promotion of pharmaceuticals or machinery for medical treatment, or re-sell a registration number for treatment at a profit.

**Nine Criteria for Incorrupt Practices of Staff of Medical Institutions**

In accordance with the Notice on Printing and Distributing of the "Nine Criteria" for Incorrupt Practices of Staff of Medical Institutions, which was promulgated and implemented by the National Health Commission, the National Healthcare Security Administration, and the State Administration of Traditional Chinese Medicine and effective on November 12, 2021, medical institutions are required to implement the policy of the "Nine Criteria", including (1) staff of medical institutions shall receive remuneration according to law and based on the services they provided and shall not accept commercial commissions, (2) staff of medical institutions shall strictly follow the principle of good faith and shall not participate in insurance fraud, (3) staff of medical institutions shall practice medicine in accordance with norms and shall not conduct excessive diagnosis and treatment, (4) staff of medical institutions shall abide by working procedures and shall not accept donations in violation of regulations, (5) staff of medical institutions shall abide by the requirement of confidentiality and shall not disclose patients' privacy, (6) staff of medical institutions shall follow the needs of diagnosis and treatment, and shall not seeking profits in referral of patients, (7) staff of medical institutions shall maintain the order of diagnosis and treatment and shall not undermine the fairness in medical treatment, (8) staff of medical institutions shall build harmonious relations and shall not accept "red packets" from patients, and (9) staff of medical institutions shall keep the bottom line of contacts and shall not accept kickbacks from enterprises. Staff of medical institutions, including but not limited to health professionals, management personnel, logistics personnel and other social practitioners who provide services within the medical institutions and are managed by the medical institutions, shall abide by the relevant requirements of the Nine Criteria, subject themselves to management and strictly implement relevant requirements. Any such stuff who violates the above requirements shall be punished in accordance with laws and regulations within administrative authority.

**Regulations on Governance of Commercial Bribery in the Purchase and Sales of Medicine**

In accordance with the Implementation Opinions on Launching Special Governance on Commercial Bribery in Medicine Purchase and Sale, promulgated and implemented by the Ministry of Health and the State Administration of Traditional Chinese Medicine and effective April 21, 2006 and the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Purchase and Sale of Medicine, which was promulgated by the National Health and Family Planning Commission on December 25, 2013 and implemented on March 1, 2014, the focus of the specialized governance framework regarding commercial bribery to procure medicine are on: (i) the act of the leaders and the relevant personnel of medical institutions of receiving property or rebate granted by the manufacturing and business enterprises and their marketing and sales personnel during the procurement of medicines, medical equipment and medical consumables, (ii) the act of the medical professionals of medical institutions of receiving property or commission granted by the manufacturing and business enterprises and their marketing and sales personnel during the clinical, diagnosis and treatment, and (iii) the act of medical institutions of receiving property granted by the manufacturing and business enterprises and their marketing and sales personnel. Personnel in violation of the relevant provisions will be punished by confiscation of the illegal goods and revocation of their business licenses. If the act constitutes a crime, criminal liability on the relevant parties will also be pursued according to laws.

[**Table of Contents**](#TableOfContents)

***Notice on Promulgation of the Key Points for the Work of Correcting Malpractice in the Medicine Purchase and Sales Field and Medical Services***

 ****

On May 8, 2023, the National Health Commission of the PRC, together with other departments, promulgated the Notice on Promulgation of the Key Points for the Work of Correcting Malpractice in the Medicine Purchase and Sales Field and Medical Services in 2023, or the 2023 Notice. The 2023 Notice demonstrates that the competent authorities have placed significant emphasis on correcting unhealthy practices within the pharmaceutical purchasing and sales field as well as the medical service sector in China. The 2023 Notice serves as a crucial step towards enhancing regulatory oversight and promoting fair competition in the health service industry. It outlines specific measures and guidelines aimed at rectifying various unethical and illicit behaviors that may exist within the pharmaceutical procurement and sales processes, as well as the provision of health care services. The implementation of this notice signifies the determination of the PRC regulatory authorities to eradicate corruption, bribery, and other forms of unfair competition within the health sector. It also underscores the commitment to ensure the highest standards of integrity, transparency, and ethical conduct in the industry. On May 17, 2024, the National Health Commission of the PRC, together with other departments, promulgated the Notice on Promulgation of the Key Points for the Work of Correcting Malpractice in the Medicine Purchase and Sales Field and Medical Services in 2024, or the 2024 Notice. The 2024 Notice further demonstrates the key points of regulatory oversight on correcting unhealthy practices within the pharmaceutical purchasing and sales field.

On June 13, 2025, the National Health Commission of the PRC, together with other departments, promulgated the Notice on Issuing the Key Points for Rectifying Unhealthy Practices in the Field of Pharmaceutical Purchase and Sale and Medical Services in 2025, or the 2025 Notice. The 2025 Notice further identified patient privacy protection, medical beauty, illegal medical advertising, false or disguised traffic diversion through purported health science popularization, video-based marketing misconduct, and compliance risks in medical device, consumables, project approval and fund use processes as key areas of rectification and coordinated enforcement.

**Regulations on medical malpractice**

**The PRC Civil Code**

The PRC Civil Code, which was promulgated by the National People's Congress on May 28, 2020, came into effect on January 1, 2021 provides that contracting parties must perform their obligations in full as agreed. The parties shall, under the principle of good faith, perform such obligations according to the nature and purpose of the contract as well as trading practices.

A lawfully established contract is legally binding on the contracting parties, each of whom must perform its own obligations in accordance with terms of the contract, and no party may unilaterally modify or terminate the contract.

The PRC Civil Code provides that, if a medical institution or the medical personnel of a medical institution are at fault for damage inflicted on a patient during the course of diagnosis and treatment, the medical institution will be liable for compensation. The medical institution is responsible for the damage caused to the patient due to the failure of the medical personnel to fulfill their statutory obligations in the course of diagnosis and treatment. Medical institutions and their medical personnel must protect the privacy of their patients and will be liable for damage caused by divulging the patients' private or medical records without consent.

**Interpretations of the Supreme People's Court on Several Issues concerning the Application of Law in Hearing Cases Involving Disputes over the Liability for Medical Damage**

According to the Interpretations of the Supreme People's Court on Several Issues concerning the Application of Law in Hearing Cases Involving Disputes over the Liability for Medical Damage, which was promulgated by the Supreme People's Court on December 13, 2017, became effective on December 14, 2017 and was amended on December 29, 2020, after a patient has filed a lawsuit against some of the medical institutions where he or she was treated, such medical institutions are allowed to file an application to bring in other medical institutions where the patient has received treatment as joint defendants or third parties. The people's court may also bring related parties into the lawsuit according to the law when the court deems it necessary.

**Regulations on Handling Medical Malpractice**

The Regulations on Handling Medical Malpractice, which was promulgated by the State Council on April 4, 2002 and came into effect on September 1, 2002, provides a legal framework and detailed provisions regarding the prevention, identification, disposition, compensation and penalties of or relating to cases involving personal injury to patients caused by medical institutions or medical personnel due to malpractice. Medical accidents shall, according to the seriousness of personal injuries to patients, be classified into four grades. The criteria for specific grades shall be formulated by the health administration department of the State Council.

[**Table of Contents**](#TableOfContents)

**Trial Administrative Measures of the Health Department of Guangdong Province on Point Deductions for Medical Institution Malpractice**

The Trial Administrative Measures of the Health Department of Guangdong Province on Point Deductions for Medical Institution Malpractice, or the Guangdong Measures, which was promulgated and came into effect on January 4, 2011 by the Health Department of Guangdong Province, specifies certain circumstances under which a medical institution's malpractice points will be deducted and the number of malpractice points to be deducted under each circumstance. A medical institution's malpractice points may be subject to deductions each year, and when the annual renewal of the Medical Institution Practicing License is completed, the deducted malpractice points are reset to zero. From the date of renewal, if there are more than 24 points deducted within a year, the health administrative department will report the point deductions to its supervising department. Medical institutions at all levels must comply with the Guangdong Measures, provided that such medical institutions have legitimately obtained a Medical Institutions Practicing License within the administrative area of Guangdong Province.

**Regulations on Point Accumulation and Deduction for Medical Institution Malpractice in Shanghai**

On January 30, 2007, the Health Department of Shanghai promulgated the Notice on Improving the Management of Point Accumulation for Medical Institution Malpractice in Shanghai, which came into effect on the same date, establishing the archive management system and laying out detailed procedures for archive management. The Administrative Measures of Shanghai on Point Deduction for Medical Institutions Malpractice, or the Shanghai Measures which was promulgated on November 27, 2023 and came into effect on January 1, 2024 by the Health Department of Shanghai, specifies certain circumstances under which a medical institution's malpractice points will be deducted and the number of points to be deducted under each circumstance. A medical institution's malpractice points may be subject to deduction each examination and verification period following the issuance date of the Medical Institution Practicing License or the qualification date of the previous examination and verification period. Upon expiration of each deduction period, the deducted malpractice points are reset to zero. Where a medical institution has a one-year examination and verification period and its malpractice points are deducted by more than 12 during such period, or where a medical institution has a three-year examination and verification period and its malpractice points are deducted by more than 36 during such period (1) if it is within 3 months before the expiration of the current examination and verification period, the registration authority should order such medical institution to apply for examination and verification immediately and should extend the examination and verification period of such medical institution by one to six months. The medical institution must then apply for re-examination and verification upon the expiration of the extended examination and verification period, whereas, in the event that the malpractice points are deducted by more than 6 during the extended examination and verification period, the medical institution will fail the re-examination and verification and its Medical Institution Practicing License will be revoked by the registration authority; (2) the legal representative and principal responsible person of such medical institution shall take the examination regarding relevant laws and regulations of health care organized by the health administrative department. If such persons do not take the examination or fail the examination, such medical institution will be deemed unqualified for re-examination and re-verification, and its Medical Institution Practicing License will be revoked by the registration authority. Medical institutions at all levels in Shanghai must comply with the Shanghai Measures, provided that such medical institutions have legitimately obtained a Medical Institutions Practicing License within the administrative area of Shanghai.

**Regulations on Point Accumulation for Medical Institution Malpractice in Beijing**

The Health Department of Beijing promulgated the Trial Administrative Measures of Beijing on Point Accumulation for Medical Institution Malpractice on February 22, 2008, or the Beijing Measures, which came into effect on March 20, 2008, specifying certain circumstances under which a medical institution's malpractice points will be deducted and the number of points to be deducted under each circumstance. Medical institutions at all levels in Beijing must comply with the Beijing Measures, provided that such medical institutions have filed for practice registration with the health administrative department and legitimately obtained a Medical Institutions Practicing License within the administrative area of Beijing. On January 16, 2017, the Beijing Health and Family Planning Commission and Beijing Administration of Traditional Chinese Medicine jointly promulgated the Notice on Further Improving the Management of Point Accumulation for Medical Institution Malpractice, which came into effect on the same date, stating that the verification and examination of medical institutions may be postponed if a certain number of malpractice points of such medical institutions are deducted.

[**Table of Contents**](#TableOfContents)

**Administrative Measures of Hainan Province on Point Deduction for Medical Institution Malpractice**

The Administrative Measures of Hainan Province on Point Deduction for Medical Institution Malpractice, which was promulgated on March 14, 2019 and came into effect on April 1, 2019 by the Health Commission of Hainan Province, specifies certain circumstances under which a medical institution's malpractice points will be deducted and the number of points to be deducted under each circumstance. The malpractice points of a medical institution may be deducted in each year following the issuance date of such medical institution's Medical Institution Practicing License. The registration authority may extend the examination and verification period of medical institutions by six months under the following circumstances: (1) for a medical institution that has a one-year examination and verification period, its malpractice points are deducted by more than 12 points during such period, or (2) for a medical institution that has a three-year examination and verification period, its malpractice points are deducted by more than 36 points during such period. If the malpractice points of the aforementioned medical institutions are deducted by more than 6 points during the extended examination and verification period, the registration authority may deem it as a failed examination and verification situation and revoke the Medical Institution Practicing License. All medical institutions holding a Medical Institution Practicing License issued in Hainan Province must comply with these measures.

**Administrative Measures of Shandong Province on Point Deduction for Medical Institution Malpractice**

Administrative Measures of Shandong Province on Point Deduction for Medical Institution Malpractice, which was promulgated on June 11, 2023 and came into effect on July 13, 2023 by the Health and Family Planning Commission of Shandong Province, specifies certain circumstances under which a medical institution's malpractice points will be deducted and the number of points that will be deducted under each circumstance. The malpractice points of a medical institution may be deducted in each year following the issuance date of its Medical Institution Practicing License. Upon expiration of the one-year deduction period, the malpractice points are reset to zero. For a medical institution with a one-year examination and verification period, if its malpractice points are deducted by more than 18 points during such period, the registration authority may extend the examination and verification period of such medical institution by one to six months. The extended one to six months examination and verification period will also be made to a medical institution with a three-year examination and verification period if its malpractice points are deducted by more than 80 during the three-year period. The aforesaid measures are applicable to all kinds of public and private medical institutions at all levels that have obtained the Medical Institution Practicing License according to laws within the administrative areas of Shandong Province.

**Regulations on Preventing and Handling Medical Disputes**

The Regulations on Preventing and Handling Medical Disputes, which was promulgated by the State Council on July 31, 2018 and come into effect on October 1, 2018, and the Measures for Complaint Management of Medical Institutions, which was promulgated by the National Health Committee on March 6, 2019 and came into effect on April 10, 2019, require medical institutions to establish a sound system for receipt of complaints, set up a unified complaint management department or be equipped with full-time (or part-time) staff, and post medical dispute resolution measures, procedures and contacts in a conspicuous place in the medical institution to make it convenient for patients to submit complaints or feedback. For medical institutions that have not established a system to receive complaints, or such system fails to comply with the relevant requirements, it may receive rectification order, warning from and be imposed fine by the competent health administrative department, while related staff and medical personnel directly responsible may be punished under serious circumstances. If any crime is constituted, the violator shall be subject to criminal liability in accordance with the law.

**Regulations on medical advertising in the PRC**

**Advertisement Law of the People's Republic of China**

The Advertisement Law of the People's Republic of China, or the Advertisement Law, which was promulgated by the Standing Committee of National People's Congress on October 27, 1994, came into effect on February 1, 1995, and was amended on April 24, 2015, October 26, 2018 and April 29, 2021, provides that advertisements may not contain false or misleading content or deceive or mislead consumers. Advertisements related to pharmaceuticals and medical devices must be reviewed by relevant authorities in accordance with relevant rules before being distributed or broadcasted through movies, television, newspapers, journals or other means. The Advertisement Law further requires that any advertisement for medical treatment, pharmaceuticals or medical devices to not contain: (i) any assertion or guarantee regarding efficacy or safety, (ii) any statement on cure rate or effective rate, (iii) any comparison with the efficacy and safety of other pharmaceuticals or medical devices or with other medical institutions, (iv) any use of endorsements or testimonials, or (v) other items as prohibited by laws and administrative regulations.

[**Table of Contents**](#TableOfContents)

**Administrative Measures for Internet Advertisement**

The Administrative Measures for Internet Advertisement, which was promulgated by the State Administration of Market Regulation on March 24, 2023 and came into effect on May 1, 2023, provides that internet advertisement must be identifiable and can make consumers recognize it as an advertisement. For goods or services ranked according to bidding, advertisement publishers shall indicate the word "advertisement" prominently in order to make a clear distinction with the natural search results. No entity and individual may publish any advertisement of prescription pharmaceuticals by means of the internet unless otherwise provided by laws and regulations. No advertisement of any medical treatment, pharmaceuticals, medical devices, pesticides, veterinary medicines, dietary supplements, foods for special medical purpose or other advertisements which are subject to review by advertisement review authorities as required by laws and regulations may be released unless it has passed such review. Internet advertisements which are subject to review shall be released strictly in accordance with the contents which have passed such review, and shall not be edited, spliced or modified. Where the contents of advertisements which have passed review need to be modified, a new application for advertisement review shall be submitted.

**Administrative Measures on Medical Advertisement**

The Administrative Measures on Medical Advertisement, which was jointly promulgated by the State Administration of Industry and Commerce and the Ministry of Health on September 27, 1993, and was amended on November 10, 2006 and came into effect on January 1, 2007, requires medical advertisements to be reviewed by relevant health authorities and a Medical Advertisement Approval Certificate to be obtained before such advertisement may be released by a medical institution. Medical Advertisement Review Certificate has an effective term of one year and may be renewed upon application.

**Notice on Further Strengthening the Management of Medical Advertisements**

The *Notice on Further Strengthening the Management of Medical Advertisements,* which was promulgated by the Ministry of Health and came into effect on July 17, 2008, emphasizes severe censorship, regulation and punishment on medical institutions' non-compliance of medical advertisement. In case that a medical institution fails to correct its non-compliance of medical advertisement after two or more warnings, or that such non-compliance results in any patient suffering personal injuries or property losses, the medical institution shall be ordered to suspend its business for rectification, or the license for operating particular medical department or even the Medical Institution Practice License of such institution will be revoked in accordance with the provisions of the Administrative Measures on Medical Advertisement.

***Enforcement Guidance for the Medical Cosmetology Advertising***

 

The Enforcement Guidance for the Medical Cosmetology Advertising, which was promulgated by the State Administration for Market Regulation on November 1, 2021 and came into effect on the same day, stipulates that the market regulatory departments shall rectify the chaos of all kinds of medical beauty advertisements in accordance with the laws and regulations, strive to solve the problems of great harmfulness and concentrated public response, and crack down a number of illegal advertising activities.

***Medical Advertisement Supervision Work Guidelines***

 

On May 9, 2025, the State Administration for Market Regulation issued the Medical Advertisement Supervision Work Guidelines. The Guidelines further specify the enforcement principles applicable to medical advertising cases and clarify that only lawfully established medical institutions may publish medical advertisements. The Guidelines further specify the circumstances under which no administrative penalty, a lighter or mitigated penalty, or a heavier penalty may be imposed, and expressly address regulatory treatment of medical beauty advertisements that create appearance anxiety, target minors, contain absolute terms or otherwise violate advertising rules. The Guidelines further emphasize the responsibilities of internet platform operators in relation to unlawful medical advertising.

***Medical Advertisement Identification Guidelines***

 

On July 17, 2025, the State Administration for Market Regulation, together with the National Health Commission and the National Administration of Traditional Chinese Medicine, issued the Guidelines for Identifying Medical Advertisements. The Guidelines clarify the distinction between lawful medical information disclosure or health science popularization and medical advertising or disguised medical advertising. They provide that certain factual disclosures by lawfully established medical institutions through their service premises, official websites, mobile applications or platform-certified "self-media" accounts, such as institution overview, medical personnel information, service items, treatment procedures, prices, fees and complaint channels, generally do not constitute medical advertising if no promotional circumstances are involved. The Guidelines also specify that subjective promotion of a medical institution's environment, equipment, technologies, treatment procedures or treatment effects, comparisons with other medical institutions, case-based promotion, and the addition of links or traffic-diversion entrances relating to specific medical services, drugs or medical devices may constitute medical advertising or disguised medical advertising.

[**Table of Contents**](#TableOfContents)

***Notice on Regulating "Self-media" Medical Science Popularization Behavior***

 

On August 1, 2025, the Cyberspace Administration of China, together with the National Health Commission, the State Administration for Market Regulation and the National Administration of Traditional Chinese Medicine, issued the Notice on Regulating "Self-media" Medical Science Popularization Behavior. The Notice strengthens regulation of medical-related "self-media" content by requiring stricter credential verification, prominent display of credential information and clearer identification of information sources. It also prohibits uncertified accounts from producing professional medical science popularization content, strengthens regulation of content disseminated through short-video, livestream and similar online channels, prohibits the use of medical science popularization as disguised advertising or for improper traffic diversion, and requires websites and platforms to strengthen account management and content governance.

**Regulations on environmental protection related to medical institutions**

**Regulations on the Management of Medical Waste and the Management Measures for Medical Waste of Medical Institutions**

The Regulations on the Management of Medical Waste, which was promulgated by the State Council on June 16, 2003, came into effect on the same date and was revised on January 8, 2011, and the Management Measures for Medical Waste of Medical Institutions, which was promulgated by the Ministry of Health on October 15, 2003 and came into effect on the same date, require medical institutions to timely deliver medical waste to a specially designated location for centralized disposal of medical waste and categorize the medical waste in accordance with the Classified Catalog of Medical Waste. High-risk waste such as the culture medium or specimens of pathogens and the preserving liquid of bacteria strains or virus strains must be sterilized on the spot before disposal. Sewage generated by any medical institution and excretion of its patients or patients suspected of infectious diseases must be sterilized in accordance with the relevant laws, rules and regulations, and must not be discharged into sewage treatment system until the relevant standards are met.

**Regulations on Urban Drainage and Sewage Treatment**

The Regulations on Urban Drainage and Sewage Treatment, which was promulgated by the State Council on October 2, 2013 and came into effect on January 1, 2014, requires urban entities and individuals to dispose sewage through urban drainage facilities covering their geographical area in accordance with relevant rules. Companies or other entities engaging in medical activities must apply for a Sewage Disposal Drainage License before disposing sewage into urban drainage facilities. Sewage- disposing entities and individuals are required to pay a sewage treatment fee in accordance with relevant rules.

**Measures for the Administration of Permits for the Discharge of Urban Sewage into Drainage Network**

The Measures for the Administration of Permits for the Discharge of Urban Sewage into Drainage Network, which was promulgated by the Ministry of Housing and Urban-Rural Development on January 22, 2015 and came into effect on March 1, 2015, and was revised on February 1, 2023, provides that enterprises engaging in industry, construction, catering and discharging sewage into the urban drainage network must apply for and obtain a License for Drainage.

[**Table of Contents**](#TableOfContents)

**Catalog of Classified Management of Pollutant Discharge Permits for Stationary Pollution Sources (2019 Edition)**

The Catalog of Classified Management of Pollutant Discharge Permits for Stationary Pollution Sources (2019 Edition), which was promulgated by the Ministry of Ecology and Environment on December 20, 2019 and came into effect on the same date, provides that medical institutions shall either apply for a pollutant discharge permit or submit a pollutant discharge registration form through the online platform based on the standards set therein.

**Regulations on consumer protection and right of personality**

The principal legal provisions for the protection of consumer interests are set out in the Consumer Protection Law, which was promulgated by the Standing Committee of the National People's Congress on October 31, 1993, became effective as of January 1, 1994 and was amended on October 25, 2013. According to the Consumer Protection Law, the rights and interests of the consumers who buy or use commodities or receive services for the purposes of daily consumption are protected and all manufacturers and sellers involved must ensure that the products and services will not cause damage to the consumers' personal safety and properties. Violations of the Consumer Protection Law may result in the imposition of fines. In addition, the violating business operator may be ordered to suspend operations and its business license may be revoked. Criminal liability may be imposed in serious cases.

In accordance with the PRC Civil Code, the legitimate rights and interests of civil parties include reputational rights and the right to one's image, and parties that infringe on the civil rights and interests of others will be held liable for tortious acts.

The Measures for Penalties against Infringements on Consumers' Rights (2020 Revision) promulgated by State Administration of Industry and Commerce on January 5, 2015 and amended on October 23, 2020, provides that, business operator shall covenant with customer regarding the quantity, quality, price, term, after-sale service, liability, etc. under prepaid arrangement. In the event of failure to provide goods or services as agreed, business operator shall perform as requested by the customer or refund the prepaid payment and bear the interest of prepaid payment and other necessary and reasonable costs paid by the customer.

**Regulations on fire prevention**

**Fire Prevention Law**

According to The Fire Prevention Law of the PRC, or the Fire Prevention Law, which was promulgated by the Standing Committee of the National People's Congress on April 29, 1998, came into effect on May 1, 2009 and was amended on October 28, 2008, April 23, 2019 and April 29, 2021 the Ministry of Public Security and its local counterparts at or above county level must monitor and administer fire prevention affairs. The Fire Prevention Law also provides that the fire prevention design or construction of a construction project must conform to the national fire prevention technical standards, and the construction entity must submit its fire prevention design documents to the fire prevention department of the public security authority for approval or filing purposes.

Upon the completion of a construction project to which a fire prevention design has been applied, according to the requirements of the Fire Prevention Law, such project must go through an acceptance check on fire prevention by, or filed with, the relevant fire prevention departments of public security authorities. For each public assembly venue, the construction entity or entity using such venue must, prior to use and operation of any business thereof, apply for a safety inspection on fire prevention with the relevant fire prevention department under the public security authority at or above the county level where the venue is located, and such place cannot be put into use and operation if it fails to pass the safety inspection on fire prevention or fails to conform to the safety requirement for fire prevention after such inspection.

[**Table of Contents**](#TableOfContents)

**Regulations related to foreign investment in the PRC**

**Company Law of the People's Republic of China**

The Company Law of the People's Republic of China, which was promulgated by the Standing Committee of National People's Congress on December 29, 1993, came into effect on July 1, 1994, and was amended in 1999, 2004, 2005, 2013, 2018 and 2023, provides that companies established in the PRC may either be limited liability companies or companies limited by shares. Each company has the status of a legal person and owns its own assets. Assets of a company may be used in full for the company's liability. The Company Law applies to foreign-invested companies unless relevant laws provide otherwise.

**Foreign Investment Law of the People's Republic of China**

On March 15, 2019, the National People's Congress approved the Foreign Investment Law, which became effective on January 1, 2020, and replaced the Sino-foreign Equity Joint Venture Enterprise Law, the Sino-foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-invested Enterprises Law. On December 26, 2019, the State Council issued the Regulations on Implementing the Foreign Investment Law of the PRC, which came into effect on January 1, 2020, and replaced the Regulations on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law, Provisional Regulations on the Duration of Sino-Foreign Equity Joint Venture Enterprise Law, the Regulations on Implementing the Wholly Foreign-Invested Enterprise Law, and the Regulations on Implementing the Sino-foreign Cooperative Joint Venture Enterprise Law.

Under the Foreign Investment Law, the State shall implement the management systems of pre-establishment national treatment and negative list for foreign investment, according to which the treatment given to foreign investors and their investments during the investment access stage shall be not lower than that given to their domestic counterparts, and the State shall give national treatment to foreign investment beyond the negative list where special administrative measures for the access of foreign investment in specific fields is specified. Besides, the State shall protect foreign investors' investment, earnings and other legitimate rights and interests within the territory of Mainland China in accordance with the law. The State will take measures to prompt foreign investment such as ensuring fair competition for foreign-invested enterprises to participate in government procurement activities, and protection of intellectual property rights of foreign investors and foreign-invested enterprises.

On December 30, 2019, the Ministry of the Commerce and the State Administration of Market Regulation issued the Measures for the Reporting of Foreign Investment Information, which came into effect on January 1, 2020 and replaced the Provisional Administration Measures for the Registration of the Formation and Changes of Foreign Invested Enterprises. Since January 1, 2020, for foreign investors carrying out investment activities directly or indirectly in Mainland China, the foreign investors or foreign-invested enterprises shall submit investment information to the commerce authorities pursuant to these measures.

[**Table of Contents**](#TableOfContents)

**Interim Provisions on Investment Made by Foreign-Invested Enterprises in the PRC**

The Interim Provisions on Investment Made by Foreign-Invested Enterprises in the PRC, which was jointly promulgated by the Ministry of Commerce and the State Administration of Industry and Commerce on July 25, 2000, and was amended and came into effect on October 28, 2015, provides that the provisions of the Interim Provisions Guiding Foreign Investment Direction and the Industry Catalog for Guiding Foreign Investment will govern foreign-invested enterprises' investment in the PRC. Foreign-invested enterprises are not permitted to invest in any sector prohibited to receive foreign investment. Where a foreign-invested enterprise makes an investment in a restricted sector, the foreign- invested enterprise must file an application with the provincial commercial department of the place where the investee company is located. The relevant company registration authority will decide, in accordance with the relevant provisions of the Company Law and the Regulations on the Administration of Company Registration of the PRC, whether to approve the registration or not. If the registration is approved, a Business License of an Enterprise Legal Person will be issued with the designation "Invested by a Foreign-Invested Enterprise" added. The foreign-invested enterprise is required to report the establishment of the invested company within 30 days of the date of its establishment to the original examination and approval authority for record-filing.

**Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors**

The Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, which was jointly promulgated by the Ministry of Finance, the State Assets Supervision and Administration Commission, the State Administration for Taxation, the State Administration of Industry and Commerce, the China Securities Regulatory Commission, and the State Administration of Foreign Exchange on August 8, 2006, came into effect on September 8, 2006 and was amended on June 22, 2009, requires foreign investors acquiring domestic companies by means of asset acquisition or equity acquisition to comply with relevant foreign investment industry policies and be subject to approval by relevant commerce authorities.

**Catalog of Industries for Encouraged Foreign Investment and 2024 Negative List**

The current regulation regime of foreign investment in the PRC, setting aside special arrangements adopted in pilot free trade zones, preliminarily consists of three principal legal documents, i.e. the Catalog of Industries for Encouraged Foreign Investment (2022 Edition), or the 2022 Encouraged Catalog, which was promulgated jointly by the Ministry of Commerce and the National Development and Reform Commission, on October 26, 2022 and became effective on January 1, 2023, the Special Administrative Measures for Access of Foreign Investment (Negative List) (2024 Edition), which was promulgated jointly by the Ministry of Commerce and the National Development and Reform Commission, on September 6, 2024 and became effective on November 1, 2024, or the 2024 Negative List, and the Provisions Guiding Foreign Investment Direction, which was promulgated by the State Council on February 11, 2002 and came into effect on April 1, 2002. These three legal documents collectively classify all foreign investment projects into four categories: (1) encouraged projects, (2) permitted projects, (3) restricted projects, and (4) prohibited projects. If the industry in which the investment is to occur falls into the encouraged category, foreign investment, in certain cases, may receive preferential policies or benefits. If it falls into the restricted category, foreign investment may be conducted in accordance with applicable legal and regulatory restrictions. If falls into the prohibited category, foreign investment of any kind will not be allowed.

The 2022 Encouraged Catalog and 2024 Negative List govern investment activities in the PRC by foreign investors and classify industries into three categories with regard to foreign investment: "encouraged", "restricted" and "prohibited". Industries not listed in the Catalog are generally deemed as falling into a fourth category, "permitted", unless specifically restricted by other PRC laws. For some restricted industries, foreign investors can only conduct investment activities through equity or contractual joint ventures, while in other cases PRC partners are required to hold the majority interests in such joint ventures. In addition, some projects in the restricted category are subject to higher-level governmental approvals. Foreign investors are not allowed to invest in industries in the prohibited category. According to the current 2022 Encouraged Catalog and 2024 Negative List, investment into medical institutions falls within the restricted category. Foreign investment in healthcare institutions is restricted to the form of Sino-foreign cooperation or joint venture.

[**Table of Contents**](#TableOfContents)

**Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions**

The Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions, which was promulgated by the Ministry of Health and the Ministry of Foreign Trade and Economic Cooperation on May 15, 2000 and came into effect on July 1, 2000, allows foreign investors to partner with Chinese medical entities to establish a medical institution in the PRC by means of an equity joint venture or a cooperative joint venture. Establishment of equity joint venture or cooperative joint venture must meet certain requirements, including that total investment may not be less than RMB20 million, and that the equity percentage of the Chinese partner in the joint venture may not be less than 30%. Establishment of an equity joint venture or cooperative joint venture will be subject to approval by relevant authorities.

**Notice on Further Encouraging and Guiding Private Capital to Invest in Medical Institutions**

Pursuant to the Notice on Further Encouraging and Guiding Private Capital to Invest in Medical Institutions, which was promulgated on November 26, 2010, foreign investors are permitted to establish for-profit or not-for-profit medical institutions in the PRC as foreign-invested projects. Overseas medical institutions, enterprises and other economic organizations are permitted to establish medical facilities together with domestic medical institutions, enterprises or other economic organizations in the form of equity or cooperative joint ventures, and the restrictions on equity proportion for foreign capital will be gradually removed. A pilot program will be introduced and gradually expanded to permit eligible foreign investors to establish wholly foreign- owned medical institutions.

**Additional Provisions to the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions**

The Additional Provisions to the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions, which was jointly promulgated by the Ministry of Commerce and the Ministry of Health on December 30, 2007 and came into effect on January, 2008, provides that the total investment by Hong Kong or Macau service providers in establishing equity or cooperative medical institutions in the PRC may not be less than RMB10 million. Hong Kong and Macau service providers must also comply with the Closer Economic Partnership Arrangement between Mainland China and Hong Kong and Arrangement regarding Establishing Closer Economic Partnership between Mainland China and Macau, respectively. The Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions may be applied to equity or cooperative medical institutions in which by Hong Kong or Macau service providers have invested to the extent not provided under the Additional Provisions to the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions.

**Additional Provisions (Second) to the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions**

The Additional Provisions (Second) to the Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions, which was jointly promulgated by the Ministry of Commerce and the Ministry of Health on December 7, 2008 and came into effect on January 1, 2009, allows Hong Kong and Macau service providers to establish wholly- owned clinics within the Guangdong Province without any limitation on total investment. Hong Kong and Macau service providers may also partner with Chinese medical entities to establish a clinic in the Guangdong Province by means of equity joint ventures or cooperative joint ventures without any limitation on the total investment or equity percentage.

[**Table of Contents**](#TableOfContents)

**Regulations related to labor protection in the PRC**

**Labor Law of the PRC**

The Labor Law of the PRC, which was promulgated by the Standing Committee of the National People's Congress on July 5, 1994, which came into effect on January 1, 1995 and was amended on August 27, 2009 and December 29, 2018, provides that an employer must develop and improve its rules and regulations to protect the rights of its workers, such as by developing and improving its labor safety and health system, stringently implementing national protocols and standards on labor safety and health, conducting labor safety and health education for workers, guarding against labor accidents and reducing occupational hazards. Labor safety and health facilities must comply with relevant national standards. An employer must provide workers with the necessary labor protection equipment that comply with labor safety and health conditions required under national regulations, as well as provide regular health checks for workers that are engaged in operations with occupational hazards. Workers engaged in special operations must first receive specialized training and obtain the pertinent qualifications. Employers must also develop a vocational training system. Vocational training funds must be set aside and used in accordance with national regulations, and vocational training for workers must be carried out systematically based on the actual conditions of the company.

**Labor Contract Law of the PRC and its implementation regulations**

The Labor Contract Law, which was promulgated by the Standing Committee of the National People's Congress on June 29, 2007, came into effect on January 1, 2008, and was amended on December 28, 2012, and the Implementation Regulations on Labor Contract Law, which was promulgated by the State Council and effective on September 18, 2008, regulate the relation between employers and employees and contain specific provisions involving the terms of the labor contract. Labor contracts must be made in writing and may, after reaching an agreement upon due negotiations, be for a fixed-term, an un-fixed term, or conclude upon the completion of certain work assignments. An employer may legally terminate a labor contract and dismiss its employees after reaching an agreement upon due negotiations with the employee or by fulfilling the statutory conditions.

**Laws and Regulations on the Supervision over the Social Security and Housing Funds**

According to the Temporary Regulations on the Collection and Payment of Social Insurance Premium, the Regulations on Work Injury Insurance, the Regulations on Unemployment Insurance and the Trial Measures on Employee Maternity Insurance of Enterprises, enterprises in the PRC must provide beneficial plans for their employees, that include basic pension insurance, unemployment insurance, maternity insurance, work injury insurance and medical insurance. An enterprise must also provide social insurance by processing social insurance registration with local social insurance agencies, and must pay or withhold relevant social insurance premiums for or on behalf of the employees. The Law on Social Insurance, which was promulgated on October 28, 2010 and came into effect on July 1, 2011 and was amended on December 29, 2018, regulates basic pension insurance, unemployment insurance, maternity insurance, work injury insurance and medical insurance, and has elaborated in detail the legal obligations and liabilities of employers who do not comply with relevant laws and regulations on social insurance. The Regulations on the Administration of Housing Provident Fund, which was promulgated and came into effect on April 3, 1999, and was amended on March 24, 2002 and March 24, 2019, provides that housing provident fund contributions paid by an individual employee and housing provident fund contributions paid by his or her employer all belong to the individual employee.

**Program of Deepening the Reform of the Communist Party and Organs of State**

The Program of Deepening the Reform of the Communist Party and Organs of State, which was promulgated by the Central Committee of the Communist Party of the PRC on March 21, 2018, provides that in order to improve the efficiency of collection and management of social insurance funds, the basic pension insurance premium, the basic medical insurance premium, the unemployment insurance premium and other social insurance premiums should be levied by tax authorities.

**Reform Program of the Collection and Management of State Taxes and Local Taxes**

The Reform Program of the Collection and Management of State Taxes and Local Taxes, which was promulgated by the General Office of the Central Committee of the Communist Party of the PRC and the General Office of the State Council on July 20, 2018, explicitly provides that from January 1, 2019, the basic pension insurance premium, the basic medical insurance premium, the unemployment insurance premium, the employment injury insurance premium, the maternity insurance premium and other social insurance premiums should be levied by tax authorities.

[**Table of Contents**](#TableOfContents)

**Interim Measures for the Administration of Arrear Collection of Social Insurance Premiums**

The Interim Measures for the Administration of Arrear Collection of Social Insurance Premiums, which was promulgated by the Local Taxation Bureau of Guangdong Province on March 5, 2014 and became effective on May 1, 2014 and amended on June 15, 2018, provides that for overdue amounts due before July 1, 2011, if employers take the initiative to, or comply with the taxation bureau's orders to pay such overdue amounts, the overdue fine should not be collected. For overdue amounts that were due after July 1, 2011, employers should pay such overdue amounts along with the overdue fine with the rate of five over ten thousand (5/10000) per day.

**Regulations related to taxation in the PRC**

**Enterprise Income Tax**

According to the Enterprise Income Tax Law, or the EIT Law, which was promulgated by the National People**'**s Congress on March 16, 2007, came into effect on January 1, 2008, and was amended on February 24, 2017 and December 29, 2018 and the Implementation Regulations on the EIT Law, which was promulgated by the State Council on December 6, 2007 and came into effect on January 1, 2008 and lastly amended on December 6, 2024, a uniform income tax rate of 25% will be applied to domestic enterprises, foreign-invested enterprises and foreign enterprises that have established production and operation facilities in the PRC. These enterprises are classified as either resident enterprises or non-resident enterprises. Resident enterprises refer to enterprises that are established in accordance with PRC laws, or that are established in accordance with the laws of foreign countries but whose actual or de facto control is administered from within the PRC. Non-resident enterprises refer to enterprises that are set up in accordance with the laws of foreign countries and whose actual administration is conducted outside the PRC, but who (whether or not through the establishment of institutions in the PRC) derive income from the PRC. Under the EIT Law and relevant implementing regulations, a uniform corporate income tax rate of 25% is imposed on these institutions. However, if non-resident enterprises have not established institutions in the PRC, or if they have established institutions in the PRC but there is no actual relationship between the relevant income derived in the PRC and the institutions set up by them, the enterprise income tax is set at the rate of 10%.

**International Tax Treaties and Withholding Tax**

According to the Treaty on the Avoidance of Double Taxation and Tax Evasion between Mainland and Hong Kong, or the Tax Treaty, if the non-PRC parent company of a PRC enterprise is a Hong Kong resident which beneficially owns a 25% or more interest in the PRC enterprise, the 10% withholding tax rate applicable under the EIT Law may be lowered to 5% for dividends and 7% for interest payments once approvals have been obtained from the relevant tax authorities. Factors impacting the determination of beneficial ownership is indicated in the Announcement of the State Administration of Taxation on Issues concerning "Beneficial Owners" in Tax Treaties, which was issued by the State Administration of Taxation on February 3, 2018 and came into effect on April 1, 2018, according to which negative impacts will be generally imposed to the recognition of a beneficial owner if the applicant is obliged to pay more than 50% of its income to third country (region) residents within 12 months of receiving the income, or the business activities undertaken by the applicant do not constitute substantive business activities. Pursuant to the Notice on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, which was promulgated by the State Administration of Taxation and came into effect on February 20, 2009, the non-resident taxpayer or the withholding agent is required to obtain and keep sufficient documentary evidence proving that the recipient of the dividends meets the relevant requirements for enjoying a lower withholding tax rate under a tax treaty.

**Administrative Measures for Convention Treatment for Non-resident Taxpayers**

Pursuant to the Administrative Measures for Convention Treatment for Non-resident Taxpayers, which was promulgated by the State Taxation Administration on October 14, 2019 and came into effect on January 1, 2020, any non-resident taxpayer fulfilling conditions for enjoying the convention treatment may be entitled to the convention treatment on its own when filing a tax return or making a withholding declaration through a withholding agent, subject to collection and preservation of relevant materials for future reference in accordance with the Measures and the subsequent administration by the tax authorities.

[**Table of Contents**](#TableOfContents)

**Value-Added Tax**

The PRC Value-Added Tax Law, or the VAT Law, was adopted on December 25, 2024 and became effective on January 1, 2026, upon which the Interim Regulations on Value-Added Tax were repealed. Under the VAT Law, VAT rates are generally 13%, 9% and 6%, and the applicable rate for the sale of services other than those specifically subject to 13%, 9% or zero rate is 6%. Under the VAT Law, medical services provided by medical institutions are exempt from VAT. On January 30, 2026, the Ministry of Finance and the State Taxation Administration issued the Announcement on the Transition of VAT Preferential Policies Following the Implementation of the VAT Law, which clarifies that the term "medical institutions" for such exemption does not include for-profit aesthetic medical institutions. Although such announcement was issued on January 30, 2026, it applies in connection with the implementation of the VAT Law effective from January 1, 2026, and therefore the relevant VAT treatment applies from January 1, 2026. Accordingly, from January 1, 2026, for-profit aesthetic medical institutions are not entitled to the VAT exemption otherwise applicable to medical services, and relevant aesthetic medical services may become subject to VAT in accordance with applicable PRC tax rules.

As a result, our PRC operating entities that provide aesthetic medical services may incur additional VAT liabilities and related compliance obligations. If the applicable tax treatment, scope of taxable services, pricing arrangements, invoicing practices or implementation rules change, or if the competent tax authorities take a different view on the tax treatment of our services, our tax burden, margins, cash flows and results of operations may be adversely affected.

**Notice on Relevant Tax Policies on Medical and Health Institutions**

The Notice on Relevant Tax Policies on Medical and Health Institutions, which was promulgated by the Ministry of Finance and the State Administration of Tax on July 10, 2000, came into effect on the same date and amended on May 18, 2009, provides that incomes of for-profit medical institutions are taxable in accordance with relevant rules. Nevertheless, for-profit medical institution is granted a three-year tax exemption period commencing on the date of the issuance of the practice license if its revenue is directly used to improve medical and health conditions. During the no-tax period: (1)self-produced preparations for self-use by for-profit medical institutions are exempted from value- added tax, and (2) properties, land and vehicles for self-use by for-profit medical institutions are exempted from property tax, urban land use tax and vehicle and vessel usage tax. Pharmaceutical retail enterprise spun-off from pharmacy of for-profit medical institutions is subject to applicable taxations.

**Regulations related to foreign exchange in the PRC**

**Administrative Regulations of the PRC on Foreign Exchange**

Administrative Regulations of the PRC on Foreign Exchange, which was promulgated by the State Council on January 29, 1996, came into effect on April 1, 1996, and was amended on January 14, 1997 and August 5, 2008, provides that foreign exchange receipts of domestic institutions or individuals may be transferred back into the PRC or deposited abroad. The State Administration of Foreign Exchange, or the SAFE, may specify relative conditions and other requirements in accordance with the international receipts, payments status and requirements of foreign exchange control. Foreign exchange receipts under the current items may be retained or sold to financial institutions engaged in the settlement or sale of foreign exchange. Domestic institutions or individuals that make direct investments abroad or are engaged in the distribution or sale of valuable securities or derivative products overseas should register according to SAFE regulations. Such institutions or individuals subject to prior approval or record-filing with other competent authorities must obtain the required approval or finish record-filing prior to foreign exchange registration. The exchange rate for RMB follows a managed floating exchange rate system based on market demand and supply.

**Foreign Exchange Settlement, Sales and Payment**

The Administrative Regulation of the People's Bank of China Regarding Foreign Exchange Settlement, Sales and Payment, which was promulgated by the People's Bank of China on June 20, 1996 and came into effect on July 1, 1996, provides that foreign exchange receipts under the current account of foreign-invested enterprises may be retained to the fullest extent specified by the foreign exchange bureau. Any portion in excess of such amount must be sold to a designated foreign exchange bank or sold in a foreign exchange swap center.

[**Table of Contents**](#TableOfContents)

**Notice of Issues concerning Foreign Exchange Administration over the Overseas Investment and Financing and Round-trip Investment by Domestic Residents via Special Purpose Vehicles**

On July 4, 2014 the SAFE issued the Notice of Issues concerning Foreign Exchange Administration over the Overseas Investment and Financing and Round-trip Investment by Domestic Residents via Special Purpose Vehicles, or Circular 37, which provides that (i) a domestic resident (domestic institution or domestic resident individual), must register with the local branch of the SAFE before it contributes the assets of or its equity interest into a special purpose vehicle for the purpose of investment and financing as defined in the implementing guidelines of Circular 37 (the definition of domestic resident also includes certain foreigner without legal identity certificate of the PRC while habitually resides in Mainland China for economic interests), and (ii) when the special purpose vehicle undergoes a change of basic information, such as change of a PRC resident natural person shareholder, name or operating period, or a material event, such as change in share capital of a PRC resident natural person, merger or split, the domestic resident must promptly register such change with the local branch of the SAFE.

**Notice on Further Improving and Adjusting the Policies Related to Foreign Exchange Administration in Direct Investment**

The Notice on Further Improving and Adjusting the Policies Related to Foreign Exchange Administration in Direct Investment, which was promulgated by the SAFE on November 19, 2012, came into effect on December 17, 2012 and was amended on May 4, 2015, October 10, 2018 and December 30, 2019, respectively, improves foreign exchange administration in direct investment by repealing or adjusting certain approval items for foreign exchange administration in direct investment.

**Notice on Reforming the Management Approach regarding the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises**

The Notice on Reforming the Management Approach regarding the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, or Circular 19, was promulgated by the SAFE on March 30, 2015, came into effect on June 1, 2015, was amended on December 30, 2019, March 23, 2023 and was partly replaced by the Notice on Reforming and Regulating Policies on the Control over Foreign Exchange Settlement of Capital Accounts, or Circular 16, which was issued on June 9, 2016 and last amended on December 4, 2023. According to Circular 19, the foreign exchange capital of foreign invested enterprises will be subject to the willingness settlement of foreign exchange capital, or the Willingness Foreign Exchange Settlement. The Willingness Foreign Exchange Settlement means that foreign exchange capital in the capital account of a foreign invested enterprise of which the rights and interests of monetary contribution has been confirmed by the local foreign exchange bureau (or the entry registration of monetary contribution by the banks) can be settled at the banks based on the actual operational needs of the foreign invested enterprise. The proportion of the Willingness Foreign Exchange Settlement of the foreign exchange capital of a foreign invested enterprise is temporarily determined as 100%. The RMB fund converted from the foreign exchange capital shall be kept in a designated account. If a foreign invested enterprise needs to make further payments from such account, the enterprise needs to provide supporting documents and go through the review process with the banks. Furthermore, Circular 19 and Circular 16 provides that the use of capital by foreign-invested enterprises must comply with the principles of authenticity and self-use within the business scope of enterprises. The capital of a foreign invested enterprise and capital in RMB obtained by the foreign invested enterprise from foreign exchange settlement may not be used for the following purposes: (1) direct or indirect payment beyond the business scope of the enterprises or a payment prohibited by relevant laws and regulations, (2) direct or indirect investment in securities or other investment and wealth management (except for wealth management products and structured deposits with risk rating results of not higher than grade II), (3) direct or indirect grant of loans to non-affiliated enterprises (unless permitted by the scope of business), and (4) purchasing residential real estate not for self-use (except for enterprises engaging in real estate development and leasing).

**Circular on Further Promoting Cross-border Trade and Investment Facilitation**

On October 23, 2019, the SAFE issued the Circular on Further Promoting Cross-border Trade and Investment Facilitation, or SAFE Circular 28, which was amended on December 4, 2023. Among others, SAFE Circular 28 relaxes the prior restrictions and allows the foreign-invested enterprises without equity investment as in their approved business scope to use their capital obtained from foreign exchange settlement to make domestic equity investment as long as the investments are real and in compliance with the foreign investment-related laws and regulations. In addition, SAFE Circular 28 stipulates that qualified enterprises in certain pilot areas may use their capital income from registered capital, foreign debt and overseas listing, for the purpose of domestic payments without providing authenticity certifications to the relevant banks in advance for those domestic payments.

[**Table of Contents**](#TableOfContents)

***Regulations related to data security and privacy protection***

 ****

The PRC Constitution states that PRC law protects the freedom and privacy of communications of citizens and prohibits infringement of these rights. The PRC Civil Code provides in a stand-alone chapter of right of personality and reiterate that the personal information of a natural person shall be protected by the law. Any organization or individual shall legitimately obtain such person information of others in due course on a need-to-know basis and ensure the safety and privacy of such information, and refrain from excessively handling or using such information.

***Data Security Law of the PRC***

 ****

The SCNPC promulgated the Data Security Law of the PRC, or the Data Security Law on June 10, 2021, which took effect on September 1, 2021. The Data Security Law sets forth data security and privacy related compliance obligations on entities and individuals carrying out data related activities and clarifies the scope of data to cover a wide range of information records generated from all aspects of production, operation and management of government affairs and enterprises in the process of the gradual transformation of digitalization, and requires that data collection shall be conducted in a legitimate and proper manner, and theft or illegal collection of data is not permitted. Data processors shall establish and improve the whole-process data security management rules, organize, and implement data security trainings as well as take appropriate technical measures and other necessary measures to protect data security. In addition, data processing activities shall be conducted based on the graded protection system for cybersecurity. For example, a processor of important data shall designate the personnel and the management body responsible for data security, carry out risk assessments for its data processing activities and file the risk assessment reports with the competent authorities. Monitoring of the data processing activities shall be strengthened, and remedial measures shall be taken immediately in case of discovery of risks regarding data security related defects or bugs. In case of data security incidents, responding measures shall be taken immediately, and disclosure to users and report to the competent authorities shall be made in a timely manner.

***Personal Information Protection Law of the PRC***

 ****

The Personal Information Protection Law of the PRC, or the PIPL, which was promulgated by the National People's Congress of the PRC on August 20, 2021 and took effect on November 1, 2021, provides detailed rules for processing personal information and further improves the personal information protection system, it aims at protecting the personal information rights and interests, regulating the processing of personal information, ensuring the orderly and free flow of personal information in accordance with the law and promoting the reasonable use of personal information.

***Cybersecurity Law of the PRC***

 ****

On November 7, 2016, the National People's Congress of the PRC promulgated the Cybersecurity Law of the PRC, or the Cybersecurity Law, which became effective on June 1, 2017. Pursuant to Cybersecurity Law, the "personal information" refers to all kinds of information recorded by electronic or otherwise that can be used to independently identify or be combined with other information to identify individuals' personal information including but not limited to: individuals' names, dates of birth, ID numbers, biologically identified personal information, addresses and telephone numbers, etc. The Cybersecurity Law also provides that: (i) to collect and use personal information, network operators shall follow the principles of legitimacy, rightfulness, and necessity, disclose rules of data collection and use, clearly express the purposes, means and scope of collecting and using the information, and obtain the consent of the persons whose data is gathered; (ii) network operators shall neither gather personal information unrelated to the services they provide, nor gather or use personal information in violation of the provisions of laws and administrative regulations or the scopes of consent given by the persons whose data is gathered; and shall dispose of personal information they have saved in accordance with the provisions of laws and administrative regulations and agreements reached with users; (iii) network operators shall not divulge, tamper with or damage the personal information they have collected, and shall not provide the personal information to others without the consent of the persons whose data is collected. However, if the information has been processed and cannot be recovered and thus it is impossible to match such information with specific persons, such circumstance is an exception.

***Measures for the Security Assessment of Outbound Data Transfer***

 ****

On July 7, 2022, the CAC promulgated Measures for the Security Assessment of Outbound Data Transfers, which became effective on September 1, 2022 and provide that a data processor is required to apply for security assessment for cross-border data transfer in any of the following circumstances:(i)where a data processor provides critical data to offshore entities and individuals; (ii)where a critical information infrastructure operator or a data processor which processes personal information of more than one million individuals provides personal information to offshore entities and individuals; (iii)where a data processor has provided personal information in the aggregate of more than 100,000 individuals or sensitive personal information of more than 10,000 individuals in total to offshore entities and individuals since January 1 of the previous year; or (iv)other circumstances prescribed by the CAC for which application for security assessment for cross-border transfer of data is required.

[**Table of Contents**](#TableOfContents)

***Measures for the Standard Contract for Outbound Transfer of Personal Information***

 ****

The Measures for the Standard Contract for Outbound Transfer of Personal Information, which was promulgated by the CAC on February 22, 2023 and came into effect on June 1, 2023, provides the basic principles and requirements on the outbound transfer of personal information outside the PRC under the standard contract provided by the CAC. Pursuant to the Measures for the Standard Contract for Outbound Transfer of Personal Information, any personal information handler transferring personal information abroad by entering into the standard contract shall meet all of the following conditions and conduct a personal information protection impact assessment: (i) it is not a critical information infrastructure operator; (ii) it processes the personal information of less than 1 million individuals; (iii) it has cumulatively transferred abroad the personal information of less than 100,000 individuals since January 1 of the previous year; and (iv) it has cumulatively transferred abroad the sensitive personal information of less than 10,000 individuals since January 1 of the previous year. The Measures also provides that the personal information handler shall not carry out the outbound transfer until the standard contract enters into force, and shall file a record with the cyberspace authority at the provincial level within 10 working days from the effective date of the standard contract executed.

***Provisions on Promoting and Regulating Cross-border Data Flow***

 ****

On March 22, 2024, the CAC promulgated the Provisions on Promoting and Regulating Cross-border Data Flow, or the Provisions, which takes effect on the same day. According to the Provisions, a data processor is required to apply for security assessment for cross-border data transfer in any of the following circumstances: (i)where a critical information infrastructure operator provides personal information or critical data to offshore entities and individuals; (ii) where any data processor other than a critical information infrastructure operator provides critical data to offshore entities and individuals, or provides personal information (excluding sensitive personal information) of not less than one million individuals or sensitive personal information of not less than 10,000 individuals in aggregate to offshore entities and individuals since January 1 of the current year. The Provisions also provides certain exceptions where a data processor is not required to apply for security assessment for cross-border data transfer, conclude standard contract for cross-border transfer of personal information or pass authentication for personal information protection. In case of any discrepancy between the Provisions and the relevant provisions such as Measures for the Security Assessment of Outbound Data Transfer promulgated on July 7, 2022 and The Measures for the Standard Contract for Outbound Transfer of Personal Information promulgated on February 22, 2023, the Provisions shall prevail.

***Administrative Measures for the Cybersecurity of Medical and Healthcare Institution***

 ****

The Administrative Measures for the Cybersecurity of Medical and Healthcare Institution, or the measures, which were promulgated by the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Bureau of Disease Control and Prevention on August 8, 2022 and became effective on the same day. The measures require all the medical and health institutions to set up data life-cycle management systems and user participation-based cybersecurity management systems, including but not limited to strengthening system construction, implementing daily network maintenance and monitoring, conducting annual self-inspection and rectification, and classifying and grading data assets. Where personal information and data are leaked or major cybersecurity incidents occur in violation of the measures, the case shall be handled in accordance with the Cybersecurity Law, the Cryptography Law, Promotion Law on Basic Medical and Healthcare, the Personal Information Protection Law, the Regulations for the Security Protection of Critical Information Infrastructure, cybersecurity classified protection system and other laws and regulations.

[**Table of Contents**](#TableOfContents)

***Regulations on personal information protection related to medical institutions***

 ****

According to the Regulations for Medical Institutions on Medical Records Management released on November 20, 2013, and effective from January 1, 2014, the medical institutions and medical practitioners shall strictly protect the privacy information of patients. Any leakage of patients' medical records for non-medical, non-teaching or non-research purposes is prohibited. The National Health and Family Planning Commission released the Measures for Administration of Population Health Information (Trial) on May 5, 2014, referring the medical health service information as the population healthcare information, which is not allowed to be stored in a server located outside the territory of Mainland China. Pursuant to the Management Measures of Standards, Safety and Service of National Health and Medical Big Data (Trial), promulgated by the National Health Commission on July 12, 2018, the medical institutions should establish relevant safety management systems, operation instructions and technical specifications to safeguard the safety of healthcare big data generated in the process of health management service or prevention and cure service of diseases. It also stipulates that such healthcare big data should be stored in onshore servers and shall not be provided overseas without safety assessment.

***Notice on Further Strengthening the Management of the Use of Electronic Medical Record Information***

 ****

On June 30, 2025, the National Health Commission issued the Notice on Further Strengthening the Management of the Use of Electronic Medical Record Information. The Notice requires medical institutions to strengthen internal management over electronic medical record information, implement graded and classified access control, follow the minimum necessary principle, prohibit unauthorized collection, use, transmission, disclosure, copying or dissemination of patient information, and ensure full-process traceability, including through technical measures such as digital watermarking. It also requires medical institutions to strengthen management over students, visiting physicians and external service providers with access to electronic medical record information.

***Negative List for Internet Health Science Popularization by Medical Personnel (Trial)***

 ****

On October 31, 2025, the General Office of the National Health Commission, together with other authorities, issued the Negative List for Internet Health Science Popularization by Medical Personnel (Trial). Among other things, the Negative List prohibits the use of health science popularization to publish unlawful advertisements or conduct traffic diversion, prohibits livestream selling or other improper-profit activities, prohibits the disclosure of patient personal information or the display of identifiable patient images, pictures or text without authorization, and prohibits fabricated cases, exaggerated treatment effects and other misleading content. It also requires medical institutions to establish account filing, dynamic management, daily monitoring and regular inspection mechanisms over medical personnel's internet health science popularization activities.

***Opinions on Severely Cracking Down on Illegal Securities Activities According to Law***

 ****

On July 6, 2021, the General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued the Opinions on Severely Cracking Down on Illegal Securities Activities According to Law, which stressed on, among other things, improving laws and regulations on data security, cross-border data flow and management of confidential information, speeding up the revisions to regulations on strengthening the confidentiality and document management of securities issuance and listing outside the mainland of the PRC to increase the accountability of entities listed outside the mainland of the PRC to information security, and enhancing standardized management of mechanism and procedure for cross-border data transfer, enhancing the cooperation of cross-border audit supervision.

[**Table of Contents**](#TableOfContents)

***Cybersecurity Review Measures***

 ****

On December 28, 2021, the CAC issued the Cybersecurity Review Measures 2021, which became effective on February 15, 2022 and replaced the Cybersecurity Review Measures 2020. The scope of review under the Cybersecurity Review Measures 2021 extends to critical information infrastructure operators that intend to purchase internet products and services and network platform operators engaging in data processing activities, which affect or may affect national security. According to Article 7 of the Measures, network platform operators who possess personal information of over a million users shall apply to the Cybersecurity Review Office for cybersecurity reviews before listing in a foreign country. Besides, the Cybersecurity Review Measures 2021 also provide that if the relevant authorities consider that certain network products and services and data processing activities affect or may affect national security, the authorities may initiate a cybersecurity review even if the operators do not have an obligation to report for a cybersecurity review under such circumstances. The Cybersecurity Review Measures 2021 also elaborate the factors to be considered when assessing the national security risks of the relevant activities, including among others, risks of core data, important data or a large amount of personal information being stolen, leaked, destroyed, and illegally used or illegally exited the country, risks of critical information infrastructure, core data, important data or a large amount of personal information data being affected, controlled and maliciously used by foreign governments after a listing, and risks associated with Internet information security.

**4. C. Organizational Structure**

![?????? AI ?????????????????????????????????](img_001.jpg)

(1) As
of the date of this annual report, "Relevant Subsidiaries" are to, collectively, Shenzhen Pengai Xiuqi Aesthetic Medical
Hospital Co., Ltd., Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department
Co., Ltd., Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Xiuqi (formerly known as Shanghai Pengai
Jiahong) Aesthetic Medical Outpatient Department Co., Ltd., Yantai Pengai Cosmetic Surgery Hospital Co., Ltd., Beijing Aomei Yixin Investment
Consultant Co., Ltd., and its branch, Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic (collectively
"Relevant Subsidiaries"), which were held by Mr. Zhou Qiuming or Dr. Zhou Pengwu directly or indirectly, with ownership percentages
of 27%, 26%, 3%, 15%, 12%, 24%, and 25% respectively. We refer to these equity interests held by Mr. Zhou Qiuming or Dr. Zhou Pengwu
as the "Target Equity Interests," which constitute all of Mr. Zhou Qiuming or Dr. Zhou Pengwu's shareholdings in the
Relevant Subsidiaries.

(2) As
of the date of this annual report, except for the Target Equity Interests representing all of Mr. Zhou Qiuming or Dr. Zhou Pengwu's
equity interests in the Relevant Subsidiaries which we consolidate through Contractual Arrangements as further described below, the remaining
equity interest in our PRC operating subsidiaries is held by Shenzhen Pengai Investment, unaffiliated third parties and certain of our
employees.

(3) Other
major subsidiaries are those treatment center subsidiaries other than Relevant Subsidiaries under Shenzhen Pengai Hospital Investment
Management Co., Ltd. Shenzhen Pengcheng Hospital, Shenzhen Pengai Aesthetic Medical Hospital and Haikou Pengai Aesthetic Medical Hospital
Co., Ltd. were established before the effective date of the Foreign Investment Catalogue 2015 and thus, it is not subject to the 70%
foreign shareholding restrictions. The table below sets forth other major subsidiaries as of the date of this annual report and our beneficial
interest in such subsidiaries.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Subsidiaries** | **Beneficial<br> Interest** |
| Haikou Pengai Aesthetic Medical Hospital Co., Ltd. | 87.0% |
| Huizhou Pengai Aesthetic Medical Hospital Co., Ltd. | 67.5% |
| Shenzhen Pengai Aesthetic Medical Hospital | 100.0% |
| Shenzhen Pengcheng Hospital | 100.0% |

---

**Contractual Arrangements with respect to Target Equity Interests**

Pursuant to the Foreign Investment Catalog 2015, which became effective in April 2015, foreign investors in PRC medical institutions can only conduct investment activities through joint ventures. The foreign shareholding in these entities is limited to 70.0% as stipulated in the JV Interim Measures since the effective date of the Foreign Investment Catalog 2015. We historically held more than 70.0% equity interest in certain of our PRC subsidiaries that are medical institutions which we acquired or established after the effective date of the Foreign Investment Catalog 2015. Due to such restriction, we had decreased our shareholding to no more than 70.0% in such PRC subsidiaries by transferring excessive equity interests to Dr. Zhou Pengwu and certain of our employees in 2018. Between 2018 and 2025, we entered into a series of Contractual Arrangements with Dr. Zhou Pengwu, Mr. Zhou Qiuming, Shenzhen Pengai Investment, the Relevant Subsidiaries, Ms. Ma Xiuhua, and Ms. Ding Wenting regarding the Target Equity Interests. Some of these Relevant Subsidiaries were deregistered or divested during this period. However, the remaining Contractual Arrangements enable us to (i) exercise control over the Target Equity Interests in the Relevant Subsidiaries; (ii) receive economic benefits from the Target Equity Interests in the Relevant Subsidiaries; and (iii) have an exclusive option to purchase all or part of the Target Equity Interests when and to the extent permitted by PRC laws. Reference is made to the 6-K report of the Company filed with the SEC on August 17, 2023. As of December 31, 2025, Dr. Zhou Pengwu had concluded the transfer of his shares in four of the relevant subsidiaries to Mr. Zhou Qiuming, with one subsidiary remaining unaffected, namely Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd.

Our revenue generated from the Relevant Subsidiaries aggregately accounted for approximately 24.1%, 24.9% and 25.0% of our total revenue in 2023, 2024 and 2025, respectively. Our revenue is not affected by the Contractual Arrangement as we own 65% or more direct equity interest in each of the Relevant Subsidiary and do not rely on the Contractual Arrangements to exercise control over the Relevant Subsidiaries. To specifically clarify, as Shanghai Pengai Xiuqi is a subsidiary of Shanghai Pengai, our indirect ownership in Shanghai Pengai Xiuqi is calculated by multiplying our 65% direct equity interest in Shanghai Pengai by Shanghai Pengai's 80% direct ownership in Shanghai Pengai Xiuqi, resulting in an effective 52% ownership stake. We incurred net loss of RMB58.5 million in the year ended December 31, 2025. Excluding the Contractual Arrangement in the Relevant Subsidies, a net loss of RMB58.2 million would be attributable to equity holders of our Company.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Treatment centers' revenue<br> and net profit with Contractual<br> Arrangement including<br> minority interests in 2025 (RMB)** | **Treatment centers' revenue<br> and net profit with Contractual<br> Arrangement including<br> minority interests in 2025 (RMB)** | |
| <br>**Treatment centers** | **Share<br> percentage<br> registered under<br> the China State<br> Administration<br> for Market**<br>**Regulation** | **Revenue** | **Net profit/(loss)** | **Treatment<br> centers' net<br> profit without<br> Contractual<br> Arrangement<br> including<br> minority<br> interests in<br> 2025 (RMB)**<br>**Net profit/(loss)** |
| Shenzhen Pengai Xiuqi | 67% | 57187258 | 2078086 | 1517003 |
| Guangzhou Pengai Xiuqi | 70% | 12351507 | (4652463) | (4512889) |
| Shanghai Pengai | 65% | 52529087 | 2611115 | 2219448 |
| Shanghai Pengai Xiuqi (formerly known as Shanghai Pengai Jiahong) | 52% | 3331211 | (2370431) | (2085980) |
| Beijing Pengai | 70% | 23632530 | (3399914) | (2549935) |
| Yantai Pengai | 71% | 31819133 | 175583 | 133443 |

---

---

| | | |
|:---|:---|:---|
| **Group consolidated statements without Contractual Arrangement in 2025 (RMB)** | **Group consolidated statements without Contractual Arrangement in 2025 (RMB)** | **Group consolidated statements without Contractual Arrangement in 2025 (RMB)** |
| **Revenue** | **Net profit/(loss)** | **Profit/(loss) attributable to owners of the Company** |
| 722854837 | (58187690) | (57466818) |

---

[**Table of Contents**](#TableOfContents)

With respect to our control over the Target Equity Interests, the Contractual Arrangements may not be as effective as direct ownership. If the Relevant Subsidiaries and/or Mr. Zhou Qiuming and/or Dr. Zhou Pengwu fail to perform their respective obligations under the Contractual Arrangements, we may have to incur substantial costs and expend additional resources to enforce such Contractual Arrangements, and rely on legal remedies under PRC laws, including contractual remedies, which may not be sufficient or effective. See "Item 3. Key Information—3.D. Risk Factors—Risks relating to our corporate structure—The Contractual Arrangements may not be as effective in providing control as direct ownership and the Relevant Subsidiaries or Mr. Zhou Qiuming or Dr. Zhou Pengwu may fail to perform their respective obligations under the Contractual Arrangements."

There are also substantial uncertainties regarding the interpretation and application of current and future PRC laws, regulations and rules regarding the status of the rights of our Cayman Islands holding company with respect to the Contractual Arrangements. It is uncertain whether any new PRC laws or regulations relating to Contractual Arrangements will be adopted or if adopted, what they would provide. If we or any of our Relevant Subsidiaries is found to be in violation of any existing or future PRC laws or regulations, or fail to obtain or maintain any of the required permits or approvals, the relevant PRC regulatory authorities would have broad discretion to take action in dealing with such violations or failures. See "Item 3. Key Information—D. Risk Factors—Risks Relating to Our Corporate Structure—If the PRC government deems that the Contractual Arrangements do not comply with PRC laws and regulations, or if these laws and regulations or their interpretations change in the future, we could be subject to severe penalties or be forced to relinquish our interests received through the Contractual Arrangements."

The following is a summary of the currently effective Contractual Arrangements with respect to the Target Equity Interests.

**Loan agreement**

Shenzhen Pengai Investment, as the lender, entered into certain loan agreements with Mr. Zhou Qiuming or Dr. Zhou Pengwu, as the borrower. Pursuant to each of these loan agreements, Shenzhen Pengai Investment agrees to extend a loan to Mr. Zhou Qiuming or Dr. Zhou Pengwu in an equivalent amount to the purchase price to be paid by Mr. Zhou Qiuming or Dr. Zhou Pengwu for acquiring the Target Equity Interests. Pursuant to each of these loan agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu shall repay the loan by transferring the current and future economic interest of the Target Equity Interests to Shenzhen Pengai Investment.

**Economic interest transfer agreement**

Mr. Zhou Qiuming or Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries entered into certain economic interest transfer agreements. Pursuant to each of these economic interest transfer agreements, the economic interest in relation to the Target Equity Interests currently held and subsequently acquired by Mr. Zhou Qiuming or Dr. Zhou Pengwu, including but not limited to (i) incomes arising from the disposal of the Target Equity Interests (including derivative equity interest of the Target Equity Interests) under any circumstance; (ii) dividends and bonus obtained on the basis of the Target Equity Interests (including derivative equity interest of the Target Equity Interests) under any circumstance; (iii) residual assets and other economic profits allocated after the liquidation of the Relevant Subsidiary, and (iv) any other cash income, property and economic benefit arising from the Target Equity Interests (including derivative equity interest of the Target Equity Interests), shall be transferred to Shenzhen Pengai Investment. Upon the execution of each economic interest transfer agreement, the repayment obligation of Mr. Zhou Qiuming or Dr. Zhou Pengwu under each loan agreement is deemed fully discharged.

**Exclusive option agreement**

Mr. Zhou Qiuming or Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries entered into certain exclusive option agreements. Pursuant to these exclusive option agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu irrevocably granted Shenzhen Pengai Investment an exclusive right to purchase, or have its designated person(s) to purchase, at its discretion, all or part of his equity interest in the Relevant Subsidiary, and the purchase price shall be the lowest price permitted by applicable PRC law. Each of Mr. Zhou Qiuming or Dr. Zhou Pengwu and the Relevant Subsidiary undertakes that, among others, without the prior written consent of Shenzhen Pengai Investment, he or it shall or shall cause the Relevant Subsidiary not to declare any dividends or distribute any residual profits, change or amend its articles of association, increase or decrease its registered capital, or change its structure of registered capital in other manners. In the event that Mr. Zhou Qiuming or Dr. Zhou Pengwu increases its capital injection into the Relevant Subsidiary, Mr. Zhou Qiuming or Dr. Zhou Pengwu undertakes and confirms that any additional equity so acquired shall be subject to the purchase option. Unless terminated by Shenzhen Pengai Investment at its sole discretion, the exclusive option agreement will remain effective until all equity interest in the Relevant Subsidiary held by Mr. Zhou Qiuming or Dr. Zhou Pengwu are transferred or assigned to Shenzhen Pengai Investment or its designated person(s).

**Equity interest pledge agreement**

Mr. Zhou Qiuming or Dr. Zhou Pengwu as pledgor, Shenzhen Pengai Investment as pledgee, and each of the Relevant Subsidiaries entered into certain equity interest pledge agreements. Pursuant to these equity interest pledge agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu has pledged all of the Target Equity Interests in Relevant Subsidiaries and agreed to pledge all future equity interest in the Relevant Subsidiary acquired by him to Shenzhen Pengai Investment to guarantee the performance by Mr. Zhou Qiuming or Dr. Zhou Pengwu and the Relevant Subsidiary of their respective obligations under the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney. If the Relevant Subsidiary or Mr. Zhou Qiuming or Dr. Zhou Pengwu breaches any obligations under these agreements, Shenzhen Pengai Investment, as pledgee, will be entitled to dispose of the pledged equity and have priority to be compensated by the proceeds from the disposal of the pledged equity. Mr. Zhou Qiuming or Dr. Zhou Pengwu shall not permit the existence of any security interest or other encumbrance on the pledged equity interest or any portion thereof, without the prior written consent of Shenzhen Pengai Investment and the Relevant Subsidiary shall not assent to or assist in such actions. These equity interest pledge agreements will remain effective until Mr. Zhou Qiuming or Dr. Zhou Pengwu discharge all the obligations under the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney and the full payment of all direct, indirect and derivative losses and losses of anticipated profits, suffered by the pledgee, incurred as a result of any breach by Mr. Zhou Qiuming or Dr. Zhou Pengwu or the Relevant Subsidiary under these agreements or invalidity, revocation and termination of any of these agreements.

[**Table of Contents**](#TableOfContents)

**Power of attorney**

Pursuant to relevant power of attorney executed by Mr. Zhou Qiuming or Dr. Zhou Pengwu, he has irrevocably authorized Shenzhen Pengai Investment or its designated person(s) to exercise all of such shareholder's voting and other rights associated with the Target Equity Interests in each of the Relevant Subsidiaries, including but not limited to, the right to attend shareholder meetings, the right to vote, the right to sell, transfer, pledge or depose of the Target Equity Interests and the right to appoint legal representatives, directors and other management. The proxy agreement remains effective as long as Mr. Zhou Qiuming or Dr. Zhou Pengwu remains a shareholder of the Relevant Subsidiary, unless Pengai Investment has given contrary written instructions.

**Spousal consent letter**

Pursuant to relevant spousal consent letters executed by Ms. Ma Xiuhua, the spouse of Mr. Zhou Qiuming, or Ms. Ding Wenting, the spouse of Dr. Zhou Pengwu, she unconditionally and irrevocably agreed that the equity interest in each of the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming or Dr. Zhou Pengwu and registered or to be registered in his name will be disposed of pursuant to the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney. Ms. Ma Xiuhua or Ms. Ding Wenting agreed not to assert any rights over the equity interest in the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming or Dr. Zhou Pengwu. In addition, in the event that Ms. Ma Xiuhua or Ms. Ding Wenting obtains any equity interest in each of the Relevant Subsidiaries for any reason, she agreed to be bound by the Contractual Arrangements.

In the opinion of Dacheng Law Offices LLP (Wuhan), our PRC counsel, (i) the above Contractual Arrangements currently do not result in any violation of the applicable PRC laws or regulations currently in effect; and (ii) the agreements under the Contractual Arrangements among Mr. Zhou Qiuming or Dr. Zhou Pengwu, Shenzhen Pengai Investment and Relevant Subsidiaries are governed by PRC laws or regulations, are valid and binding upon each party to such arrangements and enforceable against each party thereto in accordance with their terms and applicable PRC laws and regulations currently in effect, and do not contravene applicable PRC laws or regulations currently in effect.

There are substantial uncertainties regarding the interpretation and application of current or future PRC laws and regulations. We have been further advised by our PRC legal counsel that if the PRC government finds that the above Contractual Arrangements or the agreements under the Contractual Arrangements that establish the structure for operating aesthetic medical services, do not comply with PRC government restrictions on foreign investment in such businesses, we could be subject to severe penalties including being prohibited from continuing operations. For a description of the risks related to these Contractual Arrangements and our corporate structure, please see **"**Item 3. Key Information—3.D. Risk Factors—Risks relating to our corporate structure.**"**

**4. D. Property, Plant and Equipment**

As of the date of this annual report, we own building ownership rights to certain buildings on three different parcels of land in Shenzhen and Huizhou with a total gross floor area of 2,544 sq.m. Shenzhen Pengai Investment, one of our subsidiaries, is the owner of these buildings. Shenzhen Pengai Investment has obtained the relevant property rights certificates.

Two of our owned properties, which are located in Luohu District, Shenzhen, and Huicheng District, Huizhou, Guangdong, are leased to Pengcheng Hospital and Huizhou Pengai for the operation of their businesses, respectively.

The majority of the properties on which we operate in mainland China are leased. As of the date of this annual report, we own three different properties with a total gross floor area of 2,544 sq.m and we leased properties in 10 different locations with an aggregate gross floor area of 26,117 sq.m.

The following table sets forth the number of lease agreements by expiry year.

---

| | | |
|:---|:---|:---|
| | **Number of** | **Number of** |
| <br>**Expiry year** | **leases** | **leases** |
| 2025 |  | 9 |
| 2026 |  | 3 |
| 2027+ |  | 9 |

---

[**Table of Contents**](#TableOfContents)

**Item 4. A. Unresolved Staff Comments**

Not applicable.

**Item 5. Operating and Financial Review and Prospects**

*You should read the following discussion together with our financial statements and the related notes appearing elsewhere in this annual report. Some of the information contained in this discussion or set forth elsewhere in this annual report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should read "Item 3. Key Information—3.D. Risk Factors" and "Forward-Looking Information" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.*

**5. A. Operating Results**

**Overview**

We generate revenue primarily from the provision of the following services, which represent our core business:

● Surgical aesthetic treatments, commonly referred to as plastic surgery in the United States, such as eye surgery, rhinoplasty, breast augmentation and liposuction; and

● Non-surgical aesthetic treatments, which comprise minimally invasive aesthetic treatments and energy-based treatments.

We also generate revenue from our non-core business of providing general healthcare and other aesthetic services. General healthcare comprises a range of medical services, such as internal medicine and traditional Chinese medicine, and other aesthetic medical treatments comprise aesthetic dentistry, aesthetic traditional Chinese medicine and hair loss treatments.

**Factors affecting our results of operations**

We believe our financial condition and operations are affected by the following factors:

***Further Divestment of Treatment Centers to Enhance Operating Efficiency***

 ****

In 2022, we strived to enhance operating efficiency through various measures, including spinning off our underperforming treatment centers to focus on our development in the Hong Kong and Mainland China. In October 2022, we divested two underperforming treatment centers, Changsha Pengai Aesthetic Medical Hospital Co., Ltd. and Nanchang Pengai Xiuqi Aesthetic Medical Hospital Co., Ltd., and received cash inflows of RMB4.6 million and RMB3.0 million, respectively. In December 2022, we also divested Shenzhen Miaoyan Aesthetic Medical Clinic, another underperforming treatment center, without cash inflows. In August 2022, Hangzhou Pengai Aesthetic Medical Outpatient Department was ceased operation due to underperformance.

On January 10, 2023, we entered into a share purchase agreement with a non-affiliated third party, under which we transferred 100% of the equity of our wholly-owned subsidiary, Shenzhen Miaoyan Medical Technology Investment Co., Ltd. to this third party for a consideration of RMB1.9 million due to our strategy to further focus on mature and profitable institutions. As of the date of this annual report, the transaction has been closed. In December 2023, as part of our initiative to divest non-performing assets, we closed the transaction of transferring 100% equity ownership of another wholly-owned subsidiary, Stargaze Wealth Limited, to a third party for a nominal consideration of US$1.00.

In 2024, we deregistered several subsidiaries that were not in operations, including Hangzhou Pengai E - commerce Co., Ltd. in March 2024, Shengli Aesthetic Technology Investment (Hong Kong) Company Limited in April 2024, Yantai Guangcheng Health Technology Co., Ltd. in June 2024 and Shanghai Pengai Medical Technology Co., Ltd. in June 2024. Additionally, Newa Medical Aesthetic Limited was deregistered in February 2025.

[**Table of Contents**](#TableOfContents)

**Number of procedures performed and average spending per procedure**

Revenues from surgical and non-surgical aesthetic medical services are affected by the number of such procedures performed and the average spending per procedure. The number of procedures is generally affected by market demand, the number of our treatment centers and our marketing efforts. Average spending per procedure is generally affected by our product and service mix, customers' consumption habits, our marketing strategies and our pricing policy. The provision of general healthcare services was affected by the current medical regulatory environment in China in the past, which was not favorable to privately owned general hospitals. However, we will continue to provide high-quality general healthcare services and also focus on other aesthetic medical services, and expect to continue generating revenue from these services.

**Cost of sales and services rendered**

Our ability to control costs and expenses affects our profitability. Salaries in the medical treatment industry in China have generally been increasing in recent years, and we seek to offer competitive wages and other benefits to recruit and retain quality medical professionals. In addition, our cost of inventories and consumables has been relatively significant during the past few years, comprising 56.8%, 56.1%, and 55.5% of our cost of sales and services rendered in 2023, 2024 and 2025, respectively. Cost of inventories and consumables is affected primarily by the number of procedures we perform.

**Successful marketing of our services**

In order to enhance public recognition of our brand and new treatment procedures or services in both existing and new markets, we advertise through various media platforms. We utilize various marketing tools, including advertising on traditional media and online channels, hosting promotional events and circulating promotional materials, to attract new customers, retain our existing customers and increase customers' spending. We have been seeking to optimize the marketing channels we use, and to deepen our cooperation with new media marketing channels such as Meituan, Dianping, So-Young and Xiaohongshu, in order to improve the efficiency of our sales and marketing efforts. Our advertising and marketing expenses were RMB164.2 million, RMB162.3million and RMB157.1million (US$22.5 million) in 2023, 2024 and 2025, respectively, accounting for 24.1%, 21.5% and 21.7% respectively, of our revenue for the same periods. The effectiveness of our marketing and promotional efforts will directly impact our revenue and profitability.

**Ability to introduce and develop innovative aesthetic medical service techniques**

Success in the aesthetic medical market requires us to monitor closely market trends and customer preferences, introduce new treatment procedures and services, and enhance our existing services and procedures. Our ability to adopt the latest technologies and quickly and cost-effectively respond to our customers' ever changing preferences are key to our success. We frequently encourage our doctors and management teams to attend national aesthetic medical technology conferences organized by suppliers or industry committees. This facilitates our doctors' interaction with leading domestic scholars, fostering learning and exchange of medical expertise. This practice not only elevates the reputation of our brand but also cultivates advancements and innovations in our doctors' skills, thereby enhancing our overall competency in the field of the aesthetic medical industry.

***Seasonality***

 

During 2024 and 2025, we have experienced relatively higher customer visits in the second half of each financial year, which was mainly because we experienced a higher number of customer visits for the period from October to December, primarily due to the Chinese National Day holiday, Christmas, and the subsequent New Year and Chinese New Year holidays. As such, our revenue was slightly higher in the second half of each financial year during 2024 and 2025.

[**Table of Contents**](#TableOfContents)

***Favorable Policies***

 ****

On July 26, 2022, the Development and Reform Commission of Shenzhen Municipality issued an action plan for promoting the healthcare and aesthetic medical industry in the city, with an aim to strengthen the operating standards and enhance service quality of the aesthetic medical enterprises. Pursuant to the action plan, aesthetic medical enterprises which are newly accredited by the Joint Commission on Accreditation of Healthcare Organizations shall receive a project subsidy of 20% of the total investment, up to RMB 10 million, on merit basis. Enterprises which help standardize the aesthetic medical services in Shenzhen shall also be giving a maximum subsidy of RMB0.5 million on merit basis. It is expected that these will accelerate the market consolidation as non-complying practitioners will be eliminated. The policies are expected to benefit leading aesthetic medical companies of high operational quality and compliance status such as our company.

On February 23, 2024, Focus Report, a comprehensive news program launched by China Central Television on April 1, 1994, aimed at providing in-depth news coverage, aired "Medical Aesthetics Livestream: Boosting Sales or Causing Trouble, " which clearly pointed out that aesthetics medical falls under medical activities, and the majority of current livestreams promoting "sales" in aesthetic medical industry are suspected of illegally advertising medical services. Some livestreams selling aesthetic medical products engage in extensive false advertising, who use low prices to attract viewers online, then demand additional fees or purchases of other products or services offline, deliberately misleading and defrauding consumers, and selling multiple non-compliant products. Halting these livestreams is significant as it reinstates the medical essence of aesthetic medical industry. The combination of high-quality aesthetic medical products and offline services from reputable institutions fosters a robust industry ecosystem, promoting compliance and healthy growth. This may ultimately benefit company like us, who is known for adhering to regulations.

***Our expansion through organic growth and acquisitions***

 ****

From January 1, 2019 to December 31, 2021, organic growth and the acquisition of new treatment centers were important contributors to our revenue growth. In 2020, we opened one and acquired four new treatment centers, excluding treatment centers from Hanfei as the Hanfei acquisition was terminated in 2021. These treatment centers, to the extent that they started operations, contributed RMB24.2 million additional revenue in 2020. In October 2020, the Group entered into an agreement to acquire 95% of equity interest of Beijing Aomei Yixin Investment Consultant Co., Ltd. ("Beijing Aomei Yixin") with consideration of RMB11.5 million. The transaction has been completed in January 2021 and Beijing Aomei Yixin becomes a subsidiary of the Company since then. In 2021, we acquired one treatment center, the "Guangzhou Meixi Aesthetic Medical Clinic Company Limited" whose name was then changed into "Guangzhou Pengai Xiuqi Aesthetic Medical Clinic Co., Ltd". In August 2022, Beijing Haiyue Xingguang Aesthetic Medical Clinic's name was changed into "Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic". In January 2024, Shanghai Jiahong Aesthetic Medical Outpatient Department Co., Ltd.'s name was changed into "Shanghai Pengai Jiahong Aesthetic Medical Outpatient Department Co., Ltd.", which is subsequently changed into Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. on May 16, 2024.

**Certain statements of comprehensive income line items**

**Revenue**

We have one reporting segment and generate revenue from three service offerings: (i) non-surgical aesthetic medical services, comprising minimally invasive aesthetic treatments and energy-based treatments, (ii) surgical aesthetic medical services, and (iii) general healthcare services and other aesthetic medical services. We regard our non-surgical and surgical aesthetic medical services as our core business that we believe will have the greatest impact on our future results of operations. The following table sets forth a breakdown of our revenue, as an amount and as a percentage of total revenue, by service offering for the periods indicated.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2023** | **2024** | **2024** | **2025** | **2025** | **2025** |
|  | **RMB** | | **RMB** | | **RMB** | **US$** | |
|  | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Non-surgical aesthetic medical services |  |  |  |  |  |  |  |
| Minimally invasive aesthetic treatments | 234811 | 34.4% | 235624 | 31.2% | 246172 | 35202 | 34.1% |
| Energy-based treatments | 240063 | 35.2% | 322212 | 42.6% | 294910 | 42172 | 40.8% |
| Sub-total of non-surgical aesthetic medical services | 474874 | 69.6% | 557836 | 73.8% | 541082 | 77374 | 74.9% |
| Surgical aesthetic medical services | 143057 | 21.0% | 125369 | 16.6% | 126790 | 18131 | 17.5% |
| Sub-total of aesthetic medical services | 617931 | 90.6% | 683205 | 90.4% | 667872 | 95505 | 92.4% |
| General healthcare services and other aesthetic medical services | 64656 | 9.4% | 72466 | 9.6% | 54983 | 7862 | 7.6% |
| **Total** | 682587 | 100.0% | 755671 | 100.0% | 722855 | 103367 | 100.0% |

---

We had a total revenue of RMB722.9 million (US$102.4 million) in 2025, representing an decrease of 4.3% from RMB755.7 million in 2024, primarily due to challenging market conditions and a strategic shift in business focus.

[**Table of Contents**](#TableOfContents)

Our revenue primarily depends on the number of aesthetic procedures performed and average spending by our customers per aesthetic procedure. The following table sets forth certain of our operating data for the periods indicated.

---

| | | | |
|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2024** | **2025** |
| **Number of aesthetic procedures performed** |  |  |  |
| Non-surgical aesthetic medical services |  |  |  |
| &nbsp;&nbsp;&nbsp;Minimally invasive aesthetic treatments | 90872 | 108165 | 108411 |
| &nbsp;&nbsp;&nbsp;Energy-based treatments | 398851 | 515913 | 497358 |
| Sub-total | 489723 | 624078 | 605769 |
| Surgical aesthetic medical services | 33865 | 31056 | 27227 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2024** | **2025** | **2025** |
|  | **RMB** | **RMB** | **RMB** | **US$** |
| **Average spending by our customers per aesthetic procedure** |  |  |  |  |
| Non-surgical aesthetic medical services | 970 | 894 | 893 | 128 |
| &nbsp;&nbsp;&nbsp;Minimally invasive aesthetic treatments | 2584 | 2178 | 2271 | 325 |
| &nbsp;&nbsp;&nbsp;Energy-based treatments | 602 | 625 | 593 | 85 |
| Surgical aesthetic medical services | 4224 | 4037 | 4657 | 666 |

---

From 2024 to 2025, the overall trend of average spending by our customers per aesthetic procedure had generally declined due to a number of factors. For example, as part of our marketing strategy, we encourage potential customers to try out our services by offering a small number of low-ASP treatments; in addition, in order to increase utilization of our equipment, we from time to time offer promotional events to attract new customers; and as such we may adjust our pricing policy in response to increased competition and the decrease in cost of materials, such as hyaluronic acid. These measures have negatively contributed to our overall average spending by customers per procedure, but we believe these measures are beneficial to our overall profitability and long-term growth.

*Aesthetic medical services (surgical and non-surgical)*

Our aesthetic medical services consist of surgical and non-surgical aesthetic medical services. Our revenue from aesthetic medical services was RMB617.9 million, RMB683.2 million and RMB667.9 million (US$95.5 million) in 2023, 2024 and 2025, respectively. Revenue from aesthetic medical services as a percentage of our total revenue was 90.5%, 90.4% and 92.4 % in 2023, 2024 and 2025, respectively. The total revenue from aesthetic medical services for 2025 decreased by2.2% primarily due to the decrease in our energy-based treatments segment.

● *Non-surgical aesthetic medical services.* Our non-surgical aesthetic medical services primarily consist of services such as injection treatments, energy-based treatments and thread lifts. Our revenue from non-surgical aesthetic medical services was RMB474.9 million, RMB557.8 million and RMB541.1 million (US$77.4million) in 2023, 2024 and 2025, respectively. Revenue from non-surgical aesthetic medical services as a percentage of our total revenue was 69.6%, 73.8% and 74.9% in 2023, 2024 and 2025, respectively.

 

● *Surgical aesthetic medical services.* Our surgical aesthetic medical services primarily consist of services such as eye surgery (for example, double eyelid surgery), nose surgery (rhinoplasty), breast augmentation and liposuction. Our revenue from surgical aesthetic medical services was RMB143.1 million, RMB125.4 million and RMB126.8 million (US$18.1 million) in 2023, 2024 and 2025, respectively. Revenue from surgical aesthetic medical services as a percentage of our total revenue was 21.0%, 16.3% and 17.5% in 2023, 2024 and 2025, respectively. The total revenue from surgical aesthetic medical services for 2025 increased by 1.1% primarily attributable to our strategic realignment of business priorities toward surgical aesthetic medical services, which offer higher gross profit margins.

*General healthcare services and other aesthetic medical services*

General healthcare services and other aesthetic medical services primarily consist of a range of medical services, such as internal medicine, urology, gynecology and obstetrics treatments, as well as various other aesthetic medical treatments, such as dentistry, dermatology and hair loss treatments. Our revenue from general healthcare services and other aesthetic medical services was RMB64.7 million, RMB72.5 million and RMB55.0 million (US$7.9 million), respectively, representing 9.4%, 9.6% and 7.6% of our total revenue, respectively, in 2023, 2024 and 2025. The total revenue from general healthcare services and other aesthetic medical services for 2025 decreased by 24.1% primarily driven by Shenzhen Pengcheng's decrease in other aesthetic medical services.

[**Table of Contents**](#TableOfContents)

**Cost of sales and services rendered**

Our cost of sales and services rendered primarily consists of employee benefit expenses for our medical staff, cost of inventories and consumables, inspection fee paid to third party inspection service providers, as well as operating lease and rental expenses, depreciation and amortization, and utilities and office expenses incurred in relation to our medical staff.

In 2023, 2024 and 2025, our cost of sales and services rendered amounted to RMB360.5 million, RMB417.9 million and RMB388.6 million (US$55.6 million), respectively, representing 52.8%, 55.3% and 53.8% of our total revenue, respectively.

**Gross margin**

The table below sets forth a breakdown of our gross margin by service offering for the periods indicated.

---

| | | | |
|:---|:---|:---|:---|
|  | **Gross margin** | **Gross margin** | **Gross margin** |
|  | **for the year ended December 31,** | **for the year ended December 31,** | **for the year ended December 31,** |
|  | **2023** | **2024** | **2025** |
| Non-surgical aesthetic medical services | 45.0% | 43.5% | 43.3% |
| &nbsp;&nbsp;&nbsp;Minimally invasive aesthetic treatments | 45.2% | 40.5% | 44.6% |
| &nbsp;&nbsp;&nbsp;Energy-based treatments | 44.8% | 45.7% | 42.3% |
| Surgical aesthetic medical services | 56.8% | 54.7% | 58.0% |
| General healthcare services and other aesthetic medical services | 40.9% | 36.5% | 47.7% |
| Overall | 47.2% | 44.7% | 46.2% |

---

The increase in gross margin from 2024 to 2025 is mainly due to the increase in surgical aesthetic medical services, which provide higher gross profit margin.

**Selling expenses**

Selling expenses primarily consist of advertising and marketing expenses, and the employee benefit expenses for our sales team. In 2023, 2024 and 2025, our selling expenses amounted to RMB232.3 million, RMB241.0 million and RMB226.4 million (US$32.4 million), respectively, representing34.0%, 31.9% and 31.3% of our revenue in the corresponding period. The selling expenses decreased by 6.1% to RMB226.4 million (US$32.4 million) from RMB241.0 million in 2024, primarily due to our cost control measures.

**General and administrative expenses**

General and administrative expenses primarily consist of employee benefit expenses for our management team, as well as the utility and office expense and rental expense incurred in relation to our administrative staff. In 2023, 2024 and 2025, our general and administrative expenses amounted to RMB138.6 million, RMB100.8 million and RMB102.7 million (US$14.7 million), respectively, representing 20.3%, 13.3% and 14.2% of our revenue in the corresponding period. The general and administrative expenses in 2025 slightly increased by1.9%.

**Impairment of non-current assets**

We designated our goodwill, tradenames and property, plant and equipment as a non-financial asset. They were tested annually for impairment. We recorded an impairment of non-current assets of RMB314.0 million in 2021. We recognized no impairment loss in 2023, 2024 and recognized impairment of RMB0.5 million (US$0.1 million) in 2025. The impairment was identified in 2021 primarily due to our strategic restructuring and impairment assessments at cash-generating unit level, as the recoverable amounts for certain cash-generating units were lower than their carrying amounts. For 2025, goodwill impairment was recognised mainly driven by downward revision of future cash flow projections. Relevant impairments are non-operating and non-cash items.

[**Table of Contents**](#TableOfContents)

**Income tax expense**

Our income tax expense consists of current income taxation and deferred income tax credit or charge. Our subsidiaries established and operated in the PRC are subject to PRC enterprise income tax at the rate of 25%. The following table shows a breakdown of our income tax expense for the periods indicated.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended on December 31,** | **For the year ended on December 31,** | **For the year ended on December 31,** | **For the year ended on December 31,** |
|  | **2023** | **2024** | **2025** | **2025** |
|  | **RMB** | **RMB** | **RMB** | **US$** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Current income taxation: |  |  |  |  |
| —PRC enterprise income tax | 1000 | 355 | 1269 | 182 |
| Deferred income tax (credit)/charge | (16136) | 23371 | 28080 | 4015 |
| Total | (15136) | 23726 | 29349 | 4197 |

---

Our effective tax rates were (27.5)%, 1,763.1% and 118.7% for the years ended December 31, 2023, 2024 and 2025, respectively, which fluctuation was mainly due to the tax loss not recognized, reversal of deferred income tax and certain other non-tax deductible expenses such as professional fees in relation to our financing activities but are not capitalized.

The income tax expense as a percentage of adjusted (loss)/profit before income tax is presented as a supplemental disclosure because it is used by us to analyze the fluctuation of income tax expenses. However, adjusted (loss)/profit before income tax is a non-IFRS financial measure and should not be considered in isolation or construed as an alternative to loss before income tax as an indicator normally included in IFRS-based financial results. Adjusted (loss)/profit before income tax presented in this annual report may not be comparable to other similarly titled measurements of other companies. The following table provides a quantitative reconciliation of adjusted (loss)/profit before income tax to its most directly comparable IFRS measurement, loss before income tax:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2024** | **2025** | **2025** |
|  | **RMB** | **RMB** | **RMB** | **US$** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Loss before income tax | (55058) | (1347) | (24719) | (3535) |
| Adjusted for: |  |  |  |  |
| Fair value loss of convertible note | 116 |  |  |  |
| Gains on conversion of convertible note | (20420) |  |  |  |
| Share-based compensation expenses | 7514 |  |  |  |
| Expire of convertible note |  | 1817 |  |  |
| Professional fees | 16030 | 5783 | 5681 | 812 |
| Loss on disposal of subsidiaries | 6045 | 2106 | 7195 | 1029 |
| Loss on disposal of property |  |  | 4807 | 687 |
| Government grant |  | (1650) |  |  |
| Employee reward payments |  |  | 5063 | 724 |
| Gain arising from loss of conversion right of convertible note |  | (97) |  |  |
| Compensation to former shareholders |  |  | 10084 | 1442 |
| Impairment of goodwill |  |  | 500 | 72 |
| Adjusted (loss)/ profit before income tax for the year | (45773) | 6612 | 8611 | 1231 |
| Effective tax rate based on adjusted (loss)/profit before income tax | (33.1)% | (358.9)% | (340.8)% |  |

---

Our income tax expense as a percentage of the adjusted (loss)/profit before income tax for the years ended December 31, 2023, 2024 and 2025 were (33.1)%, (358.9)% and (340.8)%, respectively.

[**Table of Contents**](#TableOfContents)

**Taxation**

**Cayman Islands**

We are an exempted company with limited liability incorporated in the Cayman Islands. Under Cayman Islands law, we are not subject to income or capital gains tax in the Cayman Islands.

**Hong Kong**

Hong Kong profits tax rate is 16.5%. During the periods under review, we did not incur any profit tax as there was no estimated assessable profit that was subject to Hong Kong profit tax.

**PRC**

Pursuant to the EIT Law, a uniform 25% EIT rate is generally applied to both foreign-invested except where a special preferential rate applies. Our PRC subsidiaries were subject to this uniform 25% EIT rate during the periods under review.

Under the EIT Law, the profits of a foreign-invested enterprise that are distributed to its immediate holding company outside the PRC will be subject to a withholding tax rate of 10%. Pursuant to a special arrangement between Hong Kong and the PRC, such rate is reduced to 5% if a Hong Kong resident enterprise owns over 25% of a PRC company during the 12 consecutive months preceding the receipt of the dividends and is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements.

**U.S. Federal Corporate Income Tax**

The U.S. federal corporate income tax rate is 21%. During the periods under review, we did not incur any U.S. federal corporate income tax as there was no estimated assessable profit subject to U.S. federal corporate income tax.

**British Virgin Islands**

Dragon Jade Holdings Limited was incorporated in the British Virgin Islands and conducts its primary business operations through its subsidiaries. Under the current laws of the British Virgin Islands, companies incorporated in the BVI are not subject to income tax or capital gains tax. In addition, no withholding tax is imposed in the BVI on dividend payments distributed by the company to its shareholders.

**Results of operations**

The following table sets forth our results of operations for the periods indicated in absolute amounts and as a percentage of revenue.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2024** | **2025** | **2025** |
|  | **RMB** | **RMB** | **RMB** | **US$** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Revenue | 682587 | 755671 | 722855 | 103367 |
| Cost of sales and services rendered | (360540) | (417885) | (388608) | (55570) |
| **Gross profit** | 322047 | 337786 | 334247 | 47797 |
| Selling expenses | (232254) | (241043) | (226362) | (32369) |
| General and administrative expenses | (138605) | (100785) | (102650) | (14679) |
| Finance income | 78 | 404 | 138 | 20 |
| Finance costs | (14474) | (8717) | (8749) | (1251) |
| Other gain/(loss) net | 8420 | (1139) | (20812) | (2977) |
| Fair value loss of convertible note | (116) |  |  |  |
| Fair value (loss)/gain of investment properties | (154) | 12147 | (31) | (4) |
| Impairment of goodwill |  |  | (500) | (72) |
| **Loss before income tax** | (55058) | (1347) | (24719) | (3535) |
| Income tax credit/(expense) | 15136 | (23726) | (29349) | (4197) |
| **Loss for the year** | (39922) | (25073) | (54068) | (7732) |

---

**Year Ended December 31, 2025 Compared to Year Ended December 31, 2024**

 ****

***Revenue***

Our revenue decreased by 4.3% to RMB722.9 million (US$102.4 million) in 2025 from RMB755.7 million in 2024, primarily due to the decrease in our energy-based treatments segment.

[**Table of Contents**](#TableOfContents)

*Non-surgical aesthetic medical services*

Revenue from non-surgical aesthetic medical services decreased by 3.0% to RMB541.1 million (US$77.4 million) in 2025 from RMB557.8 million in 2024, primarily driven by decrease in our energy-based treatments segment.

*Surgical aesthetic medical services*

Revenue from surgical aesthetic medical services increased by 1.1% to RMB126.8 million (US$18.1 million) from RMB125.3 million in 2024, primarily attributable to our strategic realignment of business priorities toward surgical aesthetic medical services, which offer higher gross profit margins.

*General healthcare services and other aesthetic medical services*

Revenue from general healthcare services and other aesthetic medical services decreased by 24.1% to RMB55.0 million (US$7.9 million) from RMB72.4 million in 2024, primarily driven by Shenzhen Pengcheng's decrease in other aesthetic medical services.

***Cost of sales and services rendered***

Cost of sales and services rendered decreased by 7.0% to RMB417.9 million (US$57.3 million) from RMB360.5 million in 2023, primarily attributable to a corresponding decline in revenue.

***Gross profit***

As a result of the foregoing, our gross profit decreased by 1.0% to RMB 334.2million (US$47.8 million) from RMB337.8 million in 2024. Our gross margin increased to 46.2% from 44.7% in 2024 primarily due to our strategic realignment of business priorities toward surgical aesthetic medical services, which offer higher gross profit margins.

*Non-surgical aesthetic medical services*

Our gross margin for non-surgical aesthetic medical services decreased to 43.3% from 43.5% in 2024. Our gross margin for minimally invasive aesthetic treatments increased to 44.6% from 40.5% in 2024 and our gross margin for energy-based treatments decreased to 42.3% from 45.7% in 2024.

In 2025, non-surgical aesthetic medical services took account for 95.7% of our total treatments in terms of the number of treatments, which increased from 95.3% in 2024.

*Surgical aesthetic medical services*

The gross margin for surgical aesthetic medical services increased to 58.0% from 54.7% in 2024.

*General healthcare services and other aesthetic medical services*

The gross margin for general healthcare services and other aesthetic medical services increased to 47.7% from 36.5% in 2024.

***Selling expenses***

Selling expenses decreased by 6.1% to RMB226.4 million (US$32.4 million) in 2025 from RMB241.0 million in 2024. Selling expenses as a percentage of our total revenue decreased to 31.3% from 31.9% in 2024.

***General and administrative expenses***

General and administrative expenses increased by 1.9% to RMB102.7 million (US$14.7 million) from RMB100.8 million in 2024.

[**Table of Contents**](#TableOfContents)

***Finance costs***

Finance costs amounted to RMB 8.7 million (US$1.2 million), which was basically consistent with that in 2024.

***Other gains/(losses), net***

We recorded other losses, net of RMB20.8 million (US$3.0 million) in 2025 compared to a gain of RMB1.1 million in 2024, primarily due to the deregistration of subsidiaries and disposal of property.

***Income tax expense***

We recorded an income tax expense of RMB29.3 million (US$4.2 million) as compared to an income tax expense of RMB23.7 million in 2024.

***Loss for the year***

As a result of the foregoing, our net loss was RMB54.1 million (US$7.7 million) in 2025, compared with a net loss of RMB25.1 million in 2024.

**Year Ended December 31, 2024 Compared to Year Ended December 31, 2023**

For a detailed description of the comparison of our operating results for the year ended December 31, 2024 with those for the year ended December 31, 2023, see **"**Item 5.A. Operating and Financial Review and Prospects—Operating Results—Results of Operation— Year ended December 31, 2024 compared to year ended December 31, 2023**"** of our Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 25, 2025.

**Recently issued accounting standards**

See notes to our audited consolidated financial statements appearing elsewhere in this annual report.

**5. B. Liquidity and Capital Resources**

Our principal sources of liquidity and capital resources have been, and are expected to continue to be, cash flow from operations, issuances of securities and bank borrowings. Our principal uses of cash have been, and we expect will continue to be, for working capital to support an increase in our scale of operations as well as investments for business expansion.

We had net current liabilities of RMB294.1 million as at December 31, 2025, which included current borrowings of RMB129.1 million. We had an operating profit of RMB 5.2million and net operating cash outflows of RMB11.9 million for the year ended December 31, 2025.

Given our current credit status and the current availability of capital, we believe that we will not encounter any major difficulties in obtaining additional bank borrowings. We plan to fund our future business plans, capital expenditures and related expenses as described in this annual report with cash from operations, the remaining net proceeds from our recent financing and short-term and long-term indebtedness. We may, however, require additional cash resources due to changing business conditions or other future developments, including any investments or acquisitions we may decide to pursue. Also see "Item 3. Key Information—3.D. Risk Factors—Risks Relating to Our Business and Industry—Any future occurrence of force majeure events, natural disasters or outbreaks of contagious diseases in the PRC could prevent us from effectively serving our customers and thus adversely affect our results of operations."

[**Table of Contents**](#TableOfContents)

**Cash flows**

The following table presents selected cash flow data from our consolidated statements of cash flows for the periods indicated.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2023** | **2024** | **2025** | **2025** |
|  | **RMB** | **RMB** | **RMB** | **US$** |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net cash generated from/(used in) operating activities | 74286 | 79669 | (12226) | (1749) |
| Net cash used in from investing activities | (52246) | (30317) | (279) | (40) |
| Net cash generated/(used in) from financing activities | 29062 | (68550) | 29928 | 4280 |
| Net increase/(decrease) in cash and cash equivalents | 51102 | (19198) | 17423 | 2491 |
| Cash and cash equivalents at beginning of the year | 12161 | 62336 | 42836 | 6125 |
| Effect of changes in foreign exchange rates | (927) | (302) |  |  |
| Cash and cash equivalents at the end of the year | 62336 | 42836 | 60259 | 8616 |

---

**Net cash generated from operating activities**

Our net cash used in operating activities in 2025 was RMB12.2 million (US$1.7 million), primarily reflecting our loss before income tax as adjusted for non-cash items, including finance costs of RMB8.7 million (US$1.2 million), depreciation of property, plant and equipment of RMB58.3 million (US$8.3 million), loss on disposal of property, plant and equipment of RMB5.4 million (US$0.8 million), loss on ceased operation of subsidiaries of RMB7.2 million (US$1.0 million).

Our net cash generated from operating activities in 2024 was RMB80.0 million (US$10.9 million), primarily reflecting our loss before income tax as adjusted for non-cash items, including finance costs of RMB8.7 million (US$1.2 million), depreciation of property, plant and equipment of RMB65.3 million (US$9.0 million), share-based compensation of RMB1.8 million (US$0.2 million) and fair value gain of investment properties of RMB12.1 million (US$1.7 million).

Our net cash generated from operating activities in 2023 was RMB74.3 million (US$10.5 million), primarily reflecting our loss before income tax as adjusted for non-cash items, including finance costs of RMB14.5 million (US$2.0 million), depreciation of property, plant and equipment of RMB65.3 million (US$9.2 million), share-based compensation of RMB4.2 million (US$0.6 million), fair value loss of convertible note of RMB0.1 million (US$0.02 million) and gains on convertible note convert into shares of RMB20.4 million (US$2.9 million).

**Net cash used in investing activities**

Our net cash used in investing activities in 2025 was RMB0.3 million (US$0.04 million). primarily reflecting the increase arising from the purchase of property, plant and equipment, which is primarily attributable to significant expenditure on hospital renovation works and the purchase of more advanced medical equipment.

Our net cash used in investing activities in 2024 was RMB30.3 million (US$4.2 million), primarily reflecting the increase in the purchase of and deposit paid for property, plant and equipment, which primarily attributable to the significant expenditure on the renovation of hospitals and the procurement of additional medical equipment required for our expanding non-surgical aesthetics medical business.

Our net cash used in investing activities in 2023 was RMB52.2 million (US$7.4 million), primarily reflecting the increase in the purchase of and deposit paid for property, plant and equipment, which primarily attributable to the significant expenditure on the renovation of large-scale hospitals and the procurement of additional medical equipment required for our expanding non-surgical aesthetics medical business.

[**Table of Contents**](#TableOfContents)

**Net cash generated/(used in) from financing activities**

Our net cash generated from financing activities in 2025 was RMB29.9 million (US$4.3 million), primarily reflecting proceeds from borrowing of RMB163.2 million (US$23.3 million), partially offset by repayment of borrowings of RMB84.9 million (US$12.1 million).

Our net cash used in financing activities in 2024 was RMB68.6 million (US$9.4 million), primarily reflecting repayment of lease liabilities of RMB38.8 million (US$5.3 million), repayment of borrowings of 179.4 million (US$24.6 million), partially offset by proceeds from borrowing of RMB159.1 million (US$21.8 million).

Our net cash generated from financing activities in 2023 was RMB29.1 million (US$4.1 million), primarily reflecting the RMB170 million private placement closed on February 16, 2023, as disclosed in our 6-K filing released on the same date to the SEC, partially offset by repayment of borrowings of RMB203.3 million (US$28.6 million), repayment of lease liabilities of RMB25.7 million (US$3.6 million) and interest paid of RMB10.1 million (US$1.4 million).

**Indebtedness**

**Bank borrowings**

The principal banks on our borrowings are Bank of Beijing, Huaxia Bank and China Everbright Bank. As of December 31, 2025, the outstanding principal balance of these loans were RMB44.1 milllion, RMB40.2 million and RMB10.0 million, respectively.

**Financial Lease from other financial institution**

In 2025, we entered into financial lease arrangements with third-party financial institution. As of December 31, 2025, the total outstanding principal balance of these borrowings was RMB49.5 million (US$7.1 million).

The loan and credit facility are guaranteed by our subsidiary and our related parties, and secured by some of their properties and/or our properties. The effective interest rate on these bank and other borrowings was 3.92% in 2025. Some of these borrowings have financial covenant requirements.

**Convertible note**

On September 17, 2020, we entered into a convertible note purchase agreement, and pursuant to which, we issued a convertible note at principal amount of US$5,000,000 (equivalent to approximately RMB33.4 million). The maturity date of such convertible note is March 17, 2023. The convertible note is convertible into our ADSs at the option of the holder after six months from the issue date to the maturity date, unless we have elected to redeem the convertible note prior to conversion. We have the right to redeem all the outstanding convertible note after one year from the issue date. The holder has a right to redeem all outstanding convertible note at maturity date at a price equivalent to 12.5% internal rate of return compounded annually from the issue date to maturity date. We can elect to redeem all outstanding convertible note after one year from the issue date at a price equivalent to 15% internal rate of return compounded annually from the issue date to the redemption date.

Before the first anniversary of the issuance of the convertible note, the convertible note is redeemable at the option of us and by giving notice in writing to the convertible note holder. We monitor the convertible note on a fair value basis, which is in accordance with our risk management strategy and do not bifurcate any feature from its debt host instrument and designate the entire hybrid contract as a financial liability at fair value through profit or loss with the changes in the fair value recorded in consolidated statement of comprehensive income.

In September 2020, we entered into a two-and-a-half year Convertible Note Purchase Agreement in a principal amount of US$10 million with ADV, of which US$5.0 million was actually drew down. In July 2022, we entered into a Share Purchase Agreement, a Subscription Agreement, a Shareholders' Agreement and a Cooperation Agreement (collectively "Financing Agreements") with Shenzhen Lafang Investment Management Co., Ltd., ADV and other parties, under which we settled with ADV on the above Convertible Note Purchase Agreement. According to the Financing Agreements, the above Convertible Note held by ADV will no longer accrue interest after July 2022 and ADV undertakes to covert the outstanding principal amount as well as interest into our ordinary shares at the price of RMB4.203 per ordinary share without cash payment upon the final settlement of the Financing Agreements. Reference is made to the press release of the Company filed with the Securities and Exchange Commission (the "SEC") on July 20, 2022 and form 6-K of the Company filed with the SEC on February 16, 2023 and August 17, 2023 in relation to, among other, entry into the Financing Agreement. We have closed our previously announced issue of a total number of 12,088,808 ordinary shares of the Company to ADV at a conversion price of US dollars equivalent of RMB4.203 per ordinary share on August 16, 2023 pursuant to the Note issued to ADV on September 17, 2020 and the cooperation agreement between ADV and its affiliate, the Company, Dr. Zhou Pengwu, Ms. Ding Wenting, Wanda and Jiechuang dated July 20, 2022.

We also entered into a Warrant Agreement with ADV, under which we were required to pay US$2.7 million to ADV to settle the financial liability under the Exit Payment (as defined in the Exit Payments Agreement entered into by ADV, the Company, the Founders on September 15, 2020) term in the Convertible Note Purchase Agreement. ADV agreed to postpone our cash payment date of US$2.7 million to December 2024 or, at its discretion, convert such amount at the price of RMB4.67 per ordinary share at any time during this period. ADV did not exercise its warrants, which expired on December 15, 2024, to convert the US$2.7 million Exit Payment into our ordinary shares. The balance of Exit Payment which is US$1.9 million as at December 31, 2025.

[**Table of Contents**](#TableOfContents)

**Capital expenditures**

Our capital expenditure in 2025 was RMB7.0 million (US$1.0 million), attributable to the purchase of property, plant and equipment and intangible assets, which mainly consists of machinery and equipment, including RMB1.5 million (US$0.2 million) for Pengcheng Hospital, RMB2.5 million (US$0.5 million) for Shenzhen Pengai, RMB0.7 million (US$0.1 million) for Haikou Pengai, RMB1.5 million (US$0.2 million) for Huizhou Pengai, RMB0.3 million(US$0.0 million) for Shenzhen Pengai Xiuqi, RMB0.3 million(US$0.0 million) for Yantai Pengai, RMB 0.1 million(US$0.0 million) for Beijing Pengai, and RMB 0.1 million(US$0.0 million) for Shenzhen Pengai Hospital Investment Management.

Our capital expenditure in 2024 was RMB30.8 million (US$4.3 million), attributable to the purchase of property, plant and equipment, which mainly consists of machinery and equipment, including RMB17.4 million (US$2.4 million) for Beijing Pengai, RMB6.0 million (US$0.8 million) for Huizhou Pengai, RMB2.6 million (US$0.4 million) for Pengcheng Hospital, RMB2.5 million (US$0.4 million) for Shenzhen Pengai.

Our capital expenditure in 2023 was RMB55.5 million (US$7.8 million), attributable to the purchase of property, plant and equipment and intangible assets, which mainly consists of machinery and equipment, including RMB5.6 million (US$0.8 million) for Pengcheng Hospital, RMB16.1 million (US$2.3 million) for Shenzhen Pengai, RMB2.8 million (US$0.4 million) for Shenzhen Xiuqi, RMB0.8 million (US$0.1 million) for Shanghai Pengai Jiahong.

We intend to fund our future capital expenditures with our existing cash balances and we will continue to make capital expenditures to meet the expected growth of our business.

**Material Cash Requirements** 

***Off-Balance Sheet Arrangements***

 ****

We have not entered into any off-balance sheet financial guarantees or other off-balance sheet commitments to guarantee the payment obligations of any unconsolidated third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder's equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.

We did not have any off-balance sheet arrangements as of December 31, 2025.

***Contractual Obligations***

 ****

The following table sets forth our contractual obligations by specified categories as of December 31, 2025. Amounts we pay in future periods may vary from those reflected in the table.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |<br>**Total** | **Less than**<br>**1 year** |<br>**1 to 2 years** |<br>**2 to 5 years** | **More than**<br>**5 years** |
|  | **RMB in thousands** | **RMB in thousands** | **RMB in thousands** | **RMB in thousands** | **RMB in thousands** |
| Operating lease obligations<sup>(1)</sup> | 154776 | 31996 | 28485 | 72990 | 21305 |
| Borrowings | 144252 | 129081 | 15171 |  |  |
| **Total** | 299028 | 161077 | 43656 | 72990 | 21305 |

---

Note:

(1) We
lease premises for aesthetic healthcare services and offices under non-cancellable operating agreements. The lease terms are between
3 and 9 years, and majority of lease agreements are renewable at the end of the lease period at market rate.

Other than the contractual obligations set forth above, we do not have any contractual obligations that are long-term debt obligations, capital (finance) lease obligations, purchase obligations or other long-term liabilities reflected on our balance sheet as of December 31, 2025.

[**Table of Contents**](#TableOfContents)

**Holding Company Structure**

We are a Cayman Islands holding company with no material operations of our own. We conduct our operations primarily through our operating subsidiaries in China. As a result, our ability to pay dividends depends upon, among others, dividends paid by our subsidiaries. If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us. In addition, our wholly-owned PRC subsidiaries are permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with the PRC accounting standards and regulations. Under the PRC laws, each of our PRC subsidiaries is required to set aside at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. Although the statutory reserves can be used, among other ways, to increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies, the reserve funds are not distributable as cash dividends except in the event of liquidation. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by the SAFE. We currently plan to reinvest all earnings from our PRC subsidiaries to their business developments and do not plan to request dividend distributions from them.

**5. C. Research and Development, Patents and Licenses, etc.**

We did not have in place research and development plans, and did not incur research and development expenses from January 1, 2023 to December 31, 2025. As of December 31, 2025, we had (i) 37 registered trademarks, 32 of which are in mainland China and 5 in Hong Kong, (ii) 40 registered domain names, of which all are registered in mainland China, and (iii) 2 registered patents, of which all are registered in mainland China. For more details, see "Item 4. Information on the Company—4.B. Business Overview—Intellectual property".

**5. D. Trend Information**

According to data from So-Young's Institute of Aesthetic Research, the non-surgical aesthetic medical market in China is projected to reach RMB415.7 billion by 2030, nearly twice the size of the surgical aesthetic market. In 2023, the non-surgical aesthetic market in China is expected to reach RMB146.1 billion, with a compound annual growth rate of approximately 16.11% from 2023 to 2030. The rapidly growing market is attributable to the steady growth of consumer disposable income and people's growing acceptance of aesthetic medicine consumption, which was supported by the increased awareness of digital marketing advertisements. To ride on the market trend and further increase our market shares, we will continue to identify new treatment trends and introduce the latest services to the market while at the same time optimizing our sales and marketing strategies to increase customer outreach and conversion rate.

Other than the above, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2023 to December 31, 2025 that are reasonably likely to have a material effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.

**5. E. Critical Accounting Estimates**

We prepare our financial statements in conformity with IFRS, which requires us to make judgments, estimates and assumptions. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experience and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates.

Some of our accounting policies require a higher degree of judgment than others in their application and require us to make significant accounting estimates.

The selection of critical accounting policies, the judgments and other uncertainties affecting application of those policies and the sensitivity of reported results to changes in conditions and assumptions are factors that should be considered when reviewing our financial statements. We believe the following accounting policies involve the most significant judgments and estimates in the preparation of our financial statements.

[**Table of Contents**](#TableOfContents)

***Revenue recognition***

 ****

Revenue is recognized when or as the control of the goods or services is transferred to the customer at an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services.

Revenue from provision of services, which includes non-surgical aesthetic medical services, comprising minimally invasive aesthetic treatments and energy-based treatments, surgical aesthetic medical services, and general healthcare services and other aesthetic medical services, is recognized at a point in time when the services have been rendered to customers. Minimally invasive aesthetic medical services, surgical aesthetic medical services and other aesthetic medical services are usually provided within a day, except for certain large-scale surgical aesthetic medical services in which customers are required to go through medical tests and screening for suitability of the surgery. The period of inpatient stays usually does not exceed more than a week. Most of our services do not require inpatient stays, though we do have inpatient facilities available upon patient request. With respect to energy- based treatments, we have certain packages that customers pay in advance. Payments for such energy-based treatments not yet rendered are recorded as contract liabilities in our consolidated balance sheets and are fully refunded to our customers upon their request. Revenue from the provision of general healthcare services and other aesthetic medical services is recognized at a point in time upon provision of such services for which the service period is usually within a day. We review the utilization pattern of contract liabilities and the treatment progress of individual customers on a regular basis to consider full recognition of the corresponding contract liabilities in profit or loss. Interest income is recognized using the effective interest method.

***Goodwill impairment assessment***

 ****

**Goodwill and Property, Plant and Equipment Impairment Assessment**

Goodwill arises on the acquisition of subsidiaries and represents the excess of the consideration transferred over our interest in the fair value of the net identifiable assets, liabilities and contingent liabilities of the acquiree and the amount of the non-controlling interests in the acquiree. Property, plant and equipment consist of tangible long-term assets held for use in the Company's operations, which are carried at cost less accumulated depreciation and accumulated impairment losses.

Our management tests annually whether goodwill and property, plant and equipment have suffered any impairment. For the purpose of impairment testing, goodwill has been allocated to individual cash-generating units, or CGUs, and property, plant and equipment are attributed to the respective CGUs or groups of CGUs where the underlying assets are utilised. All long-lived assets including goodwill and property, plant and equipment are reviewed for impairment based on forecast operating performance and future cash flows. The recoverable amounts of relevant CGUs and asset groups have been determined based on value-in-use calculations. These calculations require the extensive use of management judgements and estimates. The value-in-use calculations primarily adopt cash flow projections based on financial budgets approved by management. There are a number of significant assumptions and estimates involved in the preparation of cash flow projections for the period covered by the approved budgets. Key assumptions include the expected revenue and margin growth rates, timing and scale of future capital expenditures, operating cost trends, useful lives of tangible assets and the selection of appropriate discount rates to reflect the inherent risks of the relevant CGUs and industry environment. Our management prepares the financial budgets reflecting historical actual performance, prior year operating results and forward-looking market development expectations. Our assessment indicated that reasonably possible adverse changes in the key assumptions on which value-in-use calculations are based would not cause the carrying amounts of goodwill and property, plant and equipment within individual CGUs to exceed their respective recoverable amounts, and accordingly, no material impairment charge was recognised.

[**Table of Contents**](#TableOfContents)

***Estimated useful lives of property, plant and equipment***

 ****

We determine the estimated useful lives and related depreciation charges for our property, plant and equipment with reference to the estimated periods that we intend to derive future economic benefits from the use of these assets. We perform periodic reviews of the estimated useful lives of property, plant and equipment, and revise the depreciation charges where estimated useful lives are different than those previously estimated.

**Item 6. Directors, Senior Management and Employees**

**6. A. Directors and Executive Officers**

The following table sets forth information regarding our directors and executive officers as of the date of this annual report.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Positions(s)** |
| Zhang Chen(1) | 40 | Executive Co-chairman of the Board |
| Zhou Pengwu | 71 | Non-executive Co-chairman of the Board |
| Wu Binhua(2) | 44 | Director |
| Laurena Wu(3) | 42 | Director |
| Wu Binqi(4) | 40 | Director |
| Zhang Changsuo | 45 | Director |
| Zhou Xichun(5) | 29 | Director |
| Liu Bo | 55 | Director |
| Chen Feng | 41 | Independent Director |
| Lin Yingzhou | 67 | Independent Director |
| Li Yanyun | 45 | Independent Director |
| Hu Qing | 62 | Chief Operating Officer |
| Wu Guanhua | 44 | Chief Financial Officer |

---

(1) Mr.
Zhang is the spouse of Ms. Wu Binhua, the brother-in-law of Ms. Laurena Wu and Ms. Wu Binqi, who are also directors of the Board, and
the son-in-law of Mr. Wu Guiqian, our ultimate controller.

(2) Ms.
Wu Binhua is the spouse of Mr. Zhang Chen, the newly appointed executive co-chairman of the Board, and the daughter of Mr. Wu Guiqian
and the sister of Ms. Laurena Wu and Ms. Wu Binqi.

(3) Ms.
Laurena Wu is the daughter of Mr. Wu Guiqian and the sister of Ms. Wu Binhua and Ms. Wu Binqi.

(4) Ms.
Wu Binqi is the daughter of Mr. Wu Guiqian and the sister of Ms. Wu Binhua and Ms. Laurena Wu.

(5) Mr.
Zhou Xichun is the son of Dr. Zhou Pengwu.

The following is a biographical summary of the experience of our directors and executive officers.

**Mr. Zhang Chen** is currently our executive co-chairman of the board of directors. Mr. Zhang is a renowned entrepreneur, who had held various leadership positions in different companies, including as the general manager of Shenzhen Lafang Investment Management Co., Ltd. Currently, Mr. Zhang is the executive director of Shenzhen Lafang Investment Management Co., Ltd., executive director and general manager of Hainan Runming Biotechnology Co., Ltd., director of Hawyu (HK) Limited. Furthermore, Mr. Zhang joined the Chinese listed company, Lafang China Co., Ltd., in 2009 as a director, vice general manager, and secretary to the board of directors, where he played a crucial role in the company's success. Mr. Zhang is the spouse of Ms. Wu Binhua, the brother-in-law of Ms. Laurena Wu and Ms. Wu Binqi, who are also directors of the Board, and the son-in-law of Mr. Wu Guiqian, the Company's actual controller.

[**Table of Contents**](#TableOfContents)

**Dr. Zhou Pengwu** is one of our founders and is our non-executive co-chairman of the board of directors. Dr. Zhou has been a registered plastic surgeon since 1991. He has over 30 years of experience in aesthetic medicine and over 20 years of experience in managing aesthetic medical hospitals, beginning with the establishment of the Shenzhen Pengcheng Clinic in Shenzhen in 1997, which later became the Pengcheng Outpatient Department, then the Shenzhen Pengcheng General Hospital, and finally the Pengcheng Hospital. He acted in a variety of leadership positions in our company, including as the general manager and hospital administrator of the Pengcheng Hospital and Shenzhen Pengai Hospital, as well as chairman and general manager of Shenzhen Pengai Hospital Investment Management Co., Ltd., or Shenzhen Pengai Investment. Dr. Zhou also currently serves as an adjunct professor at the Aesthetic Medical School at Yichun University. In 2012, he was elected as vice-president of the Shenzhen Entrepreneur Association. In 2015, Dr. Zhou was elected as vice-chairman of the First Council of the Internet Aesthetic Medical Subcommittee of Chinese Cosmetic Surgery Association. He is also currently a vice-chairman member of the Fifth Council of the Aesthetic Medical Treatment Subcommittee of the Guangdong Medical Association and vice chairman of the Second Council of the Private Aesthetic Medical Treatment Institution of Chinese Cosmetic Surgery Association. In 2011, Dr. Zhou also participated in the drafting seminar of National Health and Family Planning Commission of the PRC for setting up standards for aesthetic medical treatment institutions. Dr. Zhou obtained an EMBA for hospital administrators from Peking University in October 2005. Dr. Zhou was awarded the "2017 Industry Leader Award" by China Council for the Promotion of International Trade Academy, China Economic Herald and China Business Association (Beijing) Entrepreneur Business Club.

**Ms. Wu Binhua** currently serves as a director of our company. She also serves as the general manager of Shenzhen Lafang Investment Management Co., Ltd. and Shenzhen Yijing Investment Co., Ltd., and a supervisor of Benkang Biopharmaceutical (Shenzhen) Co., Ltd., and Lafang China (Fujian) Co., Ltd. Ms. Wu Binhua is the spouse of Mr. Zhang Chen, the newly appointed executive co-chairman of the Board, and the daughter of Mr. Wu Guiqian and the sister of Ms. Laurena Wu and Ms. Wu Binqi.

**Ms. Laurena Wu** currently serves as a director of our company. She also serves as the actual controller and director of Wider Huge Group Limited and Australia Wanda International Company Limited. Ms. Laurena Wu is the daughter of Mr. Wu Guiqian and the sister of Ms. Wu Binhua and Ms. Wu Binqi.

**Ms. Wu Binqi** currently serves as a director of our company. She also serves as an executive director and the manager of Fasong Investment Management (Shanghai) Co., Ltd., Dewei (Shanghai) Cosmetics Co., Dewei Luteng (Guangzhou) Enterprise Management Co., Ltd. and Deji (Guangzhou) Life Science Technology Co., Ltd., and a supervisor of Guangdong Yitai Investment Co., Ltd. Ms. Wu Binqi is an exceptional entrepreneur and a member of Relay China Youth Elite Association. She has spent years studying fashion abroad and now has turned her attention to the Chinese cosmetics industry. With her deep knowledge of international fashion trends and design, she is poised to make a significant impact on this growing industry. Ms. Wu Binqi is the daughter of Mr. Wu Guiqian and the sister of Ms. Wu Binhua and Ms. Laurena Wu.

**Mr. Zhang Changsuo** currently serves as a director of our company. Mr. Zhang has been a leading figure in the kindergarten through twelfth grade (the "**K-12**") education industry in China for over 14 years. With a focus on K-12 and extracurricular training, he has made significant contributions to the development of the education landscape in Southwest China. Mr. Zhang Changsuo began his career in education as a partner of Xi'an Xin Fangxiang Education Technology Co., Ltd., where he soon became a prominent expert in the K-12 education industry with his focused approach and innovative ideas. In 2011, Mr. Zhang Changsuo founded Mingda Education Group (the "**Mingda**") and served as the founder and chairman until 2021. Under his leadership, Mingda became one of the most successful education groups in China. Mingda has deeply cultivated the K-12 market in Southwest China, providing students with high-quality education and extracurricular training programs. After nearly 10 years of development, Mingda has set up a total of 39 teaching centers with more than 30,000 students currently enrolled and over 1,000 professional teachers in service in Hainan Province, Fujian Province, Guizhou Province, and Guangxi Province in China. Among them, Mingda is ranked No.1 in K-12 education industry in terms of market share in Hainan Province and Guangxi Province. Mr. Zhang Changsuo received his bachelor's degree in Computer Science and Technology from Chang'an University in 2003.

**Mr. Zhou Xichun** currently serves as a director of our company. Mr. Zhou has served as an assistant to chairman since 2019 and has played a key role in the Company's initial public offering. Mr. Zhou Xichun was responsible for creating the business plan for expanding non-surgical aesthetic medical clinics, which included funding resources, operation framework, information technology management, financial projections and so on. His expertise and leadership have been integral to the Company's pioneer role in the Chinese non-surgical aesthetic medical market. Mr. Zhou Xichun graduated from the University of California, Irvine in 2021 with a bachelor's degree in Economics. Mr. Zhou Xichun is the son of Dr. Zhou Pengwu, the founder of the Company.

[**Table of Contents**](#TableOfContents)

**Mr. Liu Bo** currently serves as a director of our company. Mr. Liu has over 25 years of experience in the financial services sector and leads ADV's coverage of China. Prior to joining ADV, Mr. Liu Bo served in various senior positions in Private Equity and Corporate investment roles, including CVC Capital Partners Asia, CITIC Capital and Wanda Investment (not affiliated with Australia Wanda International Company Limited). Mr. Liu Bo holds an MBA from the University of Michigan and a Bachelor's in Finance and Economics.

**Mr. Chen Feng** has over 12 years of experience in investments and asset management as well as over 4 years of experience in auditing. Mr. Chen is currently the Vice President of ADV Partners. His earlier roles include SVP & VP Investments at FountainVest in Shanghai and CPE (formerly CITIC PE) in Beijing, Senior Investment Manager at China International Marine Containers (CIMC) in Shenzhen as well as Senior Auditor at PricewaterhouseCoopers Zhongtian Certified Public Accountants. Mr. Chen holds a Masters in Finance from London Business School and a Bachelor of International Auditing from Nanjing Audit University in China. He is a Fellow Chartered and Certified Accountant (ACCA). He is fluent in English and Chinese.

**Mr. Lin Yingzhou** currently serves as an independent director of our company. Mr. Lin has been engaged in intellectual property practice for 16 years. He has been the deputy secretary general of Shantou Patent Protection Association for three consecutive terms since 2005, and is now an expert of Guangdong Provincial Intellectual Property Expert Pool, an expert member and arbitrator of Shantou Arbitration Commission, and an expert of Shantou Intermediate People's Court Think Tank. He has been providing consulting services to Shantou enterprises on the application of the patent system and the strategy of patent rights defense.

**Ms. Li Yanyun** currently serves as an independent director of our company. Ms. Li is a seasoned financial expert with over 20 years of experience in finance and accounting, operation and professional services. She has worked in various industries such as accounting, shipping, manufacturing and agriculture, gaining extensive knowledge and expertise in these fields. Ms. Li Yanyun currently serves as the financial controller of Fubang Resources (Singapore) Pte Ltd. She is a member of the Association of Chartered Certified Accountants and a Chartered Accountant of Singapore. She received her master's degree in Finance from the Royal Melbourne Institute of Technology in 2012.

**Ms. Hu Qing** has served as a director of our company since March 2012. She is our chief operating officer, primarily responsible for the overall operations of our business. Ms. Hu has over 25 years of experience in the medical industry. From January 2004 to December 2005, Ms. Hu served as the deputy president of Shenzhen Pengcheng General Hospital. From December 2005 to December 2013, Ms. Hu consecutively served as the deputy hospital administrator, and general manager of Shenzhen Pengai Hospital. Since 2002, Ms. Hu has served as the vice-president, deputy general manager and director of Shenzhen Pengai Investment. Prior to joining us, Ms. Hu spent more than 13 years working in Japan and served as the director and the Secretary for the Beijing University of Traditional Chinese Medicine, Japanese Branch where she was in charge of daily operations, from April 1991 to March 2004. Ms. Hu received her bachelor's degree in radio engineering from the South China Engineering School (currently known as the South China University of Technology) in July 1983 and obtained an EMBA for hospital administrators from Peking University in August 2006.

**Mr. Wu Guanhua** joined our company in 2012 and has served as our chief financial officer since August 2018. Mr. Wu Guanhua has over 10 years of experience in international corporate accounting, operations, financial and strategic management. From 2006 to 2008, Mr. Wu Guanhua served as project manager of MAZARS, a global audit, accounting and consulting group. Since March 2008, Mr. Wu Guanhua has served as a partner of Beijing Junyue Investment Consultancy Co., Ltd., a company specializing in consulting services for financing, listing procedures and business development strategies to small and medium enterprise in China. Mr. Wu obtained his bachelor's degree in science from the University of Oxford Brooks in 2007. Mr. Wu is a certified accountant of The Association of Chartered Certified Accountants since 2007 and became a fellow member in 2012.

**Enforceability of Civil Liabilities**

We are incorporated in the Cayman Islands and primarily conduct our business operations in mainland China. Among our directors and officers, except for Ms. Li Yanyun, who is based in Singapore, and Ms. Laurena Wu, who resides in Hong Kong, all of our other directors and officers, including Mr. Zhang Chen, Dr. Zhou Pengwu, Ms. Wu Binhua, Ms. Wu Binqi, Mr. Zhang Changsuo, Mr. Zhou Xichun, Mr. Liu Bo, Mr. Chen Feng (replaced Ms. Xu Tianqing on October 30, 2024), Mr. Lin Yingzhou, Ms. Hu Qing and Mr. Wu Guanhua, reside in mainland China, and all or a substantial portion of their assets are located outside of the United States. All or a substantial portion of their assets are located outside of the United States. As a result, it may be difficult for a shareholder to effect service of process within the United States upon these individuals, to bring an action against us or these individuals in the United States, or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States.

[**Table of Contents**](#TableOfContents)

The United States and the Cayman Islands do not have a treaty providing for reciprocal recognition and enforcement of judgments of U.S. courts in civil and commercial matters and that there is uncertainty as to whether the courts of the Cayman Islands would (i) recognize or enforce judgments of U.S. courts obtained against us or our directors or officers, predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States, or (ii) entertain original actions brought in the Cayman Islands against us or our directors or officers, predicated upon the securities laws of the United States or any state in the United States. A judgment obtained in any federal or state court in the United States will be recognized and enforced in the courts of the Cayman Islands at common law, without any re-examination of the merits of the underlying dispute, by an action commenced on the foreign judgment debt in the Grand Court of the Cayman Islands, provided such judgment (a) is given by a foreign court of competent jurisdiction, (b) imposes on the judgment debtor a liability to pay a liquidated sum for which the judgment has been given, (c) is final, (d) is not in respect of taxes, a fine or a penalty, and (e) was not obtained in a manner and is not of a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman Islands.

However, the Cayman Islands courts are unlikely to enforce a judgment obtained from the United States courts under the civil liability provisions of the securities laws if such judgment is determined by the courts of the Cayman Islands to give rise to obligations to make payments that are penal or punitive in nature. A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.

There is uncertainty as to whether the courts of mainland China would:

● recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States; or

● entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.

The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. Courts of mainland China may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law and other applicable laws and regulations based either on treaties between mainland China and the country where the judgment is made or on principles of reciprocity between jurisdictions. Mainland China does not have any treaties or other form of reciprocity with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign judgments. As such, the courts of mainland China will review and determine the applicability of the reciprocity principle on a case-by-case basis and the length of the procedure is uncertain. In addition, according to the PRC Civil Procedures Law, courts in mainland China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a court of mainland China would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign shareholders may originate actions based on PRC law against a company in mainland China for disputes if they can establish sufficient nexus to mainland China for a court of mainland China to have jurisdiction, and meet other procedural requirements. It will be, however, difficult for U.S. shareholders to originate actions against us in mainland China in accordance with PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult for U.S. shareholders, by virtue only of holding the ADSs or ordinary shares, to establish a connection to mainland China for a court of mainland China to have jurisdiction as required under the PRC Civil Procedures Law.

Furthermore, the United States and Hong Kong do not have a bilateral treaty or multilateral convention in force on reciprocal recognition and enforcement of judgments. As a result, any United States judgment is enforceable in Hong Kong pursuant to the common law regime in Hong Kong for recognizing and enforcing foreign judgments, which provides that a foreign judgment is enforceable if (i) it is final and conclusive on the merits, (ii) the judgment has been rendered by a court of competent jurisdiction, (iii) the judgment must be for a fixed sum of money, (iv) the judgment must be between the same parties as those before the Hong Kong court, and (v) enforcement of the judgment is not a breach of natural justice or against public policy.

[**Table of Contents**](#TableOfContents)

**6. B. Compensation**

**Compensation of directors and executive officers**

For the year ended December 31, 2025, we paid an aggregate of RMB13.7 million (US$2.0 million) in cash and other benefits to our directors and executive officers. We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each employee's salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund.

For share incentive grants to our officers and directors, see "—6.B. Compensation—Share Incentive Plan."

**Employment agreements and indemnification agreements**

We have entered into employment agreements with each of our senior executive officers. Under these agreements, each of our executive officers will be employed for a specified time period, which will be automatically extended unless either we or the executive officer gives prior notice to terminate such employment. We may terminate a senior executive officer's employment for cause, at any time, without notice or remuneration, for certain acts of the officer, including, but not limited to, a conviction or plea of guilty to a felony, willful misconduct or a failure to perform agreed duties. According to the Labor Law of PRC, we can terminate the employment of an executive officer at any time and provide corresponding compensation.

Each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The senior executive officers have also agreed to disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the senior executive officer's employment with us and to assign all right, title and interest in them to us, and assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets.

In addition, each executive officer has agreed to be bound by non-competition and non-solicitation restrictions during the term of his or her employment and for one year following the termination of the employment. Specifically, each senior executive officer has agreed not to (i) approach our suppliers, customers, direct or end customers or contacts or other persons or entities introduced to the senior executive officer in his or her capacity as a representative of us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or entities; (ii) assume employment with or provide services to any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express consent; or (iii) seek directly or indirectly, to solicit the services of, or hire or engage, any person who is known to be employed or engaged by us; or (iv) otherwise interfere with our business or accounts.

We have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify them against certain liabilities and to reimburse them for expenses in connection with claims made by reason of their being a director or officer of our company.

**Share Incentive Plan**

In June 2019, our shareholders and board of directors approved the Aesthetic Medical International Holdings Group Limited Share Incentive Plan, or the Share Incentive Plan, to attract and retain the best available personnel, provide additional incentives to employees, directors and consultants, and promote the success of our business. The maximum aggregate number of ordinary shares that could be issued pursuant to all awards under the Share Incentive Plan was 5,940,452 shares. As of the date of this annual report, all options under the Share Incentive Plan to purchase ordinary shares have been fully granted, with 1,128,750 ordinary shares are outstanding.

The following paragraphs describe the principal terms of the Share Incentive Plan.

*Types of Awards.* The Share Incentive Plan permits the awards of options, share appreciation rights, restricted shares or any other type of awards approved by the plan administrator.

[**Table of Contents**](#TableOfContents)

*Plan Administration.* The Share Incentive Plan will be administered by our board of directors, or one or more committees appointed by the board of directors, as the case may be, which will act as the plan administrator. The committee(s) or the full board of directors will determine the matters related to the Share Incentive Plan, including but not limited to: the participants to receive awards, the form, type and number of awards to be granted to each participant, and the terms and conditions of each award grant.

*Award Agreement.* Awards granted under the Share Incentive Plan are evidenced by an award agreement in writing, approved by the plan administrator, setting forth the terms of an award that has been duly authorized and approved.

*Eligibility.* We may grant awards to our board members, directors of one of our affiliates, officers, employees, consultants and other eligible persons.

*Vesting Schedule.* In general, the plan administrator in its sole discretion determines the vesting schedule, which is specified in the relevant award agreement.

*Exercise of Options.* The plan administrator in its sole discretion determines the exercise price for each award, which is stated in the relevant award agreement.

*Transfer Restrictions.* Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the Share Incentive Plan or the relevant award agreement or as otherwise determined by the plan administrator, such as transfers back to us, transfers by gift to one or more 'family members', transfers by will or the laws of descent and distribution.

*Termination and Amendment of the Share Incentive Plan.* Unless terminated earlier, the Share Incentive Plan has a term of ten years. Our board of directors or relevant committee appointed by the board of directors has the authority to amend or terminate the plan. However, no such action may adversely affect in any material way any awards previously granted unless agreed by the recipient.

As of the date of this annual report, our directors and executive officers as a group and our other employees as a group held outstanding options to purchase 1,128,750 ordinary shares of our company, at an exercise price of US$0.001 per share.

On June 1, 2019, we issued 5,940,452 ordinary shares to Shengli Family Limited at par value. We established Pengai Employees Trust pursuant to a declaration of trust dated June 17, 2019 among our company, as the settlor, Zedra Trust Company (Cayman) Limited, as the trustee, and Dr. Zhou Pengwu, as the enforcer, for the benefit of the grantees under our Share Incentive Plan. All of the issued shares of Shengli Family Limited have been transferred to Zedra Trust Company (Cayman) Limited as trust fund. Upon satisfaction of vesting conditions and request by relevant grantees, Shengli Family Limited will transfer the ordinary shares underlying the exercised share options to relevant grantees with the consent of the enforcer. Pursuant to the terms of the declaration of trust, the trustee shall not exercise the voting rights attached to those ordinary shares of our Company under its control without first obtaining written consent of the enforcer. On November 30, 2023, the enforcer was changed from Dr. Zhou Pengwu to solely the Company. Such shares are treated as treasury shares for accounting purposes only.

**Performance Incentive Plan**

In September 2019, our shareholders and board of directors approved the Aesthetic Medical International Holdings Group Limited 2019 Performance Incentive Plan, or the Performance Incentive Plan, to attract, motivate, retain and reward selected employees and other eligible persons, and to promote the success of our company. The maximum aggregate number of ordinary shares that could be issued pursuant to all awards under the Performance Incentive Plan is a number up to 10% of total issued and outstanding ordinary shares. On July 29, 2022, the Company issued 1,927,793 new ordinary shares to certain employees, representing an aggregate 2.0% of the total number of outstanding ordinary shares, at nil consideration in accordance with the 2019 Performance Incentive Plan proposed in September 2019. The purpose of this share option plan is to recognize contributions made by key employees on the negotiation and execution of the financing with Lafang China Co., Ltd. and Jiechuang, as well as to provide an incentive to retain a long-term relationship with the Company under the alignment of interests.

The following paragraphs describe the principal terms of the Performance Incentive Plan.

*Types of Awards.* The Performance Incentive Plan permits the awards of options, share appreciation rights, restricted shares, performance shares, share units, restricted share units, similar rights to purchase or acquire shares, cash awards or dividend equivalent rights.

[**Table of Contents**](#TableOfContents)

*Plan Administration.* The Performance Incentive Plan will be administered by our board of directors, or one or more committees or subcommittees appointed by the board of directors, as the case may be, which will act as the plan administrator. The committee(s) or the full board of directors will determine the matters related to the Performance Incentive Plan, including but not limited to: the participants to receive awards, the form, type and number of awards to be granted to each participant, and the terms and conditions of each award grant.

*Award Agreement.* Awards granted under the Performance Incentive Plan are evidenced by an award agreement in writing, approved by the plan administrator, setting forth the terms of an award that has been duly authorized and approved.

*Eligibility.* We may grant awards to our board members, directors of one of our affiliates, officers, employees, consultants and other eligible persons.

*Vesting Schedule.* In general, the plan administrator in its sole discretion determines the vesting schedule, which is specified in the relevant award agreement.

*Exercise of Options.* The plan administrator in its sole discretion determines the exercise price for each award, which is stated in the relevant award agreement.

*Transfer Restrictions.* Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the Performance Incentive Plan or the relevant award agreement or as otherwise determined by the plan administrator, such as transfers back to us, transfers by gift to a 'family member' or former 'family member', transfers by will or the laws of descent and distribution, and transfers to a third party who provide financing under the plan administrator's authorization for 'cashless exercise' procedures.

*Termination and Amendment.* Unless terminated earlier, the Performance Incentive Plan has a term of ten years. Our board of directors has the authority to amend or terminate the plan. However, no such action may adversely affect in any material way any awards previously granted unless agreed by the recipient.

**6. C. Board Practices**

**Board of directors**

Our board of directors consists of 11 directors. A director is not required to hold any shares in our company to qualify to serve as a director. Except as required by our corporate governance policies, a director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with the Company shall declare the nature of his interest at a meeting of the directors. A director may vote with respect to any contract or any proposed contract or arrangement notwithstanding that he may be interested therein, and if he does so his vote shall be counted and he may be counted in the quorum at any meeting of our directors at which any such contract or proposed contract or arrangement is considered. Pursuant to our related party transaction policy currently effective, our audit committee, or in the event that any member of the audit committee is a related party in the transaction to be reviewed, any non-conflicted member(s) of our audit committee, shall have the authority to approve proposed related party transactions as defined thereunder, subject to exceptions under certain standing pre-approval. Our directors may exercise all the powers of our company to borrow money, mortgage or charge its undertaking, property and uncalled capital and to issue debentures or other securities whenever money is borrowed or as security for any debt, liability or obligation of our company or of any third party.

None of our directors has a service contract with us that provides for benefits upon termination of service.

[**Table of Contents**](#TableOfContents)

**Committees of the board of directors**

We have three committees under the board of directors: an audit committee, a compensation committee, and a nominating and corporate governance committee. We have adopted a charter for each of the three committees. Each committee's members and functions are described below.

***Audit committee.*** Our audit committee currently consists of Ms. Li Yanyun, Mr. Lin Yingzhou and Mr. Chen Feng (replaced Ms. Xu Tianqing on October 30, 2024), and is chaired by Ms. Li Yanyun. Each of them satisfies the independence standards under Rule 10A-3 under the Exchange Act. Our audit committee consists solely of independent directors who satisfy the SEC requirements. We have determined that Ms. Li Yanyun qualifies as an "audit committee financial expert" within the meaning of the SEC rules. The audit committee oversees our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things:

● selecting the independent registered public accounting firm and pre-approving all auditing and non-auditing services permitted to be performed by the independent registered public accounting firm;

● reviewing with the independent registered public accounting firm any audit problems or difficulties and management's response;

● reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;

● discussing the annual audited financial statements with management and the independent registered public accounting firm;

● reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of material control deficiencies;

● annually reviewing and reassessing the adequacy of our audit committee charter;

● meeting separately and periodically with management and the independent registered public accounting firm; and

● reporting regularly to the board.

***Compensation committee.*** Our compensation committee currently consists of Ms. Li Yanyun, Mr. Lin Yingzhou and Ms. Wu Binhua, and is chaired by Mr. Lin Yingzhou. The compensation committee assists the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated upon. The compensation committee is responsible for, among other things:

● reviewing the total compensation package for our executive officers and making recommendations to the board with respect to it;

● reviewing the compensation of our non-employee directors and making recommendations to the board with respect to it; and

● periodically reviewing and approving any long-term incentive compensation or equity plans, programs or similar arrangements, annual bonuses, and employee pension and welfare benefit plans.

***Nominating and corporate governance committee.*** Our nominating and corporate governance committee concurrently consists of Ms. Li Yanyun, Mr. Lin Yingzhou and Mr. Zhang Chen, and is chaired by Mr. Zhang Chen. The nominating and corporate governance committee assists the board in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things:

● recommending nominees to the board for election or re-election to the board, or for appointment to fill any vacancy on the board;

● reviewing annually with the board the current composition of the board with regards to characteristics such as independence, age, skills, experience and availability of service to us;

● selecting and recommending to the board the names of directors to serve as members of the audit committee and the compensation committee, as well as of the nominating and corporate governance committee itself; and

● monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

[**Table of Contents**](#TableOfContents)

**Appointment of directors by our principal shareholders**

According to the Shareholders' Agreement signed by and among Seefar Global Holdings Limited, Jubilee Set Investments Limited, Dr. Zhou Pengwu, Ms. Ding Wenting, ADV, Hawyu, Wanda, Jiechuang, the Board of Directors shall be subject to the following arrangements upon Closing (as defined in the Share Purchase Agreement among our company, Wanda, Seefar Global Holdings Limited and Jubilee Set Investments Limited dated 20 July 2022) (the "**SPA Closing**").

&nbsp;&nbsp;&nbsp;&nbsp;(a) Number
and Composition of the Board of Directors. The number of directors shall constitute the Board of Directors shall be no more than eleven
(11) persons. Specifically, (i) Jiechuang shall have the right to designate, appoint, remove from the office, replace and reappoint four
(4) directors; (ii) Wanda shall have the right to designate, appoint, remove from the office, replace and reappoint two (2) directors;
(iii) Hawyu (HK) Limited shall have the right to designate, appoint, remove from the office, replace and reappoint one (1) director;
(iv) (A) if the Founders hold in the aggregate no less than five percent (5%) of the issued shares of the Company, Seefar Global Holdings
Limited shall have the right to designate, appoint, remove from the office, replace and reappoint two (2) directors; (B) if the Founders
and their affiliates hold in the aggregate no less than two percent (2%) but less than five percent (5%) of the issued shares of the
Company, Seefar Global Holdings Limited shall have the right to designate, appoint, remove from the office, replace and reappoint one
(1) director (for the avoidance of doubt, Seefar Global Holdings Limited shall not have the right to appoint a director in any other
circumstances); and (v) if ADV and/or its affiliates hold no less than ten percent (10%) of the issued shares of the Company, it shall
have the right (but not the obligation) to designate, appoint, appoint, remove from the office, replace and reappoint up to two (2) directors.
The Directors appointed by Jiechuang shall include at least one (1) independent director, the Directors appointed by Wanda shall include
at least one (1) independent director, and the Directors appointed by ADV shall include at least one (1) independent director, so as
to satisfy the requirements for directors on the U.S. NASDAQ Stock Exchange of "independency" despite our company no longer
being listed on Nasdaq as of this annual report. For the avoidance of doubt, any employee of ADV or its affiliates can serve as the one
(1) independent director appointed by ADV.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Resignation
and Removal of Directors: if a Director fails to satisfy the condition that the shareholders hold the relevant outstanding shares of
the Company as specified in the above section (a), or is otherwise no longer suitable to act as a Director ("Cause of Resignation"),
such Director shall submit his or her written resignation to the Company within five (5) Business Days after the occurrence of such resignation.
In addition, a Director shall only be removed by the shareholder who appointed such Director at any time with or without cause upon written
notice to the Board of Directors. However, any Director shall be removable by the Board of Directors in cases of fraud, gross negligence
or gross fault, breach of his duties as a Director or where the Director no longer satisfies the condition that the shareholders hold
the corresponding issued shares under the above section (a), and does not give his resignation within a prescribed period of time.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Indemnification
and Insurance: The Company shall purchase and maintain D&O liability insurance policies for the Directors, in an amount and with
companies satisfactory to the Board. The charter documents of the Company shall at all times provide that the Company shall indemnify
each Director against all claims and liabilities incurred by him by reason of the exercise of any powers or the performance of any duties
in his capacity as a Director to the fullest extent permitted by the laws of the Cayman Islands.

&nbsp;&nbsp;&nbsp;&nbsp;(d) Chairman
of the Board: The Board shall have two (2) co-chairmen, one of whom shall be the Executive Chairman who shall be the Director appointed
by Wanda and Jiechuang, and the other of whom shall be the Non-executive Chairman and shall be Dr. Zhou Pengwu. (for the avoidance of
doubt, Dr.Zhou Pengwu (current executive director of the Company) will be designated as a non-executive director of the Company on or
about the date of the SPA Closing). The Executive Chairman shall take full charge of the Company's daily management and business
operation, while the Non-executive Chairman shall take charge of cultural affairs such as the dissemination of core values and shall
not participate in any actual daily management and business operation of the Company.

**Duties of directors**

Under Cayman Islands law, our directors have a fiduciary duty to act honestly in good faith with a view to our best interests. Our directors also have a duty to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time. Our company has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder has the right to seek damages if a duty owed by our directors is breached.

[**Table of Contents**](#TableOfContents)

Our board of directors has all the powers necessary for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include, among others:

● convening shareholders' annual and extraordinary general meetings and reporting its work to shareholders at such meetings;

● declaring dividends and distributions;

● appointing officers and determining the term of office of the officers;

● exercising the borrowing powers of our company and mortgaging the property of our company; and

● approving the transfer of shares in our company, including the registration of such shares in our share register.

**Terms of directors and executive officers**

Pursuant to our fourth amended and restated articles of association (as revised),our directors may be elected by a resolution of our board of directors, or by an ordinary resolution of our shareholders. Our directors are not subject to a term of office and hold office until such time as they are removed from office by ordinary resolution of the shareholders. A director will cease to be a director if, among other things, the director (i) becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors; or (ii) dies or becomes of unsound mind; or (iii) resigns his office by notice in writing to us. Although there is no term limit, pursuant to our corporate governance guidelines, unless our board of directors determines in a particular instance that longer tenure is in the best interests of our company and its shareholders: (i) no director shall be nominated by our board of directors for re-election at an annual shareholders meeting coinciding with or next following his or her 72nd birthday, and (ii) inside directors shall retire on the date of their retirement or termination of employment with our company or its affiliates.

All of our executive officers are appointed by and serve at the discretion of our board of directors.

**6. D. Employees**

**Overview**

We had 1,286, 1,309 and 1,139 employees (full-time) in our wholly- or majority-owned medical institutions as of December 31, 2023, 2024 and 2025, respectively. The following table sets forth certain information about our employees by function as of December 31, 2025.

---

| | | |
|:---|:---|:---|
| <br>**Function<sup>(1)</sup>** | **Number of**<br>**Employees\*** | **Percent of total**<br>**employees** |
| Management | 4 | 0.4% |
| Doctors | 114 | 10.0% |
| Other Medical Staff<sup>(2)</sup> | 282 | 24.8% |
| Sales and Marketing | 166 | 14.6% |
| Image Consultants | 94 | 8.3% |
| Customer Service | 270 | 23.7% |
| Finance and Accounting | 66 | 5.8% |
| Human Resource and Administration | 103 | 9.0% |
| Auxiliary Medical Staff<sup>(3)</sup> | 40 | 3.4% |
| **Total** | **1139** | **100%** |

---

Notes:

(1) Includes
full-time numbers.

(2) Includes
nurses and medical technicians who are required to hold licenses.

(3) Includes
unlicensed medical staff who perform auxiliary functions during treatments.

[**Table of Contents**](#TableOfContents)

Since our inception, we have not experienced any significant turnover of staff or any disruption to our business operations due to labor disputes as our employees are not represented by a labor union. There had been no complaints or claims from employees that materially and adversely affected our business operations during the historical period.

Our employees typically enter into standard employment contracts with us. Recruitment is centralized across our treatment centers based on identified employee needs. Each treatment center then enters into standard employment contracts with its own employees, while the decisions to employ the general manager and finance and accounting directors at each treatment center are made at the headquarters level.

We provide both in-house and external training for our employees to improve their skills and knowledge. Remuneration packages for our employees mainly comprise base salary, overtime allowance (if applicable) and a performance-related bonus. We set performance targets for our employees primarily based on their position and department and annually review their performance. The results of such reviews are used in their salary determinations, bonus awards, and promotion appraisals.

**Qualified medical professionals**

The qualification and expertise of doctors are vital to the quality of our healthcare services and our competitiveness. As of December 31, 2025 all of our 156 doctors (full-time and part-time) had obtained Doctor Qualification Certificates, and all our nursing staff have obtained Nurse Practice Certificates.

We place great emphasis on recruiting, training and retaining our employees. We maintain a high standard in selecting quality medical professionals and provide competitive compensation packages to them. Peer referral represents an important recruitment channel for us as a significant proportion of our doctors are sourced through this channel, indicative of our strong branding and reputation in the medical community. Our full-time doctors, who work for us exclusively during the term of their employment, are typically employed under three to five year employment contracts. We also have doctors who are contractors and not our employees. As part of ongoing development, we provide periodic training to our employees to enhance their skills and knowledge. Our administrative department and medical control department regularly review the profiles of our doctors and prompt them to apply for their next professional rank when they become eligible. Our medical professionals are assigned to various departments in our treatment centers based on the scope of their licenses. Medical professionals usually are not allowed to practice in departments other than their designated department. The medical service department of each treatment center reviews the prescriptions issued by doctors and inspects each department to ensure no medical professionals practice beyond the scope of their licenses. As of the date of this annual report, there have been no material complaints or penalties in relation to our medical professionals practicing beyond the scope of their respective licenses.

As of December 31, 2025, our team of 156 doctors (including full-time and part-time) comprised 3 chief physician, 24 associate-chief physicians, 58 attending physicians, 71 resident physicians in China. The majority of our doctors worked exclusively at our treatment centers while 23 of our doctors split their practice with other hospitals as of December 31, 2025. Our doctors typically receive compensation in the form of a salary plus bonus based on the number of procedures performed. Our doctors were supported by 282 other medical staff, including nurses and pharmacists, as of December 31, 2025.

**6. E. Share Ownership**

The following table sets forth information concerning the beneficial ownership of our ordinary shares as of the date of this annual report by:

● each of our directors and executive officers; and

● each person known to us to beneficially own 5% or more of our ordinary shares.

[**Table of Contents**](#TableOfContents)

The calculations in the table below are based on 146,062,754 ordinary shares outstanding, excluding 1,263,750 treasury shares as of the date of this annual report, except for the calculation of Shengli Family Limited, which holds 1,128,750 shares. Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person.

---

| | | |
|:---|:---|:---|
|  | **Ordinary Shares** | **Ordinary Shares** |
|  | **Beneficially Owned** | **Beneficially Owned** |
|  | **Number** | **Percent** |
| **Directors and executive officers \*:** | | |
| Zhang Chen |  |  |
| Zhou Pengwu<sup>(1)</sup> | 6947842 | 4.8% |
| Wu Binhua |  |  |
| Laurena Wu<sup>(2)</sup> | 33431735 | 21.9% |
| Wu Binqi |  |  |
| Zhang Changsuo |  |  |
| Zhou Xichun<sup>(3)</sup> | 642597 | 0.4% |
| Chen Feng |  |  |
| Lin Yingzhou |  |  |
| Li Yanyun |  |  |
| Hu Qing<sup>(3)</sup> | 1142984 | 0.8% |
| Wu Guanhua<sup>(3)</sup> | 1489455 | 1.0% |
| **All executive officers and directors as a group** | 43654613 | 28.6% |
| **Principal shareholders:** |  |  |
| MY Universe (HK) Limited<sup>(4)</sup> | 36402570 | 24.9% |
| Hawyu (HK) Limited<sup>(5)</sup> | 21413276 | 14.7% |
| Australia Wanda International Company Limited<sup>(6)</sup> | 33431735 | 21.9% |
| Seefar Global Holdings Limited<sup>(7)</sup> | 6947842 | 4.8% |
| Jubilee Set Investments Limited<sup>(8)</sup> | 4248972 | 2.9% |
| Peak Asia Investment Holdings V Limited<sup>(9)</sup> | 27665768 | 18.9% |
| Shengli Family Limited<sup>(10)</sup> | 1128750 | 0.8% |

---

\* The business address of all directors and officers is 1122 Nanshan Boulevard, Nanshan District, Shenzhen, Guangdong Province, China.

(1) Represents
6,947,842 ordinary shares held by Seefar Global Holdings Limited as further disclosed in note (7) below Dr. Zhou Pengwu and Ms. Ding
Wenting, the beneficial owner of Jubilee Set Investments Limited are spouses and each of Dr. Zhou Pengwu and Ms. Ding Wenting may be
deemed to have the beneficial ownership of the shares held by each other.

(2) Represents
(i) 27,007,752 ordinary shares beneficially owned by Australia Wanda International Company Limited and (ii) warrants to purchase 6,423,983
ordinary shares granted to Australia Wanda International Company Limited as further disclosed in note (6) below. Ms. Laurena Wu is the
daughter of Mr. Wu Guiqian, the beneficial owner of MY Universe (HK) Limited and Hawyu (HK) Limited and each of Ms. Laurena Wu and Mr.
Wu Guiqian may be deemed to have the beneficial ownership of the shares held by each other.

(3) See
"-6.B. Compensation-Share Incentive Plan" and "-Performance Incentive Plan" for a description of equity-based
awards we have granted and may grant to our directors, officers and other individuals as a group.

(4) Represents
36,402,570 ordinary shares held by MY Universe (HK) Limited. MY Universe (HK) Limited is a company incorporated in Hong Kong, which is
wholly owned by Hainan Oriental Jiechuang Investment Partnership (Limited Partnership). Hainan Oriental Jiechuang Investment Partnership
(Limited Partnership) is a company incorporated in Hainan Province, China, which is invested and managed by two general partners as to
Shenzhen Lafang Investment Management Co., Ltd. and Shenzhen Venture Capital M&A Fund Management (Shenzhen) Co., Ltd.

[**Table of Contents**](#TableOfContents)

(5) Represents
21,413,276 ordinary shares held by Hawyu (HK) Limited. Hawyu (HK) Limited is a company incorporated in Hong Kong, which is wholly owned
by Hainan Runming Biotechnology Co., Ltd. Hainan Runming Biotechnology Co., Ltd. is a company incorporated in Hainan Province, China,
which is wholly owned by Lafang China Co., Ltd, a Chinese listed company incorporated in Guangdong Province, China.

(6) Represents
(i) 27,007,752 ordinary shares beneficially owned by and (ii) warrants to purchase 6,423,983 ordinary shares granted to Australia Wanda
International Company Limited. This company, incorporated in Hong Kong, is wholly owned by Wider Huge Group Limited, which in turn is
wholly owned by Ms. Laurena Wu. On December 11, 2024, Australia Wanda International Company Limited acquired 3,313,680 ordinary shares
and 2,372,110 ordinary shares of our company respectively from the Founders for a nominal consideration pursuant to a settlement agreement.

(7) Represents
6,947,842 ordinary shares held by Seefar Global Holdings Limited. Seefar Global Holdings Limited is a company incorporated in the BVI,
which is wholly owned by Dr. Zhou Pengwu. The registered address of Seefar Global Holdings Limited is Vistra Corporate Services Centre,
Wickham's Cay II, Road Town, Tortola, VG1110, BVI.

(8) Represents
4,248,972 ordinary shares held by Jubilee Set Investments Limited. Jubilee Set Investments Limited is a company incorporated in the BVI,
which is wholly owned by Ms. Ding Wenting. The registered address of Jubilee Set Investments Limited is Vistra Corporate Services Centre,
Wickham's Cay II, Road Town, Tortola, VG1110, BVI.

(9) Represents
27,665,768 ordinary shares beneficially owned by Peak Asia Investment Holdings V Limited, which did not exercise its warrants that expired
on December 15, 2024, to convert the US$2.7 million exit payment into our ordinary shares. Peak Asia Investment Holdings V Limited is
a company limited by shares and registered in the BVI. Peak Asia Investment Holdings V Limited is wholly owned by Beacon Technology Investment
Holdings Limited, a company registered in Hong Kong, which in turn is wholly owned by ADV Opportunities Fund I, L.P., a Cayman exempted
limited partnership. The general partner of ADV Opportunities Fund I, L.P. is ADV Opportunities Fund I, GP, L.P., a Cayman exempted limited
partnership whose general partner is ADV Opportunities Fund I GP Ltd, a Cayman exempted company, which is wholly owned by ADV Partners
Holdings Ltd, a Cayman exempted company. ADV Partners Holdings Ltd. is in turn wholly owned by Mr. Bradley Dean Landes, Mr. Suresh Eshwara
Prabhala and Mr. Zhu Jianyi (Kenichi Shu). The registered address of Peak Asia Investment Holdings V Limited is Flemming House, Wickhams
Cay, P.O. Box 662, Road Town, Tortola, BVI. Each of Mr. Chen Feng (replaced Ms. Xu Tianqing on October 30, 2024) and Mr. Liu Bo was appointed
as our director by ADV pursuant to the shareholders' agreement dated July 20, 2022. For the purpose of this section, none of Mr.
Chen Feng and Mr. Liu Bo is regarded as a beneficial owner of the shares held by ADV.

(10) Represents
1,128,750 ordinary shares held by Shengli Family Limited, a company incorporated in the BVI, which is wholly owned by Zedra Trust Company
(Cayman) Limited, the trustee of Pengai Employees Trust. We established Pengai Employees Trust pursuant to a declaration of trust dated
June 17, 2019 among our company, as the settlor, Zedra Trust Company (Cayman) Limited, as the trustee, and Dr. Zhou Pengwu, as the enforcer,
who was then replaced by the Company on November 30, 2023, for the benefit of the grantees under our Share Incentive Plan. Upon satisfaction
of vesting conditions and request by relevant grantees, Shengli Family Limited will transfer the ordinary shares underlying the exercised
share options to relevant grantees with the consent of the enforcer. In addition, the voting rights attached to those ordinary shares
held by Shengli Family Limited cannot be exercised without written consent of the Company. For details, see "—6.B. Compensation
of Directors and Executive Officers—Share Incentive Plan." The registered address of Shengli Family Limited is Sertus Incorporations
(BVI) Limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, BVI.

As of the date of this annual report, to our knowledge, approximately 18.9% of our outstanding ordinary shares are held by ADV, a record holder in the United States. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. Hainan Oriental Jiechuang Investment Partnership (Limited Partnership) is a limited partnership incorporated in Hainan Province, China, which has two general partners, namely, Shenzhen Lafang Investment Management Co., Ltd. ("LaFang Investment") and Shenzhen Venture Capital M&A Fund Management (Shenzhen) Co., Ltd. ("SVC"). The majority of the equity interest of SVC is collectively and beneficially owned by several government-owned entities of the PRC.

[**Table of Contents**](#TableOfContents)

Pursuant to the Limited Partnership Agreement of Jiechuang, LaFang Investment acts as the executive general partner and is responsible for directing and managing the day-to-day operations and shall act as a legal representative for Jiechuang vis-a-vis third parties. LaFang Investment's responsibilities with regard to Jiechuang include but not limited to, (i) executing investment, (ii) procurement, management and disposal of assets; (iii) directing and managing day-to-day operations and (iv) execution, delivery and performance contracts. Conversely, SVC, as a general partner, has the right to (a) monitor the opening, maintenance and cancellation of bank accounts on behalf of Jiechuang and (b) receive prior notice from LaFang Investment and give written consent over certain matters, including but not limited to decisions made by LaFang Investment related to investment, legal proceeding, and contractual obligations. LaFang Investment, as the executive general partner of Jiechuang, is responsible for directing and managing the day-to-day operations, including making decisions on voting and the disposal of the ordinary shares of our Company held by Jiechuang (the "Jiechuang Shares"). Such decisions will be initiated by LaFang Investment in its discretion, and SVC's consent right is in comparison passive and protective in nature.

In addition, Shenzhen Luohu Red Earth Venture Capital Asset Management Limited ("Red Earth") acts as a manager of Jiechuang. Red Earth is mainly responsible for fund management related matters, including but not limited to procuring limited partners, fund raising, evaluating investment opportunities and monitoring invested companies. Red Earth is a government-owned enterprise. Red Earth's role as a manager of Jiechuang focuses on fund management of Jiechuang and not the decision making and direction of voting in relation to the Jiechuang Shares.

Furthermore, pursuant to the shareholder agreement among the Company, Jiechuang and certain other shareholders entered into on July 20, 2022, the board of directors of our Company shall be no more than eleven members, and Jiechuang has the right to nominate four directors of our Company. Jiechuang has indicated to the Company that if and when Jiechuang designates nominees for directors of the Company, the nomination will be made by LaFang Investment subject to notification to and consent by SVC. As of the date of this annual report, Jiechuang has nominated the directors to the board of directors of the Company.

**6. F. Disclosure of a registrant's action to recover erroneously awarded compensation**

Not applicable.

**Item 7. Major Shareholders and Related Party Transactions**

**7. A. Major Shareholders**

Please refer to "Item 6. Directors, Senior Management and Employees—6.E. Share Ownership."

**7. B. Related Party Transactions**

**Agreements and transactions with investors**

*Convertible note*

 ****

As at December 31, 2025 and the date of this annual report, the convertible note outstanding was nil. For details, see "Item 5. Operating and Financial Review and Prospects—5.A. Operating Results—Indebtedness—Convertible note."

 

**Shareholder and note holder agreement in 2018**

On November 15, 2018, we entered into an amended and restated shareholder and note holder agreement, with certain of our investors. Except for the registration rights, all the rights under the shareholder and note holder agreement terminated upon the completion of our initial public offering.

Pursuant to the shareholder and note holder agreement, we have granted certain registration rights to our investors. Such registration rights would terminate upon the earlier of (i) five years following the consummation of our initial public offering or (ii) such time at which all registrable securities held by a shareholder proposed to be sold may be sold under Rule 144 of the Securities Act in any 90-day period without registration in compliance with Rule 144 of the Securities Act. Set forth below is a description of the registration rights granted under the agreement. Set forth below is a description of the registration rights granted under the agreement.

[**Table of Contents**](#TableOfContents)

*Demand registration rights*

At any time after the earlier of (i) December 8, 2020 or (ii) the date 12 months following the an initial public offering, upon a written request from the holders of at least 50% of the voting power of the registrable securities, we must file a registration statement covering the offer and sale of the registrable securities held by the requesting holders (a) representing at least twenty percent (20%) of the then outstanding registrable securities held by such holders, or (b) having an anticipated aggregate offering price, net of underwriting discounts and commissions, in excess of US$5,000,000, on any internationally recognized exchange that is reasonably acceptable to such requesting holders.

Registrable securities include, among others, our ordinary shares from the automatic conversion and re-designation of the preferred shares.

We are not obligated to effect a registration, among other things, if we have, within the 12-month period preceding the date of the request, already effected two registrations under the Securities. We have the right to defer filing of a registration statement for up to 90 days if our board of directors determines in good faith that the filing of a registration statement would be materially detrimental to us and our shareholders, but we cannot exercise the deferral right for more than 90 days on any one occasion or more than once in any 12-month period.

*F-3 or S-3 registration rights*

When we are eligible for registration on Form F-3 or S-3, upon a written request from any holder all registrable securities, we must effect a registration on Form F-3 or S-3 and any related qualification or compliance covering the offer and sale of the registrable securities.

We are not obligated to effect a Form F-3 or S-3 registration, among other things, if we have, within the 12-month period preceding the date of the request, already effected two registrations under the Securities Act or if the holders of registrable securities proposed to sell at an aggregate price to the public less than US$500,000. We have the right to defer filing of a registration statement for up to 90 days if our board of directors determines in good faith that the filing of a registration statement would be materially detrimental to us and our shareholders, but we cannot exercise the deferral right for more than 90 days on any one occasion or more than once in any 12-month period.

*Piggyback registration rights*

If we propose to file a registration statement under the Securities Act for purposes of effecting a public offering of our securities (including, but not limited to, registration statements relating to secondary offerings of our securities, but excluding registration statements relating to any employee benefit plan or a corporate reorganization), we must afford holders of registrable securities an opportunity to include in that registration all or any part of their registrable securities then held. We have the right to terminate or withdraw any registration initiated by us under the piggyback registration rights prior to the effectiveness of such registration whether or not any holder has elected to include securities in such registration. The underwriters of any underwritten offering have the right to limit the number of shares with registration rights to be included in the registration statement, subject to certain limitations.

*Expenses of registration*

We will pay all expenses relating to any demand, Form F-3 or S-3, or piggyback registration except for the underwriting discounts and selling commissions applicable to the sale of registrable securities and certain other limited exceptions.

[**Table of Contents**](#TableOfContents)

**Shareholders' agreement in 2023**

Reference is made to the press release of the Company filed with the Securities and Exchange Commission (the **"**SEC**"**) on July 20, 2022 and form 6-K of the Company filed with the SEC on August 17, 2023. The Company, Dr. Zhou Pengwu, Ms. Ding Wenting, ADV and certain other parties thereto entered into a Shareholders**'** Agreement. The Shareholders**'** Agreement contains certain provisions regarding, among other things, the appointment of the Company**'**s board of directors and senior management, the notice, quorum and Directors**'** voting arrangement of board meetings, certain lock-up commitments of the Founders and their affiliates and pre-emptive rights mechanisms for the Company**'**s ordinary shares. Pursuant to the Shareholders**'** Agreement, the Company has delivered two separate tranches of warrants to purchase ordinary shares of the Company to Seefar and Wanda, respectively, on August 16, 2023 and one tranche of warrants to Seefar on December 13, 2024.

**Contractual Arrangements with respect to Target Equity Interests**

See "Item 4. Information on the Company—4.C. Organizational Structure—Contractual Arrangements with respect to Target Equity Interests."

**Corporate guarantee**

In 2018, our bank borrowings in total amount of RMB24.0 million (US$3.5 million) were guaranteed by our subsidiary and our related parties and secured by some of their properties and/or our properties.

As at December 31, 2025, the outstanding bank borrowing and other borrowings guaranteed by our related parties and secured by some of their properties and/or our properties was RMB144.3 million (US$20.6 million).

**Lease agreement**

In November 2017, Pengcheng Hospital entered into a lease agreement with Shenzhen Jiayan Investment Industrial Development Co., Ltd. or Shenzhen Jiayan, which is wholly owned by our directors, Dr. Zhou Pengwu and Ms. Ding Wenting. Pursuant to the lease agreement, Pengcheng Hospital will pay Shenzhen Jiayan a monthly rent of RMB188,521. The lease agreement expired in October 2022. As of December 31, 2025, we had a finance lease loan of RMB45.9 million (US$6.6 million) with Far East Horizon (Tianjin) Financial Leasing Co., Ltd., and a finance lease loan of RMB3.9 million (US$0.6 million) with Jiangsu Yurong Financial Leasing Co., Ltd.

**Loans to directors and executive officers**

In 2018, we provided loans to certain of our directors and executive officers. The loans are interest-free and payable on demand. As of December 31, 2025 and the date of this annual report, there was no outstanding loan provided by us to our directors and executive officers and the balance due from our directors and executive officers were both nil.

**Employment agreements and indemnification agreements**

See "Item 6. Directors, Senior Management and Employees—6.B. Compensation—Employment agreements and indemnification agreements."

**Equity incentive plans**

See "Item 6. Directors, Senior Management and Employees—6.B. Compensation—Share Incentive Plan" and "—Performance Incentive Plan" for a description of share options and restricted share units we have granted and may grant to our directors, officers and other individuals as a group.

**7. C. Interests of Experts and Counsel**

Not applicable.

[**Table of Contents**](#TableOfContents)

**Item 8. Financial Information**

**8. A. Consolidated Statements and Other Financial Information**

We have appended consolidated financial statements filed as part of this annual report.

**Legal proceedings**

As an aesthetic medical service and general healthcare service provider in China, we are subject to legal or arbitration proceedings, disputes or claims in the ordinary course of business. Except for those disclosed in "Item 3. Key Information—3.D. Risk Factors—Risks relating to our business and our industry—We are subject to customer complaints, claims and legal proceedings in the regular course of our operations from time to time, which could result in significant costs and materially and adversely affect our brand image, reputation and results of operations," each of these proceedings had been settled as of the date of this annual report or is, in our view, immaterial in terms of their impact on our financial and operational conditions.

Save as disclosed above and based on the information available to us, we are not, as of the date of this annual report, engaged in any litigation, arbitration or claim of material importance, and no litigation, arbitration of claim of material importance is known to us to be pending or threatened by or against us that may have a material adverse effect on our business, financial condition and operating results.

**Dividend Policy**

We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our shares or the ADSs representing our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business.

We are a holding company incorporated in the Cayman Islands. We rely principally on dividends from our PRC subsidiaries for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. Dividend distributions from our PRC subsidiary to us are subject to PRC taxes, including withholding tax. In addition, regulations in the PRC currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits as determined in accordance with its articles of association and the accounting standards and regulations in China. For more details, see "Item 4. Information of the Company—4.B. Business Overview—Regulation" and "Item 3. Key Information—3.D. Risk Factors—Risks relating to doing business in the PRC."

Our board of directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, subject to the provisions in our articles of association, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our Board of Directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares represented by the ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares represented by the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder.

**8. B. Significant Changes**

Except as otherwise disclosed in this report, we have not experienced any significant changes since the date of the annual financial statements included herein.

[**Table of Contents**](#TableOfContents)

**Item 9. The Offer and Listing**

**9. A. Offering and Listing Details**

Our ADSs, each representing three of our ordinary shares, par value US$0.001 per share, were listed on the Nasdaq Global Market under the symbol "AIH" from October 25, 2019 to January 19, 2023.

On June 2, 2022, we received a staff determination letter from the Nasdaq notifying us that, based on our stockholders' equity as reported in our annual report for the year ended December 31, 2021, we did not meet the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(1)(A) (the "Rule"). As provided in the Rule, we have 45 calendar days to submit a play to regain compliance with the minimum stockholders' equity requirement. On December 1, 2022, we received a staff determination letter from the Nasdaq notifying us that because we have not regained compliance with the Rule, unless we request an appeal of this determination, our ADSs would be scheduled for delisting from the Nasdaq Global Market. We requested a hearing before the Nasdaq Hearings Panel and subsequently submitted an application to transfer the listing of our ADSs from the Nasdaq Global Market to the Nasdaq Capital Market. The Listing Qualifications of Nasdaq approved our request to the Transfer Listing on January 17, 2023. Subsequently, our ADSs have been listed on the Nasdaq Capital Market uninterruptedly under the symbol "AIH" since January 19, 2023.

On May 17, 2024, we received a determination letter of the Hearings Panel (the "Panel") of Nasdaq, notifying us that the Panel determined to delist the Company's securities from Nasdaq, due to the failure to satisfy the continued listing conditions as previously disclosed. On July 19, 2024, we were delisted from Nasdaq when the staff of the Nasdaq Stock Market LLC filed a Form 25 Notification of Delisting. Our ADSs have been quoted on the Pink Open Market initially under the symbol "PAIYY" since the Nasdaq suspended the trading of our ADSs on May 21, 2024. Subsequently, we applied to upgrade from the Pink Open Market to the OTCQX Best Market and received approval on July 10, 2024. Our ADSs are currently quoted on the OTCQX Best Market under the symbol "PAIYY".

For more details, please see "Item 3.Key Information—3.D. Risk Factors—Risks relating to the ADSs —The trading price of the ADSs has been, and may continue to be, volatile due to our delisting from Nasdaq and transition to the OTCQX Best Market, potentially resulting in substantial losses for investors." and "Item 3.Key Information—3.D. Risk Factors—Risks relating to the ADSs — We may not be able to maintain the minimum bid price for continued qualification for the OTCQX Best Market."

**9. B. Plan of Distribution**

Not applicable.

**9. C. Markets**

See "—9.A. Offering and Listing Details."

**9. D. Selling Shareholders**

Not applicable.

**9. E. Dilution**

Not applicable.

**9. F. Expenses of the Issue**

Not applicable.

**Item 10. Additional Information**

**10. A. Share Capital**

Not applicable.

[**Table of Contents**](#TableOfContents)

**10. B. Memorandum and Articles of Association**

We are a Cayman Islands company and our affairs are governed by our fourth amended and restated memorandum and articles of association, as amended from time to time and the Companies Act (As Revised) of the Cayman Islands, which we refer to as the "Companies Act" below, and the common law of the Cayman Islands.

We incorporate by reference into this annual report our fourth amended and restated memorandum and articles of association, which was filed as Exhibit 3.2 to our registration statement on Form F-1 (File Number 333-234022) initially filed with the Securities and Exchange Commission on September 30, 2019 and declared effective on October 24, 2019. Our shareholders adopted our fourth amended and restated memorandum and articles of association by way of a special resolution passed on October 15, 2019, which became effective immediately prior to completion of our initial public offering of ADSs representing our ordinary shares, i.e., on October 29, 2019. The fourth amended and restated memorandum and articles of association was further amended by way of a special resolution passed at the annual general meeting of the Company held on 22 September 2022.

The following are summaries of material provisions of our fourth amended and restated memorandum and articles of association (as revised) and the Companies Act as they relate to the material terms of our ordinary shares.

**Registered Office and Objects**

Our registered office in the Cayman Islands is at the offices of Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands.

According to clause 3 of our fourth amended and restated memorandum of association, the objects for which we are established are unrestricted and we shall have full power and authority to carry out any object not prohibited by the Companies Act or as the same may be revised from time to time, or any other law of the Cayman Islands.

**Board of Directors**

See "Item 6. Directors, Senior Management and Employees."

**Ordinary Shares**

**General**

All of our outstanding ordinary shares are fully paid and non-assessable. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their ordinary shares. Under the Companies Act, we are not permitted to issue bearer shares. Our fourth amended and restated memorandum and articles prohibit us from issuing negotiable shares. Our company will issue only non-negotiable shares in registered form, which will be issued when registered in our register of members.

***Dividends***

Our board of directors may, from time to time, declare dividends on the shares subject to our fourth amended and restated memorandum and articles of association (as revised) and the Companies Act. The holders of our ordinary shares are entitled to receive such dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. No dividend may be declared and paid unless our directors determine that, immediately after the payment, we will be able to pay our debts as they fall due in the ordinary course of business and we have funds lawfully available for such purpose. Under Cayman Islands law, payment of the dividends may be made out of the following:

● profits, realized or unrealized, or any reserve set aside from profits;

● "share premium account," which represents the excess of the price paid to our company on issue of its shares over the par or "nominal" value of those shares, which is similar to the U.S. concept of additional paid in capital; or

● any other fund or account which can be authorized for this purposes in accordance with the Companies Act.

However, no dividend shall bear interest against our company.

[**Table of Contents**](#TableOfContents)

**Voting rights**

Holders of our ordinary shares may vote on all matters submitted to a vote of our shareholders, except as may otherwise be required by law. At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless voting by poll is demanded by the chairman of the meeting or by one or more shareholder(s) at such general meeting.

Any ordinary resolution to be made by the shareholders requires the affirmative vote of a simple majority of the votes of the ordinary shares cast in a general meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes of the ordinary shares cast.

Under Cayman Islands law, some matters, such as amending the memorandum and articles of association, changing the name or resolving to be registered by way of continuation in a jurisdiction outside the Cayman Islands, require approval of shareholders by a special resolution.

No person will be entitled to vote at any general meeting or at any separate meeting of the holders of the ordinary shares unless the person is registered as of the record date for such meeting and unless all calls or other sums presently payable by the person in respect of ordinary shares in our company have been paid.

**Transfer of ordinary shares**

Subject to the restrictions contained in our fourth amended and restated articles of association (as revised), any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.

Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up, or which is issued under any share incentive scheme for employees upon which a restriction on transfer imposed thereby still subsists, or on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless:

● the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;

● the instrument of transfer is in respect of only one class of ordinary shares;

● the instrument of transfer is properly stamped, if required;

● in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; and

If our directors refuse to register a transfer, they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.

The registration of transfers may, after compliance with any notice required of the OTC Market, be suspended and the register of members closed at such times and for such periods as our board of directors may from time to time determine, provided, however, that the registration of transfers shall not be suspended nor the register of members closed for more than 30 days in any year as our board may determine.

[**Table of Contents**](#TableOfContents)

**Winding up; liquidation**

Pursuant to our fourth amended and restated articles of association (as revised), if our company shall be wound up the liquidator may, with the sanction of a special resolution of our company, divide amongst the shareholders in specie or kind the whole or any part of the assets of our company (whether they shall consist of property of the same kind or not) and may for such purpose set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out as between the shareholders or different classes of shareholders. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the contributories as the liquidator, with the like sanction shall think fit, but so that no shareholder shall be compelled to accept any shares or other securities whereon there is any liability.

**Calls on ordinary shares and forfeiture of ordinary shares**

Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. Any ordinary shares that have been called upon and remain unpaid are subject to forfeiture.

**Repurchase, redemption and surrender of ordinary shares**

The Companies Act and our fourth amended and restated articles of association (as revised) permit us to purchase our own shares. In accordance with our fourth amended and restated articles of association (as revised) and provided the necessary shareholders or board approval have been obtained, we may issue shares on terms that are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner, including out of capital, as may be determined by our board of directors. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company's profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding, or (c) if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.

**Variations of rights of shares**

All or any of the special rights attached to any class of shares may, subject to the provisions of the Companies Act, be varied or abrogated with the consent in writing of at least two thirds of the shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu with such existing class of shares.

**General meetings of shareholders**

Shareholders' meetings may be convened by a majority of our board of directors or our chairman or any director where required to do so pursuant to a requisition by one or more shareholders holding at the date of deposit of the requisition shares which carry in aggregate not less than 40% of all votes attaching to the issued and outstanding shares that carry the right to vote at general meetings. Advance notice of not less than seven calender days is required for the convening of our annual general shareholders' meeting and any other general meeting of our shareholders. A quorum required for and throughout a meeting of shareholders consists of at least one shareholder entitled to vote and present in person or by proxy or (in the case of a shareholder being a corporation) by its duly authorized representative representing not less than one-third of our total number of shares in issue.

**Inspection of books and records**

The notice of registered office is a matter of public record. A list of the names of the current directors and alternate directors (if applicable) are made available by the Registrar of Companies in the Cayman Islands for inspection by any person on payment of a fee. The register of mortgages is open to inspection by creditors and members.

Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements. See "Where You Can Find More Information."

[**Table of Contents**](#TableOfContents)

**No preemptive rights**

Holders of ordinary shares will have no preemptive or preferential right to purchase any securities of our company under our fourth amended and restated articles of association (as revised) and the Companies Act.

**Changes in capital**

We may from time to time by ordinary resolution:

● increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe;

● consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;

● sub-divide our existing shares, or any of them into shares of a smaller amount; or

● cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so canceled.

We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law.

**Exempted company**

We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:

● does not have to file an annual return of its shareholders with the Registrar of Companies;

● is not required to open its register of members for inspection;

● does not have to hold an annual general meeting;

● may issue shares with no par value;

● may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);

● may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;

● may register as a limited duration company; and

● may register as a segregated portfolio company.

"Limited liability" means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company.

[**Table of Contents**](#TableOfContents)

**Reserved matters**

To the fullest extent permitted by law but in addition to such other requirements as may be provided in our fourth amended and restated articles of association (as revised) and the applicable laws, notwithstanding anything therein to the contrary, in no event shall the following actions be taken, or otherwise permitted, by or on behalf of us or any of our subsidiaries, unless and until approved by an ordinary resolution, or, if required by the Companies Act, a special resolution:

● any voluntary delisting of our securities;

● a Change of Control Event (as defined in our fourth amended and restated articles of association (as revised)); and

● any transfer or other disposal of any assets, businesses or securities of any of us and our subsidiaries, which are (i) outside the ordinary course of business of our relevant subsidiary; or (ii) which involve the transfer or disposal of 50% or greater of our and our subsidiaries' consolidated assets or accounted for 50% or greater of our and our subsidiaries' consolidated revenue, each as presented in our latest audited consolidated financial statements.

**10. C. Material Contracts**

We have not entered into any material contracts other than in the ordinary course of business and other than those described in "Item 4. Information on the Company" or elsewhere in this annual report during the two years immediately preceding the date of this annual report.

**10. D. Exchange Controls**

Substantially all of our operations are in PRC and our business is subject to supervision and regulation by the PRC government. For PRC regulations that may affect the import or export of capital and the remittance of dividends, interest or other payments to non-PRC resident holders of our ordinary shares and ADSs, see "Item 4. Information on the Company—4.B. Business Overview—Regulation— Regulations related to foreign exchange in the PRC" and "—Regulations related to taxation in the PRC."

**10. E. Taxation**

The following summary of Cayman Islands, PRC and U.S. federal income tax consequences of an investment in the ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in the ADSs or ordinary shares, such as the tax consequences under state, local and other tax laws, or tax laws of jurisdictions other than the Cayman Islands, the PRC and the United States. To the extent that the discussion relates to matters of PRC tax law, it represents the opinion of Dacheng Law Offices LLP (Wuhan), our counsel as to PRC law.

**Cayman Islands taxation**

The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes levied by the government of the Cayman Islands that are likely to be material to holders of ordinary shares except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on transfers of shares of Cayman Islands companies except those which hold interests in land in the Cayman Islands. The Cayman Islands is party to a double tax treaty with the United Kingdom in 2010 but is otherwise is not party to any double tax treaties which are applicable to any payments made by or to our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.

Payments of dividends and capital in respect of our ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of our ordinary shares, nor will gains derived from the disposal of our ordinary shares be subject to Cayman Islands income or corporation tax.

[**Table of Contents**](#TableOfContents)

Pursuant to Section 6 of the Tax Concessions Act (2011 Revision) of the Cayman Islands, we have obtained an undertaking from the Governor in Cabinet:

&nbsp;&nbsp;&nbsp;&nbsp;(1) that
no law which is enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains or appreciations shall apply to
us or our operations; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) that
the aforesaid tax or any tax in the nature of estate duty or inheritance tax shall not be payable on our shares debenture or other obligations.

The undertaking for us is for a period of twenty years from July 29, 2014.

**People's Republic of China taxation**

We are a holding company incorporated in the Cayman Islands. Under the EIT Law and its implementation rules, an enterprise established outside of Mainland China with a "*de facto* management body" within Mainland China is considered a "resident enterprise," and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term "*de facto* management body" as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In 2009, the State Administration of Taxation issued SAT Circular 82, which provides certain specific criteria for determining whether the "*de facto* management body" of a PRC-controlled enterprise that is incorporated offshore is located in Mainland China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of Taxation's general position on how the "*de facto* management body" text should be applied in determining the tax resident status of all offshore enterprises. According to SAT Circular 82, all offshore enterprises controlled by a PRC enterprise or a PRC enterprise will be regarded as a PRC tax resident by virtue of having its "*de facto* management body" in Mainland China only if all of the following conditions are met:

&nbsp;&nbsp;&nbsp;&nbsp;(i) the
primary location of the day-to-day operational management is in the PRC;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) decisions
relating to the enterprise's financial and human resource matters are made or are subject to approval by organizations or personnel
in the PRC;

&nbsp;&nbsp;&nbsp;&nbsp;(iii) the
enterprise's primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or
maintained in Mainland China; and

&nbsp;&nbsp;&nbsp;&nbsp;(iv) at
least 50% of voting board members or senior executives habitually reside in Mainland China.

We believe that none of Aesthetic Medical International Holdings Group Limited and its subsidiaries outside of Mainland China is a PRC resident enterprise for PRC tax purposes. Aesthetic Medical International Holdings Group Limited is not controlled by a PRC enterprise or PRC enterprise group, and we do not believe that Aesthetic Medical International Holdings Group Limited meets all of the conditions above. Aesthetic Medical International Holdings Group Limited is a company incorporated outside Mainland China. As a holding company, some of its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside Mainland China. For the same reasons, we believe our other subsidiaries outside of Mainland China are also not PRC resident enterprises. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term "*de facto* management body."

[**Table of Contents**](#TableOfContents)

If the PRC tax authorities determine that Aesthetic Medical International Holdings Group Limited is a PRC resident enterprise for EIT purposes, we may be required to withhold tax at a rate of 10% on dividends we pay to our shareholders, including holders of the ADSs, that are non-resident enterprises. In addition, non-resident enterprise shareholders (including the ADS holders) may be subject to a 10% PRC withholding tax on gains realized on the sale or other disposition of ADS or ordinary shares, if such income is treated as sourced from within Mainland China. Furthermore, gains derived by our non-PRC individual shareholders from the sale of our shares and ADSs may be subject to a 20% PRC withholding tax. It is unclear whether our non-PRC individual shareholders (including the ADS holders) would be subject to any PRC tax (including withholding tax) on dividends received by such non-PRC individual shareholders in the event we are determined to be a PRC resident enterprise. If any PRC tax were to apply to dividends realized by non-PRC individuals, it will generally apply at a rate of 20%. The PRC tax liability may be reduced under applicable tax treaties. However, it is unclear whether non-PRC shareholders of Aesthetic Medical International Holdings Group Limited would be able to claim the benefits of any tax treaty between their country of tax residence and China in the event that Aesthetic Medical International Holdings Group Limited is treated as a PRC resident enterprise. See "Item 3. Key Information—3.D. Risk Factors—Risks relating to doing business in the PRC—If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders."

Pursuant to the EIT Law and its implementation rules, if a non-resident enterprise has not set up an organization or establishment in Mainland China, or has set up an organization or establishment but the income derived has no actual connection with such organization or establishment, it will be subject to a withholding tax on its PRC-sourced income at a rate of 10%. Pursuant to the Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, the tax rate in respect to dividends paid by a PRC enterprise to a Hong Kong enterprise is reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, or SAT Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in order to enjoy the reduced tax rate: (i) it must directly own the required percentage of equity interests and voting rights in the PRC resident enterprise; and (ii) it must have directly owned such percentage in the PRC resident enterprise throughout the 12 months prior to receiving the dividends. There are also other conditions for enjoying the reduced tax rate according to other relevant tax rules and regulations. Accordingly, our subsidiary Peng Oi Investment (Hong Kong) Holdings Limited may be able to enjoy the 5% tax rate for the dividends it receives from its PRC incorporated subsidiaries if they satisfy the conditions prescribed under SAT Circular 81 and other relevant tax rules and regulations and obtain the approvals as required. However, according to SAT Circular 81, if the relevant tax authorities determine our transactions or arrangements are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable tax rate on dividends in the future.

If our Cayman Islands holding company, Aesthetic Medical International Holdings Group Limited, is not deemed to be a PRC resident enterprise, holders of the ADSs and ordinary shares who are not PRC residents will not be subject to PRC income tax on dividends distributed by us or gains realized from the sale or other disposition of our shares or ADSs.

**United States federal income taxation**

The following is a general discussion of certain U.S. federal income tax considerations relating to the ownership and disposition of the ADSs or ordinary shares by U.S. Holders (as defined below) that acquire the ADSs or ordinary shares and hold the ADSs or ordinary shares as "capital assets" (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended or the "Code". This discussion does not address any aspect of U.S. federal gift or estate tax, alternative minimum tax, the Medicare tax on net investment income, or the state, local or non-U.S. tax consequences of an investment in the ADSs and ordinary shares. This discussion is based on the Code, existing, temporary and proposed regulations promulgated thereunder, published rulings, court decisions and, if applicable in the event that we are deemed to be a PRC resident enterprise under the PRC tax law, the income tax treaty between the United States and PRC (the "Treaty"), all as of the date hereof. These laws are subject to change, possibly on a retroactive basis. No ruling has been obtained and no ruling will be requested from the U.S. Internal Revenue Service (the "IRS") with respect to any of the U.S. federal income tax consequences described below, and as a result, there can be no assurance that the IRS will not disagree with or challenge any of statements provided below.

[**Table of Contents**](#TableOfContents)

This discussion is not a complete description of all tax considerations that may be relevant to particular investors in light of their individual circumstances or investors subject to special tax rules, such as:

● broker or dealers in securities or currencies;

● dealers or traders in securities that elect to use a mark-to-market method of accounting for securities holdings;

● banks or certain financial institutions;

● insurance companies;

● tax-exempt organizations;

● individual retirement accounts and other tax deferred accounts;

● partnerships or other entities treated as partnerships or other pass-through entities for U.S. federal income tax purposes or persons holding ADSs or ordinary shares through any such entities;

● regulated investments companies or real estate investment trusts;

● persons that hold ADSs or ordinary shares as part of a hedge, straddle, constructive sale, conversion transaction or other integrated investment;

● persons whose functional currency for tax purposes is not the U.S. dollar;

● U.S. expatriates;

● persons that are resident or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States;

● persons who acquired the ADSs or ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;

● persons liable for alternative minimum tax;

● persons holding ADSs or ordinary shares in connection with a trade or business outside the United States; or

● persons that own or are deemed to own 10% or more of (i) the total combined voting power of all classes of our voting stock or (ii) the total value of all classes of our stock (including ADSs and ordinary shares).

Prospective investors are urged to consult their own tax advisor concerning the particular U.S. federal income tax consequences to them of the ownership and disposition of the ADSs and ordinary shares, as well as the consequences to them arising under the laws of any other taxing jurisdictions.

For purposes of the U.S. federal income tax discussion below, a "U.S. Holder" is a beneficial owner of ADSs or ordinary shares who or that is:

● An individual citizen or resident of the United States for U.S. federal income tax purposes;

● a corporation, or other entity classified as a corporation, that was created or organized in or under the laws of the United States or any state thereof or the District of Columbia;

● an estate the income of which is subject to U.S. federal income tax regardless of its source; or

● a trust if (i) a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii) the trust has a valid election in effect to be treated as a U.S. person.

[**Table of Contents**](#TableOfContents)

For U.S. federal income tax purposes, income earned through an entity or arrangement classified as a partnership for U.S. federal income tax purposes is attributed to its owners. Accordingly, if an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds the ADSs or ordinary shares, the tax treatment of a partner in such a partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding our ADSs or ordinary shares and their partners are urged to consult their tax advisors regarding the U.S. federal income tax consequences to them of an investment in ADSs or ordinary shares.

If a U.S. Holder holds ADSs, for U.S. federal income tax purposes, the U.S. Holder generally will be treated as the owner of the underlying ordinary shares that are represented by such ADSs. Accordingly, exchanges of ADSs for underlying ordinary shares represented by such ADSs will not be subject to U.S. federal income tax.

**Taxation of distributions on ADSs and ordinary shares**

The following discussion is subject to the discussion under "Passive Foreign Investment Company" below. If we make cash distributions and you are a U.S. Holder, the gross amount of any distributions with respect to your ADSs and ordinary shares (including the amount of any taxes withheld therefrom) will be includible in your gross income on the day you actually or constructively receive such income as dividend income if the distributions are made from our current or accumulated earnings and profits, determined under U.S. federal income tax principles. We do not intend to calculate our earnings and profits according to U.S. federal income tax principles. Thus, you should expect that distributions on the ADSs and ordinary shares, if any, will generally be treated as dividend income for U.S. federal income tax purposes. Dividends received on the ADSs or ordinary shares will not be eligible for the dividends received deduction allowed to corporations.

With respect to non-corporate U.S. Holders, certain dividends received from a qualified foreign corporation may be subject to reduced tax rates. A non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or in the preceding taxable year) generally will be treated as a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States that includes an exchange of information program or (ii) with respect to any dividend it pays on stock which is readily tradable on an established securities market in the United States. Since we do not expect our ordinary shares to be listed on an established securities market, we do not believe that dividends we pay on our ordinary shares that are not represented by ADSs will meet the conditions required for the reduced tax rate. There can be no assurance that the ADSs will be considered readily tradable on an established securities market in later years. Non-corporate U.S. Holders of the ADSs that do not meet a minimum holding period requirement and certain other requirements will not be eligible for the reduced tax rate with respect to our dividends regardless of our status as a qualified foreign corporation. In the event that we are deemed to be a PRC resident enterprise under PRC tax law (see "Taxation—People's Republic of China taxation), we may be eligible for the benefits of the Treaty. Dividends we pay on the ADSs or ordinary shares to non-corporate U.S. Holders during the course of a taxable year during which we are eligible for such benefits would be eligible for the reduced tax rate, in the case of ordinary shares regardless of whether they are represented by the ADSs. You should consult your own tax advisor regarding the availability of the reduced tax rate for dividends paid with respect to the ADSs and ordinary shares.

For U.S. foreign tax credit purposes, dividends we pay on the ADSs or ordinary shares generally will be treated as income from foreign sources and generally will constitute passive category income. In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, a U.S. Holder may be subject to PRC withholding taxes on dividends paid on our ADSs or ordinary shares (see "—Taxation—People's Republic of China taxation"). For U.S. federal income tax purposes, the amount of the dividend income will include any amounts withheld in respect of PRC withholding tax. Depending on your individual facts and circumstances, you may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of foreign withholding taxes (to the extent that such withholding taxes are not refundable under the Treaty) that may be imposed on dividends received on the ADSs or ordinary shares. In lieu of claiming a credit, you may elect to deduct such PRC taxes in computing taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. You should consult your own tax advisors as to your ability, and the various limitations on your ability, to claim foreign tax credits in connection with the receipt of dividends.

[**Table of Contents**](#TableOfContents)

**Sales and other dispositions of ADSs or ordinary shares**

The following discussion is subject to the discussion under "Passive Foreign Investment Company" below. If you are a U.S. Holder, when you sell or otherwise dispose of ADSs or ordinary shares, you will recognize capital gain or loss in an amount equal to the difference between the amount realized on the sale or other disposition and your adjusted tax basis in the ADSs or ordinary shares. Your adjusted tax basis will generally be equal the amount you paid for the ADSs or ordinary shares. Any gain or loss you recognize will generally be long-term capital gain or loss if your holding period in the ADSs or ordinary shares is more than one year at the time of disposition. If you are a non-corporate U.S. Holder, including an individual, any such long-term capital gain will generally be eligible for a reduced rate of taxation. The deductibility of a capital loss is subject to limitations.

Gains from dispositions of the ADSs or ordinary shares may be subject to PRC tax if such gains are deemed as income derived from sources within Mainland China for PRC tax purposes (see "Taxation— People's Republic of China taxation). In that case, a U.S. Holder's amount realized would include the gross amount of the proceeds of the sale or disposition before deduction of the PRC tax. Any gain generally would constitute U.S. source income for foreign tax credit limitation purposes, which would generally limit the availability of foreign tax credits. However, in the event we are deemed to be a PRC resident enterprise, a U.S. Holder that is eligible for the benefits of the Treaty may be able to elect to treat its gain as foreign source gain for foreign tax credit purposes. If a U.S. Holder is not eligible for the benefits of the Treaty or fails to make the election to treat any gain as foreign source, then such U.S. Holder may not be able to use the foreign tax credit arising from any PRC tax imposed on the disposition of the ADSs or ordinary shares unless such credit can be applied (subject to applicable limitations) against United States federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). You should consult your own tax advisors regarding your eligibility for benefits under the Treaty and the creditability of any PRC tax on disposition gains in your particular circumstances.

**Passive foreign investment company**

If we were classified as a passive foreign investment company or "PFIC" in any taxable year in which you hold the ADSs or ordinary shares, as a U.S. Holder, you would generally be subject to adverse U.S. federal income tax consequences, in the form of increased tax liabilities (unless certain elections described below are timely made) and special U.S. tax reporting requirements.

In general, we will be classified as a PFIC for any taxable year if either (i) at least 75% of our gross income for the taxable year is passive income or (ii) at least 50% of the value of our assets (based on a quarterly value of the assets during the taxable year) is attributable to assets that produce or are held for the production of passive income (the "asset test"). For purposes of making the PFIC determination, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the gross income of any other corporation of which we are, directly or indirectly, a 25% or greater shareholder (by value). For purposes of the asset test, any cash and cash invested in short-term, interest bearing, debt instruments, or bank deposits that are readily convertible into cash will generally count as producing passive income or held for the production of passive income.

Based the composition of our assets and income, including goodwill, which is based on the price of ADSs, we do not expect to be classified as a PFIC for the taxable year ending December 31, 2024. However, there can be no assurance that we will not be a PFIC for the current taxable year. In addition, there can be no assurance that we will not be a PFIC for any future taxable year. PFIC status is a factual determination that tested each taxable year and will depend on the composition of our assets and income in each such taxable year. In particular, in determining the average percentage value of our gross assets, the aggregate value of our assets will generally be deemed to be equal to our market capitalization (the sum of the aggregate value of our outstanding equity) plus our liabilities. Accordingly, we could become a PFIC if our market capitalization were to decrease significantly while we hold substantial cash, cash equivalents or other assets that produce or are held for the production of passive income. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income and assets as non-passive or our valuation of our tangible and intangible assets, which could result in a determination that we were a PFIC for the current or subsequent taxable years.

If we were a PFIC for any taxable year during which you held ADSs or ordinary shares, certain adverse U.S. federal income tax rules would apply. You would generally be subject to additional taxes and interest charges on certain "excess distributions" we make and on any gain realized on the disposition or deemed disposition of your ADSs or ordinary shares, regardless of whether we continue to be a PFIC in the year in which you receive an "excess distribution" or dispose of or are deemed to have disposed of, your ADSs or ordinary shares. Distributions in respect of your ADSs or ordinary shares during a taxable year would generally constitute "excess distributions" if, in the aggregate, they exceed 125% of the average amount of distributions with respect to your ADSs or ordinary shares over the three preceding taxable years or, if shorter, the portion of your holding period before such taxable year.

[**Table of Contents**](#TableOfContents)

To compute the tax on "excess distributions" or any gain, (i) the "excess distribution" or the gain would be allocated ratably to each day in your holding period, (ii) the amount allocated to the current year and any tax year prior to the first taxable year in which we were a PFIC would be taxed as ordinary income in the current year, (iii) the amount allocated to other taxable years would be taxable at the highest applicable marginal rate in effect for that year, and (iv) an interest charge at the rate for underpayment of taxes for any period described under (iii) above would be imposed on the resulting tax liability on the portion of the "excess distribution" or gain that is allocated to such period. In addition, if we were a PFIC, no distribution that you receive from us would qualify for taxation at the reduced tax rate discussed in the "—Dividends on ADSs and Ordinary Shares" section above in the taxable year in which such distribution is made or in the preceding taxable year.

Under certain attribution rules, if we were a PFIC, you would be deemed to own your proportionate share of lower-tier PFICs, and would be subject to U.S. federal income tax on (i) a distribution on the shares of a lower-tier PFIC and (ii) a disposition of shares of a lower-tier PFIC, both as if you directly held the shares of such lower-tier PFIC. Under the PFIC rules, if we were considered a PFIC at any time that you hold ADSs or ordinary shares, we would continue to be treated as a PFIC with respect to your ADSs or ordinary shares unless we have ceased to be a PFIC and you have made a "deemed sale" election under the PFIC rules.

Alternatively, if we were a PFIC and if the ADSs were "regularly traded" while they were listed on the Nasdaq, a U.S. Holder could make a mark-to-market election that would result in tax treatment different from the general tax treatment for PFICs described in the preceding paragraph with respect to its taxable year that ended before the taxable year in which our ADSs were delisted from the Nasdaq. U.S. Holders should note that the OTCQX Best Market, on which the prices of our ADSs are currently quoted, is not a "qualified exchange" for purposes of the mark-to-market rules. Therefore, a mark-to-market treatment of the ADSs is not available for as long as the ADSs continue to be delisted from, or not regularly traded on, the Nasdaq or any other qualified stock exchange.

If we were a PFIC in any year, you would generally be able to avoid the "excess distribution" rules described above by making a timely so-called "mark-to-market" election with respect to your ADSs provided they are "marketable." The ADSs will be "marketable" as long as they remain regularly traded on a national securities exchange, such as the Nasdaq Capital Market. If you made this election in a timely fashion, you would generally recognize as ordinary income or ordinary loss the difference between the fair market value of your ADSs as of the close of any taxable year and your adjusted tax basis in such ADSs. Any income resulting from this election would generally be taxed at ordinary income rates. Any ordinary losses would be deductible, but only to the extent of the net amount of previously included income as a result of the mark-to-market election, if any. Your basis in the ADSs or ordinary shares would be adjusted to reflect any such income or loss.

U.S. Holders that made (or wish to make) a mark-to-market election with respect to a prior taxable year for which the election may have been available should consult their tax advisers regarding the availability and advisability of making the election in their particular circumstances and the effect the election would have on their income inclusion with respect to, and the tax basis in, their ADSs. You should also note that the mark-to-market election cannot be made with respect to Lower-tier PFICs, if any, or with respect to our ordinary shares. If you make a mark-to-market election with respect to the ADSs, but for a later taxable year either the ADSs no longer constitute "marketable stock" or we cease being a PFIC, you will not be subject to the mark-to-market rules described above for such taxable year.

The PFIC rules provide for a separate election, referred to as a qualified electing fund election, which, if available, results in a tax treatment different (and generally less adverse than) the general PFIC tax treatment described above. That election, however, will not be available to you as we do not intend to provide the information you would need to make or maintain that election.

If you own the ADSs or ordinary shares during any taxable year that we are a PFIC, you will generally be required to file an annual report containing such information as the United States Treasury Department may require. You should consult with your own tax advisor concerning the U.S. federal income tax consequences of holding and disposing of the ADSs or ordinary shares if we are or become classified as a PFIC.

**U.S. information reporting and backup withholding rules**

Dividend payments with respect to the ADSs and ordinary shares and the proceeds received on the sale or other disposition of ADSs and ordinary shares may be subject to information reporting to the IRS and to backup withholding. Backup withholding will not apply, however, if (i) a U.S. Holder is an exempt recipient, or if (ii) the U.S. Holder provides a taxpayer identification number, certifying that the U.S. Holder is not subject to backup withholding. U.S. Holders who are required to establish their exempt status may be required to provide such certification on IRS Form W-9. Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules from a payment to a U.S. Holder will be refunded or credited against such U.S. Holder's U.S. federal income tax liability, provided that the required information is timely provided to the IRS.

[**Table of Contents**](#TableOfContents)

Certain U.S. Holders who hold "specific foreign financial assets", including stock of a non-U.S. corporation that is not held in an account maintained by a U.S. "financial institution" may be required to attach to their tax returns for the year certain specified information. A U.S. Holder who fails to timely furnish the required information may be subject to a penalty. You are advised to consult with its own tax advisor regarding the application of the U.S. information reporting and backup withholding rules to your particular circumstances.

**PROSPECTIVE INVESTORS OF OUR ADSS AND ORDINARY SHARES SHOULD CONSULT WITH THEIR OWN TAX ADVISOR REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES RESULTING FROM OWNING OR DISPOSING OUR ADSS AND ORDINARY SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF THE TAX LAWS OF ANY STATE, LOCAL OR NON-US JURISDICTION AND INCLUDING ESTATE, GIFT AND INHERITANCE LAWS.**

**10. F. Dividends and Paying Agents**

Not Applicable.

**10. G. Statement by Experts**

Not Applicable.

**10. H. Documents on Display**

We previously filed with the SEC our registration statement on Form F-1 (Registration No. 333-234022), as amended, including the prospectus contained therein, to register our ordinary shares in relation to our initial public offering. We have also filed with the SEC a related registration statement on F-6 (Registration No. 333-234191) to register the ADSs.

We are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form 20-F within four months after the end of each fiscal year, which is December 31. Copies of reports and other information, when so filed, may be inspected without charge and may be obtained at prescribed rates at the public reference facilities maintained by the Securities and Exchange Commission at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. The public may obtain information regarding the Washington, D.C. Public Reference Room by calling the Commission at 1-800-SEC-0330. The SEC also maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and officers, directors and principal shareholders are exempt from the short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

We will furnish Deutsche Bank Trust Company Americas, the depositary of our ADSs, with our annual reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with IFRS as issued by the IASB, and all notices of shareholders' meetings and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our request, will mail to all record holders of ADSs the information contained in any notice of a shareholders' meeting received by the depositary from us.

We will post this annual report on our website *https://ir.aihgroup.net*. In addition, we will provide hardcopies of our annual report to shareholders, including ADS holders, free of charge upon request.

**10. I. Subsidiary Information**

Not applicable.

**10. J. Annual Report to Security Holders**

Not applicable.

[**Table of Contents**](#TableOfContents)

**Item 11. Quantitative and Qualitative Disclosures About Market Risk**

In the normal course of business, we are exposed to various types of financial risks as described below.

***Foreign exchange risk***

 

Substantially all of our transactions are denominated in renminbi. As a result, we do not believe we are exposed to significant foreign exchange rate risks. However, as the proceeds of our initial public offering are denominated in U.S. dollars, any appreciation of the renminbi against the U.S. dollar will reduce the amount of proceeds we receive in terms of renminbi. On the other hand, a depreciation of the renminbi would adversely affect the value, translated or converted into U.S. dollars, of our net assets, earnings and any dividends we declare. We do not engage in hedging activities to manage such exchange rate risk.

With all other variables held constant, if the average exchange rate of RMB against US$ had strengthened or weakened by 5%, our post-tax results would increase or decrease by RMB4,000 (2023: RMB2,000).

 ****

**Credit risk**

We have no significant concentrations of credit risk. The carrying amounts of pledged bank deposits, cash at banks, trade receivables, deposits and other receivables and amounts due from related companies included in the consolidated statements of financial position represent our maximum exposure to credit risk in relation to our financial assets. Our objective is to seek continual revenue growth while minimizing losses incurred due to increased credit risk exposure. The majority of our pledged deposits and cash at banks are deposited in major reputable financial institutions located in the PRC. Most of our revenue is settled by cash or credit cards. Our trade receivables are mainly due from financial institutions with sound financial standing. There has been no history of default in relation to these external parties. We do not expect any losses arising from non-performance by these counterparties.

**Interest rate risk**

Our interest rate risk relates primarily to our bank deposits and bank borrowings. Bank borrowings issued at variable rates expose us to cash flow interest rate risk. Bank borrowings issued at fixed rates expose us to fair value interest rate risk. We have not entered into interest rate swaps to hedge against our exposure to changes in fair values of our borrowings. We will, however, continue to monitor interest rate risk exposure and will consider hedging significant interest rate risk exposure should the need arise.

In 2021, interest rates on borrowings had been 10 basis points higher/ lower with all other variables held constant, our post-tax results for the year would have been RMB48,070 lower/higher, mainly as a result of higher/lower interest expenses on floating rate borrowings. In 2022, 2023, 2024 and 2025, the interest rate risk was effectively mitigated through a contractual agreement with banks that secured a fixed interest rate.

**Liquidity risk**

Our policy is to regularly monitor current and expected liquidity requirements to ensure that we maintain sufficient cash and cash equivalents and adequate amounts of committed credit facilities to meet our liquidity requirements in the short and long term. Our primary cash requirements have been the payment for operating expenses and we have historically met our working capital requirements primarily from cash generated from operations.

**Price risk**

We are exposed to price risk in respect of our convertible redeemable preferred shares, exchangeable note and convertible note carried at fair value with changes in fair value recognized in profit or loss. The fair value of the convertible redeemable preferred shares and exchangeable note is affected by changes in our market value. As the convertible redeemable preferred shares and exchangeable note were converted into ordinary shares immediately prior to the completion of our initial public offering, we currently are not exposed to this risk.

[**Table of Contents**](#TableOfContents)

**Item 12. Description of Securities Other Than Equity Securities**

**12. A. Debt Securities**

Not applicable.

**12. B. Warrants and Rights**

Not applicable.

**12. C. Other Securities**

Not applicable.

**12. D. American Depositary Shares**

Deutsche Bank Trust Company Americas, an indirect wholly – owned subsidiary of Deutsche Bank A.G., with its principal office at 60 Wall Street, New York, NY 10005, United States of America, acts in its capacity as the depositary bank to our ADR program since October 2019.

As an ADS holder, you will be required to pay the following service fees to the depositary bank and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs):

---

| | | |
|:---|:---|:---|
| **Service** | **Service** | **Fees** |
| ● | To any person to which ADSs are issued or to any person to which a distribution is made in respect of ADS distributions pursuant to stock dividends or other free distributions of stock, bonus distributions, stock splits or other distributions (except where converted to cash) | Up to US$0.05 per ADS issued |
| ● | Cancellation of ADSs, including the case of termination of the deposit agreement | Up to US$0.05 per ADS cancelled |
| ● | Distribution of cash dividends | Up to US$0.05 per ADS held |
| ● | Distribution of cash entitlements (other than cash dividends) and/or cash proceeds from the sale of rights, securities and other entitlements | Up to US$0.05 per ADS held |
| ● | Distribution of ADSs pursuant to exercise of rights | Up to US$0.05 per ADS held |
| ● | Distribution of securities other than ADSs or rights to purchase additional ADSs | Up to US$0.05 per ADS held |
| ● | Depositary services | Up to US$0.05 per ADS held on the applicable record date(s) established by the depositary bank |

---

As an ADS holder, you will also be responsible to pay certain fees and expenses incurred by the depositary bank and certain taxes and governmental charges (in addition to any applicable fees, expenses, taxes and other governmental charges payable on the deposited securities represented by any of your ADSs) such as:

● Fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the ordinary shares in the Cayman Islands (i.e., upon deposit and withdrawal of ordinary shares).

● Expenses incurred for converting foreign currency into U.S. dollars.

[**Table of Contents**](#TableOfContents)

● Expenses for cable, telex and fax transmissions and for delivery of securities.

● Taxes and duties upon the transfer of securities, including any applicable stamp duties, any stock transfer charges or withholding taxes (i.e., when ordinary shares are deposited or withdrawn from deposit).

● Fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.

● Fees and expenses incurred in connection with complying with exchange control regulations and other regulatory requirements applicable to ordinary shares, deposited securities, ADSs and ADRs.

● Any applicable fees and penalties thereon.

The depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary bank by the brokers (on behalf of their clients) receiving the newly issued ADSs from the depositary bank and by the brokers (on behalf of their clients) delivering the ADSs to the depositary bank for cancellation. The brokers in turn charge these fees to their clients. Depositary fees payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as of the applicable ADS record date.

The depositary fees payable for cash distributions are generally deducted from the cash being distributed or by selling a portion of distributable property to pay the fees. In the case of distributions other than cash (i.e., share dividends, rights), the depositary bank charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in direct registration), the depositary bank sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary bank generally collects its fees through the systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients' ADSs in DTC accounts in turn charge their clients' accounts the amount of the fees paid to the depositary banks.

In the event of refusal to pay the depositary fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.

The depositary may make payments to us or reimburse us for certain costs and expenses, by making available a portion of the ADS fees collected in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.

[**Table of Contents**](#TableOfContents)

**PART II.**

**Item 13. Defaults, Dividend Arrearages and Delinquencies**

None.

**Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds**

**14. A. — 14.D. Material Modifications to the Rights of Security Holders**

See "Item 10. Additional Information" for a description of the rights of shareholders, which remain unchanged.

**14. E. Use of Proceeds**

The following "Use of Proceeds" information relates to the registration statement on Form F-1 (File No. 333-234022), as amended, including the annual report contained therein, which registered 7,500,000 ordinary shares represented by 2,500,000 ADSs and was declared effective by the SEC on October 24, 2019, for our initial public offering, which closed on October 29, 2019. Cantor Fitzgerald & Co., Haitong International Securities Company Limited and Prime Number Capital, LLC were the representatives of the underwriters.

For the period from October 24, 2019, the date that the registration statement on Form F-1 was declared effective by the SEC, to December 31, 2019, the total expenses incurred for our company's account in connection with our initial public offering was approximately US$6.5 million, which included US$2.1 million in underwriting discounts and commissions for the initial public offering and approximately US$4.4 million in other costs and expenses for our initial public offering. None of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity securities or our affiliates. None of the net proceeds from the initial public offering were paid, directly or indirectly, to any of our directors or officers or their associates, persons owning 10% or more of our equity securities or our affiliates.

For the period from October 24, 2019, the date that the registration statement on Form F-1 was declared effective by the SEC, to December 31, 2020, we used approximately US$28.2 million of the proceeds received from the initial public offering for purposes including redemption of certain convertible note, working capital, strategic acquisitions, establishment of new treatment centers and facility upgrades.

As a result, as of 2021, we used approximately all of the proceeds received from the initial public offering for the purposes mentioned.

**Item 15. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our executive co-chairman and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report, as required by Rule 13a-15(b) under the Exchange Act.

Based upon that evaluation, our management, with the participation of our executive co-chairman and chief financial officer, has concluded that, due to the outstanding material weakness described below, as of December 31, 2025, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our executive co-chairman and chief financial officer, to allow timely decisions regarding required disclosure.

**Management's Annual Report on Internal Control over Financial Reporting**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act of 1934. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with International Financial Reporting Standards. Because of its inherent limitations, a system of internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

[**Table of Contents**](#TableOfContents)

**Internal Control over Financial Reporting**

Our management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, it used the criteria established within the Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013 framework). Based on this assessment, our management has concluded that, as of December 31, 2025, our internal control over financial reporting was effective. We did not identify any material weaknesses in our internal control over financial reporting during the reporting period.

As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

The Company has maintained robust control procedures with respect to the evaluation and accounting of complex non-routine transactions. We have continued to sustain and enhance the internal control measures previously implemented, including the application of internal accounting and internal control guidance covering complex non-routine transactions, and the execution of ongoing IFRS training programs for our accounting and finance personnel.

We have consistently adopted a series of measures to further improve and optimize our internal control over financial reporting. These measures include retaining experienced senior financial officers with in-depth knowledge and extensive practical experience in complex transaction accounting, providing regular and sufficient financial reporting and IFRS professional training for finance team members, and conducting ongoing review and refinement of key financial reporting controls. The Company remains fully committed to maintaining a sound and effective internal control environment and continuously optimizing our financial reporting control system.

In the fiscal years 2023, 2024 and 2025, we have not identified any material weaknesses in our internal control over financial reporting.

We cease to be an "emerging growth company" as of December 31, 2024 because we have exceeded the fifth fiscal year post-IPO as such term is defined in the JOBS Act, but we remain classified as a "non-accelerated filer" based on our current public float and revenue levels, thereby benefiting from certain reduced reporting requirements, including exemption from the auditor attestation requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 for internal control over financial reporting.

**Attestation Report of the Registered Public Accounting Firm**

Since we are an "non-accelerated filer" as defined under the Securities Act, our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting as we are exempt from the requirement to comply with the auditor attestation requirements that our independent registered public accounting firm attest to and report on the effectiveness of our internal control structure and procedures for financial reporting.

**Changes in Internal Control over Financial Reporting**

Other than as described above, no changes in our internal controls over financial reporting occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

**ITEM 16. [Reserved]**

**Item 16. A. Audit Committee Financial Expert**

Our board of directors has determined that Ms. Li Yanyun, an independent director and chair of our audit committee, qualifies as an "audit committee financial expert" as defined in Item 16A of Form 20-F and satisfies the "independence" requirements of Rule 10A-3 under the Exchange Act.

[**Table of Contents**](#TableOfContents)

**Item 16. B. Code of Ethics**

Our board of directors has adopted a code of ethics that applies to all directors, officers and employees of the Company, whether they work for the Company on a full-time, part-time, consultative or temporary basis. Certain provisions thereof apply specifically to our chief executive officer, chief financial officer, other chief senior officers, senior finance officer, controller, vice presidents and any other persons who perform similar functions for us*.*** We have posted a copy of our code of business conduct and ethics on our website at *https://ir.aihgroup.net*.

**Item 16. C. Principal Accountant Fees and Services**

The following table sets forth the aggregate fees by the categories specified below in connection with certain professional services rendered by Union Power HK CPA Limited and Onestop Assurance PAC, our independent registered public accounting firms, for the periods indicated. We may incur minor miscellaneous fees to our auditors during the periods other than the fees indicated below.

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| Audit fees<sup>(1)</sup> |  |  |  |
| Onestop Assurance PAC | 2627 | 2228 | 1958 |
|  | 2627 | 2228 | 1958 |

---

(1) "Audit
fees" means the aggregate fees billed for professional services rendered by our principal auditors for the audit of our annual
financial statements and assistance with review of documents filed with the SEC and other statutory and regulatory filings.

The policy of our audit committee is to pre-approve all auditing services and all non-audit services permitted to be performed by our independent registered public accounting firms, including audit services as described above, other than those for de minimus services which are approved by our audit committee prior to the completion of the audit.

**Item 16. D. Exemptions from the Listing Standards for Audit Committees**

Not applicable.

**Item 16. E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers**

In October 2020, our board of directors announced a share repurchase program pursuant to which we would repurchase up to US$6.0 million worth of our ADSs. 45,000 ADSs were repurchased in 2020, and no ADS was repurchased from January 1, 2021 up to December 31, 2025 in the open market pursuant to the applicable share repurchase programs. As of December 31, 2025, we have not retired the treasure shares of 45,000 ADSs.

**Item 16. F. Change in Registrant's Certifying Accountant**

We engaged Union Power HK CPA Limited ("Union Power") on January 28, 2022 to audit our consolidated financial statements for the two years ended December 31, 2021 and 2022. We received the formal resignation notice dated December 13, 2023 from Union Power in December 2023. Effective on December 12, 2023, we appointed Onestop Assurance PAC ("Onestop") as our independent registered public accounting firm for the audit of our financial results of the three fiscal years ended December 31, 2023. We did not consult Onestop on the application of accounting principles to any specified transaction or any matter that was the subject of any disagreement or reportable event, as such terms are described in Item 16F(a) of Form 20-F. The change was approved by our audit committee and board of directors.

Union Power's reports on our consolidated financial statements as of and for the years ended December 31, 2021 and 2022 did not contain any adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

[**Table of Contents**](#TableOfContents)

During the fiscal years ended December 31, 2021 and 2022 and the subsequent interim period through December 12, 2023, there were no "disagreements" (as described under Item 16F(a)(1)(iv) of Form 20-F and the related instructions thereto) between the Company and Union Power on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, that, if not resolved to the satisfaction of Union Power, would have caused them to make reference to the subject matter of the disagreement in connection with its audit reports on our consolidated financial statements for the two fiscal years ended December 31, 2021 and 2022.

We provided a copy of this disclosure to Union Power and requested that Union Power furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made above, and if not, stating the respects in which it does not agree. A copy of Union Power's letter dated December 13, 2023 is attached as Exhibit 16.1 herein.

On December 8, 2025, Onestop confirmed its continuation as our independent registered public accounting firm for the audit of our financial results for the financial year ending December 31, 2025.

**Item 16. G. Corporate Governance**

As a foreign private issuer, we are permitted to take advantage of certain corporate governance requirements under the OTC Market continued eligibility criteria and ongoing disclosure obligations that allow us to follow Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law had no corporate governance regime which prescribes specific corporate governance standards as of the date of this annual report. To the extent we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.

**Item 16. H. Mine Safety Disclosure**

Not applicable.

**Item 16. I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

Not applicable.

**ITEM 16J. Insider Trading Policies**

We have internally established insider trading policies and procedures to provide guidance on the purchases, sales, and other dispositions of our securities by our directors, officers, and employees, with the goal of promoting compliance with applicable insider trading laws, rules, regulations, and any applicable listing standards. For details on our insider trading policies, please refer to our Code of Business Conduct and Ethics and other corporate governance documents, which are accessible on our website at *https://ir.aihgroup.net/corporate-governance/governance-documents/*.

**ITEM 16K. Cybersecurity** 

**Cybersecurity Risk Management and Strategy**

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.

Our cybersecurity risk management aligns with and shares common methodologies and reporting channels with our broader risk management.

Key features of our cybersecurity risk management program include, but are not limited to, the following:

● risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise IT Systems environment;

[**Table of Contents**](#TableOfContents)

● a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;

● processes for monitoring for vulnerabilities of our technology which includes code review (as necessary), testing and analysis of software across the software lifecycle;

● the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;

● physical and technical security measures, including encryption, authentication, and access controls;

● cybersecurity awareness training and internal cybersecurity resources for our employees;

● a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and

● a third-party risk management process for service providers, suppliers, and vendors who access our system and information.

We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See "Item 3. Key Information—D. Risk Factors — Risks Relating to Our Business — Cybersecurity incidents, including data security breaches or computer viruses, could harm our business by disrupting our delivery of services, damaging our reputation or exposing us to liability."

**Cybersecurity Governance**

Our board of directors considers cybersecurity risk as part of its risk oversight function and undertakes overall risk management, including oversight of cybersecurity and other information technology risks.

Our board of directors receives quarterly reports from management on our cybersecurity risks. In addition, management updates our board of directors, as necessary, regarding any significant cybersecurity incidents. Our board of directors also receives briefings from management on our cyber risk management program.

Our management has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our management and the security team, including our chief financial officer, Mr. Wu Guanhua and IT director, Mr. Chen Wenhui, are responsible for assessing and managing our material risks from cybersecurity threats. Our team's experience includes extensive backgrounds in cybersecurity strategy, risk assessment, incident response, and regulatory compliance. Additionally, they possess deep expertise in network security architecture, penetration testing, threat intelligence analysis, and security operations center management. They also have experience in ensuring the security of financial data.

Our management oversees efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our IT Systems environment.

[**Table of Contents**](#TableOfContents)

**PART III.**

**Item 17. Financial Statements**

We have elected to provide financial statements pursuant to Item 18.

**Item 18. Financial Statements**

The consolidated financial statements of Aesthetic Medical International Holdings Group Limited and its subsidiaries are included at the end of this annual report.

**Item 19. Exhibits**

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **1.1** | **[Fourth amended and restated memorandum and articles of association of the registrant, as currently in effect as amended, initially filed with the SEC on September 30, 2019 and as further amended by a special resolution passed at the annual general meeting of the Company held on 8 September 2022 (incorporated herein by reference to Exhibit 1.1 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 25, 2024)](http://www.sec.gov/Archives/edgar/data/1757143/000110465923048414/aih-20221231xex1d1.htm)** |
| **2.1** | **[Deposit Agreement, among the Registrant, the depositary and holder of the American Depositary Receipts (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form S-8 (File No. 333-237835) filed with the SEC on April 24, 2020)](https://www.sec.gov/Archives/edgar/data/1757143/000110465920051042/a20-16331_1ex4d3.htm)** |
| **2.2** | **[Form of registrant's specimen American depositary receipt (included in Exhibit 2.1)](https://www.sec.gov/Archives/edgar/data/1757143/000110465920051042/a20-16331_1ex4d3.htm)** |
| **2.3** | **[Registrant's specimen certificate for its ordinary shares (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-4_3.htm)** |
| **2.4** | **[Further amended and restated shareholder and note holder agreement between the registrant and other parties named therein dated December 31, 2018 (incorporated herein by reference to Exhibit 4.4 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-4_4.htm)** |
| **2.5** | **[Form of letter agreement in relation to the exchangeable notes between the holder and issuers of the exchangeable notes dated September 30, 2019 (incorporated herein by reference to Exhibit 4.6 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-4_6.htm)** |
| **2.6** | **[Form of the exchangeable notes between the holder and issuers of the exchangeable notes (incorporated herein by reference to Exhibit 4.7 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-4_7.htm)** |
| **2.7** | **[Convertible note dated December 8, 2016 between the registrant and Peak Asia Investment Holdings V Limited (incorporated herein by reference to Exhibit 4.5 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-4_5.htm)** |
| **2.8** | **[Description of Securities (incorporated herein by reference to Exhibit 2.8 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex2d8.htm#Exhibit2_8_104324)** |
| **4.1** | **[Form of indemnification agreement between the registrant and directors and officers (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_1.htm)** |
| **4.2** | **[Form of employment agreement between the registrant and officers (incorporated herein by reference to Exhibit 10.2 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_2.htm)** |
| **4.3** | **[Share incentive plan of Aesthetic Medical International Holdings Group Limited (incorporated herein by reference to Exhibit 10.55 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_55.htm)** |
| **4.4** | **[2019 performance incentive plan of Aesthetic Medical International Holdings Group Limited (incorporated herein by reference to Exhibit 10.2 to the registration statement on Form S-8 (File No. 333-237835) filed with the SEC on April 24, 2020)](https://www.sec.gov/Archives/edgar/data/1757143/000110465920051042/a20-16331_1ex10d2.htm)** |
| **4.5** | **[English translation of loan agreement dated November 5, 2018 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.7 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_7.htm)** |
| **4.6** | **[English translation of economic interest transfer agreement dated November 5, 2018 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Yantai Pengai Jiayan Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.8 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_8.htm)** |
| **4.7** | **[English translation of exclusive option agreement dated November 5, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Yantai Pengai Jiayan Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.9 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_9.htm)** |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **4.8** | **[English translation of equity interest pledge agreement dated November 5, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Yantai Pengai Jiayan Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.10 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_10.htm)** |
| **4.9** | **[English translation of power of attorney dated November 5, 2018 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Yantai Pengai Jiayan Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.11 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_11.htm)** |
| **4.10** | **[English translation of spousal consent letter dated November 5, 2018 by Ding Wenting (incorporated herein by reference to Exhibit 10.12 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_12.htm)** |
| **4.11** | **[English translation of amended and restated loan agreement dated April 1, 2019 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.13 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_13.htm)** |
| **4.12** | **[English translation of amended and restated economic interest transfer agreement dated April 1, 2019 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Hangzhou Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.14 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_14.htm)** |
| **4.13** | **[English translation of amended and restated exclusive option agreement dated April 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Hangzhou Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.15 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_15.htm)** |
| **4.14** | **[English translation of amended and restated equity interest pledge agreement dated April 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Hangzhou Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.16 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_16.htm)** |
| **4.15** | **[English translation of amended and restated power of attorney dated April 1, 2019 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Hangzhou Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.17 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_17.htm)** |
| **4.16** | **[English translation of amended and restated spousal consent letter dated April 1, 2019 by Ding Wenting (incorporated herein by reference to Exhibit 10.18 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_18.htm)** |
| **4.17** | **[English translation of amended and restated loan agreement dated January 1, 2019 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.19 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_19.htm)** |
| **4.18** | **[English translation of amended and restated economic interest transfer agreement dated January 1, 2019 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Chongqing Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.20 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_20.htm)** |
| **4.19** | **[English translation of amended and restated exclusive option agreement dated January 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Chongqing Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.21 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_21.htm)** |
| **4.20** | **[English translation of amended and restated equity interest pledge agreement dated January 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Chongqing Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.22 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_22.htm)** |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **4.21** | **[English translation of amended and restated power of attorney dated January 1, 2019 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Chongqing Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.23 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_23.htm)** |
| **4.22** | **[English translation of amended and restated spousal consent letter dated January 1, 2019 by Ding Wenting (incorporated herein by reference to Exhibit 10.24 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_24.htm)** |
| **4.23** | **[English translation of amended and restated loan agreement dated March 1, 2019 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.25 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_25.htm)** |
| **4.24** | **[English translation of amended and restated economic interest transfer agreement dated March 1, 2019 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.26 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_26.htm)** |
| **4.25** | **[English translation of amended and restated exclusive option agreement dated March 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.27 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_27.htm)** |
| **4.26** | **[English translation of amended and restated equity interest pledge agreement dated March 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.28 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_28.htm)** |
| **4.27** | **[English translation of amended and restated power of attorney dated March 1, 2019 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.29 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_29.htm)** |
| **4.28** | **[English translation of amended and restated spousal consent letter dated March 1, 2019 by Ding Wenting (incorporated herein by reference to Exhibit 10.30 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_30.htm)** |
| **4.29** | **[English translation of loan agreement dated September 29, 2018 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.31 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_31.htm)** |
| **4.30** | **[English translation of economic interest transfer agreement dated September 29, 2018 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Shanghai Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.32 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_32.htm)** |
| **4.31** | **[English translation of exclusive option agreement dated September 29, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Shanghai Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.33 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_33.htm)** |
| **4.32** | **[English translation of equity interest pledge agreement dated September 29, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Shanghai Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.34 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_34.htm)** |
| **4.33** | **[English translation of power of attorney dated September 29, 2018 by Dr. Zhou Pengwu and Shenzhen Pengai Hospital Investment Management Co., Ltd. and Shanghai Pengai Aesthetic Medical Clinic Co., Ltd. (incorporated herein by reference to Exhibit 10.35 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_35.htm)** |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **4.34** | **[English translation of spousal consent letter dated September 29, 2018 by Ding Wenting (incorporated herein by reference to Exhibit 10.36 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_36.htm)** |
| **4.35** | **[English translation of loan agreement dated August 10, 2018 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.37 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_37.htm)** |
| **4.36** | **[English translation of economic interest transfer agreement dated August 10, 2018 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Shenzhen Pengai Xiuqi Aesthetic Medical Hospital (incorporated herein by reference to Exhibit 10.38 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_38.htm)** |
| **4.37** | **[English translation of exclusive option agreement dated August 10, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Shenzhen Pengai Xiuqi Aesthetic Medical Hospital (incorporated herein by reference to Exhibit 10.39 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_39.htm)** |
| **4.38** | **[English translation of equity interest pledge agreement dated August 10, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Shenzhen Pengai Xiuqi Aesthetic Medical Hospital (incorporated herein by reference to Exhibit 10.40 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_40.htm)** |
| **4.39** | **[English translation of power of attorney dated August 10, 2018 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Shenzhen Pengai Xiuqi Aesthetic Medical Hospital (incorporated herein by reference to Exhibit 10.41 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_41.htm)** |
| **4.40** | **[English translation of spousal consent letter dated August 10, 2018 by Ding Wenting (incorporated herein by reference to Exhibit 10.42 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_42.htm)** |
| **4.41** | **[English translation of loan agreement dated October 29, 2018 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.43 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_43.htm)** |
| **4.42** | **[English translation of economic interest transfer agreement dated October 29, 2018 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Changsha Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.44 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_44.htm)** |
| **4.43** | **[English translation of exclusive option agreement dated October 29, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Changsha Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.45 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_45.htm)** |
| **4.44** | **[English translation of equity interest pledge agreement dated October 29, 2018 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Changsha Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.46 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_46.htm)** |
| **4.45** | **[English translation of power of attorney dated October 29, 2018 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Changsha Pengai Aesthetic Medical Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.47 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_47.htm)** |
| **4.46** | **[English translation of spousal consent letter dated October 29, 2018 by Ding Wenting (incorporated herein by reference to Exhibit 10.48 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_48.htm)** |
| **4.47** | **[English translation of loan agreement dated January 1, 2019 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 10.49 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_49.htm)** |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **4.48** | **[English translation of economic interest transfer agreement dated January 1, 2019 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Jinan Pengai Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.50 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_50.htm)** |
| **4.49** | **[English translation of exclusive option agreement dated January 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Jinan Pengai Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.51 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_51.htm)** |
| **4.50** | **[English translation of equity interest pledge agreement dated January 1, 2019 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Jinan Pengai Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.52 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_52.htm)** |
| **4.51** | **[English translation of power of attorney dated January 1, 2019 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Jinan Pengai Cosmetic Surgery Hospital Co., Ltd. (incorporated herein by reference to Exhibit 10.53 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_53.htm)** |
| **4.52** | **[English translation of spousal consent letter dated January 1, 2019 by Ding Wenting (incorporated herein by reference to Exhibit 10.54 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005741/a2239805zex-10_54.htm)** |
| **4.53** | **[English translation of the Equity Interest Transfer Agreement between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu dated April 23, 2021 (incorporated herein by reference to Exhibit 4.53 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d53.htm#Exhibit4_53_112852)** |
| **4.54** | **[English translation of loan agreement dated April 23, 2021 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 4.54 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d54.htm#Exhibit4_54_010836)** |
| **4.55** | **[English translation of economic interest transfer agreement dated April 23, 2021 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Beijing Aomei Yixin Investment Consultation Co., Ltd. (incorporated herein by reference to Exhibit 4.55 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d55.htm#Exhibit4_55_121135)** |
| **4.56** | **[English translation of exclusive option agreement dated April 23, 2021 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Beijing Aomei Yixin Investment Consultation Co., Ltd. (incorporated herein by reference to Exhibit 4.56 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d56.htm#Exhibit4_56_023335)** |
| **4.57** | **[English translation of equity interest pledge agreement dated April 23, 2021 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Beijing Aomei Yixin Investment Consultation Co., Ltd. (incorporated herein by reference to Exhibit 4.57 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d57.htm#EXHIBIT4_57_125120)** |
| **4.58** | **[English translation of power of attorney dated April 23, 2021 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Beijing Aomei Yixin Investment Consultation Co., Ltd. (incorporated herein by reference to Exhibit 4.58 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d58.htm#Exhibit4_58_010851)** |
| **4.59** | **[English translation of spousal consent letter dated April 23, 2021 by Ding Wenting (incorporated herein by reference to Exhibit 4.59 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d59.htm#Exhibit4_59_011626)** |
| **4.60** | **[English translation of the Equity Interest Transfer Agreement between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu dated April 23, 2021 (incorporated herein by reference to Exhibit 4.60 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d60.htm#Exhibit4_60_123614)** |
| **4.61** | **[English translation of loan agreement dated April 23, 2021 by and between Shenzhen Pengai Hospital Investment Management Co., Ltd. and Dr. Zhou Pengwu (incorporated herein by reference to Exhibit 4.61 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d61.htm#Exhibit4_61_124720)** |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **Exhibit<br> Number** |  |
| **4.62** | **[English translation of economic interest transfer agreement dated April 23, 2021 by and among Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Jiangsu Liangyan Hospital Management Co., Ltd. (incorporated herein by reference to Exhibit 4.62 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d62.htm#Exhibit4_62_023502)** |
| **4.63** | **[English translation of exclusive option agreement dated April 23, 2021 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Jiangsu Liangyan Hospital Management Co., Ltd. (incorporated herein by reference to Exhibit 4.63 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d63.htm#Exhibit4_63_023608)** |
| **4.64** | **[English translation of equity interest pledge agreement dated April 23, 2021 by and among Shenzhen Pengai Hospital Investment Management Co., Ltd., Dr. Zhou Pengwu and Jiangsu Liangyan Hospital Management Co., Ltd. (incorporated herein by reference to Exhibit 4.64 to the annual report on Form 20-F (File No. 001-39088) filed with the SEC on April 30, 2021).](https://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d64.htm#EXHIBIT4_64_125644)** |
| **4.65** | **[English translation of power of attorney dated April 23, 2021 by Dr. Zhou Pengwu, Shenzhen Pengai Hospital Investment Management Co., Ltd. and Jiangsu Liangyan Hospital Management Co., Ltd.](http://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d65.htm#Exhibit4_65_011714)** |
| **4.66** | **[English translation of spousal consent letter dated April 23, 2021 by Ding Wenting](http://www.sec.gov/Archives/edgar/data/1757143/000110465921058304/a21-5155_1ex4d66.htm#Exhibit4_66_012900)** |
| **4.67** | **[English translation of supplemental real estate lease agreement dated May 9, 2017 by and between Shenzhen Pengai Aesthetic Medical Hospital and the lessor (incorporated herein by reference to Exhibit 10.3 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_3.htm)** |
| **4.68** | **[English translation of real estate lease agreement dated February 28, 2017 by and between Shenzhen Pengcheng Hospital and the lessor (incorporated herein by reference to Exhibit 10.4 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_4.htm)** |
| **4.69** | **[English translation of real estate lease agreement dated February 28, 2017 by and between Shenzhen Pengcheng Hospital and the lessor (incorporated herein by reference to Exhibit 10.5 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_5.htm)** |
| **4.70** | **[English translation of real estate lease agreement dated March 28, 2015 by and between Shenzhen Pengai Aesthetic Medical Hospital and the lessor (incorporated herein by reference to Exhibit 10.6 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-10_6.htm)** |
| **8.1\*** | **[List of principal subsidiaries of the registrant](paiyyex8-1.htm)** |
| **11.1** | **[Code of business conduct and ethics of the registrant (incorporated herein by reference to Exhibit 99.1 to the registration statement on Form F-1 (File No. 333-234022), as amended, initially filed with the SEC on September 30, 2019)](https://www.sec.gov/Archives/edgar/data/1757143/000104746919005529/a2239585zex-99_1.htm)** |
| **12.1\*** | **[Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](paiyyex12-1.htm)** |
| **12.2\*** | **[Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](paiyyex12-2.htm)** |
| **13.1\*\*** | **[Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](paiyyex13-1.htm)** |
| **13.2\*\*** | **[Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](paiyyex13-2.htm)** |
| 15.1\* | [Consent of Dacheng Law Offices LLP (Wuhan)](paiyyex15-1.htm) |
| 15.2\* | [Consent of Onestop Assurance PAC](paiyyex15-2.htm) |
| 16.1 | [Letter dated December 13, 2023 from Union Power HK CPA Limited, pertaining to the change in independent public accounting firm](http://www.sec.gov/Archives/edgar/data/1757143/000110465924052049/aih-20231231xex16d1.htm) |
| 97.1 | [Clawback Policy](http://www.sec.gov/Archives/edgar/data/1757143/000110465924052049/aih-20231231xex97d1.htm) |
| 101.INS\* | Inline XBRL Instance Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Scheme Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Filed herewith.

\*\* Furnished herewith.

[**Table of Contents**](#TableOfContents)

**SIGNATURES**

The registrant hereby certifies that it meets all of the requirements for filing its annual report on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

---

| | | |
|:---|:---|:---|
|  | Aesthetic Medical International Holdings Group Limited | Aesthetic Medical International Holdings Group Limited |
|  | By: | /s/ Zhang Chen |
|  | Name: | Zhang Chen |
| Date: April 23, 2026 | Title: | Chairman |

---

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 AND 2025**

---

| | |
|:---|:---|
| [REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 6732)](#fin_001) | F-2 |
| [CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS](#fin_002) | F-4 |
| [CONSOLIDATED BALANCE SHEETS](#fin_003) | F-6 |
| [CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY](#fin_004) | F-8 |
| [CONSOLIDATED STATEMENTS OF CASH FLOWS](#fin_005) | F-9 |
| [NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS](#fin_006) | F-10 |

---

[**Table of Contents**](#TableOfContents)

**Report of Independent Registered Public Accounting Firm**

To the Shareholders and the Board of Directors of Aesthetic Medical International Holdings Group Limited.

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Aesthetic Medical International Holdings Group Limited and its subsidiaries (collectively, the "Company") as of December 31, 2025 and 2024, the related consolidated statements of comprehensive loss, shareholders' equity, and cash flows for each of the three years in the period ended December 31, 2025 and the related notes to the consolidated financial statements and schedule (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

**Material Uncertainty relating to Going Concern**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2.1 to the consolidated financial statements, the Company had a loss of RMB54.1 million and net current liabilities of RMB294.1 million as at December 31, 2025, and together with other conditions raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2.1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion**

These consolidated financial statements are the responsibility of the Group's management. Our responsibility is to express an opinion on the Group's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Group is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

[**Table of Contents**](#TableOfContents)

**Impairment of goodwill and property, plant and equipment**

*Critical Audit Matter Description*

As of December 31, 2025, property, plant and equipment and goodwill amounted to RMB279.5 million and RMB29.3 million respectively. As discussed in Note 2.8 to the consolidated financial statements, goodwill is evaluated for impairment annually, or more frequently if events or circumstances indicate that the carrying value may not be recoverable. Further discussed in Note 15 to the consolidated financial statements, management reviews the business performance of each cash generating unit ("CGU") including the related goodwill and the recoverable amount of a CGU is determined based on a value-in-use calculation. As a result, impairment tests were performed over the CGU and the fair value of each CGU is estimated using a discounted cash flow model covering a five-year period.

We identified the impairment of cash generating unit as a critical audit matter. There was significant judgment made by management in estimating projected revenue growth, profit margins and discount rates. This in turn lead to high degree of auditor judgment, and effort in performing procedures to evaluate the significant assumption in the value in use estimation.

*How We Addressed the Matter in Our Audit*

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These audit procedures included:

● Evaluated the reasonableness of the estimation methodology and testing the aforementioned significant assumptions and the completeness, accuracy, and relevance of underlying data used.

● Significant assumptions were compared to current available economic trends data and known regulatory changes and evaluations were made of how changes to such assumptions, and other factors would affect the outcomes.

● Assessed the arithmetical correctness of the cash flow model and the completeness of disclosures in the consolidated financial statements.

**Going concern**

*Critical Audit Matter Description*

As discussed in Note 2.1 to the consolidated financial statements, the Company had a loss of RMB54.1 million for the year ended December 31, 2025 and as of December 31, 2025, the Company had net current liabilities of RMB294.1 million. This raises substantial doubt about its ability to continue as a going concern. Management seeks to obtain the financial support from Ms. Wu Binhua, a director of the Company, and other financing to satisfy the Company's obligations as and when they become due for at least one year from the financial statements issuance date.

We determined that Company's ability to continue as a going concern is a critical matter due to the estimation and uncertainty regarding the Company's available funding and the risk of bias in management's judgement and assumptions in their determination.

*How We Addressed the Matter in Our Audit*

 

Our principal audit procedures included, amount others:

● Obtained an understanding, and evaluating management's assessment on whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time;

● Assessed the management's plans and obtained sufficient appropriate audit evidence to determine whether or not substantial doubt can be alleviated or still exists;

● Reviewed the relevant disclosures to the consolidated financial statements.

/s/ Onestop Assurance PAC

We have served as the Company's auditor since 2023.

Singapore

April 23, 2026

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Note** | **2023** | **2024** | **2025** |
|  | | **RMB'000** | **RMB'000** | **RMB'000** |
| Revenue | 5 | 682587 | 755671 | 722855 |
| Cost of sales and services rendered | 6 | (360540) | (417885) | (388608) |
| **Gross profit** |  | 322047 | 337786 | 334247 |
| Selling expenses | 6 | (232254) | (241043) | (226362) |
| General and administrative expenses | 6 | (138605) | (100785) | (102650) |
| Operating result |  | (48812) | (4042) | 5235 |
| Finance income | 8 | 78 | 404 | 138 |
| Finance costs | 8 | (14474) | (8717) | (8749) |
| Other gains/(losses), net | 9 | 8420 | (1139) | (20812) |
| Fair value loss of convertible note |  | (116) |  |  |
| Fair value (loss)/gain of investment properties |  | (154) | 12147 | (31) |
| Impairment of goodwill |  |  |  | (500) |
| **Loss before income tax** |  | (55058) | (1347) | (24719) |
| Income tax credit/(expense) | 10 | 15136 | (23726) | (29349) |
| **Loss for the year** |  | (39922) | (25073) | (54068) |
| **Other comprehensive (loss)/income:** |  |  |  |  |
| *<u>Items that may be subsequently reclassified to profit or loss</u>* |  |  |  |  |
| Currency translation differences |  | (790) | (302) | 1502 |
| Revaluation of investment properties upon transfer from property, plant and equipment |  | (1498) |  |  |
| **Total other comprehensive (loss)/income for the year, net of tax** |  | (2288) | (302) | 1502 |
| **Total comprehensive loss for the year** |  | (42210) | (25375) | (52566) |
| **Loss attributable to:** |  |  |  |  |
| Owners of the Company |  | (37432) | (19945) | (53347) |
| Non-controlling interests |  | (2490) | (5128) | (721) |
| **Loss for the year** |  | (39922) | (25073) | (54068) |

---

The above consolidated statements of comprehensive loss should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Note** | **2023** | **2024** | **2025** |
|  | | **RMB'000** | **RMB'000** | **RMB'000** |
| **Loss per share for loss attributable to owners of the Company (in RMB per share)** |  |  |  |  |
| —Basic | 11 | (0.28) | (0.14) | (0.40) |
| —Diluted | 11 | (0.28) | (0.14) | (0.40) |
| **Total comprehensive loss attributable to:** |  |  |  |  |
| Owners of the Company |  | (39720) | (20247) | (51845) |
| Non-controlling interests |  | (2490) | (5128) | (721) |
| **Total comprehensive loss for the year** |  | (42210) | (25375) | (52566) |

---

The above consolidated statements of comprehensive loss should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED BALANCE SHEETS**

---

| | | | |
|:---|:---|:---|:---|
|  | **Note** | **2024** | **2025** |
|  | | **RMB'000** | **RMB'000** |
| **ASSETS** |  |  |  |
| **Non-current assets** |  |  |  |
| Property, plant and equipment | 12 | 266235 | 279514 |
| Investment properties | 14 | 35058 | 35027 |
| Intangible assets | 15 | 36584 | 31581 |
| Prepayments and deposits | 16 | 6704 | 7051 |
| Deferred income tax assets | 21 | 53560 | 23314 |
|  |  | 398141 | 376487 |
| **Current assets** |  |  |  |
| Inventories | 17 | 14907 | 18798 |
| Trade receivables | 16 | 8793 | 6399 |
| Other receivables, deposits and prepayments | 16 | 18379 | 42190 |
| Amounts due from related parties | 29 | 2156 | 1656 |
| Restricted cash | 18 | 1012 | 5102 |
| Cash and cash equivalents | 18 | 42836 | 60259 |
|  |  | 88083 | 134404 |
| **Total assets** |  | 486224 | 510891 |
| **EQUITY AND LIABILITIES** |  |  |  |
| **Equity attributable to owners of the Company** |  |  |  |
| Share capital | 19a | 998 | 998 |
| Treasury shares | 19b | (2023) | (2023) |
| Accumulated losses |  | (1198148) | (1251495) |
| Other reserves | 20 | 1229630 | 1231920 |
|  |  | 30457 | (20600) |
| **Non-controlling interests** |  | (21111) | (22633) |
| **Total equity** |  | 9346 | (43233) |

---

The above consolidated balance sheets should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED BALANCE SHEETS (CONTINUED)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Note** | **2024** | **2025** |
|  | | **RMB'000** | **RMB'000** |
| **LIABILITIES** |  |  |  |
| **Non-current liabilities** |  |  |  |
| Borrowings | 22 | 13723 | 15171 |
| Lease liabilities | 13 | 61115 | 110400 |
|  |  | 74838 | 125571 |
| **Current liabilities** |  |  |  |
| Trade payables | 23 | 48373 | 34748 |
| Accruals, other payables and provisions | 23 | 43147 | 42412 |
| Contract liabilities | 24 | 193931 | 186066 |
| Borrowings | 22 | 72215 | 129081 |
| Lease liabilities | 13 | 32251 | 25933 |
| Current income tax liabilities |  | 12123 | 10313 |
|  |  | 402040 | 428553 |
| **Total liabilities** |  | 476878 | 554124 |
| **Total equity and liabilities** |  | 486224 | 510891 |

---

The above consolidated balance sheets should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Attributable to owners of the Company** | **Attributable to owners of the Company** | **Attributable to owners of the Company** | **Attributable to owners of the Company** | **Attributable to owners of the Company** | **Attributable to owners of the Company** | **Attributable to owners of the Company** |
|  | **Share**<br>**capital** | **Treasury**<br>**shares** | **Other<br> reserves**<br>**(Note 20)** | **Accumulated**<br>**losses** |<br>**Sub-total** | **Non-<br> controlling**<br>**interests** | **Total<br> equity/**<br>**(deficit)** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| **Balance at 31 December 2022 and 1 January 2023** | 626 | (2023) | 1028510 | (1140771) | (113658) | (12222) | (125880) |
| **Comprehensive loss** |  |  |  |  |  |  |  |
| Loss for the year |  |  |  | (37432) | (37432) | (2490) | (39922) |
| Currency translation differences |  |  | (790) |  | (790) |  | (790) |
| Revaluation of investment properties upon transfer from property, plant and equipment |  |  | (1498) |  | (1498) |  | (1498) |
| **Total comprehensive loss for the year** |  |  | (2288) | (37432) | (39720) | (2490) | (42210) |
| **Transactions with owners** |  |  |  |  |  |  |  |
| Share-based payment | 14 |  | 7500 |  | 7514 |  | 7514 |
| Disposal of subsidiaries (Note 26) |  |  | (5) |  | (5) |  | (5) |
| Distribution of dividends |  |  |  |  |  | (546) | (546) |
| Addition of paid-in capital |  |  | 170001 |  | 170001 |  | 170001 |
| Convertible note convert into shares | 338 |  | 24417 |  | 24755 |  | 24755 |
| **Total transactions with owners** | 352 |  | 201913 |  | 202265 | (546) | 201719 |
| **Balance at 31 December 2023 and 1 January 2024** | 978 | (2023) | 1228135 | (1178203) | 48887 | (15258) | 33629 |
| **Comprehensive loss** |  |  |  |  |  |  |  |
| Loss for the year |  |  |  | (19945) | (19945) | (5128) | (25073) |
| Currency translation differences |  |  | (302) |  | (302) |  | (302) |
| **Total comprehensive loss for the year** |  |  | (302) | (19945) | (20247) | (5128) | (25375) |
| **Transactions with owners** |  |  |  |  |  |  |  |
| Expire of convertible note | 20 |  | 1797 |  | 1817 |  | 1817 |
| Distribution of dividends |  |  |  |  |  | (225) | (225) |
| Repurchase from non-controlling interests |  |  |  |  |  | (500) | (500) |
| **Total transactions with owners** | 20 |  | 1797 |  | 1817 | (725) | 1092 |
| **Balance at 31 December 2024 and 1 January 2025** | 998 | (2023) | 1229630 | (1198148) | 30457 | (21111) | 9346 |
| **Comprehensive loss** |  |  |  |  |  |  |  |
| Loss for the year |  |  |  | (53347) | (53347) | (721) | (54068) |
| Ceased operation of subsidiaries |  |  | 1502 |  | 1502 |  | 1502 |
| **Total comprehensive loss for the year** |  |  | 1502 | (53347) | (51845) | (721) | (52566) |
| **Transactions with owners** |  |  |  |  |  |  |  |
| Ceased operation of subsidiaries |  |  | 788 |  | 788 |  | 788 |
| Distribution of dividends |  |  |  |  |  | (801) | (801) |
| **Total transactions with owners** |  |  | 788 |  | 788 | (801) | (13) |
| **Balance at 31 December 2025** | 998 | (2023) | 1231920 | (1251495) | (20600) | (22633) | (43233) |

---

The above consolidated statements of changes in equity should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Note** | **2023** | **2024** | **2025** |
|  | | **RMB'000** | **RMB'000** | **RMB'000** |
| **Cash flows from operating activities** |  |  |  |  |
| Cash generated from/(used in) operations | 25 | 74306 | 80192 | (10818) |
| Income tax paid |  | (20) | (523) | (1408) |
| **Net cash generated from/(used in) operating activities** |  | 74286 | 79669 | (12226) |
| **Cash flows from investing activities** |  |  |  |  |
| Proceeds from disposal of property, plant and equipment |  | 11 | 66 | 6562 |
| Purchase of and deposit paid for property, plant and equipment |  | (55244) | (30599) | (6903) |
| Purchase of and deposit paid for intangible assets |  | (215) | (187) | (76) |
| Restricted cash |  | 1547 |  |  |
| Balances with related parties |  | 717 |  |  |
| Loan granted to a third party |  |  | (66000) | (39666) |
| Loan repayment from the third party |  |  | 66000 | 39666 |
| Interest income received |  | 78 | 404 | 138 |
| Proceeds from disposal of associate |  | 80 |  |  |
| Proceeds from disposal of subsidiaries | 27 | 824 |  |  |
| Proceeds from ceased operation of subsidiaries |  | (44) | (1) |  |
| **Net cash used in investing activities** |  | (52246) | (30317) | (279) |
| **Cash flows from financing activities** |  |  |  |  |
| Proceeds from borrowings |  | 85166 | 67000 | 80230 |
| Repayment of borrowings |  | (130190) | (63045) | (21916) |
| Repayment of lease liabilities |  | (25672) | (38842) | (38836) |
| Proceeds from other borrowings |  | 13547 | 92093 | 83000 |
| Repayment of other borrowings |  | (73098) | (116314) | (63000) |
| Interest paid |  | (10146) | (8717) | (8749) |
| Addition of paid-in capital |  | 170001 |  |  |
| Capital contribution from non-controlling interests |  |  | (500) |  |
| Dividends paid to non-controlling interests |  | (546) | (225) | (801) |
| **Net cash generated from/(used in) financing activities** |  | 29062 | (68550) | 29928 |
| **Net increase/(decrease) in cash and cash equivalents** |  | 51102 | (19198) | 17423 |
| Cash and cash equivalents at beginning of the year |  | 12161 | 62336 | 42836 |
| Effect of changes in foreign exchange rates |  | (927) | (302) |  |
| **Cash and cash equivalents at end of the year** | 18 | 62336 | 42836 | 60259 |

---

The above consolidated statements of cash flows should be read in conjunction with the accompanying notes.

[**Table of Contents**](#TableOfContents)

**AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| **1** | **General information** |

---

Aesthetic Medical International Holdings Group Limited (the "Company") was incorporated in the Cayman Islands on 27 May 2011 as an exempted company with limited liability under the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of its registered office is Offshore Incorporations (Cayman) Limited, Scotia Centre, 4th Floor, P.O. Box 2804, George Town, Grand Cayman KY1-1112, Cayman Islands.

The Company and its subsidiaries (together, the "Group") are engaged in the provision of non-surgical aesthetic medical services, surgical aesthetic medical services, other aesthetic medical services and general healthcare services in the People's Republic of China (the "PRC"). The principal activities of the subsidiaries are set out in Note 27.

The Company completed its initial public offering and listing of American Depositary Shares ("ADSs") on the NASDAQ Global Market in October, 2019, and raised net proceeds of US$27,600,000 from the offering. Each ADS represents three ordinary shares. On May 21, 2024, the Company's ADSs were quoted on the Pink Open Market initially under the symbol "PAIYY" since the Nasdaq suspended the trading of the ADSs. Subsequently, the Company applied to upgrade from the Pink Open Market to the OTCQX Best Market and received approval on July 10, 2024.

These consolidated financial statements are presented in Renminbi ("RMB") and rounded to the nearest thousand yuan, unless otherwise stated.

---

| | |
|:---|:---|
| **2** | **Material accounting policies** |

---

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

**2.1** **Basis of preparation** 

The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. These consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of convertible note, investment properties and assets held for sale, which were carried at fair value.

**Going Concern**

The consolidated financial statements of the Group have been prepared assuming that the Group will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As a result, the Group had a loss of RMB54,068,000 for the year ended 31 December 2025. As of 31 December 2025, the Group had net current liabilities of RMB294,041,000.

These factors raise substantial doubt about the Group's ability to continue as a going concern. Besides continuing to negotiate with the banks, the Group is evaluating several measures of financing, such as external financings, which will also be considered. Currently, the Group intends to raise loans from financial institutions and potential funders to maintain its normal operations. The Group's ability to continue as a going concern is primarily dependent on the Group's ability to arrange adequate financing arrangements and generate cash flows from its operations.

The Group closed its private placement with Hainan Oriental Jiechuang Investment Partnership ("Jiechuang") for aggregate gross proceeds of RMB170 million in February 2023 and utilized the money to fund its business development and working capital. Ms. Wu Binhua, the director of the Company, signed a letter of continuing financial support with the Group, in which she undertakes to enable the Group to meet its liabilities and obligations as and when they fall due, for at least 12 months from the date of 20-F for the year ended December 31, 2025. In addition to the aforementioned financial support, Ms. Wu Binhua also leverages her corporate management and talent training advantages to optimize the operations of the Group.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.1** **Basis of preparation (Continued)** 

**Going Concern (Continued)**

No assurance can be provided that these additional financings will be available on acceptable terms or at all. If management is unable to execute this plan, there would likely be a material adverse effect on the Group's business. These consolidated financial statements have been prepared on a going concern basis, which assumes that the Group will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

**2.2** **Interpretations and amendments to published standards effective in 2025** 

On 1 January 2025, the Group has adopted the new or amended IFRS and interpretations issued by the IFRS Interpretations Committee (IFRS lC) that are mandatory for application for the financial year. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective IFRS and IFRS IC.

The adoption of these new or amended IFRS and IFRS IC did not result in substantial changes to the Group's accounting policies and had no material effect on the amounts reported for the current or prior financial years.

**2.3** **Subsidiaries** 

**Consolidation**

A subsidiary is an entity (including a structured entity) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Business combinations

The Group applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred to a assumed from the former owners of the acquiree and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date.

The Group recognises any non-controlling interest in the acquiree on an acquisition by acquisition basis. Non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation are measured at either fair value or the present ownership interests' proportionate share in the recognised amounts of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at their acquisition date fair value, unless another measurement basis is required by IFRS.

Acquisition-related costs are expensed as incurred.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognised in consolidated statement of comprehensive income.

Any contingent consideration to be transferred by the Group is recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration that is deemed to be an asset or liability is recognised in accordance with IFRS 9 in consolidated statement of comprehensive income. Contingent consideration that is classified as equity is not remeasured, and its subsequent settlement is accounted for within equity.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.3** **Subsidiaries (Continued)** 

**Consolidation (Continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Business combinations (Continued)

The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired is recorded as goodwill. If the total of consideration transferred, non-controlling interest recognised and previously held interest measured is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in the statement of comprehensive income.

Intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Changes in ownership interests in subsidiaries without change
of control

Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions - that is, as transactions with the owners of the subsidiary in their capacity as owners. The difference between fair value of any consideration paid and the relevant share acquired of the carrying amount of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Disposal of subsidiaries

When the Group ceases to have control, any retained interest in the entity is re-measured to its fair value at the date when control is lost, with the change in carrying amount recognised in consolidated statement of comprehensive income. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. It means the amounts previously recognised in other comprehensive income are reclassified to the consolidated statement of comprehensive income or transferred to another category of equity as specified/permitted by applicable IFRSs.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.3** **Subsidiaries (Continued)** 

**Consolidation (Continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Contractual arrangements with respect to equity interests
in certain PRC subsidiaries

Since the Industry Catalog for Guiding Foreign Investment (Revision 2015) became effective in April 2015, PRC law only allows foreign investment in PRC medical institutions through joint venture entities, and the foreign shareholding in these entities is limited to 70.0%. The Company historically held more than 70.0% equity interest in certain of its PRC subsidiaries that are medical institutions which the Company acquired or established after the effective date of the Industry Catalog for Guiding Foreign Investment (Revision 2015). The Company had decreased its shareholding to 70.0% in such PRC subsidiaries by transferring excessive equity interests to Dr. Zhou Pengwu and certain employees of the Group since 2018. As of December 31, 2025, Shenzhen Pengai Xiuqi Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd., Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd., Shanghai Pengai Jiahong Aesthetic Medical Outpatient Department Co., Ltd., Yantai Pengai Cosmetic Surgery Hospital Co., Ltd., Beijing Aomei Yixin Investment Consultant Co., Ltd., and its branch, Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic (collectively "Relevant Subsidiaries"), which were held by Mr. Zhou Qiuming or Dr. Zhou Pengwu directly or indirectly as to 27%, 26%, 3%, 15%, 12%, 24%, and 25% respectively. Among the entities with contractual arrangements, Changsha Pengai Aesthetic Medical Hospital Co., Ltd. and Nanchang Pengai Xiuqi Aesthetic Medical Hospital Co., Ltd. were divested in October 2022 and Hangzhou Pengai Aesthetic Medical Outpatient Department was ceased operation in August 2022 and was deregistered in March 2024. Shenzhen Miaoyan Aesthetic Medical Clinic was divested in December 2022. These Contractual Arrangements enable the Company to (i) exercise control over the Target Equity Interests in the Relevant Subsidiaries; (ii) receive economic benefits from the Target Equity Interests in Relevant Subsidiaries; and (iii) have an exclusive option to purchase all or part of the Target Equity Interests when and to the extent permitted by PRC laws.

As of December 31, 2025, the principal terms of the Contractual Arrangements are described below:

*(i).* *Loan agreement*

Shenzhen Pengai Investment, as the lender, entered into certain loan agreements with Mr. Zhou Qiuming or Dr. Zhou Pengwu, as the borrower. Pursuant to each of these loan agreements, Shenzhen Pengai Investment agrees to extend a loan to Mr. Zhou Qiuming or Dr. Zhou Pengwu in an equivalent amount to the purchase price to be paid by Mr. Zhou Qiuming or Dr. Zhou Pengwu for acquiring the Target Equity Interests. Pursuant to each of these loan agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu shall repay the loan by transferring the current and future economic interest of the Target Equity Interests to Shenzhen Pengai Investment.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.3** **Subsidiaries (Continued)** 

**Consolidation (Continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Contractual arrangements with respect to equity interests
in certain PRC subsidiaries (Continued)

*(ii).* *Economic interest transfer agreement*

Mr. Zhou Qiuming or Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries entered into certain economic interest transfer agreements. Pursuant to each of these economic interest transfer agreements, the economic interest in relation to the Target Equity Interests currently held and subsequently acquired by Mr. Zhou Qiuming or Dr. Zhou Pengwu, including but not limited to (i) incomes arising from the disposal of the Target Equity Interests (including derivative equity interest of the Target Equity Interests) under any circumstance; (ii) dividends and bonus obtained on the basis of the Target Equity Interests (including derivative equity interest of the Target Equity Interests) under any circumstance; (iii) residual assets and other economic profits allocated after the liquidation of the Relevant Subsidiaries, and (iv) any other cash income, property and economic benefit arising from the Target Equity Interests (including derivative equity interest of the Target Equity Interests), shall be transferred to Shenzhen Pengai Investment. Upon the execution of each economic interest transfer agreement, the repayment obligation of Mr. Zhou Qiuming or Dr. Zhou Pengwu under each loan agreement is deemed fully discharged.

*(iii).* *Exclusive option agreement*

Mr. Zhou Qiuming or Dr. Zhou Pengwu, Shenzhen Pengai Investment and each of the Relevant Subsidiaries entered into certain exclusive option agreements. Pursuant to these exclusive option agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu irrevocably granted Shenzhen Pengai Investment an exclusive right to purchase, or have its designated person(s) to purchase, at its discretion, all or part of his equity interest in the Relevant Subsidiaries, and the purchase price shall be the lowest price permitted by applicable PRC law. Each of Mr. Zhou Qiuming or Dr. Zhou Pengwu and the Relevant Subsidiaries undertakes that, among others, without the prior written consent of Shenzhen Pengai Investment, he or it shall or shall cause the Relevant Subsidiaries not to declare any dividends or distribute any residual profits, change or amend its articles of association, increase or decrease its registered capital, or change its structure of registered capital in other manners. In the event that Mr. Zhou Qiuming or Dr. Zhou Pengwu increases his capital injection into the Relevant Subsidiaries, Mr. Zhou Qiuming or Dr. Zhou Pengwu undertakes and confirms that any additional equity so acquired shall be subject to the purchase option. Unless terminated by Shenzhen Pengai Investment at its sole discretion, the exclusive option agreement will remain effective until all equity interest in the Relevant Subsidiaries held by Mr. Zhou Qiuming or Dr. Zhou Pengwu is transferred or assigned to Shenzhen Pengai Investment or its designated person(s).

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.3** **Subsidiaries (Continued)** 

**Consolidation (Continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Contractual arrangements with respect to equity interests
in certain PRC subsidiaries (Continued)

*(iv).* *Power of attorney*

Pursuant to a relevant power of attorney executed by Mr. Zhou Qiuming or Dr. Zhou Pengwu, he has irrevocably authorized Shenzhen Pengai Investment or its designated person(s) to exercise all of such shareholder's voting and other rights associated with the Target Equity Interests in each of the Relevant Subsidiaries, including but not limited to, the right to attend shareholder meetings, the right to vote, the right to sell, transfer, pledge or dispose of the Target Equity Interests and the right to appoint legal representatives, directors and other management. The proxy agreement remains effective as long as Mr. Zhou Qiuming or Dr. Zhou Pengwu remains a shareholder of the Relevant Subsidiaries, unless Shenzhen Pengai Investment has given contrary written instructions.

*(v).* *Equity interest pledge agreement*

Mr. Zhou Qiuming or Dr. Zhou Pengwu as pledgor, Shenzhen Pengai Investment as pledgee, and each of the Relevant Subsidiaries entered into certain equity interest pledge agreements. Pursuant to these equity interest pledge agreements, Mr. Zhou Qiuming or Dr. Zhou Pengwu has pledged all of the Target Equity Interests in Relevant Subsidiaries and agreed to pledge all future equity interest in the Relevant Subsidiaries acquired by him to Shenzhen Pengai Investment to guarantee the performance by Mr. Zhou Qiuming or Dr. Zhou Pengwu and the Relevant Subsidiaries of their respective obligations under the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney. If the Relevant Subsidiaries or Mr. Zhou Qiuming or Dr. Zhou Pengwu breach any obligations under these agreements, Shenzhen Pengai Investment, as pledgee, will be entitled to dispose of the pledged equity and have priority to be compensated by the proceeds from the disposal of the pledged equity. Mr. Zhou Qiuming or Dr. Zhou Pengwu shall not permit the existence of any security interest or other encumbrance on the pledged equity interest or any portion thereof, without the prior written consent of Shenzhen Pengai Investment and the Relevant Subsidiaries shall not assent to or assist in such actions. These equity interest pledge agreements will remain effective until Mr. Zhou Qiuming or Dr. Zhou Pengwu discharges all the obligations under the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney and the full payment of all direct, indirect and derivative losses and losses of anticipated profits, suffered by the pledgee, incurred as a result of any breach by Mr. Zhou Qiuming or Dr. Zhou Pengwu or the Relevant Subsidiaries under these agreements or invalidity, revocation and termination of any of these agreements.

*(vi).* *Spousal consent letter*

Pursuant to relevant spousal consent letters executed by Ms. Ma Xiuhua or Ms. Ding Wenting, she unconditionally and irrevocably agreed that the equity interest in each of the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming or Dr. Zhou Pengwu and registered or to be registered in his name will be disposed of pursuant to the loan agreement, the economic interest transfer agreement, the exclusive option agreement and the power of attorney. Ms. Ma Xiuhua or Ms. Ding Wenting agreed not to assert any rights over the equity interest in the Relevant Subsidiaries held or to be held by Mr. Zhou Qiuming or Dr. Zhou Pengwu. In addition, in the event that Ms. Ma Xiuhua or Ms. Ding Wenting obtains any equity interest in each of the Relevant Subsidiaries for any reason, she agreed to be bound by the Contractual Arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(e)* *Risks in relation to the Contractual Arrangements* 

In the opinion of the Company's management, the Contractual Arrangements are in compliance with the current PRC laws and are legally binding and enforceable. However, uncertainties in the interpretation and enforcement of the PRC laws, regulations and policies could limit the Company's ability to enforce these contractual arrangements.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.3** **Subsidiaries (Continued)** 

**Consolidation (Continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** **Risks in relation to the Contractual Arrangements (Continued)** 

In January 2015, the Ministry of Commerce ("MOFCOM"), released for public comment a proposed PRC law, the Draft Foreign Investment Enterprises ("FIE") Law, that appears to include contractual arrangements within the scope of entities that could be considered to be FIEs, that would be subject to restrictions under existing PRC law on foreign investment in certain categories of industry. Specifically, the Draft FIE Law introduces the concept of "actual control" for determining whether an entity is considered to be an FIE. In addition to control through direct or indirect ownership or equity, the Draft FIE Law includes control through contractual arrangements within the definition of "actual control". If the Draft FIE Law is passed by the People's Congress of the PRC and goes into effect in its current form, these provisions regarding control through contractual arrangements could be construed to include the Company's contractual arrangements, and as a result, the Relevant Subsidiaries could become explicitly subject to the current restrictions on foreign investment in certain categories of industry. The Draft FIE Law includes provisions that would exempt from the definition of FIEs where the ultimate controlling shareholders are either entities organized under PRC law or individuals who are PRC citizens. The Draft FIE Law is silent as to what type of enforcement action might be taken. If the restrictions and prohibitions on FIEs included in the Draft FIE Law are enacted and enforced in their current form, the Company's ability to use the contractual arrangements and the Company's ability to conduct business through the contractual arrangements could be severely limited.

The Company's ability to control the Target Equity Interests in the Relevant Subsidiaries also depends on the power of attorney exercised by Shenzhen Pengai Investment to vote on all matters requiring shareholders' approvals in the Relevant Subsidiaries. As noted above, the Company believes these powers of attorney are legally binding and enforceable but may not be as effective as direct equity ownership. In addition, if the Company's corporate structure or the contractual arrangements were found to be in violation of any existing PRC laws and regulations, the PRC regulatory authorities could, within their respective jurisdictions:

● revoke the Contractual Arrangements;

● impose fines, confiscating the income from the Relevant Subsidiaries, or imposing other requirements with which the Company may not be able to comply;

● discontinue or restrict the Company's operations in the PRC;

● impose conditions or requirements with which the Company may not be able to comply; or

● take other regulatory or enforcement actions that could be harmful to the Company's business.

The imposition of any of these restrictions or actions may result in a material adverse effect on the Company's ability to conduct its business. In addition, if the imposition of any of these restrictions causes the Company to lose the right to direct the activities of the Relevant Subsidiaries or the right to receive their economic benefits, the Company may no longer be able to consolidate the financial statements of the Relevant Subsidiaries. In the opinion of management, the likelihood of losing the benefits in respect of the Company's current ownership structure or the contractual arrangements is remote.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.4** **Segment reporting** 

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, which is the Board of Directors. In the respective periods presented, the Company had one single operating and reportable segment, namely the provision of non- surgical aesthetic medical services, surgical aesthetic medical services, other aesthetic medical services and general healthcare services. As the Company's long-lived assets are substantially all located in the PRC and substantially all of the Company's revenue is derived from within the PRC, no geographical information is presented.

**2.5** **Foreign currency translation** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Functional and presentation currency

Items included in the consolidated financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in RMB, which is the Company's functional and the Group's presentation currency.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.5** **Foreign currency translation (Continued)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are re- measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in consolidated statement of comprehensive income.

Exchange differences on convertible note and exchangeable note liabilities were recorded in "fair value loss of convertible note" and "fair value (loss)/gain of exchangeable note liabilities", respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Group companies

The results and financial position of all the Group entities (none of which has the currency of a hyper-inflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) assets and liabilities for each balance sheet presented are
translated at the closing rate at the reporting date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) income and expenses for each statement of comprehensive income
are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates
prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions);
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) all resulting exchange differences are recognised in other
comprehensive income.

Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. Currency translation differences arising are recognised in other comprehensive income.

**2.6** **Property, plant and equipment** 

Property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to the consolidated statement of comprehensive income during the financial period in which they are incurred.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.6** **Property, plant and equipment (Continued)** 

Depreciation of property, plant and equipment is calculated using the straight-line method to allocate cost of each asset to their residual values over their estimated useful lives, as follows:

---

| | |
|:---|:---|
| - Buildings | 20 - 50 years |
| - Leasehold improvements | Shorter of remaining lease term and the estimated useful lives of the assets |
| - Machinery and equipment | 10 years |
| - Office equipment, furniture, fixture and motor vehicles | 5 - 10 years |
| - Right of use assets | Shorter of the asset's useful life and the lease term on a straight-line basis |

---

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised within "general and administrative expenses" in the consolidated statement of comprehensive income.

Gains and losses on lease modification relating to the full termination of the leases are recognised within "general and administrative expenses" in the consolidated statement of comprehensive income.

**2.7** **Investment properties** 

Properties that are held for long – term rental yields or for capital appreciation or both, and that are not occupied by the companies in the Group, are classified as investment properties in the consolidated financial statements. Investment properties are carried at fair value basis and its movement will be reviewed annually.

If an owner-occupied property becomes an investment property because its use has changed, any difference resulting between the carrying amount and the fair value of this property at the date of transfer is recognised in equity as a revaluation of property, plant and equipment. However, if the fair value of the property at the date of transfer which results in a reversal of the previous impairment loss, the write-back is recognised in the consolidated income statement.

Subsequent expenditure is included to the asset's carrying amount only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance costs are expensed in consolidated statement of comprehensive income during the financial periods in which they are incurred.

**2.8** **Intangible assets** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Goodwill

Goodwill arising on the acquisition of subsidiaries represents the excess of the consideration transferred, the amount of any non-controlling interest in the acquire and the acquisition- date fair value of any previous equity interest in the acquiree over the fair value of the identified net assets acquired.

For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units ("CGUs"), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.8** **Intangible assets (Continued)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Goodwill (Continued)

Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate a potential impairment. The carrying value of the CGU containing the goodwill is compared to the recoverable amount, which is the higher of value in use and the fair value less costs of disposal. Any impairment is recognised immediately as an expense and is not subsequently reversed. See note 15 for the goodwill impairment charges recognised in the respective years presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Computer software

Acquired computer software licenses are capitalised on the basis of the costs incurred to acquire and bring the specific software into usage. These costs are amortised using the straight-line method over their estimated useful lives of 5 years. Cost associated with maintaining computer software programmes are recognised as an expense as incurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Medical licenses and tradenames

Medical licenses and tradenames acquired through business combinations are initially recognised at fair value. Medical licences are amortised on a straight-line basis over respective license periods (ranged from 2 to 16 years). Tradenames are amortised on a straight-line basis over respective useful lives of 19 to 20 years.

**2.9** **Impairment of non-financial asset** 

Intangible assets that have an indefinite useful life or intangible assets not ready to use are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For purposes of periodic impairment assessment performed at each reporting date, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at each reporting date.

**2.10** **Financial assets** 

**2.10.1** **Classification** 

The Group classifies its financial assets in the following measurement categories:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) those to be measured subsequently at fair value (either through
other comprehensive income, or through profit or loss), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) those to be measured at amortised cost.

The classification depends on the Group's business model for managing the financial assets and the contractual terms of the cash flows.

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.10** **Financial assets (Continued)** 

**2.10.1** **Classification (Continued)** 

For assets measured at fair value, gain and loss will either be recorded in profit or loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income.

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

**2.10.2** **Recognition and measurement** 

*Debt instruments*

Subsequent measurement of debt instruments depends on the Group's business model for managing the asset and the cash flow characteristics of the asset. There are two measurement categories into which the Group classifies its debt instruments:

● Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in the consolidated statement of profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

● Fair value through profit or loss: Assets that do not meet the criteria for amortised cost or financial assets at fair value through other comprehensive income are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in profit or loss and presented net in 'other gains, net' in the period in which it arises.

*Equity instruments*

The Group subsequently measures all equity investments at fair value. Where the Group's management has elected to present fair value gains and losses on equity investments in other comprehensive income, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognised in profit or loss as other income when the Group's right to receive payments is established.

Changes in the fair value of financial assets at fair value through profit or loss are recognised in other gains, net in the consolidated statement of comprehensive income as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at fair value through other comprehensive income are not reported separately from other changes in fair value.

**2.10.3** **Derecognition** 

Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Material accounting policies (Continued)** |

---

**2.11** **Offsetting financial instruments** 

Financial assets and liabilities are offset and the net amount reported in the consolidated statements of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

**2.12** **Impairment of financial assets** 

The Group has the following types of financial assets subject to IFRS 9's expected credit loss model:

● Trade receivables

● Other receivables and deposits

● Cash and cash equivalents

● Amounts due from related parties

The Group assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost.

For trade receivables, the Group applies the simplified approach permitted by IFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

Impairment on other receivables, deposits, amounts due from related parties are measured as either 12-month expected credit losses or lifetime expected credit loss, depending on whether there has been a significant increase in credit risk since initial recognition, then impairment is measured as lifetime expected credit losses.

To manage risk arising from pledged deposits and cash and cash equivalents, the Group only transacts with state-owned or reputable financial institutions. There has been no recent history of default in relation to these financial institutions.

**2.13** **Inventories** 

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average method. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

**2.14** **Cash and cash equivalents** 

In the consolidated statement of cash flows, cash and cash equivalents includes cash in hand and deposits held at call with banks.

**2.15** **Assets (or disposal groups) held-for-sale** 

Assets (or disposal groups) are classified as held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. The assets (except for certain assets as explained below), (or disposal groups), are stated at the lower of carrying amount and fair value less costs to sell. Deferred tax assets, assets arising from employee benefits, financial assets (other than investments in subsidiaries and associates) and investment properties, which are classified as held for sale, would continue to be measured in accordance with the policies set out elsewhere in Note 2.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.16** **Share capital** 

Ordinary shares are classified as equity. Mandatorily redeemable preference shares are classified as liabilities.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

**2.17** **Trade and other payables** 

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities.

Trade and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

**2.18** **Borrowings** 

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in consolidated statement of comprehensive income over the periods of the borrowings using the effective interest method.

Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a pre-payment for liquidity services and amortised over the periods of the facility to which it relates.

Preference shares, if mandatorily redeemable at a specific date or redeemable at the option of the holder, are classified as liabilities. The dividends on these preference shares are recognised in the consolidated statement of comprehensive income as interest expense.

Borrowings are removed from the consolidated balance sheets when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in consolidated statement of comprehensive income as other income or finance costs.

Where the terms of a financial liability are renegotiated and the entity issues equity instruments to a creditor to extinguish all or part of the liability (debt for equity swap), a gain or loss is recognised in consolidated statement of comprehensive income, which is measured as the difference between the carrying amount of the financial liability and the fair value of the equity instruments issued.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting period.

**2.19** **Current and deferred income tax** 

The income tax expense for the year comprises current and deferred tax. Tax is recognised in the consolidated statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.19** **Current and deferred income tax (Continued)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a)* *Current income tax* 

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the reporting date in the countries where the Company's subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b)* *Deferred income tax* 

*<u>Inside basis differences</u>*

Deferred income tax is recognised, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

*<u>Outside basis differences</u>*

Deferred income tax liabilities are provided on taxable temporary differences arising from investments in subsidiaries and associates, except for deferred income tax liability where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Generally the Group is unable to control the reversal of the temporary difference of associates. Only when there is an agreement in place that gives the Group the ability to control the reversal of the temporary difference in the foreseeable futures, deferred tax liability in relation to taxable temporary difference arising from the associate's undistributed profits is not recognised.

Deferred income tax assets are recognised on deductible temporary differences arising from investments in subsidiaries and associates only to the extent that it is probable the temporary difference will reverse in the future and there is sufficient taxable profit available against which the temporary difference can be utilised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(c)* *Offsetting* 

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income taxes levied by the same taxation authority on either the taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.20** **Employee benefits** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Pension obligations

The group companies incorporated in the PRC contribute based on certain percentage of the salaries of the employees to a defined contribution retirement benefit plan organised by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and future retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Profit-sharing and bonus plans

The Group recognises a liability and an expense for bonuses, based on performance and takes into consideration the profit attributable to the Group's shareholders after certain adjustments. The Group recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Share based compensation

The Group measures share-based compensation at the grant date based on the fair value of the equity awards determined using the Binomial option-pricing model. As the Group has granted share options with a service-only condition, the Group elected to recognize compensation expense over the period in which the recipient is required to provide service in exchange for the equity award.

**2.21** **Provisions** 

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount has been reliably estimated.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

**2.22** **Revenue recognition** 

Revenue is recognised when or as the control of the goods or services is transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services. Depending on the terms of the contract and the applicable laws, services may be provided over time or at a point in time.

When control of goods or services is transferred over time, revenue is recognised over the period of the contract by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognised at a point in time when the customer obtains control of the goods or services.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.22** **Revenue recognition (Continued)** 

The progress towards complete satisfaction of the performance obligation is measured based on one of the following methods that best depict the Group's performance in satisfying the performance obligation:

● direct measurements of the value transferred by the Group to the customer; or

● the Group's efforts or inputs to the satisfaction of the performance obligation.

A contract asset is the Group's right to consideration in exchange for goods and services that the Group has transferred to a customer. A receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.

A contract liability is recognised when the Group has the obligation to transfer services to the customers for which the consideration received (or an amount of considerations is due) exceeds the measure of the remaining unsatisfied performance obligations.

The Group recognises the costs of obtaining and fulfilling a contract with a customers within the contract assets if the Group expects to recover those costs.

The following is a description of the accounting policy for the principal revenue streams of the Group:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Non-surgical aesthetic medical services, surgical aesthetic
medical services and other aesthetic medical services

The period of these services rendered is usually within a day, except for certain large-scale surgical aesthetic medical services in which customers receive inpatient treatment. The period of inpatient stays usually does not exceed more than a week.

The Group has certain aesthetic medical services package in 2024 and 2025 for which customers pay in advance. The packages can be utilized for one year from the effective date. If the package has not been used within one year time period, any payment received is recorded as a contract liability in the consolidated balance sheets.

Revenue is recognised at a point in time when the respective services are rendered or a contract lability has been fulfilled. For certain aesthetic medical services package issued in 2024 and 2025, revenue is recognised over time according to the proportion of the services performed as compared to the total services offered.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) General healthcare services

Revenues are recognised upon the provision of the relevant services for which the service period is usually within a day.

Revenue is recognised at a point in time when the respective services are rendered.

Management reviews the utilisation pattern of contract liabilities and treatment progress of individual customers on a regular basis to determine full recognition of the corresponding contract liabilities in the consolidated statement of comprehensive income.

**2.23** **Interest income** 

Interest income is recognised using the effective interest method.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | **Material accounting policies (Continued)** |

---

**2.24** **Leases** 

The Group leases certain properties. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants.

Leases are recognised as a right-of-use asset and a corresponding liability at the date on which the leased asset is available for use by the Group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

● fixed payments (including in-substance fixed payments), less any lease incentives receivable; and

● payments of penalties for terminating the lease, if the lease reflects the lessee exercising that option

The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the Group's incremental borrowing rate.

Right-of-use assets are measured at cost comprising the following:

● the amount of the initial measurement of lease liability;

● any lease payments made at or before the commencement date less any lease incentives received; and

● any initial direct costs

The right-of-use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.

Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of less than 12 months.

**2.25** **Compound financial instruments** 

Compound financial instruments of the Group is convertible note.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **2** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Material accounting policies (Continued)** |

---

**2.25** **Compound financial instruments (Continued)** 

*Convertible notes in 2020*

The Group designated the convertible note as a financial liability at fair value through profit or loss. Convertible note is initially recognised at fair value. Any directly attributable transaction costs are recognised as finance costs in the consolidated statement of comprehensive income.

Subsequent to initial recognition, the convertible note is carried at fair value with changes in fair value recognised in the consolidated statement of comprehensive income.

The convertible note is classified as a non-current liability unless the Group has an obligation to settle the liability within 12 months after the end of the reporting period.

For the convertible note issued in 2020, it is redeemable at the option of the Company and the holder. This instrument can be converted into American Depository Receipts of the Company.

Reference is made to the press release of the Company filed with the Securities and Exchange Commission (the "SEC") on July 20, 2022, form 6-K of the Company filed with the SEC on February 16, 2023 and form 6-K of the Company filed with the SEC on August 17, 2023 (collectively, "Previous Disclosure"). Further to its Previous Disclosure, the Company has closed its previously announced the issue of a total number of 12,088,808 ordinary shares of the Company to ADV at a conversion price of US dollars equivalent of RMB4.203 per ordinary share on August 16, 2023 pursuant to the Note issued to ADV on September 17, 2020 and the cooperation agreement between ADV and its affiliate, the Company, Dr. Zhou Pengwu, Ms. Ding Wenting, Wanda and Jiechuang dated July 20, 2022.

The Company also entered into a Warrant Agreement with ADV, under which the Company was required to pay US$2.7 million to ADV to settle the financial liability under the Exit Payment (as defined in the Exit Payments Agreement entered into by ADV, the Company, the Founders on September 15, 2020) term in the Convertible Note Purchase Agreement. ADV agreed to postpone the Company's cash payment date of US$2.7 million to December 2024 or, at its discretion, convert such amount at the price of RMB4.67 per ordinary share at any time during this period. ADV did not exercise its warrants, which expired on December 15, 2024, to convert the US$2.7 million Exit Payment into the Company's ordinary shares. The balance of Exit Payment which is US$0.6 million as at December 31, 2025.

Dividend distribution to the Company's shareholders is recognised as a liability in the Group's consolidated financial statements in the period in which the dividends are approved by the Company's Board of Directors.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **3** | **Financial risk management** |

---

**3.1** **Financial risk factors** 

The Group's activities expose it to a variety of financial risks: market risk (including currency risk, fair value interest rate risk and cash flow interest rate risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Market risk

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Foreign exchange risk

The majority of Group companies operate in the PRC and the majority of the transactions are denominated in RMB which is the Company's and other Group Company's functional currency, except for the US$ denominated convertible note.

With all other variables held constant, if the average exchange rate of RMB against US$ had strengthened or weakened by 5%, the Group's post-tax results would increase or decrease by RMB31,000 (2024: RMB4,000).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Credit risk

The Group has no significant concentrations of credit risk. The carrying amounts of cash at banks, trade receivables, deposits and other receivables and amounts due from related parties included in the consolidated balance sheets represent the Group's maximum exposure to credit risk in relation to its financial assets.

The majority of the Group's cash at banks are deposited in major reputable financial institutions located in the PRC. Most of the Group's revenue are settled by cash or credit cards. Trade receivables of the Group are mainly due from financial institutions with sound financial standing. There has been no history of default in relation to these external parties. Management does not expect any losses arising from non-performance by these counterparties.

Based on the Group's historical experiences in collection of trade receivables, other receivables and amounts due from related parties, the directors consider the Group's credit risk of these receivables to be low.

The Group considers that adequate provision for unrecoverable trade receivables, other receivables and amounts due from related parties has been made in the relevant accounting period after considering the Group's experience in collection of trade receivables, other receivables and amounts due from related parties. Management does not expect any losses from non-performance by these counterparties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Cash flow and fair value interest-rate risk

The Group's income and operating cash flows are substantially independent of changes in market interest rates as the Group has no significant interest-bearing assets except for cash at banks. The Group's exposures to changes in interest rates are mainly attributable to its borrowings and loans.

Borrowings issued at variable rates expose the Group to cash flow interest rate risk which is partially offset by cash held at variable rates.

In 2023, 2024 and 2025, the interest rate risk was effectively mitigated through a contractual agreement with banks that secured a fixed interest rate.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **3** | **Financial risk management (Continued)** |

---

**3.1** **Financial risk factors (Continued)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Liquidity risk

The Group is exposed to liquidity risk due to the post-impact of COVID–19 and it had net current liabilities of RMB294,041,000 as at 31 December 2025 As detailed in Note 2.1, the directors of the Company concluded that the Group has sufficient financial resources to meet its financial obligations as and when they fall due in the coming twelve months after the issuance of these consolidated financial statements.

Prudent liquidity management implies maintaining sufficient cash and cash equivalents and the availability of funding through an adequate amount of committed credit facilities.

The Group's primary cash requirements have been the payments for operating expenses and purchases of fixed assets. The Group mainly finances its working capital requirements through internal resources and proceeds from bank borrowings and issuance of ordinary shares.

The Group's policy is to regularly monitor current and expected liquidity requirements to ensure it maintains sufficient cash and cash equivalents and adequate amount of committed credit facilities to meet its liquidity requirements in the short and long term.

At the reporting date, the contractual undiscounted cash flows of the Group's current financial liabilities approximate their respective carrying amounts due to their short maturities.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **3** | **Financial risk management (Continued)** |

---

**3.1** **Financial risk factors (Continued)** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Liquidity risk (Continued)

The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows, including interest if applicable.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Less than**<br>**1 year**<br>**RMB'000** | **Between 1 and**<br>**2 years**<br>**RMB'000** | **Between 2 and**<br>**5 years**<br>**RMB'000** | **After**<br>**5 years**<br>**RMB'000** |<br>**Total**<br>**RMB'000** |
| At 31 December 2024 |  |  |  |  |  |
| Borrowings | 72215 | 9571 | 4152 |  | 85938 |
| Lease liabilities | 34148 | 19799 | 38683 | 8360 | 100990 |
| Trade payables | 48373 |  |  |  | 48373 |
| Accruals and other payables (excluding accrued employee benefits, other taxes, provision and deposits received) | 23336 |  |  |  | 23336 |
|  | 193892 | 50964 | 54682 | 20534 | 320072 |
| At 31 December 2025 |  |  |  |  |  |
| Borrowings | 129081 | 15171 |  |  | 144252 |
| Lease liabilities | 31996 | 28485 | 72990 | 21305 | 154776 |
| Trade payables | 34748 |  |  |  | 34748 |
| Accruals and other payables (excluding accrued employee benefits, other taxes, provision and deposits received) | 22865 |  |  |  | 22865 |
|  | 218690 | 43656 | 72990 | 21305 | 356641 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **3** | **Financial risk management (Continued)** |

---

**3.2** **Capital risk management** 

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Group may adjust the dividend payments to shareholders, return capital to shareholders, issue new shares or obtain bank borrowings.

Consistent with others in the industry, the Group monitors capital on the basis of the gearing ratio. This ratio is calculated as net debt divided by total capital. Net debt is calculated as total borrowings (include current and non-current bank borrowings, convertible note as shown in the consolidated balance sheets) less cash and cash equivalents and restricted bank deposit. Total capital is calculated as "equity", as shown in the consolidated balance sheets, plus net debt.

The gearing ratios at 31 December 2024 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Total borrowings | 85938 | 144252 |
| Less: Cash and cash equivalents (Note 18) | (42836) | (60259) |
| Restricted cash (Note 18) | (1012) | (5102) |
| Net debt | 42090 | 78891 |
| Total equity | 9346 | (43233) |
| Total capital | 51436 | 35658 |
| Gearing ratio | 81.83% | 221.24% |

---

**3.3** **Fair value estimation** 

The table below analyses financial instruments carried at fair value as at 31 December 2024 and 2025 by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorised into three levels with a fair value hierarchy as follows:

● Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).

● Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).

● Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **3** | **Financial risk management (Continued)** |

---

**3.3** **Fair value estimation (Continued)** 

The following table presents the Group's financial assets, non-finacial assets and finanial liabilities that are mearsure at fair value as at 31 December 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1**<br>**RMB'000** | **Level 2**<br>**RMB'000** | **Level 3**<br>**RMB'000** | **Total**<br>**RMB'000** |
| **As at 31 December 2025** | | | | |
| **Assets** | | | | |
| Investment properties (Note 14) |  |  | 35027 | 35027 |
|  |  |  | 35027 | 35027 |

---

The fair value of financial instruments that are not traded in an active market (for example, over- the-counter derivatives) is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Specific valuation techniques used to value financial instruments include:

● Quoted market prices or dealer quotes for similar instruments.

● Other techniques, such as discounted cash flow analysis including dividend growth model, are used to determine fair value for the remaining financial instruments.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **4** | **Critical accounting estimates and judgments** |

---

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

(a) Goodwill and property, plant and equipment impairment assessment

The Group tests annually whether goodwill and property, plant and equipment have suffered any impairment, in accordance with the accounting policy stated in Note 2.8(a) and Note 2.9. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of estimates. The value-in-use calculations primarily use cash flow projections based on financial budgets approved by the Board of Directors. There is a number of assumptions and estimates involved in the preparation of cash flow projections for the periods covered by the approved budgets. Key assumptions include the expected growth rates, timing of future capital expenditures and selection of discount rates to reflect the risks involved.

Management prepares the financial budgets reflecting actual and prior year performance and market development expectations.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **4** | **Critical accounting estimates and judgments (Continued)** |

---

(b) Estimated useful lives of property, plant and equipment and
intangible assets

The Group's management determines the estimated useful lives and related depreciation and the amortisation charges for the Group's property, plant and equipment and intangible assets with reference to the estimated periods that the Group intends to derive future economic benefits from the use of these assets. Management performs periodic review of the estimated useful lives of property, plant and equipment and intangible assets, and will revise the depreciation and amortisation charges where estimated useful lives are different than those previously estimated.

(c) Deferred tax assets

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits, together with future tax planning strategies.

The Group has RMB92,075,000 (2024: RMB315,079,000) of tax losses carried forward. These losses relate to subsidiaries that have a history of losses and may not be used to offset taxable income elsewhere in the Group. The Group has considered the future utilization of accumulated tax losses by performing cash flow forecasts. On this basis, the Group has determined that deferred tax assets of RMB23,314,000 (2024: RMB53,560,000) was recognised for the tax losses carried forward.

---

| | |
|:---|:---|
| **5** | **Revenue** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Non-surgical aesthetic medical services | 474874 | 557836 | 541082 |
| Surgical aesthetic medical services | 143057 | 125369 | 126790 |
| General healthcare services and other aesthetic medical services | 64656 | 72466 | 54983 |
|  | 682587 | 755671 | 722855 |

---

---

| | |
|:---|:---|
| **6** | **Expenses by nature** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Employee benefit expenses (Note 7) | 221971 | 238580 | 237016 |
| Advertising and marketing expenses | 164236 | 162267 | 157116 |
| Cost of inventories and consumables | 204881 | 234487 | 215692 |
| Operating lease rental expenses | 9374 | 9965 | 5790 |
| Amortisation and depreciation | 65897 | 65964 | 58888 |
| Utilities and office expenses | 38329 | 30961 | 25539 |
| Travelling and entertainment expenses | 8451 | 5293 | 4291 |
| Bank charges | 4890 | 4881 | 3985 |
| Legal and professional fees | 11355 | 5314 | 7648 |
| Other expenses | 2015 | 2001 | 1655 |
|  | 731399 | 759713 | 717619 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **7** | **Employee benefit expenses** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Wages and salaries | 198988 | 218098 | 213721 |
| Share-based compensation expenses | 7514 |  |  |
| Expire of convertible note |  | 1817 |  |
| Pension costs - defined contribution plans | 10616 | 14657 | 18941 |
| Other staff welfare expenses | 4853 | 4008 | 4354 |
|  | 221971 | 238580 | 237016 |

---

---

| | |
|:---|:---|
| **8** | **Finance income and costs** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Finance costs |  |  |  |
| Interest expense on bank borrowings | (4105) | (948) | (521) |
| Interest expense on other borrowings | (4511) | (2986) | (1485) |
| Interest expense on lease liabilities | (5858) | (4783) | (6743) |
|  | (14474) | (8717) | (8749) |
| Finance income |  |  |  |
| Interest income on short-term bank deposits | 78 | 404 | 138 |
| Finance costs – net | (14396) | (8313) | (8611) |

---

---

| | |
|:---|:---|
| **9** | **Other gains/(losses) net** |

---

The Company recognised other losses, net of RMB20.8 million in 2025 and other losses, net of RMB1.1 million in 2024. The other losses in 2025 were mainly due to the deregistration of subsidiaries, disposal of property and compensation payments, partially offset by rental income of RMB0.4 million.

---

| | |
|:---|:---|
| **10** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Income tax (credit)/expense** |

---

PRC corporate income tax have been provided for subsidiaries established and operating in Mainland China at the rate of 25% (2023 and 2024: 25%) on the estimated assessable profit for the year.

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| **Current tax** |  |  |  |
| PRC enterprise income tax | 1000 | 355 | 1269 |
| **Deferred tax** |  |  |  |
| PRC enterprise income tax previous years | (5890) |  |  |
| Origination and reversal of temporary differences (Note 21) | (10246) | 23371 | 28080 |
| Income tax (credit)/expense | (15136) | 23726 | 29349 |

---

The taxation on the Group's loss before income tax differs from the theoretical amount that would arise using the taxation rate of PRC, the principal place of the Group's operations, as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Loss before income tax | (55058) | (1347) | (24719) |
| Calculated at a taxation rate of 25% | (13765) | (336) | (6179) |
| Expenses not tax deductible | 4121 | 4686 | 1580 |
| Utilisation of previously unrecognised tax losses |  | (4580) | (4546) |
| Reversal of deferred income tax |  | 30085 | 30246 |
| Tax losses not recognized | 1124 | (6131) | 8280 |
| Difference in overseas tax rates | (364) | 2 | (32) |
| Over-provision in respect of prior years | (6252) |  |  |
| Income tax (credit)/expense | (15136) | 23726 | 29349 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **10** | **Income tax (credit)/expense (Continued)** |

---

**(a)** **Cayman Islands Income Tax** 

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law of Cayman Islands and accordingly, is exempted from Cayman Islands income tax.

**(b)** **Hong Kong Profits Tax** 

Hong Kong profits tax rate has been provided at the rate of 16.5% on the estimated assessable profit for each of the years ended 31 December 2023, 2024 and 2025.

**(c)** **PRC Enterprise Income Tax ("EIT")** 

The income tax provision of the Group in respect of operations in the PRC has been calculated at the tax rate of 25% on the estimated assessable profits for each of the years, based on the existing legislation, interpretations and practices in respect thereof.

**(d)** **U.S. Federal Corporate Income Tax** 

U.S. federal corporate income tax has been provided at the rate of 21% on the estimated assessable profit for each of the years ended December 31, 2023, 2024 and 2025.

**(e)** **British Virgin Islands** 

Dragon Jade Holdings Limited was incorporated in the British Virgin Islands and conducts its primary business operations through the subsidiaries. Under the current laws of the British Virgin Islands, the BVI company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the company to its shareholders, no BVI withholding tax will be imposed.

---

| | |
|:---|:---|
| **11** | **Loss per share** |

---

**(a)** **Basic loss per share** 

Basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares in issue during the year.

**(b)** **Diluted loss per share** 

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the year ended 31 December 2023, 2024 and 2025, the Company has two categories of dilutive securities: Convertible Note and share option. These dilutive securities are assumed to have been converted into ordinary shares, and the net losses for the year is adjusted to eliminate the fair value gain or loss of these dilutive potential ordinary shares less related income tax effect.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **11** | **Loss per share (Continued)** |

---

**(b)** **Diluted Loss per share (Continued)** 

The following table sets forth the computation of basic and diluted loss per share:

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| **Numerator:** |  |  |  |
| Loss attributable to owners of the Company – basic | (37432) | (19945) | (57745) |
| Loss attributable to owners of the Company – diluted | (37432) | (19945) | (57745) |
| **Shares (denominator):** |  |  |  |
| Weighted average number of shares – basic | 131658595 | 143504373 | 143504373 |
| Weighted average number of shares – diluted | 131658595 | 143504373 | 143504373 |
| Loss per share – basic (RMB) | (0.28) | (0.14) | (0.40) |
| Loss per share – diluted (RMB) (Note i) | (0.28) | (0.14) | (0.40) |

---

---

| | |
|:---|:---|
| Note | i As the Group incurred losses for the years ended 31 December 2024 and 2025, share option and the conversion of convertible note would be anti-dilutive and therefore, related changes in fair value are not included in the computation of diluted loss per share. Diluted loss per share and basic loss per share are the same for the year ended 31 December 2024 and 2025. |

---

---

| | |
|:---|:---|
| **12** | **Property, plant and equipment** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |<br><br>**Buildings**<br>**RMB'000** |<br>**Leasehold**<br>**improvements**<br>**RMB'000** |<br>**Machinery**<br>**and**<br>**equipment**<br>**RMB'000** | **Office equipment,**<br>**furniture fixtures**<br>**and motor**<br>**vehicles**<br>**RMB'000** |<br>**Right of use**<br>**assets**<br>**RMB'000** |<br><br>**Total**<br>**RMB'000** |
| At 31 December 2024 |  |  |  |  |  |  |
| Opening net book amount | 36491 | 86235 | 60114 | 6510 | 114869 | 304219 |
| Additions |  | 7516 | 7388 | 1769 | 16103 | 32776 |
| Disposal |  |  | (2898) | (231) | (2294) | (5423) |
| Depreciation charges | (1983) | (16395) | (10277) | (1593) | (35089) | (65337) |
| Closing net book amount | 34508 | 77356 | 54327 | 6455 | 93589 | 266235 |
| At 31 December 2024 |  |  |  |  |  |  |
| Cost | 38560 | 311569 | 126340 | 25746 | 233280 | 735495 |
| Accumulated depreciation and impairment | (4052) | (234213) | (72013) | (19291) | (139691) | (469260) |
| Net book amount | 34508 | 77356 | 54327 | 6455 | 93589 | 266235 |
| At 31 December 2025 |  |  |  |  |  |  |
| Opening net book amount | 34508 | 77356 | 54327 | 6455 | 93589 | 266235 |
| Additions |  | 1380 | 7967 | 732 | 121382 | 131461 |
| Disposal | (16333) |  | (2365) | (192) | (39471) | (58361) |
| Disposal of subsidiaries (Note 26) |  | (118) | (1073) | (336) |  | (1527) |
| Depreciation charges | (1676) | (11019) | (9245) | (1547) | (34807) | (58294) |
| Closing net book amount | 16499 | 67599 | 49611 | 5112 | 140693 | 279514 |
| At 31 December 2025 |  |  |  |  |  |  |
| Cost | 20139 | 312210 | 125197 | 23692 | 251510 | 732748 |
| Accumulated depreciation and impairment | (3640) | (244611) | (75586) | (18580) | (110817) | (453234) |
| Net book amount | 16499 | 67599 | 49611 | 5112 | 140693 | 279514 |

---

As at 31 December 2024 and 2025, property, plant and equipment with net book value amounting to approximately RMB10,228,000 and RMB8,146,000 respectively, were pledged as security for the bank and other borrowings.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **13** | **Lease** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amounts recognised in the consolidated balance sheets:

Right-of-use assets are classified as property, plant and equipment (Note 12).

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at** | **As at** | **As at** | **As at** |
|  | **31 December** | **31 December** | **31 December** | **31 December** |
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| **Lease liabilities** | | | | |
| Current |  | 32251 |  | 25933 |
| Non-current | | 61,115 | | 110,400 |
|  | | 93,366 | | 136,333 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Amounts recognised in the consolidated statements of comprehensive
income:

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Interest expense (included in finance costs) (Note 8) | 5858 | 4783 | 6743 |
| Expense relating to short-term leases (included in cost of goods sold and administrative expenses) | 9374 | 9965 | 5790 |

---

The total cash outflows for leases in 2025 was approximately RMB45,868,000 (2024: RMB38,842,000).

---

| | |
|:---|:---|
| **14** | **Investment properties** |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| **Fair value** |  |  |
| At 1 January | 22911 | 35058 |
| Fair value gain/(loss) of investment properties | 12147 | (31) |
| At 31 December | 35058 | 35027 |

---

Investment properties represents buildings held in the PRC.

Investment properties with fair value amounting to RMB35,027,000 as of December 31, 2025 were pledged as security for the bank loans at the reporting date.

Amounts recognised in the consolidated income statements for investment properties:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2023** | **2023** | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Rental income | | 240 | | 411 | | 411 |

---

As at 31 December 2025, the fair values of the investment property are based on valuation performed by Dacheng Assessment, an accredited independent valuer. Dacheng Assessment is a specialist in valuing these types of investment properties in China. A valuation model in accordance with that recommended by the International Valuation Standards Committee has been applied.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **15** | **Intangible assets** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |<br>**Goodwill**<br>**RMB'000** | **Computer**<br>**software**<br>**RMB'000** | **Medical**<br>**licenses**<br>**RMB'000** |<br>**Tradenames**<br>**RMB'000** |<br>**Total**<br>**RMB'000** |
| **Year ended 31 December 2024** | | | | | |
| Opening net book amount | 32999 | 759 |  | 3123 | 36881 |
| Additions |  | 330 |  |  | 330 |
| Amortisation |  | (345) |  | (282) | (627) |
| Closing net book amount | 32999 | 744 |  | 2841 | 36584 |
| **At 31 December 2024** |  |  |  |  |  |
| Cost | 54213 | 13139 | 9585 | 5040 | 81977 |
| Accumulated impairment | (21214) | (3954) |  | (719) | (25887) |
| Accumulated amortisation |  | (8441) | (9585) | (1480) | (19506) |
| Net book amount | 32999 | 744 |  | 2841 | 36584 |
| **Year ended 31 December 2025** |  |  |  |  |  |
| Opening net book amount | 32999 | 744 |  | 2841 | 36584 |
| Additions |  | 70 |  |  | 70 |
| Disposal of subsidiaries (Note 26) | (3223) |  |  | (756) | (3979) |
| Amortisation |  | (311) |  | (283) | (594) |
| Impairment loss | (500) |  |  |  | (500) |
| Closing net book amount | 29276 | 503 |  | 1802 | 31581 |
| **At 31 December 2025** |  |  |  |  |  |
| Cost | 50990 | 12874 | 1260 | 3726 | 68850 |
| Accumulated impairment | (21714) | (3954) |  | (719) | (26387) |
| Accumulated amortisation |  | (8417) | (1260) | (1205) | (10882) |
| Net book amount | 29276 | 503 |  | 1802 | 31581 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **15** | **Intangible assets (Continued)** |

---

During the year ended 31 December 2021, the Company decided to strategically focus on treatment centres in East China, South China and Southwest China and devote much less resources to treatment centres in other regions of China. As a result, the Company recognized impairment of goodwill of RMB122,099,000 (2020: RMB18,809,000), tradenames of RMB43,679,000 (2020: RMB8,124,000), computer software of RMB3,956,000 (2020: nil), property, plant and equipment of RMB139,818,000 (2020: RMB6,036,000) and associate of RMB4,407,000 (2020: nil) of certain treatment centres in other regions of China.

During the year ended 31 December 2023 and 2024, the Company has not recognized any impairment to property, plant and equipment and intangible assets. For the year ended 31 December 2025, the Company recognized an impairment loss on goodwill amounting to RMB500,000. The impairment was assessed based on the value-in-use calculation of the relevant cash-generating units, driven by downward revisions to future cash flow forecasts. The recoverable amount of the cash-generating unit was determined to be lower than its carrying amount, leading to the recognition of the goodwill impairment.

Management reviews the business performance of each operating entity (also regarded as a CGU). Goodwill is allocated to relevant operating entities.

The recoverable amount of a CGU is determined based on a value-in-use calculation. It is calculated using pre-tax discounted cash flow projections based on financial budgets approved by management covering a five-year period. Cash flow beyond the five-year period is extrapolated using the estimated growth rates as stated below.

---

| | | |
|:---|:---|:---|
|  | **2024** | **2025** |
| Annual compound revenue growth rate | 6.0% ~ 20.0% | 2.2% ~ 16.9% |
| Annual gross profit ratio | 26.0% ~ 57.0% | 26.1% ~ 57.2% |
| Discount rate | 4.34% | 4.20% |

---

Management considers that because of their experience and expertise knowledge in the aesthetic medical treatment business in the PRC, a cash flow period of five years is reasonable.

Management determined budgeted gross margin based on past performance and its expectations of the market development. The average annual revenue growth rate used is consistent with the forecasts of the market from an industry study. The discount rate used is pre-tax and reflects specific risks relating to the entity. The cash flows beyond the five year periods are extrapolated using a 4% (2024: 4%) growth rate.

---

| | |
|:---|:---|
| **16** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Trade and other receivables, deposits and prepayments** |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Trade receivables | 8793 | 6399 |
| Other receivables | 524 | 10622 |
| Deposits | 6567 | 6832 |
| Prepayments | 16986 | 30115 |
| Advances to employees | 1006 | 1672 |
|  | 25083 | 49241 |
| **Less: Non-current portion** |  |  |
| Prepayments and deposits | (6704) | (7051) |
| **Current portion** | 18379 | 42190 |

---

The carrying amounts of trade and other receivables, deposits and prepayments are denominated in RMB and approximate their fair values.

Trade receivables are all aged within 30 days and no bad debts accrued.

Prepayments mainly consist of advances to suppliers and recognition of VAT input tax credits at the year end of 2025.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **17** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Inventories** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Pharmaceuticals |  | 592 |  | 1337 |
| Medical consumables | | 14,315 | | 17,461 |
|  | | 14,907 | | 18,798 |

---

The cost of inventories recognised as expense and included in cost of inventories and consumables amounted to RMB215,692,000 (2024: RMB234,487,000).

---

| | |
|:---|:---|
| **18** | **Restricted cash and cash and cash equivalents** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Restricted cash | | 1,012 | | 5,102 |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Cash and cash equivalents |  |  |
| Cash at banks | 42829 | 60202 |
| Cash on hand | 7 | 57 |
| Total | 42836 | 60259 |

---

The analysis of bank and cash balances for the purpose of the consolidated statement of cash flows is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Cash and cash equivalents | | 42,836 | | 60,259 |

---

The carrying amounts of the Group's restricted bank deposit and cash and cash equivalents are denominated in the following currencies:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| RMB |  | 42738 |  | 59651 |
| US dollars |  | 98 |  | 819 |
| Hong Kong dollars | |  | | 159 |
|  | | 42,836 | | 60,259 |

---

Cash at banks earns interest at floating rates based on daily bank deposit rates. The Group's balances of cash at bank which are denominated in RMB are deposited with banks in the PRC. The conversion of these RMB-denominated balances into foreign currencies and the remittance of funds out of the Mainland China are subject to the rules and regulations of foreign exchange control promulgated by the Government of the PRC.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **19a** | **Share capital** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Ordinary shares of USD0.001 each** | **Ordinary shares of USD0.001 each** | **Ordinary shares of USD0.001 each** |
|  | **Number of**<br>**shares** | **Nominal**<br>**value** | **Nominal**<br>**value** |
|  | | **USD'000** | **RMB'000** |
| **Authorised:** | | | |
| As at 1 January 2020, 31 December 2020, 1 January 2021, 31 December 2021, 1 January 2022, 31 December 2022, 1 January 2023 and 31 December 2023 | 1500000000 | 1500 | 10599 |
| **Issued and paid:** |  |  |  |
| As at 31 December 2021 and 1 January 2022 | 70838671 | 72 | 469 |
| Issuance of shares to Hawyu (HK) Limited (Note i) | 21413276 | 21 | 144 |
| Issuance of shares under Performance Incentive Plan (Note ii) | 1927793 | 2 | 13 |
| As at 31 December 2022<sup>\*</sup> | 94179740 | 95 | 626 |
| Issuance of shares to MY Universe (HK) Limited (Note iii) | 36402570 | 36 | 250 |
| Issuance of shares to Peak Asia Investment Holdings V Limited (Note iv) | 12088808 | 12 | 88 |
| Issuance of shares to Seefar Global Holdings Limited (Note v) | 1956516 | 2 | 14 |
| As at 31 December 2023<sup>\*\*</sup> | 144627634 | 145 | 978 |
| Issuance of shares to Seefar Global Holdings Limited (Note vi) | 2698870 | 3 | 20 |
| As at 31 December 2024<sup>\*\*</sup> | 147326504 | 148 | 998 |
| As at 31 December 2025 | 147326504 | 148 | 1035 |

---

Note i:

In May 2021, we entered into definite share subscription agreement for the issuance of 5,329,410 ordinary shares to Lafang China Co., Ltd. ("Lafang"), a daily consumer products producer in China, at a sale price of US$8.50 for every three ordinary shares (equivalent to US$8.50 per American Depositary Share of the Company), which amounted to US$15.1 million in proceeds. In May 2022, we entered into an amendment to the above share subscription agreement with Lafang. Pursuant to this amendment, we issued 21,413,276 ordinary shares to Hawyu (HK) Limited, a wholly-owned subsidiary of Lafang, at a sale price of RMB4.67 per ordinary share (equivalent to approximately US$2.1 per American Depositary Share based on the exchange rate as of 31 May 2022), which amounted to RMB100 million (US$15 million) in proceeds. The private placement was closed in July 2022. We utilized the money from this private placement to fund our business development and working capital.

Note ii:

On 29 July 2022, the Company issued 1,927,793 new ordinary shares to certain employees, representing an aggregate 2.0% of the total number of outstanding ordinary shares, at nil consideration in accordance with the 2019 Performance Incentive Plan proposed in September 2019. The purpose of this share option plan is to recognize contributions made by key employees on the negotiation and execution of the financing with Lafang China Co., Ltd. and Jiechuang, as well as to provide an incentive to retain a long-term relationship with the Company under the alignment of interests**.**

Note iii:

Reference is made to the 6-K report of the Company filed with the SEC on February 16, 2023. Further to its press release on July 20, 2022, the Company has closed its previously announced private placement offering through the issuance and allotment of 36,402,570 new ordinary shares of the Company (the "Subscription Shares") to MY Universe (HK) Limited as designated by Hainan Oriental Jiechuang Investment Partnership (Limited Partnership) at a price of RMB4.67 per Subscription Share for the aggregate gross proceeds of RMB170 million.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **19a** | **Share capital (Continued)** |

---

Note iv:

Reference is made to the press release of the Company filed with the Securities and Exchange Commission (the "SEC") on July 20, 2022, form 6-K of the Company filed with the SEC on February 16, 2023 and form 6-K of the Company filed with the SEC on August 17, 2023 (collectively, "Previous Disclosure"). Further to its Previous Disclosure, the Company has closed its previously announced the issue of a total number of 12,088,808 ordinary shares of the Company to ADV at a conversion price of US dollars equivalent of RMB4.203 per ordinary share on August 16, 2023 pursuant to the Note issued to ADV on September 17, 2020 and the cooperation agreement between ADV and its affiliate, the Company, Dr. Zhou Pengwu, Ms. Ding Wenting, Wanda and Jiechuang dated July 20, 2022. As of December 31, 2023, the Company has no convertible note outstanding.

Note v:

Further to the Company's Previous Disclosure mentioned in Note iv, Seefar Global Holdings Limited exercised its warrants, converting them into 1,956,516 ordinary shares of the Company on August 18, 2023.

Note vi:

Further to the Company's Previous Disclosure mentioned in Note iv, Seefar Global Holdings Limited exercised its warrants, converting them into 2,698,870 ordinary shares of the Company on December 13, 2024.

\* The treasury shares as of December 31, 2022 were 135,000 ordinary shares, represented by 45,000 ADSs repurchased in 2020 pursuant to the Company's repurchase program in October 2020.

\*\* The treasury shares as of December 31, 2023 and 2024 were 1,263,750 ordinary shares, including 135,000 ordinary shares represented by 45,000 ADSs repurchased in 2020 pursuant to the Company's repurchase program in October 2020, and 1,128,750 ordinary shares held by Shengli Family Limited, which have not been granted to any employee but are reserved for the purpose of incentive shares.

---

| | |
|:---|:---|
| **19b** | **Treasury Shares** |

---

---

| | | |
|:---|:---|:---|
|  | **Number of**<br>**shares** |<br>**RMB'000** |
| As at 31 December 2020, 1 January 2021, 31 December 2021, 1 January 2022, 31 December 2022, 1 January 2023, 31 December 2023, 1 January 2024 (Note i) | 135000 | 2023 |
| Options outstanding under the Share Incentive Plan | 1128750 |  |
| As at 31 December 2024 | 1263750 | 2023 |
| As at 31 December 2025 | 1263750 | 2023 |

---

Note i:

On 13 October 2020, the Company announced that its board of directors had approved a share repurchase program, under which the Company was authorized to repurchase in the open market up to US$6.0 million worth of its American depositary shares ("ADSs") from time to time until 12 October 2021, depending on general market conditions, trading price and other factors, as well as subject to the applicable laws and the Company's securities trading policy. During the applicable period, 135,000 ordinary shares were repurchased as treasury shares with a total consideration of approximately RMB2 million.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **20** | **Other reserves** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |<br>**Capital**<br>**reserve**<br>**RMB'000** |<br>**Merger**<br>**reserve**<br>**RMB'000** |<br>**Statutory**<br>**reserve**<br>**RMB'000** | **Share-based**<br>**compensation**<br>**reserve**<br>**RMB'000** |<br>**Other**<br>**reserve**<br>**RMB'000** |<br>**Total**<br>**RMB'000** |
|  | **Note (a)** | **Note (b)** | **Note (c)** | **Note (d)** | **Note (e)** | |
| At 1 January 2024 | 991350 | (10000) | 42772 | 265192 | (61179) | 1228135 |
| Translation of foreign operations |  |  |  |  | (302) | (302) |
| Expire of convertible note |  |  |  | 1797 |  | 1797 |
| At 31 December 2024 | 991350 | (10000) | 42772 | 266989 | (61481) | 1229630 |
| At 31 December 2024 and 1 January 2025 | 991350 | (10000) | 42772 | 266989 | (61481) | 1229630 |
| Ceased operation of subsidiaries |  |  | 788 |  | 1502 | 2209 |
| At 31 December 2025 | 991350 | (10000) | 43560 | 266989 | (59979) | 1231920 |

---

**(a)** **Capital reserve** 

The capital reserve mainly represents capital contribution made by an owner and shareholders of the Company.

**(b)** **Merger reserve** 

Merger reserve is mainly attributable to business combinations under common control.

**(c)** **Statutory reserve** 

In accordance with the PRC regulations and the articles of association of the companies now comprising the Group, before distributing the net profit of each year, companies registered in the PRC are required to set aside 10% of their statutory net profit for the year after offsetting any prior year's losses as determined under relevant PRC accounting standards to the statutory surplus reserve fund. When the balance of such reserve reaches 50% of each company's share capital, any further appropriation is optional.

**(d)** **Share-based compensation reserve** 

For the year ended 31 December 2022, share-based compensation expenses amounting to RMB27,515,000 was charged to share-based compensation reserve, which was attributable to share options which were granted to certain consultants and employees of the Group in previous years.

For the year ended 31 December 2023, share-based compensation expenses amounting to RMB4,226,000 was charged to share-based compensation reserve.

**(e)** **Other reserve** 

Other reserve mainly represents the currency translation differences and loss on the conversion of property, plant and equipment to investment properties.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **21** | **Deferred income tax assets** |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| The deferred tax assets comprise attributable to: |  |  |
| - Tax losses | 53265 | 23019 |
| - Other temporary differences | 295 | 295 |
|  | 53560 | 23314 |
| The deferred tax liabilities comprise temporary differences attributable to: |  |  |
| - Others |  |  |

---

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current income tax assets against current income tax liabilities and when the deferred income taxes relate to the same fiscal authority. The balances shown in the consolidated balance sheets are as follows:

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Deferred income tax assets: |  |  |
| - Deferred income tax assets to be recovered after more than 12 months | 53560 | 23314 |
|  | 53560 | 23314 |
| Deferred income tax liabilities: |  |  |
| - Deferred income tax liabilities to be settled after more than 12 months |  |  |

---

The movement in deferred income tax assets and liabilities during the year, without taking into consideration the offsetting of balances within the same taxation jurisdiction is as follows:

The gross movement on deferred income tax accounts is as follows:

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| At 1 January | 76929 | 53560 |
| Disposal of subsidiaries (Note 26) |  | (2166) |
| Credited to consolidated statement of comprehensive income | (23371) | (28080) |
| Translation adjustment | 2 |  |
| At 31 December | 53560 | 23314 |

---

**Deferred income tax assets**

---

| | | | |
|:---|:---|:---|:---|
|  | **Tax losses**<br>**RMB'000** | **Others**<br>**RMB'000** | **Total**<br>**RMB'000** |
| At 1 January 2024 | 76572 | 366 | 76938 |
| Credited to consolidated statement of comprehensive income | (23309) | (71) | (23380) |
| Translation adjustment | 2 |  | 2 |
| At 31 December 2024 and 1 January 2025 | 53265 | 295 | 53560 |
| Disposal of subsidiaries (Note 26) | (2166) |  | (2166) |
| Credited to consolidated statement of comprehensive income | (28080) |  | (28080) |
| At 31 December 2025 | 23019 | 295 | 23314 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **21** | **Deferred income tax assets (Continued)** |

---

**Deferred income tax liabilities**

---

| | | | |
|:---|:---|:---|:---|
|  | **Medical licenses**<br>**and tradenames**<br>**RMB'000** |<br>**Others**<br>**RMB'000** |<br>**Total**<br>**RMB'000** |
| At 1 January 2023 |  |  |  |
| Credited to consolidated statement of comprehensive income | (9) |  | (9) |
| At 31 December 2023 and 1 January 2024 | (9) |  | (9) |
| Credited to consolidated statement of comprehensive income | 9 |  | 9 |
| At 31 December 2024 |  |  |  |

---

Deferred income tax assets are recognised for tax loss carry-forwards to the extent that the realisation of the related tax benefit through future taxable profits is probable. The Group has tax losses as at 31 December 2025 of RMB23,019,000 (2024: RMB53,265,000) which can be carried forward against future taxable income and their expiry dates are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Tax loss expiring within 5 years | | 53,265 | | 23,019 |

---

---

| | |
|:---|:---|
| **22** | **Borrowings** |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| **Non-current** |  |  |
| Other borrowings |  |  |
| - secured | 13723 | 15171 |
|  | 13723 | 15171 |
| **Current** |  |  |
| Bank borrowings |  |  |
| - secured | 61781 | 94398 |
| Other borrowings |  |  |
| - secured | 10434 | 34683 |
|  | 72215 | 129081 |
|  | 85938 | 144252 |

---

The carrying amounts of borrowings approximate their fair values and are denominated in RMB. The effective interest rates on the borrowings from banks was 3.92% as at 31 December 2025.

Bank borrowings are secured by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) property, plant and equipment and investment properties of
the Group (Note 12 and Note 14);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) personal properties provided by Dr. Zhou Pengwu and Ms. Ding
Wenting (Note 29(d));

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) personal guarantee provided by Dr. Zhou Pengwu, Dr. Zhou Yitao
and Ms. Ding Wenting, Mr Zhou Xichun (Note 29(d)); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) corporate guarantee provided by a related company controlled
by Dr. Zhou Pengwu (Note 29(d)).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) personal guarantee provided by Ms. Wu Binhua (Note 29(d)).

Other borrowings are secured by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) property, plant and equipment of the Group (Note 12).

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **23** | **Trade payable, accruals, other payables and provisions** |

---

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Trade payables | 48373 | 34748 |
| Accrued employee benefits | 18385 | 17505 |
| Accrued operating expenses | 14829 | 15848 |
| Accrued professional service fees | 6249 | 6419 |
| Deposits received | 376 | 428 |
| Duty and tax payable other than corporate income tax | 1050 | 1614 |
| Other payables to suppliers of plant and equipment | 208 | 217 |
| Others | 2050 | 381 |
|  | 91520 | 77160 |

---

The carrying amounts of trade and other payables are denominated in RMB. The carrying amounts approximate their fair values due to their short-term maturities.

---

| | |
|:---|:---|
| **24** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Contract liabilities** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Advance receipt for treatment packages | | 193,931 | | 186,066 |

---

As at end of 31 December 2025, the contract liabilities are aged within one year from the date when the sales contracts in respect of treatment packages were entered into.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **25** | **Cash generated from operations** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2023**<br>**RMB'000** | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| **Loss before income tax** | (55058) | (1347) | (24719) |
| Adjustments for: |  |  |  |
| Finance income | (78) | (404) | (138) |
| Finance costs | 14474 | 8717 | 8749 |
| Amortisation of intangible assets (Note 15) | 574 | 627 | 594 |
| Depreciation of property, plant and equipment (Note 12) | 65323 | 65337 | 58294 |
| Loss on disposal of property, plant and equipment | 1981 | 4060 | 5428 |
| Gain on early termination of lease |  |  | (6851) |
| Fair value loss of investment properties | 154 | (12147) | 31 |
| Fair value loss of convertible note | 116 |  |  |
| Convertible note convert into shares | (20420) |  |  |
| Share-based payment | 7514 |  |  |
| Expire of convertible note |  | 1817 |  |
| Impairment for goodwill |  |  | 500 |
| Loss on disposal of associates | 220 |  |  |
| Loss on disposal of subsidiaries (Note 26) | 4860 |  |  |
| Loss on liquidation of subsidiaries | 373 |  |  |
| Loss on ceased operation of subsidiaries | 813 | 2106 | 7196 |
|  | 20846 | 68766 | 49084 |
| **Changes in working capital:** |  |  |  |
| - Inventories | 12272 | 674 | (3979) |
| - Trade receivables | (3966) | 1115 | 1597 |
| - Other receivables, deposits and prepayments | 3088 | (1251) | (21080) |
| - Restricted bank balances |  | (1012) | (4090) |
| - Trade payables | 28019 | 5971 | (12189) |
| - Accruals, other payables and provisions | (9283) | 5040 | (12746) |
| - Contract liabilities | 23330 | 889 | (7415) |
| Cash flow from operating activities | 74306 | 80192 | (10818) |

---

This section sets out an analysis of net debt and the movements in net debt for the years:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Liabilities from financing activities** | **Liabilities from financing activities** | **Liabilities from financing activities** | **Liabilities from financing activities** | **Liabilities from financing activities** |
| <br>**Net debt** |<br>**Borrowing**<br>**due within**<br>**1 year**<br>**RMB'000** |<br>**Borrowing**<br>**due after**<br>**1 year**<br>**RMB'000** | **Lease**<br>**liabilities**<br>**due within**<br>**1 year**<br>**RMB'000** | **Lease**<br>**liabilities**<br>**due after**<br>**1 year**<br>**RMB'000** | <br><br>**Total**<br>**RMB'000** |
| As at 1 January 2023 | (172766) | (29110) | (27352) | (99304) | (328532) |
| Cash flows | 98833 | (2300) | (11318) | 5906 | 91121 |
| As at 31 December 2023 | (73933) | (31410) | (38670) | (93398) | (237411) |
| As at 1 January 2024 | (73933) | (31410) | (38670) | (93398) | (237411) |
| Cash flows | 1718 | 17687 | 4522 | 26556 | 50483 |
| As at 31 December 2024 | (72215) | (13723) | (34148) | (66842) | (186928) |
| As at 1 January 2025 | (72215) | (13723) | (34148) | (66842) | (186928) |
| Cash flows | (58314) |  | 45579 |  | (12735) |
| Non-cash | 1448 | (1448) | (43427) | (55938) | (99365) |
| As at 31 December 2025 | (129081) | (15171) | (31996) | (122780) | (299028) |

---

Non-cash items mainly arise from new lease recognition and early lease termination.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **26** | **Disposals of subsidiaries** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Shenzhen Miaoyan Medical Technology Investment Co., Ltd.

In May 2023, the Group disposed of its entire equity interest in Shenzhen Miaoyan Medical Technology Investment Co., Ltd. to a third party. Details of the net assets of Shenzhen Miaoyan Medical Technology Investment Co., Ltd. disposed of and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| Property, plant and equipment | (25) |
| Intangible assets | 6 |
| Deferred tax assets | 6 |
| Prepayments | 192 |
| Investment in associate | 860 |
| Trade and other receivables | 20294 |
| Cash and cash equivalents | 26 |
| Trade payables and other payables | (16558) |
| Contract liabilities | (13) |
| Income tax liabilities | 209 |
| Reserve | (5) |
| Net assets of subsidiary | 4992 |
| Loss on disposal of subsidiary | (3092) |
| Cash consideration | 1900 |

---

An analysis of the net outflow of cash and cash equivalents in respect of the disposal of the subsidiary is as follows:

---

| | |
|:---|:---|
|  | **2023**<br>**RMB'000** |
| Cash received | 1900 |
| Cash and cash equivalents disposed of | (26) |
| Net cash inflow in respect of disposal | 1874 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Ningbo Beilun Pengai Aesthetic Medical Clinic Co., Ltd.

In October 2023, the Group disposed of its entire equity interest in Ningbo Beilun Pengai Aesthetic Medical Clinic Co., Ltd. to a third party. Details of the net assets of Ningbo Beilun Pengai Aesthetic Medical Clinic Co., Ltd. disposed of and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| Property, plant and equipment | 543 |
| Intangible assets | 24 |
| Trade and other receivables | 508 |
| Cash and cash equivalents | 76 |
| Trade payables and other payables | (995) |
| Net assets of subsidiary | 156 |
| Loss on disposal of subsidiary | (156) |
| Cash consideration |  |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **26** | **Disposals of subsidiaries (Continued)** |

---

An analysis of the net outflow of cash and cash equivalents in respect of the disposal of the subsidiary is as follows:

---

| | |
|:---|:---|
|  | **2023**<br>**RMB'000** |
| Cash received |  |
| Cash and cash equivalents disposed of | (76) |
| Net cash outflow in respect of disposal | (76) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Stargaze Wealth Limited.

In December 2023, the Group disposed of its entire equity interest in Stargaze Wealth Limited. to a third party. Details of the net assets of Stargaze Wealth Limited. disposed of and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| &nbsp;&nbsp;&nbsp;Property, plant and equipment | 842 |
| &nbsp;&nbsp;&nbsp;Prepayments | 1 |
| &nbsp;&nbsp;&nbsp;Asset held-for-sale | 1083 |
| &nbsp;&nbsp;&nbsp;Trade and other receivables | 16690 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | 974 |
| &nbsp;&nbsp;&nbsp;Trade payables and other payables | (18114) |
| &nbsp;&nbsp;&nbsp;Exchange reserve | 136 |
| Net assets of subsidiary | 1612 |
| Loss on disposal of subsidiary | (1612) |
| Cash consideration |  |

---

An analysis of the net outflow of cash and cash equivalents in respect of the disposal of the subsidiary is as follows:

---

| | |
|:---|:---|
|  | **2023**<br>**RMB'000** |
| Cash received |  |
| Cash and cash equivalents disposed of | (974) |
| Net cash outflow in respect of disposal | (974) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Shanghai Pengai Medical Technology Co., Ltd.

In June 2024, Shanghai Pengai Medical Technology Co., Ltd. has been dissolved. Details of the net assets of Shanghai Pengai Medical Technology Co., Ltd. and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| Deferred income tax assets | 65 |
| Trade and other receivables | 3583 |
| Cash and cash equivalents | 1 |
| Trade payables and other payables | (1543) |
| Net assets of subsidiary | 2106 |
| Loss on disposal of subsidiary | (2106) |
| Cash consideration |  |

---

An analysis of the net outflow of cash and cash equivalents in respect of the disposal of the subsidiary is as follows:

---

| | |
|:---|:---|
|  | **2024**<br>**RMB'000** |
| Cash received |  |
| Cash and cash equivalents disposed of | (1) |
| Net cash outflow in respect of disposal | (1) |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **26** | **Disposals of subsidiaries (Continued)** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Shanghai Pengai xiuqi Aesthetic Medical Hospital Co., Ltd.

In December 2025, Shanghai Pengai xiuqi Aesthetic Medical Hospital Co., Ltd. has been dissolved. Details of the net assets of Shanghai Pengai xiuqi Aesthetic Medical Hospital Co., Ltd. and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| Property, plant and equipment | 420 |
| Intangible assets | 756 |
| Goodwill | 3223 |
| Deferred income tax assets | 1787 |
| Inventories | 15 |
| Trade and other receivables | 822 |
| Amounts due from related parties | 500 |
| Trade payables and other payables | (3044) |
| Contract liability | (439) |
| Net assets of subsidiary | 4040 |
| Loss on disposal of subsidiary | (4040) |
| Cash consideration |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Newa Medical Aesthetics Limited

In February 2025, Newa Medical Aesthetics Limited has been dissolved. Details of the net assets of Newa Medical Aesthetics Limited and their financial impacts are summarised as follows:

---

| | |
|:---|:---|
|  | **RMB'000** |
| Net assets disposed of: |  |
| Property, plant and equipment | 1107 |
| Deferred income tax assets | 379 |
| Inventories | 73 |
| Trade and other receivables | 627 |
| Other reserve | 788 |
| Exchange reserve | 1502 |
| Trade payables and other payables | (327) |
| Contract liability | (11) |
| Current income tax liabilities | (982) |
| Net assets of subsidiary | 3156 |
| Loss on disposal of subsidiary | (3156) |
| Cash consideration |  |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **27** | **Summarised financial information of subsidiaries with material non-controlling interests** |

---

Set out below is the summarised financial information for each subsidiary that has non-controlling interests that are material to the Group.

As at 31 December 2023, 2024 and 2025, the non-controlling interests attributable to these entities accounted for 40%, 40% and 40% of the total non-controlling interests for the respective year end.

**Summarised balance sheets**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Huizhou Pengai** | **Huizhou Pengai** | **Huizhou Pengai** | **Shanghai Pengai** | **Shanghai Pengai** | **Shanghai Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Current |  |  |  |  |  |  |
| - Assets | 33060 | 21781 | 36551 | 20587 | 24301 | 41670 |
| - Liabilities | (23017) | (23699) | (36058) | (56395) | (80348) | (93683) |
| Total current net assets/(liabilities) | 10043 | (1918) | 493 | (35808) | (56047) | (52013) |
| Non-current |  |  |  |  |  |  |
| - Assets | 8958 | 13333 | 16384 | 46180 | 40940 | 27034 |
| - Liabilities | (9167) |  | (4348) | (39215) | (22558) | (10075) |
| Total non-current net assets | (209) | 13333 | 12036 | 6965 | 18382 | 16959 |
| Net assets/(liabilities) | 9834 | 11415 | 12529 | (28843) | (37665) | (35054) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Xiuqi Pengai** | **Xiuqi Pengai** | **Xiuqi Pengai** | **Haikou Pengai** | **Haikou Pengai** | **Haikou Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Current |  |  |  |  |  |  |
| - Assets | 19509 | 18096 | 36090 | 5339 | 2638 | 2466 |
| - Liabilities | (46968) | (42734) | (57745) | (25022) | (25581) | (27681) |
| Total current net liabilities | (27459) | (24638) | (21655) | (19683) | (22943) | (25215) |
| Non-current |  |  |  |  |  |  |
| - Assets | 36573 | 30987 | 28051 | 12256 | 6751 | 6140 |
| - Liabilities | (4631) | (2031) |  | (4640) | (3562) | (2431) |
| Total non-current net assets | 31942 | 28956 | 28051 | 7616 | 3189 | 3709 |
| Net assets/(liabilities) | 4483 | 4318 | 6396 | (12067) | (19754) | (21506) |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **27** | **Summarised financial information of subsidiaries with material non-controlling interests (Continued)** |

---

**Summarised balance sheets (Continued)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Yantai Pengai** | **Yantai Pengai** | **Yantai Pengai** |
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| Current |  |  |  |
| - Assets | 3441 | 2280 | 2141 |
| - Liabilities | (31624) | (28907) | (28929) |
| Total current net liabilities | (28183) | (26627) | (26788) |
| Non-current |  |  |  |
| - Assets | 29119 | 18899 | 18995 |
| - Liabilities | (17088) | (10060) | (9820) |
| Total non-current net assets | 12031 | 8839 | 9175 |
| Net assets/(liabilities) | (16152) | (17788) | (17613) |

---

**Summarised statements of comprehensive income**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Huizhou Pengai** | **Huizhou Pengai** | **Huizhou Pengai** | **Shanghai Pengai** | **Shanghai Pengai** | **Shanghai Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Revenue | 36952 | 44802 | 51520 | 44422 | 50287 | 52529 |
| Profit/(loss) before income tax | 6252 | 4140 | 4774 | (7031) | (7409) | 2611 |
| Income tax (expense)/credit | (1563) | (1035) | (1194) | 1758 | (1412) |  |
| Profit/(loss) and total comprehensive income/(loss) for the year | 4689 | 3105 | 3580 | (5273) | (8821) | 2611 |
| Total comprehensive income/(loss) allocated to non-controlling interests | 1524 | 1009 | 1164 | (1055) | (1764) | 522 |
| Dividend paid to non-controlling interests | 2685 | 496 | 802 |  |  |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Xiuqi Pengai** | **Xiuqi Pengai** | **Xiuqi Pengai** | **Haikou Pengai** | **Haikou Pengai** | **Haikou Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Revenue | 51431 | 62418 | 57187 | 32421 | 27922 | 25024 |
| (Loss)/Profit before income tax | (2776) | 1600 | 2771 | (5369) | (5623) | (1752) |
| Income tax credit/(expense) | 1068 | (1765) | (693) | 1342 | (2064) |  |
| (Loss)/Profit and total comprehensive (loss)/income for the year | (1708) | (165) | 2078 | (4027) | (7687) | (1752) |
| Total comprehensive (loss)/income allocated to non-controlling interests | (102) | (10) | 125 | (523) | (999) | (228) |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Yantai Pengai** | **Yantai Pengai** | **Yantai Pengai** |
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| Revenue | 28874 | 33688 | 31819 |
| (Loss)/profit before income tax | (8099) | 479 | 234 |
| Income tax credit/(expense) | 2378 | (2115) | (59) |
| (Loss)/profit and total comprehensive income/(loss) for the year | (5721) | (1636) | 175 |
| Total comprehensive (loss)/income allocated to non-controlling interests | (286) | (82) | 9 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **27** | **Summarised financial information of subsidiaries with material non-controlling interests (Continued)** |

---

**Summarised statements of cash flows**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Huizhou Pengai** | **Huizhou Pengai** | **Huizhou Pengai** | **Shanghai Pengai** | **Shanghai Pengai** | **Shanghai Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| **Cash flows from operating activities** |  |  |  |  |  |  |
| Cash generated from operations | (1127) | 19058 | (5767) | (1110) | 15096 | 4665 |
| Income tax paid |  | (8) | (2040) |  |  |  |
| Net cash (used in)/generated from operating activities | (1127) | 19050 | (7807) | (1110) | 15096 | 4665 |
| Net cash used in investing activities | (2955) | (5992) | (1360) | (715) | (1250) | (21) |
| Net cash generated from/(used in) financing activities | 6344 | (13283) | 6112 | 2380 | (13166) | (5703) |
| **Net increase/(decrease) in cash and cash equivalents** | 2262 | (225) | (3055) | 555 | 680 | (1059) |
| Cash and cash equivalents at beginning of the year | 1106 | 3368 | 3143 | 123 | 678 | 1358 |
| Cash and cash equivalents at end of the year | 3368 | 3143 | 88 | 678 | 1358 | 299 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Xiuqi Pengai** | **Xiuqi Pengai** | **Xiuqi Pengai** | **Haikou Pengai** | **Haikou Pengai** | **Haikou Pengai** |
|  | **2023** | **2024** | **2025** | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| **Cash flows from operating activities** |  |  |  |  |  |  |
| Cash (used in)/generated from <br>operations | (3492) | 8472 | (10091) | 1771 | (1057) | 1052 |
| Income tax paid |  |  |  | (20) |  |  |
| Net cash (used in)/generated from operating activities | (3492) | 8472 | (10091) | 1751 | (1057) | 1052 |
| Net cash used in investing activities | (997) | (569) | (285) | (30) | (549) | (417) |
| Net cash generated from/(used in) financing activities | 8817 | (9111) | 7160 |  |  | (1272) |
| **Net increase/(decrease) in cash and cash equivalents** | 4328 | (1208) | (3216) | 1721 | (1606) | (637) |
| Cash and cash equivalents at beginning of the year | 104 | 4432 | 3224 | 525 | 2246 | 640 |
| Cash and cash equivalents at end of the year | 4432 | 3224 | 8 | 2246 | 640 | 3 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **27** | **Summarised financial information of subsidiaries with material non-controlling interests (Continued)** |

---

**Summarised statements of cash flows (Continued)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Yantai Pengai Jiayan** | **Yantai Pengai Jiayan** | **Yantai Pengai Jiayan** |
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| **Cash flows from operating activities** |  |  |  |
| Cash generated from/(used in) operations | 1691 | (584) | 1447 |
| Income tax paid |  |  |  |
| Net cash generated from operating activities | 1691 | (584) | 1447 |
| Net cash used in investing activities | (421) | (494) | (310) |
| Net cash used in financing activities |  |  | (1670) |
| **Net increase/ (decrease) in cash and cash equivalents** | 1270 | (1078) | (533) |
| Cash and cash equivalents at beginning of the year | 341 | 1611 | 533 |
| Cash and cash equivalents at end of the year | 1611 | 533 |  |

---

---

| | |
|:---|:---|
| **28** | **Commitments** |

---

**(a)** **Operating lease commitments** 

The Group leases premises for aesthetic healthcare services and offices under non-cancellable operating agreements. The lease terms are between 3 and 9 years, and a majority of lease agreements are renewable at the end of the lease period at market rate.

From 1 January 2021, the Group has recognised right-of-use assets for these leases, except for short-term as stated in note 2.24 and note 13.

The future aggregate minimum lease payments under non-cancellable operating leases as follows:

---

| | | |
|:---|:---|:---|
|  | **2024**<br>**RMB'000** | **2025**<br>**RMB'000** |
| Less than 1 year | 34148 | 31996 |
| 1 to 2 years | 19799 | 28485 |
| 2 to 5 years | 38683 | 72990 |
| More than 5 years | 8360 | 21305 |
| Total | 100990 | 154776 |

---

**(b)** **Contingencies** 

Certain subsidiaries of the Company have been named as defendants in two litigations in the PRC. The maximum amount of the damages claimed by the plaintiffs amounted to an aggregate of approximately RMB9,360,000 (2024: RMB44,985,000). The restricted cash of RMB5,102,000 was reserved as at December 31, 2025.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **29** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Related party transactions** |

---

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control, common significant influence or joint control. Members of key management and their close family member of the Group are also considered as related parties.

The following significant transactions were carried out between the Group and its related parties in addition to the related party information shown elsewhere in these consolidated financial statements. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties.

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** **Transactions with related parties** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Depreciation, interest expense and building rental | | | | |
| - A related company |  | 1915 |  | 1560 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Balances with related parties** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| **Current (Note i)** | | | | |
| **Amounts due from related parties** | | | | |
| Amounts due from related companies |  | 1500 |  | 1000 |
| Amounts due from non-controlling interests | | 656 | | 656 |
|  | | 2,156 | | 1,656 |

---

Note i: Balances due from related parties are unsecured, interest free, repayable on demand and are denominated in RMB. Their carrying values approximate to their fair values.

&nbsp;&nbsp;&nbsp;&nbsp;**(c)** **Key management compensation** 

Key management includes directors and senior managements. The compensation paid or payable to key management for employee services is shown below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Basic salaries and bonus |  | 13907 |  | 13446 |
| Pension costs - defined contribution plans | | 246 | | 276 |
|  | | 14,153 | | 13,722 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(d)** **Personal guarantees from Dr. Zhou Pengwu, Dr. Zhou Yitao, Mr. Zhou Xichun and Ms. Ding Wenting and corporate guarantee from a related company controlled by Dr. Zhou Pengwu** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2024** | **2024** | **2025** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** | **RMB'000** |
| Bank borrowings of the Group secured by personal guarantees from Ms. Wu Binhua | | 61,781 | | 94,398 |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **30** | **Particulars of the subsidiaries** |

---

The following is a list of the principal subsidiaries at 31 December 2023 and 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | **Interest held** | **Interest held** |
| <br>**Name** | **Place of**<br>**incorporation/**<br>**establishment** | <br>**Registered capital/**<br>**issued share capital** | <br>**Principal activities** | **2024** | **2025** |
| *Directly hold:* |  |  |  |  |  |
| Dragon Jade Holdings Limited | British Virgin Islands (The "BVI") | Registered capital of 1 share without par value | Investment holding and provision of management services | 100% | 100% |
| (龍翠控股有限公司) |  |  |  |  |  |
| *<u>Indirectly hold:</u>* |  |  |  |  |  |
| Peng Oi Investment (Hong Kong) Holdings Limited | Hong Kong | 10,000 ordinary shares | Investment holding and provision of management services | 100% | 100% |
| (鵬愛投資(香港)集團有限公司) |  |  |  |  |  |
| Peng Yida Business Consulting (Shenzhen) Co., Ltd. | The PRC | Registered capital of Hong Kong dollar 500,000,000 | Investment holding and provision of management services | 100% | 100% |
| (鵬意達商務諮詢(深圳)有限公司) |  |  |  |  |  |
| Shenzhen Pengai Hospital Investment Management Co., Ltd. | The PRC | Registered capital of RMB500,000,000 | Investment holding and provision of management services | 100% | 100% |
| (深圳鵬愛醫院投資管理有限公司) |  |  |  |  |  |
| Shenzhen Pengcheng Hospital Co., Ltd. | The PRC | Registered capital of RMB85,000,000 | Provision of aesthetic medical services and general healthcare services | 100% | 100% |
| (深圳鵬程醫院有限公司) |  |  |  |  |  |
| Shenzhen Pengai Aesthetic Medical Hospital Co., Ltd. | The PRC | Registered capital of RMB130,000,000 | Provision of aesthetic medical services | 100% | 100% |
| (深圳鵬愛醫療美容醫院有限公司) |  |  |  |  |  |
| Haikou Pengai Aesthetic Medical Hospital Co., Ltd. | The PRC | Registered capital of RMB3,000,000 | Provision of aesthetic medical services | 87% | 87% |
| (海口鵬愛醫療美容醫院有限公司) |  |  |  |  |  |
| Huizhou Pengai Aesthetic Medical Hospital Co., Ltd. | The PRC | Registered capital of RMB6,000,000 | Provision of aesthetic medical services | 67.5% | 67.5% |
| (惠州鵬愛醫療美容醫院有限公司) |  |  |  |  |  |
| Shanghai Pengai Medical Technology Co., Ltd. | The PRC | Registered capital of RMB500,000 | Provision of medical aesthetic technical consulting and management services | —% | —% |
| (上海鵬愛醫療科技有限公司) |  |  |  |  |  |
| Shengli Aesthetic Technology Investment,Hong Kong Company Limited | Hong Kong | 10,000 ordinary shares | Investment holding and provision of management services | —% | —% |
| Aih Investment Management Corp. | U.S.A | Registered capital of 1,000,000 shares with a par of USD 0.01 per share | Investment holding and provision of management services | 100% | 100% |

---

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **30** | **Particulars of the subsidiaries (Continued)** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | **Interest held** | **Interest held** |
| <br>**Name** | **Place of**<br>**incorporation/**<br>**establishment** |<br>**Registered capital/**<br>**issued share capital** | <br>**Principal activities** | **2024** | **2025** |
| Indirectly hold (Continued): |  |  |  |  |  |
| Shenzhen Pengai Culture Broadcast Co., Ltd.<br> (深圳鵬愛文化傳播有限公司) | The PRC | Registered capital of RMB1,000,000 | Provision of cultural, artistic activities, corporate image, exhibition planning and advertising service | 100% | 100% |
| Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd.<br> (上海鵬愛醫療美容門診部有限公司) | The PRC | Registered capital of RMB3,000,000 | Provision of aesthetic medical services | 80% | 80% |
| Newa Medical Aesthetics Limited | Hong Kong | 1,000,000 ordinary shares | Provision of aesthetic medical services | 100% | —% |
| Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd.<br> (廣州鵬愛醫療美容醫院有限公司) | The PRC | Registered capital of RMB18,800,000 | Provision of aesthetic medical services | 96% | 96% |
| Shenzhen Pengai Xiuqi Aesthetic Medical Hospital Co. Ltd.<br> (深圳鵬愛秀琪醫療美容醫院有限公司) | The PRC | Registered capital of RMB12,000,000 | Provision of aesthetic medical services | 94% | 94% |
| Shanghai Pengai Jiahong (formerly known as Shanghai Mingyue Yueji) Aesthetic Medical Outpatient Department Co., Ltd.<br> (上海鵬愛嘉泓医疗美容门诊部有限公司) | The PRC | Registered capital of RMB5,000,000 | Provision of aesthetic medical services | 64% | —% |
| Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. (廣州鵬愛秀琪醫療美容門診部有限公司) | The PRC | Registered capital of RMB1,000,000 | Provision of aesthetic medical services | 73% | 73% |
| Beijing Aomei Yixin Investment Consultant Co., Ltd. (北京澳美醫信投資顧問有限公司) | The PRC | Registered capital of RMB500,000 | Investment holding and provision of management services | 95% | 95% |
| Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai (formerly known as Beijing Haiyue Xingguang) Aesthetic Medical Clinic (北京澳美醫信投資顧問有限公司鵬愛醫療美容診所) | The PRC |  | Provision of aesthetic medical services | 95% | 95% |
| Yantai Pengai Cosmetic Surgery Hospital Co., Ltd. (煙台鵬愛美容整形醫院有限公司) | The PRC | Registered capital of RMB10,000,000 | Provision of aesthetic medical services | 95% | 95% |
| Shenzhen Ruimei Enterprise Management Co., Ltd. (深圳市睿美企業管理有限公司) | The PRC | Registered capital of RMB100,000 | Investment holding and provision of management services | 100% | 100% |

---

---

| | |
|:---|:---|
| **31** | **Additional information: condensed financial statements of the Company** |

---

The condensed financial statements of Aesthetic Medical International Holdings Group Limited have been prepared in accordance with Securities and Exchange Commission Regulation S-X Rule 5-04 and Rule 12-04.

The Company records its investments in subsidiaries under the equity method of accounting. Such investments and loans to subsidiaries are presented on the condensed financial statements as "Investment in subsidiaries and due from subsidiaries" and the profit of the subsidiaries is presented as "Profit from subsidiaries" in the condensed statements of comprehensive income.

The footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these financial statements should be read in conjunction with the notes to the consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted.

As of December 31, 2024 and 2025, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those, if any, which have been separately disclosed in the consolidated financial statements.

[**Table of Contents**](#TableOfContents)

---

| | |
|:---|:---|
| **31** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Additional information: condensed financial statements of the Company (Continued)** |

---

Condensed balance sheets of the parent company

---

| | | |
|:---|:---|:---|
|  | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** |
| **ASSETS** |  |  |
| **Non-current assets** |  |  |
| Investments in subsidiaries and due from subsidiaries |  |  |
| **Current assets** |  |  |
| Cash and cash equivalents | 99 | 979 |
|  | 99 | 979 |
| **Total assets** | 99 | 979 |
| **EQUITY AND LIABILITIES** |  |  |
| **Equity attributable to owners of the Company** |  |  |
| Share capital and treasury shares | (1025) | (1025) |
| Other reserves | (18722) | (15857) |
| Total equity | (19747) | (16882) |
| **LIABILITIES** |  |  |
| **Current liabilities** |  |  |
| Accruals, other payables and provisions | 19846 | 17861 |
| **Total liabilities** | 19846 | 17861 |
| **Total equity and liabilities** | 99 | 979 |

---

**Condensed statements of comprehensive income of the parent company**

---

| | | | |
|:---|:---|:---|:---|
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| Loss/(gain) from subsidiaries | (26521) | (18663) | 9093 |
| General and administrative expenses | (14089) | 3338 | (7494) |
| Finance income |  | 2343 | 1266 |
| Finance costs | (528) |  |  |
| Other loss, net | 20420 |  |  |
| Fair value loss of convertible note | (116) |  |  |
| **(Loss)/Profit before income tax** | (20834) | (12982) | 2865 |
| Income tax expense |  |  |  |
| **(Loss)/Profit for the year** | (20834) | (12982) | 2865 |
| **Other comprehensive (loss)/income** |  |  |  |
| *<u>Items that may be subsequently reclassified to profit or loss</u>* |  |  |  |
| Currency translation differences | (791) | (302) | 1259 |
| **Total other comprehensive (loss)/income for the year, net of tax** | (791) | (302) | 1259 |
| **Total comprehensive (loss)/income for the year** | (21625) | (13284) | 4124 |

---

**Condensed statements of cash flows of the parent company**

---

| | | | |
|:---|:---|:---|:---|
|  | **2023** | **2024** | **2025** |
|  | **RMB'000** | **RMB'000** | **RMB'000** |
| Net cash used in operating activities | (170915) | (1987) | (5588) |
| Net cash generated from investing activities |  |  | 6468 |
| Net cash generated from financing activities | 170883 | 2034 |  |
| **Net (decrease)/increase in cash and cash equivalents** | (32) | 47 | 880 |
| Cash and cash equivalents at beginning of the year | 84 | 52 | 99 |
| Cash and cash equivalents at end of the year | 52 | 99 | 979 |

---

## Exhibit 8.1

**Exhibit 8.1**

**LIST OF PRINCIPAL SUBSIDIARIES OF THE REGISTRANT**

---

| | |
|:---|:---|
| **Subsidiaries** | **Place of Incorporation** |
| Dragon Jade Holdings Limited | BVI |
| Aih Investment Management Corp. | U.S.A. |
| Peng Oi Investment (Hong Kong) Holdings Limited | Hong Kong |
| Xi'an New Pengai Yueji Aesthetic Medical Outpatient Department Co., Ltd. | PRC |
| Chengdu Pengai Yueji Aesthetic Medical Outpatient Department Co., Ltd. | PRC |
| Beijing Aomei Yixin Investment Consultant Co., Ltd. | PRC |
| Beijing Aomei Yixin Investment Consultant Co., Ltd. Pengai Aesthetic Medical Clinic | PRC |
| Guangzhou Pengai Aesthetic Medical Hospital Co., Ltd. | PRC |
| Haikou Pengai Aesthetic Medical Hospital Co., Ltd. | PRC |
| Huizhou Pengai Aesthetic Medical Hospital Co., Ltd. | PRC |
| Peng Yida Business Consulting (Shenzhen) Co., Ltd. | PRC |
| Shanghai Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. | PRC |
| Shanghai Pengai Aesthetic Medical Outpatient Department Co., Ltd. | PRC |
| Shenzhen Pengai Aesthetic Medical Hospital | PRC |
| Shenzhen Pengai Culture Broadcast Co., Ltd. | PRC |
| Shenzhen Pengai Hospital Investment Management Co., Ltd. | PRC |
| Shenzhen Pengai Xiuqi Aesthetic Medical Hospital | PRC |
| Shenzhen Pengcheng Hospital | PRC |
| Yantai Pengai Cosmetic Surgery Hospital Co., Ltd. | PRC |
| Guangzhou Pengai Xiuqi Aesthetic Medical Outpatient Department Co., Ltd. | PRC |
| Shenzhen Ruimei Enterprise Management Co., Ltd. | PRC |

---

## Exhibit 12.1

**Exhibit 12.1**

**Certification by the Principal Executive Officer**

**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Zhang Chen, certify that:

1. I have reviewed this annual report on Form 20-F of Aesthetic
Medical International Holdings Group Limited;

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;

4. The company's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the company's internal control over financial reporting that
occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company's internal control over financial reporting; and

5. The company's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee
of the company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report
financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the company's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: April 23, 2026 | Date: April 23, 2026 |
| By: | /s/ Zhang Chen |
| Name: | Zhang Chen |
| Title: | Chairman |
|  | (*principal executive officer*) |

---

## Exhibit 12.2

**Exhibit 12.2**

**Certification by the Principal Financial Officer**

**Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Wu Guanhua, certify that:

1. I have reviewed this annual report on Form 20-F of Aesthetic
Medical International Holdings Group Limited;

2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;

4. The company's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the company's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the company's internal control over financial reporting that
occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the
company's internal control over financial reporting; and

5. The company's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee
of the company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report
financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the company's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: April 23, 2026 | Date: April 23, 2026 |
| By: | /s/ Wu Guanhua |
| Name: | Wu Guanhua |
| Title: | Chief Financial Officer |
|  | (*principal financial officer*) |

---

## Exhibit 13.1

**Exhibit 13.1**

**Certification by the Principal Executive Officer<br> Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Annual Report of Aesthetic Medical International Holdings Group Limited (the "Company") on Form 20-F for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zhang Chen, Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: April 23, 2026 | Date: April 23, 2026 |
| By: | /s/ Zhang Chen |
| Name: | Zhang Chen |
| Title: | Chairman |
|  | (*principal executive officer*) |

---

## Exhibit 13.2

**Exhibit 13.2**

**Certification by the Principal Financial Officer<br> Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Annual Report of Aesthetic Medical International Holdings Group Limited (the "Company") on Form 20-F for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wu Guanhua, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: April 23, 2026 | Date: April 23, 2026 |
| By: | /s/ Wu Guanhua |
| Name: | Wu Guanhua |
| Title: | Chief Financial Officer |
|  | (*principal financial officer*) |

---

## Exhibit 15.1

**Exhibit 15.1**

---

| | |
|:---|:---|
| Dacheng Law Offices LLP (Wuhan)<br> 32-33/F, Tower T5, Yuexiu International Financial Center, 1 Jingwu Road,<br> Jianghan District, Wuhan, Hubei Province, China | ![](ex15-1_001.jpg) |

---

Date: April 23, 2026

**Aesthetic Medical International Holdings Group Limited**

1122 Nanshan Boulevard,

Nanshan District, Shenzhen,

Guangdong Province, China 518052

Dear Sirs/Madams,

We hereby consent to the reference to our firm in Aesthetic Medical International Holdings Group Limited's annual report on Form 20-F for the fiscal year ended December 31, 2025, which will be filed by Aesthetic Medical International Holdings Group Limited in April 2026 with the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and further consent to the incorporation by reference of the summaries of our opinions that appear in the annual report on Form 20-F into the Registration Statements (No. 333-237835) on Form S-8 and Form F-3 (No. 333-265667).

In giving such consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.

---

| |
|:---|
| Yours sincerely, |
| /s/ Dacheng Law Offices LLP (Wuhan) |
| **DACHENG LAW OFFICES LLP (WUHAN)** |

---

## Exhibit 15.2

**Exhibit 15.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement of Aesthetic Medical International Holdings Group Limited on Form F-3 (File No. 333-265667) of our report dated April 23, 2026, with respect to the consolidated balance sheets of Aesthetic Medical International Holdings Group Limited as of December 31, 2025 and 2024, the related consolidated statements of comprehensive loss, changes in shareholders' equity and cash flows for each of the three years in the period ended December 31, 2025, which report is included in this Annual Report on Form 20-F of Aesthetic Medical International Holdings Group Limited for the year ended December 31, 2025.

We also consent to the reference to us under the heading "Experts" in such Registration Statement.

---

| |
|:---|
| /s/ Onestop Assurance PAC |
| Singapore |
| April 23, 2026 |

---